IL322139A - Cyclin-dependent kinase (cdk2) inhibitors - Google Patents

Cyclin-dependent kinase (cdk2) inhibitors

Info

Publication number
IL322139A
IL322139A IL322139A IL32213925A IL322139A IL 322139 A IL322139 A IL 322139A IL 322139 A IL322139 A IL 322139A IL 32213925 A IL32213925 A IL 32213925A IL 322139 A IL322139 A IL 322139A
Authority
IL
Israel
Prior art keywords
pyrimidin
pyrrolo
amino
pyrazol
spiro
Prior art date
Application number
IL322139A
Other languages
Hebrew (he)
Inventor
Karin Briner
Xin Chen
Sajan Joseph
Vivek Rauniyar
Fr?d?ric ZECRI
Original Assignee
Novartis Ag
Karin Briner
Xin Chen
Sajan Joseph
Vivek Rauniyar
Fr?d?ric ZECRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Karin Briner, Xin Chen, Sajan Joseph, Vivek Rauniyar, Fr?d?ric ZECRI filed Critical Novartis Ag
Publication of IL322139A publication Critical patent/IL322139A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

PAT059456 FF CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS FIELD OF THE INVENTION The invention relates to compounds which inhibit CDK2 (Cyclin-Dependent Kinase 2 or Cell Division protein Kinase 2), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK2.
BACKGROUND OF THE INVENTION CDK2 is a serine/threonine kinase that regulates the mammalian cell cycle. After binding to cyclin- E1, cyclin-E2, cyclin-A1 orcyclin-A2, the activated CDK2-cyclin complex phosphorylates a variety of cellular substrates (Chi et al 2020). For example, it phosphorylates and inactivates the retinoblastoma protein (pRB), thus de-represses the E2F family of transcription factors that promotes expression of cell cycle related genes (Sherr & Roberts 1999, 2004). As such, CDKpropels the cell from the G1 phase into S phase of the cell cycle, when nuclear DNA is replicated in preparation of mitosis. CDK2 and its activity are often dysregulated in human cancers (Corsino et al 2008, Ying et al 2018, Nie et al 2019). One such dysregulation mechanism involves, but not limited to, the amplification or overexpression of cyclin-E1 , which leads to hyperactivation of CDKand promotes cellular proliferation (Schraml et al. 2003). Depending on lineage, dysregulation of CDK2/E occurs in up to 40% of human cancers (cbioportal.org ), including but not limited to uterine carcinosarcoma (~40%) ovarian (~20%), gastric (~12%), esophageal (~10%), endometrial (~10%), and breast cancers (~10%). Cyclin-E1 amplification and overexpression is also associated with poor prognosis across cancers (Nakayama et al 2010, Zhao et al 2019). In many of these cancers, besides radiation and chemotherapy, there is no targeted therapy available to patients. Thus, the development of a targeted agent against CDK2 would potentially benefit cancer patients.
Chi Y., Carter J.H, Swanger J., Mazin A.V., Moritz R.L, and Clurman B.E. (2020). A novel landscape of nuclear human CDksubstrates revelaed by in situ phosphorylation. Sci. Adv 6, eaaz9899Sherr CJ, Roberts JM. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501- 1512.Sherr CJ, Roberts JM. (2004). Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699-2711.Corsino PE, Davis BJ, Norgaard PH, Parker NN, Law M, Dunn W and Law BK. Mammary tumors initiated by constitutive Cdkactivation contain an invasive basal-like component. Neoplasia 2008; 10: 1240-1252Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, et al. Ubiquitin-dependent degradation of CDK2 drives the therapeutic diferentiation of AML by targeting PRDX2. Blood J Am SocHematol. 2018;131(24):2698-711 PAT059456 FF Nie L, Wei Y, Zhang F, Hsu Y-H, Chan L-C, Xia W, et al. CDK2-mediated site-specifc phosphorylation of EZH2 drives and maintains triplenegative breast cancer. Nat Commun. 2019;10(1):1—15Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003;200(3):375-383.Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, et al. GeneamplificationCCNEI is related to poor survival and potential therapeutic target in ovarian cancer.Cancer 2010:NA-NA.Guo Q, Lin X, Ye L, et al. . Comparative efficacy of Cdk4/6 inhibitors plus aromatase inhibitors versus fulvestrant for the first-line treatment of hormone receptor-positive advanced breast cancer: a network meta-analysis. Target Oncol 2019:14:139-48Gao JJ, Cheng J, Bloomquist E, et al. . Cdk4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis. Lancet Oncol 2020:21:250-60 WO2020/168178 is directed to various CDK2 inhibitors structurally related to those disclosed herein. For example, compounds such as (Example 12) WO2023/278326 (Blueprint) discloses compounds such as (Example 3) F. Notably, the Blueprint compounds bind to the CDK2 ATP-binding site in a very different manner to the Incyte compounds, as shown in Figure 1 and the associated brief description.
PAT059456 FF SUMMARY OF INVENTION The applicant has surprisingly found that compounds of formula (I) as described herein, which include a(n optionally substituted) 5 membered heteroaryl in place of the bulkierN— motif of HN (Incyte) provide a novel vector for potency and selectivity overother kinases along with optimal in-vivo PK properties.
Thus, according to a first aspect of the invention, there is hereby provided a compound according to formula (1): (1); wherein: Y1 is a bond or CH2 (e.g. Y1 is a bond); Y2 is a bond, 0, NR5 or CR6R7 (e.g. Y2 is a bond); R1 and R2 are each independently selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl, or R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl (e.g. Rand R2 join together to form C3-C4cycloalkyl, e.g. R1 and R2 join together to form C3cycloalkyl); each R3 is independently selected from the group consisting of hydroxyl, halo, C1-C6alkyl and C1- Cshaloalkyl; R4 is selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl (e.g. R4 is H); PAT059456 FF R5 is selected from the group consisting of H, C1-C6alkyl, C(=O)-C1-C6alkyl orC(=O)-O-C1-C 6alkyl; R6 and R7 join together to form, together with the carbon atom to which they are mutually attached, a C3-C6cycloalkyl or a 3-6 membered heterocyclyl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein said C3-C6cycloalkyl or 3-6 membered heterocyclyl is substituted with 0-3 substituents R8; each R8 is independently selected from the group consisting of C1-C6alkyl, C(=O)C1-C6alkyl, halo, C1-C6haloalkyl, S-C1-C6alkyl, SO-C1-C6alkyl, SO2-C1-C6alkyl, cyano, hydroxyl, or wherein two Rsubstituents on the same ring atom join together to form =0. n is 0 to 3 (e.g. n is 1, e.g. n is 1 and R3 is hydroxyl); m is 1 to 5 (e.g. m is 4); ( A )W is a 5 membered heteroaryl comprising 1 to 3 heteroatoms independently selected from N, and S (e.g. 2 heteroatoms independently selected from N, O and S, e.g. 2 heteroatoms which are both N), said 5 membered heteroaryl being substituted with 0 to 3 substituents RA; each RA is independently *L1-X1, wherein * indicates the point of attachment to W, each L1 is independently selected from bond, O, S, SO, SO2, C=C, C(=0), *C(=O)-O**, C1-C6alkylene, 01- Cshaloalkylene, *O-C1-C6alkylene**, *O-C1-C6haloalkylene**, *O-C1-C6hydroxyalkylene**, 01- C6alkylene-O-C1-C 6alkylene, *O-C3-C6cycloalkylene**, *0-3-6 membered heterocyclylene**, 01- Czhydroxyalkylene, C3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising heteroatom which is 0), O-C1-C6alkylene-O, *O-C1-C6alkylene-O-C 3-C6cycloalkylene** and *0- O1-O6alkylene-O-3-6 membered heterocyclylene**, wherein * indicates the point of attachment to ( A )W, and ** indicates the point of attachment to X1; and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C(=O)-C1- C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl substituted by 0-3 R8 groups, O-C1-C6alkyl, S-C1-C6alkyl, S(O)-C1-C6alkyl, S(O)2-C1-C6alkyl, N(C1-C6alkyl) 2, C(=O)N(C1-C6alkyl) 2, C1-C6hydroxyalkyl, 3-membered heterocyclyl (e.g. comprising 1 or 2 heteroatoms independently selected from 0, N and S) substituted by 0-3 R8 groups, 5-10 membered heteroaryl (e.g. 5, 6, 9 or 10 membered heteroaryl) comprising 1-4 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups, 5-10 membered partially saturated heterocyclyl comprising 1 to 4 heteroatoms PAT059456 FF independently selected from the group consisting of 0, N and S substituted by 0-3 R8 groups, 7- membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from 0, N and S substituted by 0-3 R8 groups and C7-C10spirocycloalkyl substituted by 0-3 R8 groups; or two RA substituents located on adjacent ring atoms join together to form with said adjacent ring atoms a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S, with the proviso that at least one heteroatom is N; or a pharmaceutically acceptable salt and/or tautomer thereof.
According to a second aspect of the invention, there is hereby provided a compound selected from any one of the Examples or any one of the synthetic intermediates, or a pharmaceutically acceptable salt and/or tautomer thereof.
According to a third aspect of the invention, there is hereby provided a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention and one or more pharmaceutically acceptable carriers.
According to a fourth aspect of the invention, there is hereby provided a combination comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention, and one or more therapeutically active agents.
According to a fifth aspect of the invention, there is hereby provided a method of modulating CDKactivity in a subject comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention.
According to a sixth aspect of the invention, there is hereby provided a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention.
According to a seventh aspect of the invention, there is hereby provided a compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention for use as a medicament.
PAT059456 FF According to a eighth aspect of the invention, there is hereby provided a compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention for use in the treatment of cancer.
According to a ninth aspect of the invention, there is hereby provided use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention in the treatment of cancer.
According to a tenth aspect of the invention, there is hereby provided use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention in the manufacture of a medicament for the treatment of cancer.
BRIEF DESCRIPTION OF THE DRAWINGS FIGURE 1 shows (top) the putative binding modes of N (Incyte) and (bottom) F (Blueprint) to the CDK2 ATP-binding site. These putativebinding modes were modeled by the molecular modeling software package Maestro® (Schrodinger, LLC).
The Incyte compound forms two hydrogen bonds with the hinge region of CDK2 (L83). It also forms a hydrogen bond with the catalytic K33 in the rear. In contrast, the blueprint compound forms three hydrogen bonds with the hinge region of CDK2 (L83 and E81), and it doesn ’t form any polar interactions in the rear, including at K33. Instead, it forms two different hydrogen bonds with residues at the front (K20 and E8). In conclusion, the binding modes of the Incyte and Blueprint compounds to the CDK2 ATP-binding site are very different to one another.
PAT059456 FF FIGURE 2 shows the putative binding mode of a compound according to formula (1). The binding (Incyte), but very different to that of is broadly similar to (Blueprint). These putative binding modes were modeled by themolecular modeling software package Maestro® (Schrodinger, LLC).
FIGURE 3 shows the impact of 3 days of oral BID dosing with indicated compounds on PD marker (RB phosphorylation) in the Cyclin E amplified OVCAR3 xenograft model. Data is shown as percentage of untreated animals.
Compound 1 = Compound 2 = PAT059456 FF <:Compound 3 = 0 DETAILED DESCRIPTION OF THE INVENTION The invention therefore, in a first aspect, provides a compound according to formula (1): Y1 is a bond or CH2 (e.g. Y1 is a bond); Y2 is a bond, 0, NR5 or CR6R7 (e.g. Y2 is a bond); R1 and R2 are each independently selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl, or R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl (e.g. R1and R2 join together to form C3-C4cycloalkyl, e.g. R1 and R2 join together to form C3cycloalkyl); each R3 is independently selected from the group consisting of hydroxyl, halo, C1-C6alkyl and C1- Cshaloalkyl; R4 is selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl (e.g. R4 is H); R5 is selected from the group consisting of H, C1-C6alkyl, C(=O)-C1-C6alkyl orC(=O)-O-C1-C 6alkyl; R6 and R7 join together to form, together with the carbon atom to which they are mutually attached, a C3-C6cycloalkyl or a 3-6 membered heterocyclyl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein said C3-C6cycloalkyl or 3-6 membered heterocyclyl is substituted with 0-3 substituents R8; (1); wherein: PAT059456 FF each R8 is independently selected from the group consisting of C1-C6alkyl, C(=O)C1-C6alkyl, halo, C1-C6haloalkyl, S-C1-C6alkyl, SO-C1-C6alkyl, SO2-C1-C6alkyl, cyano, hydroxyl, or wherein two Rsubstituents on the same ring atom join together to form =0. n is 0 to 3 (e.g. n is 1, e.g. n is 1 and R3 is hydroxyl); m is 1 to 5 (e.g. m is 4); 0/ is a 5 membered heteroaryl comprising 1 to 3 heteroatoms independently selected from N, and S (e.g. 2 heteroatoms independently selected from N, O and S, e.g. 2 heteroatoms which are both N), said 5 membered heteroaryl being substituted with 0 to 3 substituents RA; each RA is independently *L1-X1, wherein * indicates the point of attachment to , each L1 is independently selected from bond, O, S, SO, SO2, C=C, C(=0), *C(=O)-O**, C1-C6alkylene, 01- Cshaloalkylene, *O-C1-C6alkylene**, *O-C1-C6haloalkylene**, *O-C1-C6hydroxyalkylene**, 01- C6alkylene-O-C1-C 6alkylene, *O-C3-C6cycloalkylene**, *0-3-6 membered heterocyclylene**, 01- Czhydroxyalkylene, C3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising heteroatom which is 0), O-C1-C6alkylene-O, *O-C1-C6alkylene-O-C3-C 6cycloalkylene** and *0- O1-O6alkylene-O-3-6 membered heterocyclylene**, wherein * indicates the point of attachment to V-V , and ** indicates the point of attachment to X1; and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C(=0)-C1- C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl substituted by 0-3 R8 groups, O-C1-C6alkyl, S-C1-C6alkyl, S(O)-C1-C6alkyl, S(O)2-C1-C6alkyl, N(C1-C6alkyl) 2, C(=O)N(C1-C6alkyl) 2, C1-C6hydroxyalkyl, 3-membered heterocyclyl (e.g. comprising 1 or 2 heteroatoms independently selected from 0, N and S) substituted by 0-3 R8 groups, 5-10 membered heteroaryl (e.g. 5, 6, 9 or 10 membered heteroaryl) comprising 1-4 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups, 5-10 membered partially saturated heterocyclyl comprising 1 to 4 heteroatoms independently selected from the group consisting of O, N and S substituted by 0-3 R8 groups, 7- membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups and C7-C10spirocycloalkyl substituted by 0-3 R8 groups; or PAT059456 FF two RA substituents located on adjacent ring atoms join together to form with said adjacent ring atoms a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S, with the proviso that at least one heteroatom is N; or a pharmaceutically acceptable salt and/or tautomer thereof.
In relation to the L1 groups defined above, it should be understood that for certain groups such as C1-C6alkylene and 0-C1-C6alkylene-0 * and ** are undefined because the substituent is symmetrical i.e. *C1-C6alkylene** is the same as **C1-C6alkylene* In an embodiment, Y1 is a bond.
In an alternative (less favored) embodiment, Y1 is CH2 and R2 is H.
In an embodiment, Y2 is a bond.
In an embodiment, m is 4.
In an embodiment, n is 1 to 3, e.g. n is 1.
In an embodiment, at least one R3 is OH.
In an embodiment, the compound of formula (I) is a compound of formula (la): (la), wherein R1, R2, R3, R4 and are as defined above.In an embodiment, the compound of formula (I) is a compound of formula (lb): I A /(lb), wherein R1, R2, R3, R4 and ' are as defined above.
PAT059456 FF In an embodiment, the compound of formula (1) is a compound of formula (Ic): (1c), wherein R1, R2, R3, R4 and are as defined above.
In an embodiment, the compound of formula (I) is a compound of formula (Id): (Id), wherein R1, R2, R4 andCCx —/ are as defined above.
In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl.
In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl.
In an embodiment, R1 and R2 join together to form C3cycloalkyl.
In an embodiment, R4 is H.
In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H.
In an embodiment, R1 and R2 join together to form C3cycloalkyl, and R4 is H.
In an embodiment, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl.
In an embodiment, m is 4 and R1 and R2 join together to form C3cycloalkyl.
In an embodiment, m is 4 and R4 is H.
In an embodiment, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is H. in an embodiment, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, Y1 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H.
In an embodiment, Y1 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H.
PAT059456 FF In an embodiment, Y1 is a bond, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl.
In an embodiment, Y1 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl.
In an embodiment, Y1 is a bond, m is 4 and R4 is H.
In an embodiment, Y1 is a bond, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 isH.
In an embodiment, Y1 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, Y2 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H.
In an embodiment, Y2 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H.
In an embodiment, Y2 is a bond, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl.
In an embodiment, Y2 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl.
In an embodiment, Y2 is a bond, m is 4 and R4 is H.
In an embodiment, Y2 is a bond, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is H.
In an embodiment, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, Y1 is a bond, Y2 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H.
In an embodiment, Y1 is a bond, Y2 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H.
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R1 and R2 join together to form C3- C4cycloalkyl.
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl.
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R4 is H.
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3- C4cycloalkyl and R4 is H.
PAT059456 FF In an embodiment, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, is a 5 membered heteroaryl comprising 2 heteroatoms independently selected from N, O and S, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined above. is a 5 membered heteroaryl comprising 2 heteroatoms independently selected from N, O and S, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined above, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, is a 5 membered heteroaryl comprising 2 heteroatoms independently selected from N and O, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA,wherein RA is as defined above.
In an embodiment, is a 5 membered heteroaryl comprising 2 heteroatoms independentlyselected from N and O, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined above, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, W is a 5 membered heteroaryl comprising 1 to 3 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined above.
! A )In an embodiment, W is a 5 membered heteroaryl comprising 1 to 3 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined above, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
PAT059456 FF (''a'')In an embodiment, W is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined above.
In an embodiment, W is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined above, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
)؟(In an embodiment, x / is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 2 substituents RA, wherein RA is as defined above.
In an embodiment, x_V is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 2 substituents RA, wherein RA is as defined above, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
)؟(In an embodiment, v_v is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 or 1 substituent RA, wherein RA is *L1-X1, and L1 and X1 are as defined above.
In an embodiment, V_V is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 or 1 substituent RA, wherein RA is *L1-X1, and L1 and X1 are as defined above, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.*wwow ( a )In an embodiment, VVjs selected from the group consisting of: PAT059456 FF In an embodiment, is selected from the group consisting of: Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, W is selected from the group consisting of H and , Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to formC3cycloalkyl and R4 is H.
In an embodiment, is selected from the group consisting of: PAT059456 FF PAT059456 FF Ra Ra 44) Ra , 45) Ra , 46) Ra , 47) rA^X^‘ and 48) RA , and X is selected from 0, NH and S (e.g. X is NH).
( AIn an embodiment, V. ^■־־־^ nD1) x ,2) RA /is selected from the group consisting of: RAV> > R>H O NARA HN. > Ns Xra N. XrA,3) X , 4) X K , 5) Ra ,6) X K , Rax RA ^xV pT 7) RA , 8) RA , 9) X N™/" X, i jH raJ 13) RA ,14) rA^X^rA, 15) rt r-Z ״ v? ra-،?n18) R , 19) K X ,20) X > R>n /F^pA ־"x RAX. , N ,—.K N R N־ 23 ) Ra ,24) Ra ,25) 'X R׳ ra ra raHq n'^ ) Ra ؟, 28 ) X 29) X 1 a pAx, / X, /*^.pA10) RA , 11) R x ,12) x R RaA« FV rA^n^rA ftRa , 16) Ra , 17) x' , ra >x ץ־ך M ^;nx ,N । ־" p A) K X , 22) Ra , Xj rV /־3-1 ^ M n؟, 26 ) Ra ,27) 'X ؟, A RA rA rAi IV J ITV | ؛ 1 N 1 N,31) Ra ,32) Ra PAT059456 FF 33) Ra RA , 35) X is selected from O, NH and S (e.g. X is NH), Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 jointogether to form C3cycloalkyl and R4 is H. is selected from the group consisting of: In an embodiment, PAT059456 FF is selected from the group consisting of: In an embodiment, 6) PAT059456 FF PAT059456 FF 44) Ra , 45)bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H. is selected from the group consisting of: In an embodiment, and S. is selected from the group consisting of: In an embodiment, , and X is selected from O, NHand S, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H. 10pis selected from the group consisting of: In an embodiment, and In an embodiment, is selected from the group consisting of: PAT059456 FF R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, i) V_Vj s selected from the group consisting of: H and H ) and RA is selected from a) halo, b) cyano, c) C1-C6alkyl, d) C1-C6haloalkyl, e) C1-C6hydroxyalkyl, f) O-C1-C6alkyl, g) C(=O)-O-C1-C6alkyl, h) C1-C6alkylene-O-C1-C 6alkyl, i) O-C1-C6alkylene-O-C1-C 6alkyl, j) C3-C6cycloalkyl substituted by 0-3 R8 groups, k) 5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N,O and S substituted by 0-3 R8 groups, I) 5-10 membered partially saturated heterocyclyl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, m) O-C3-C6cycloalkyl substituted by 0-3 R8 groups, PAT059456 FF n) C=C-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, 0) S-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected fromN, O and S substituted by 0-3 R8 groups, p) C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, q) O-C1-C6haloalkyl, r) O-C1-C6alkylene-N(C1-C 6alkyl)2, s) O-C1-C6hydroxyalkylene-O-C1-C 6alkyl, t) O-C1-C6alkylene-C 3-C6cycloalkyl substituted by 0-3 R8 groups, u) O-C1-C6alkylene-3-6 membered heterocyclyl comprising 1 or 2 heteroatomsindependently selected from 0, N and S substituted by 0-3 R8 groups, v) O-C1-C6alkylene-C(=O)-N(C1-C 6alkyl)2, w) C1-C6alkylene-5-10 membered partially saturated heterocyclyl comprising 1-4heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, x) O-C1-C6alkylene-7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from 0, N and S substituted by 0-3 R8 groups, y) O-C1-C6alkylene-S(O)2-C1-C 6alkyl, z) O-C1-C6hydroxyalkyl, aa) O-C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, bb) 0-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, cc) 0-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups, dd) CEC-C3-C6cycloalkyl substituted by 0-3 R8 groups, ee) S-C1-C6haloalkyl, PAT059456 FF ff) O-C1-C6alkylene-O-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from 0, N and S substituted by 0-3 R8 groups gg) and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S substituted by 0-3 R8 groups; or ii)PA and the RA substituents join together to form, with the ring atoms to whichthey are attached, a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S. is selected from the group consisting of: In an embodiment, i) (e.g.and RA is selectedfrom a) halo, b) cyano, c) C1-C6alkyl, d) C1-C6haloalkyl, e) C1-C6hydroxyalkyl, f) O-C1-C6alkyl, g) C(=O)-O-C1-C6alkyl, h) C1-C6alkylene-O-C1-C 6alkyl, i) O-C1-C6alkylene-O-C1-C 6alkyl, j) C3-C6cycloalkyl substituted by 0-3 R8 groups, PAT059456 FF k) 5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, I) 5-10 membered partially saturated heterocyclyl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, m) O-C3-C6cycloalkyl substituted by 0-3 R8 groups, n) C=C-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, 0) S-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected fromN, O and S substituted by 0-3 R8 groups, p) C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, q) O-C1-C6haloalkyl, r) O-C1-C6alkylene-N(C1-C 6alkyl)2, s) O-C1-C6hydroxyalkylene-O-C1-C 6alkyl, t) O-C1-C6alkylene-C 3-C6cycloalkyl substituted by 0-3 R8 groups, u) O-C1-C6alkylene-3-6 membered heterocyclyl comprising 1 or 2 heteroatomsindependently selected from O, N and S substituted by 0-3 R8 groups, v) O-C1-C6alkylene-C(=O)-N(C1-C 6alkyl)2, w) C1-C6alkylene-5-10 membered partially saturated heterocyclyl comprising 1-4heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, x) O-C1-C6alkylene-7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups, y) O-C1-C6alkylene-S(O)2-C1-C 6alkyl, z) O-C1-C6hydroxyalkyl, aa) O-C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, PAT059456 FF bb) 0-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, cc) 0-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from 0, N and S substituted by 0-3 R8 groups, dd) C=C-C3-C6cycloalkyl substituted by 0-3 R8 groups, ee) S-C1-C6haloalkyl, ff) O-C1-C6alkylene-O-3-6 membered heterocyclyl comprising 1 or 2 heteroatomsindependently selected from O, N and S substituted by 0-3 R8 groups gg) and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S substituted by 0-3 R8 groups; or ii)RA and the RA substituents join together to form, with the ring atoms to whichthey are attached, a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, each R8 is independently selected from the group consisting of halo (e.g. fluoro), C1-C6alkyl (e.g. methyl), hydroxyl, cyano, S(O2)-C1-C6alkyl (e.g. S(O2)CH3), C(=O)-C1- Cgalkyl (e.g. C(=O)CH3), O-C1-C6alkyl (e.g. OCH3) and C1-C6haloalkyl (e.g. C1 haloalkyl, e.g. CHF2), or wherein two R8 substituents on the same ring atom join together to form =0. is selected from the group consisting of: In an embodiment, C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, O-C1-C6alkyl, C(=O)-O-C1-C6alkyl, C1-C6alkylene-O- C1-C6alkyl, O-C1-C6alkylene-O-C1-C 6alkyl, C3-C6cycloalkyl and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S; or PAT059456 FF ii) V_V is Ra and the RA substituents join together to form, with the ring atoms to which they are attached, a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S.
( A )In an embodiment, is selected from the group consisting of: RH , H H and H , and RA is selected from halo, cyano, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, O-C1-C6alkyl, C(=O)-O-C1-C6alkyl, C1-C6alkylene-O- C1-C6alkyl, O-C1-C6alkylene-O-C1-C 6alkyl, C3-C6cycloalkyl and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S; or is Ra and the RA substituents join together to form, with the ring atoms to which they are attached, a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
( A )In an embodiment, - is I A )In an embodiment, — is H , Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
PAT059456 FF Rax In an embodiment,ץ N. 2A ) N-Vis H and RA is CH3 or OCH3.
In an embodiment, V.V is H and RA is CH3, OCH3 or OCH2CH3.
RAx > In an embodiment, is H and RA is CH3 or OCH3, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, Vv is H and RA is CH3, OCH3 or OCH2CH3, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H.
In an embodiment, each L1 is independently selected from bond, O, C(=O), *C(=O)-O**, C1- C6alkylene, C1-C6haloalkylene, *O-C1-C6alkylene**, C1-C6alkylene-O-C1-C 6alkylene, C1- Czhydroxyalkylene, C3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising heteroatom which is 0) and O-C1-C6alkylene-O, wherein *indicates the point of attachment to W, and ** indicates the point of attachment to X1; and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, O-C1-C6alkyl, C1-C6hydroxyalkyl and 3-6 membered heterocyclyl (e.g.comprising 1 heteroatom that is 0).
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): PAT059456 FF '״OH(Id-I), whereinA )is as described in any one of the embodiments, and each L1 is independently selected from bond, 0, C(=O), *C(=O)-O**, C1-C6alkylene, C1-Czhaloalkylene, *O-C1-C6alkylene**, C1-C6alkylene-O-C1-C 6alkylene, C1-C6hydroxyalkylene, C3-Cscycloalkylene, 3-6 membered heterocyclylene (e.g. comprising 1 heteroatom which is 0) and O-C1-C6alkylene-O, wherein *indicates the point of attachment to point of attachment to X1; A ;-V, and ** indicates the and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, O-C1-C6alkyl, C1-C6hydroxyalkyl and 3-6 membered heterocyclyl (e.g.comprising 1 heteroatom that is 0).
In an embodiment, each L1 is independently selected from bond, O, C(=O), *C(=O)-O**, C1-C2alkylene, Cihaloalkylene, *O-C1-C2alkylene**, C1-C2alkylene-O-C1alkylene, C1- hydroxyalkylene, C3cycloalkylene, 5-6 membered heterocyclylene comprising 1 heteroatom ( A )which is O and O-C2alkylene-O, wherein *indicates the point of attachment to W, and indicates the point of attachment to X1.
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): is as described in any one of the embodiments, and each L1 is independently selected from bond, 0, C(=O), *C(=O)-O**, C1-C2alkylene, Cihaloalkylene, *O-C1-C2alkylene**, C1-C2alkylene-O-C1alkylene, C1-hydroxyalkylene, C3cycloalkylene, 5-6 membered heterocyclylene comprising 1 heteroatom which is 0 and O- ( A )C2alkylene-O, wherein *indicates the point of attachment to W, and ** indicates the point of attachment to X1.
PAT059456 FF In an embodiment, each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C2alkyl (e.g. Cialkyl), Cihaloalkyl, C3cycloalkyl, O-C1-C2alkyl, C1 hydroxyalkyl and 5-6 membered heterocyclyl comprising 1 heteroatom that is 0.
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): 'OH ( A )(Id-I), wherein W is as described in any one of the embodiments, andeach X1 is independently selected from H, halo, cyano, hydroxyl, C1-C2alkyl (e.g. Cialkyl), Cihaloalkyl, C3cycloalkyl, O-C1-C2alkyl, C1 hydroxyalkyl and 5-6 membered heterocyclyl comprising 1 heteroatom that is 0.
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): wherein W is selected from the group consisting of and H , and RA is selected from the list consisting of C!-C6alkyl, C1-C6alkylene-O-C1-C 6alkyl, C1-C6haloalkyl, C(=O)-O-C1-C6alkyl, C1-C6hydroxyalkyl, 3-membered heteroatom comprising 1 heteroatom that is 0, halo, O-C1-C6alkyl, C3-C6cycloalkyl, cyano and O-C1-C6alkylene-O-C1-C 6alkyl.
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): ,OH A)(Id-I), wherein V-V is as described in any one of the embodiments,and RA is selected from the list consisting of C1-C6alkyl, C1-C6alkylene-O-C1-C 6alkyl, C!- PAT059456 FF Cshaloalkyl, C(=0)-0-C1-C6alkyl, C1-C6hydroxyalkyl, 3-6 membered heteroatom comprising heteroatom that is 0, halo, O-C1-C6alkyl, C3-C6cycloalkyl, cyano and O-C1-C6alkylene-O-C1- Cgalkyl.
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): selected from the group consisting of CH3, CH2CH2OCH3, CHF2, C(=O)-O-CH3, CH heteroatom that is 0, 6 membered heteroatom , and RA is selected from the list consisting of 2OH, 5 membered heteroatom comprising comprising 1 heteroatom that is 0, CH2OCH3,OCH3, CI, C3cycloalkyl, CF3, cyano, OCH2CH2OCH3 and OCH2CH3.
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): In an embodiment, the compound of formula (I) is a compound of formula (Id-I): R , and RA is selected from the list consisting of In an embodiment, the compound of formula (I) is a compound of formula (Id-I): PAT059456 FF CH3؛ OCH3 and OCH2CH3.
In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl, and 52)is a 5 membered heteroaryl selected from the group consisting of 1) Rawherein X is selected from 0, NH and S (e.g. X is NH).
In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl, and is a 5 membered heteroaryl selected from the group consisting of 1) 107)from O, NH and S (e.g. X is NH).Ra , 8) Rawherein X is selected PAT059456 FF In an embodiment, R1 and R2 join together to form C3cycloalkyl, and is a 5 membered heteroaryl selected from the group consisting of 1) from 0, NH and S (e.g. X is NH). is a 5 membered heteroaryl selected from the group In an embodiment, R4 is H, and NH).
In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and membered heteroaryl selected from the group consisting of 1) X wherein X is selected from O, NH and S (e.g. X is NH). is a 5 PAT059456 FF is a 5 In an embodiment, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and X is selected from 0, NH and S (e.g. X is NH). is a 5 In an embodiment, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl, and X is selected from O, NH and S (e.g. X is NH).
AIn an embodiment, m is 4 and R1 and R2 join together to form C3cycloalkyl, and is a 5 X is selected from O, NH and S (e.g. X is NH).
PAT059456 FF In an embodiment, m is 4 and R4 is H, and is a 5 membered heteroaryl selected from the NH).7)wherein X is selected from O, NH and S (e.g. X is In an embodiment, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is H, and 3)is a 5 membered heteroaryl selected from the group consisting of 1) X is selected from O, NH and S (e.g. X is NH). t A ?In an embodiment, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H, and is 103)a 5 membered heteroaryl selected from the group consisting of 1) X is selected from O, NH and S (e.g. X is NH).
PAT059456 FF In an embodiment, Y1 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and is a 5 membered heteroaryl selected from the group consisting of 1) wherein X is selected from O, NH and S (e.g. X is NH).
In an embodiment, Y1 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and 0is a 5 membered heteroaryl selected from the group consisting of 1) wherein X is selected from O, NH and S (e.g. X is NH).
In an embodiment, Y1 is a bond, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl, and is a 5 membered heteroaryl selected from the group consisting of 1) wherein X is selected from O, NH and S (e.g. X is NH).
PAT059456 FF In an embodiment, Y1 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl, and X is selected from O, NH and S (e.g. X is NH). i A )In an embodiment, Y1 is a bond, m is 4 and R4 is H, and W is a 5 membered heteroaryl selected Xis NH).
In an embodiment, Y1 is a bond, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is is a 5 membered heteroaryl selected from the group consisting of 1)2) Rawherein X is selected from O, NH and S (e.g. X is NH).
PAT059456 FF In an embodiment, Y1 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H, and2)is a 5 membered heteroaryl selected from the group consisting of 1) In an embodiment, Y2 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and wherein X is selected from O, NH and S (e.g. X is NH).
In an embodiment, Y2 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and 0x—is a 5 membered heteroaryl selected from the group consisting of 1) wherein X is selected from O, NH and S (e.g. X is NH).
PAT059456 FF In an embodiment, Y2 is a bond, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl, and is a 5 membered heteroaryl selected from the group consisting of 1) wherein X is selected from O, NH and S (e.g. X is NH).
In an embodiment, Y2 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl, and 3)is a 5 membered heteroaryl selected from the group consisting of 1) X is selected from O, NH and S (e.g. X is NH).
In an embodiment, Y2 is a bond, m is 4 and R4 is H, and is a 5 membered heteroaryl selected Xis NH).
PAT059456 FF In an embodiment, Y2 is a bond, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is 2) is a 5 membered heteroaryl selected from the group consisting of 1) In an embodiment, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H, 2) is a 5 membered heteroaryl selected from the group consisting of 1) Rawherein X is selected from O, NH and S (e.g. X is NH).
In an embodiment, Y1 is a bond, Y2 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and is a 5 membered heteroaryl selected from the group consisting of 1) PAT059456 FF Ra wherein X is selected from 0, NH and S (e.g. X is NH).
In an embodiment, Y1 is a bond, Y2 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and is a 5 membered heteroaryl selected from the group consisting of 1) RAwherein X is selected from O, NH and S (e.g. X is NH).
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R1 and R2 join together to form C3- (A)C4cycloalkyl, andV^Y is a 5 membered heteroaryl selected from the group consisting of 1) ,8) Ra wherein X is selected from O, NH and S (e.g. X is NH).
PAT059456 FF In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R1 and R2 join together to form ( A )C3cycloalkyl, andV-V is a 5 membered heteroaryl selected from the group consisting of 1) , 8) Ra wherein X is selected from O, NH and S (e.g. X is NH). is a 5 membered In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R4 is H, and from O, NH and S (e.g. X is NH).
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3- is a 5 membered heteroaryl selected from the group consisting C4cycloalkyl and R4 is H, and ra g) ra wherein X is selected from O, NH and S (e.g. X is NH).
PAT059456 FF In an embodiment, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl ( A )and R4 is H, and —/ is a 5 membered heteroaryl selected from the group consisting of 1) , 8) Ra wherein X is selected from O, NH and S (e.g. X is NH).
In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl, and is selected from In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl, and ־( 6In an embodiment, R1 and R2 join together to form C3cycloalkyl, and / is selected from the PAT059456 FF In an embodiment, R4 is H, andis selected from the group consisting of RAand In an embodiment, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and selected from the group consisting of Ra and(e.g. is selected is In an embodiment, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and In an embodiment, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl, and selected from the group consisting of and(e.g.is is selected In an embodiment, m is 4 and R1 and R2 join together to form C3cycloalkyl, and PAT059456 FF ©In an embodiment, m is 4 and R4 is H, and is selected from the group consisting of RA and(e.g.
In an embodiment, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is H, and is selected from the group consisting of RAand(e.g.Ns N is H ( A )In an embodiment, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H, and W is selected from the group consisting of andNH (e.g.A RA Nv Nis H In an embodiment, Y1 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and In an embodiment, Y1 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and is selected from the group consisting of and(e.g.
PAT059456 FF In an embodiment, Y1 is a bond, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl, and In an embodiment, Y1 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl, and is selected from the group consisting In an embodiment, Y1 is a bond, m is 4 and R4 is H, and In an embodiment, Y1 is a bond, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is In an embodiment, Y1 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H, PAT059456 FF In an embodiment, Y2 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and In an embodiment, Y2 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and In an embodiment, Y2 is a bond, m is 4 and R1 and R2 join together to form C3-C4cycloalkyl, and is selected from the group consisting of and(e.g.
In an embodiment, Y2 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl, and is selected from the group consisting In an embodiment, Y2 is a bond, m is 4 and R4 is H, and PAT059456 FF In an embodiment, Y2 is a bond, m is 4, R1 and R2 join together to form C3-C4cycloalkyl and R4 is is selected from the group consisting of Ra and H (e.g. H, and In an embodiment, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H, is selected from the group consisting of and(e.g.
In an embodiment, Y1 is a bond, Y2 is a bond, R1 and R2 join together to form C3-C4cycloalkyl, and R4 is H, and In an embodiment, Y1 is a bond, Y2 is a bond, R1 and R2 join together to form C3cycloalkyl, and R4 is H, and H )■ PAT059456 FF In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R1 and R2 join together to form C3- n /ךץ( A ) 'aC4cycloalkyl, and V-V is selected from the group consisting of R andNH (e.g.
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R1 and R2 join together to form C3cycloalkyl, and is selected from the group consisting of Ra and H (e.g.
In an embodiment, Y1 is a bond, Y2 is a bond, m is 4 and R4 is H, and is selected from the group consisting of RA In an embodiment, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3- 10is selected from the group consisting of RAand C4cycloalkyl and R4 is H, PAT059456 FF In an embodiment, Y1 is a bond, Y2 is a bond, m is 4, R1 and R2 join together to form C3cycloalkyl and R4 is H, and is selected from the group consisting of Ra and H (e.g.
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): NH).
In an embodiment, the compound of formula (I) is a compound of formula (Id-I): PAT059456 FF According to a second aspect of the invention, there is hereby provided a compound selected from the group consisting of: 1) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 3) 2'-((3-(difluoromethyl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 4) methyl 4-((7'-((1 R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1 H-pyrazole-3-carboxylate; ) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1 H-pyrazol-5-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 6) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(hydroxymethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7) 7'-((1 R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 8) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydrofuran-3-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 9) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF ) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydro-2H-pyran-2-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 11) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((2-(methoxymethyl)-1 H-imidazol-5- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 12) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methoxy-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 13) 2'-((3-chloro-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 14) 2'-((3-cyclopropyl-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(trifluoromethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 16) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1-(2-methoxyethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 17) 7'-(3-hydroxycycloheptyl)-2'-((3-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 18) 7'-((1 R,3R)-3-hydroxycycloheptyl)-2'-((3-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 19) 2'-((3-chloro-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycycloheptyl)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-2'-yl)amino)-1 H-pyrazole-3-carbonitrile; 21) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(methoxymethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 22) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-methoxyethoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 23) 2'-((3-ethoxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF or a pharmaceutically acceptable salt and/or tautomer thereof.
In an embodiment, the compound is , or a pharmaceutically acceptablesalt and/or tautomer thereof.
In an embodiment, the compound isacceptable salt and/or tautomer thereof.
In an embodiment, the compound isacceptable salt and/or tautomer thereof.
In an embodiment, the compound is or a pharmaceuticallyacceptable salt and/or tautomer thereof.
In an embodiment, the compound is or a pharmaceuticallyacceptable salt and/or tautomer thereof.
PAT059456 FF In an embodiment, the compound isacceptable salt and/or tautomer thereof.
In an embodiment, the compound isacceptable salt and/or tautomer thereof.
In an embodiment, the compound issalt and/or tautomer thereof.
In an embodiment, the compound isacceptable salt and/or tautomer thereof.
In an embodiment, the compound is or a pharmaceutically or a pharmaceutically , or a pharmaceutically acceptable or a pharmaceutically or a pharmaceuticallyacceptable salt and/or tautomer thereof.
PAT059456 FF In an embodiment, the compound is acceptable salt and/or tautomer thereof.
According to a third aspect of the invention there is hereby provided a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first of the second aspect of the invention and one or more pharmaceutically acceptable carriers.
According to a fourth aspect of the invention there is hereby provided a combination comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention, and one or more therapeutically active agents.
According to a fifth aspect of the invention there is hereby provided a method of modulating CDKactivity in a subject comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention.
According to a sixth aspect of the invention there is hereby provided a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention.
According to a seventh aspect of the invention there is hereby provided a compound orpharmaceutically acceptable salt and/or tautomer thereof according to the first or the secondaspect of the invention for use as a medicament.
According to an eighth aspect of the invention there is hereby provided a compound orpharmaceutically acceptable salt and/or tautomer thereof according to the first or the secondaspect of the invention for use in the treatment of cancer.
According to a ninth aspect of the invention there is hereby provided use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention in the treatment of cancer. or a pharmaceutically PAT059456 FF According to a tenth aspect of the invention there is hereby provided use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to the first or the second aspect of the invention in the manufacture of a medicament for the treatment of cancer.
In an embodiment (of the sixth, eighth, ninth or tenth aspects of the invention), the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
In an embodiment (of the sixth, eighth, ninth or tenth aspects of the invention), the cancer is a cyclin E amplified cancer.
The invention therefore provides the following numbered embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.
Embodiment 1. A compound according to formula (I), z (I); wherein: Y1 is a bond or CH2 (e.g. Y1 is a bond); Y2 is a bond, 0, NR5 or CR6R7 (e.g. Y2 is a bond); R1 and R2 are each independently selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl, or R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl (e.g. Rand R2 join together to form C3-C4cycloalkyl, e.g. R1 and R2 join together to form C3cycloalkyl); each R3 is independently selected from the group consisting of hydroxyl, halo, C1-C6alkyl and C1- Cshaloalkyl; R4 is selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl (e.g. R4 is H); R5 is selected from the group consisting of H, C1-C6alkyl, C(=O)-C1-C6alkyl orC(=O)-O-C1-C 6alkyl; R6 and R7 join together to form, together with the carbon atom to which they are mutually attached, a C3-C6cycloalkyl or a 3-6 membered heterocyclyl comprising 1-3 heteroatoms independently PAT059456 FF selected from the group consisting of 0, N and S, wherein said C3-C6cycloalkyl or 3-6 membered heterocyclyl is substituted with 0-3 substituents R8; each R8 is independently selected from the group consisting of C1-C6alkyl, C(=O)C1-C6alkyl, halo, C1-C6haloalkyl, S-C1-C6alkyl, SO-C1-C6alkyl, SO2-C1-C6alkyl, cyano, hydroxyl, or wherein two Rsubstituents on the same ring atom join together to form =0. n is 0 to 3 (e.g. n is 1, e.g. n is 1 and R3 is hydroxyl); m is 1 to 5 (e.g. m is 4); ( A )W is a 5 membered heteroaryl comprising 1 to 3 heteroatoms independently selected from N, and S (e.g. 2 heteroatoms independently selected from N, O and S, e.g. 2 heteroatoms which are both N), said 5 membered heteroaryl being substituted with 0 to 3 substituents RA; each RA is independently *L1-X1, wherein * indicates the point of attachment to , each L1 is independently selected from bond, O, S, SO, SO2, C=C, C(=0), *C(=O)-O**, C1-C6alkylene, 01- Cshaloalkylene, *O-C1-C6alkylene**, *O-C1-C6haloalkylene**, *O-C1-C6hydroxyalkylene**, 01- C6alkylene-O-C1-C 6alkylene, *O-C3-C6cycloalkylene**, *0-3-6 membered heterocyclylene**, 01- Czhydroxyalkylene, C3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising heteroatom which is 0), O-C1-C6alkylene-O, *O-C1-C6alkylene-O-C 3-C6cycloalkylene** and *0- O1-O6alkylene-O-3-6 membered heterocyclylene**, wherein * indicates the point of attachment to ( A )W, and ** indicates the point of attachment to X1; and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C(=0)-C1- C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl substituted by 0-3 R8 groups, O-C1-C6alkyl, S-C1-C6alkyl, S(O)-C1-C6alkyl, S(O)2-C1-C6alkyl, N(C1-C6alkyl) 2, C(=O)N(C1-C6alkyl) 2, C1-C6hydroxyalkyl, 3-membered heterocyclyl (e.g. comprising 1 or 2 heteroatoms independently selected from 0, N and S) substituted by 0-3 R8 groups, 5-10 membered heteroaryl (e.g. 5, 6, 9 or 10 membered heteroaryl) comprising 1-4 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups, 5-10 membered partially saturated heterocyclyl comprising 1 to 4 heteroatoms independently selected from the group consisting of O, N and S substituted by 0-3 R8 groups, 7- membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups and C7-C10spirocycloalkyl substituted by 0-3 R8 groups; PAT059456 FF or two RA substituents located on adjacent ring atoms join together to form with said adjacent ring atoms a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S, with the proviso that at least one heteroatom is N; or a pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 2. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 1, wherein Y1 is a bond.
Embodiment 3. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 1 or Embodiment 2, wherein Y2 is a bond.
Embodiment 4. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments, wherein m is 4.
Embodiment 5. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments, wherein n is 1 to 3, e.g. n is 1.
Embodiment 6. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 5, wherein at least one R3 is OH.
Embodiment 7. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 1, wherein the compound of formula (I) is a compound of formula (la): (la), wherein R1, R2, R3, R4 and are as defined in Embodiment 1.Embodiment 7a. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 7, wherein the compound of formula (la) is a compound of formula (la- I): PAT059456 FF are as defined in Embodiment 1.
Embodiment 8. The compound or pharmaceutically acceptable salt and/or tautomerthereof according to Embodiment 1, wherein the compound of formula (I) is a compound of formula (lb): (lb), wherein R1, R2, R3, R4 and are as defined in Embodiment 1.
Embodiment 8a. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiments, wherein the compound of formula (lb) is a compound of formula (lb- I): (Ib-I), wherein R3 and are as defined in Embodiment 1.
Embodiment 9. The compound or pharmaceutically acceptable salt and/or tautomer thereof according Embodiment 1, wherein the compound of formula (I) is a compound of formula (Ic): PAT059456 FF ( A )(Ic), wherein R1, R2, R3, R4 and W are as defined in Embodiment 1.
Embodiment 9a. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 9, wherein the compound of formula (Ic) is a compound of formula (Ic- I): are as defined in Embodiment 1.
Embodiment 10. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 1, wherein the compound of formula (I) is a compound offormula (Id): 0(Id), wherein R1, R2, R4 and are as defined in Embodiment 1.
Embodiment 10a. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 10, wherein the compound of formula (Id) is a compound of formula (Id-I): PAT059456 FF (Id-I), wherein Embodiment 11. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments, wherein R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl.
Embodiment 12. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 11, wherein R1 and R2join together to form C3-C4cycloalkyl.
Embodiment 13. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 12, wherein R1 and R2 join together to form C3cycloalkyl.
Embodiment 14. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments, wherein R4 is H.
Embodiment 15. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments, wherein is a 5 memberedheteroaryl comprising 2 heteroatoms independently selected from N, 0 and S, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined in any one of the preceding Embodiments.
Embodiment 16. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 15, wherein is a 5 membered heteroaryl comprising 2heteroatoms independently selected from N and O, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined in any one of the preceding Embodiments.
Embodiment 17. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 14, wherein is a 5 membered heteroarylcomprising 1 to 3 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined in any one of the preceding Embodiments.
PAT059456 FF Embodiment 18. The compound or pharmaceutically acceptable salt and/or tautomer ( A )thereof according to any one of the preceding Embodiments, wherein - is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 3 substituents RA, wherein RA is as defined in any one of the preceding Embodiments.
Embodiment 19. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments, wherein is a 5 memberedheteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 to 2 substituents RA, wherein RA is as defined in any one of the precedingEmbodiments.
Embodiment 20. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments, wherein VV is a 5 membered heteroaryl comprising 2 heteroatoms which are each N, said 5 membered heteroaryl being substituted with 0 or 1 substituent RA, wherein RA is *L1-X1, and L1 and X1 are as defined in any one of the preceding Embodiments.
Embodiment 21. The compound or pharmaceutically acceptable salt and/or tautomer (5thereof according to any one of Embodiments 1 to 14, wherein V-/ is selected from the group consisting of: PAT059456 FF Embodiment 22. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 14 and 21, wherein is selected from the group consisting of Embodiment 23. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 14, wherein is selected from the groupconsisting of: PAT059456 FF Ra Ra Ra Ra wherein X is selected from O, NH and S (e.g. X is NH).
Embodiment 24. The compound or pharmaceutically acceptable salt and/or tautomer 6thereof according to any one of Embodiments 1 to 14 and 22, wherein V.V is selected from the group consisting of: PAT059456 FF 533) H , 34) RA ,35) H , 36) 39) PAT059456 FF Embodiment 25. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 14 and 23, wherein is selected from thegroup consisting of: and wherein X is selected fromO, NHandS.
Embodiment 26. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 14 and 25, wherein is selected from thegroup consisting of: Embodiment 27. The compound or pharmaceutically acceptable salt and/or tautomerthereof according to any one of Embodiments 1 to 14 and 26, wherein: is selected from the group consisting of: ) and RA is selected andfrom a) halo, b) cyano, PAT059456 FF c) C1-C6alkyl, d) C1-C6haloalkyl, e) C1-C6hydroxyalkyl, f) O-C1-C6alkyl, g) C(=O)-O-C1-C6alkyl, h) C1-C6alkylene-O-C1-C 6alkyl, i) O-C1-C6alkylene-O-C1-C 6alkyl, j) C3-C6cycloalkyl substituted by 0-3 R8 groups, k) 5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, and S substituted by 0-3 R8 groups, I) 5-10 membered partially saturated heterocyclyl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, m) O-C3-C6cycloalkyl substituted by 0-3 R8 groups, n) C=C-5-10 membered heteroaryl comprising 1 -4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, 0) S-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N,O and S substituted by 0-3 R8 groups, p) C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, q) O-C1-C6haloalkyl, r) O-C1-C6alkylene-N(C1-C 6alkyl)2, s) O-C1-C6hydroxyalkylene-O-C1-C 6alkyl, t) O-C1-C6alkylene-C3-C 6cycloalkyl substituted by 0-3 R8 groups, u) O-C1-C6alkylene-3-6 membered heterocyclyl comprising 1 or 2 heteroatomsindependently selected from O, N and S substituted by 0-3 R8 groups, v) O-C1-C6alkylene-C(=O)-N(C1-C 6alkyl)2, PAT059456 FF w) C1-C6alkylene-5-10 membered partially saturated heterocyclyl comprising 1-heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, x) O-C1-C6alkylene-7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatomsindependently selected from 0, N and S substituted by 0-3 R8 groups, y) O-C1-C6alkylene-S(O)2-C1-C 6alkyl, z) O-C1-C6hydroxyalkyl, aa) O-C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independentlyselected from N, O and S substituted by 0-3 R8 groups, bb) 0-5-10 membered heteroaryl comprising 1 -4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, cc) 0-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from 0, N and S substituted by 0-3 R8 groups, dd) CEC-C3-C6cycloalkyl substituted by 0-3 R8 groups, ee) S-C1-C6haloalkyl, ff) O-C1-C6alkylene-O-3-6 membered heterocyclyl comprising 1 or 2 heteroatomsindependently selected from O, N and S substituted by 0-3 R8 groups gg) and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O andS substituted by 0-3 R8 groups; or (?) ii ) Wis Ra and the RA substituents join together to form, with the ring atoms to which they are attached, a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S.
Embodiment 27a. The compound or pharmaceutically acceptable salt and/or tautomer Cmthereof according to any one of Embodiments 1 to 14 and 26, wherein W is selected from the group consisting of: PAT059456 FF a) O-C1-C6haloalkylene-O-C1-C 6alkyl; b) hydroxyl; c) S-C1-C6alkyl; d) C1-C6alkylene-S-C1-C 6alkyl; and e) C=C-C1-C6alkyl.
Embodiment 28. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 27, wherein each R8 is independently selected from the group consisting of halo (e.g. fluoro), C1-C6alkyl (e.g. methyl), hydroxyl, cyano, S(O2)-C1-C6alkyl (e.g. S(02)CH3), C(=O)-C1-C6alkyl (e.g. C(=O)CH3), O-C1-C6alkyl (e.g. OCH3) and C1-C6haloalkyl (e.g. C1 haloalkyl, e.g. CHF2), or wherein two R8 substituents on the same ring atom join together to form =0.
Embodiment 29. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 27, wherein: i) is selected from the group consisting of: H , and RA is selected from halo, cyano, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, O-C1-C6alkyl, C(=O)-O-C1-C6alkyl, C1-C6alkylene-O- C1-C6alkyl, O-C1-C6alkylene-O-C1-C 6alkyl, C3-C6cycloalkyl and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S; or ii) is R" and the RA substituents join together to form, with the ring atoms to which they are attached, a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S.
PAT059456 FF Embodiment 29a. The compound or pharmaceutically acceptable salt and/or tautomer is a 5 membered heteroaryl thereof according to any one of Embodiments 1 to 14, wherein and S (e.g. X is NH).
Embodiment 29b. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 14, wherein is selected from the group Embodiment 30. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 14, 28 and 29, whereinRA is CH3, OCH2CH3 or OCH3.
Embodiment 31. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 27, wherein each L1 is independently selected from bond, 0, C(=O), *C(=O)-O**, C1-C6alkylene, C1-C6haloalkylene, *O-C1-C6alkylene**, C1-C6alkylene-O-C1-C 6alkylene, C1-C6hydroxyalkylene, C3-C6cycloalkylene, 3-6 memberedheterocyclylene (e.g. comprising 1 heteroatom which is 0) and O-C1-C6alkylene-O, wherein *indicates the point of attachment to and ** indicates the point of attachment to X1; PAT059456 FF and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, O-C1-C6alkyl, C1-C6hydroxyalkyl and 3-6 membered heterocyclyl (e.g. comprising 1 heteroatom that is 0).
Embodiment 31a. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 31, wherein each L1 is independently selected from bond, 0, C(=O), *C(=O)-O**, C1-C2alkylene, Cihaloalkylene, *O-C1-C2alkylene**, C1-C2alkylene-O- Cialkylene, C1-hydroxyalkylene, C3cycloalkylene, 5-6 membered heterocyclylene comprising ( A ) heteroatom which is 0 and O-C2alkylene-O, wherein *indicates the point of attachment to W, and ** indicates the point of attachment to X1.
Embodiment 31b. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 31 or Embodiment 31a, wherein each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C2alkyl (e.g. Cialkyl), C1 haloalkyl, C3cycloalkyl, O-C1- C2alkyl, C1 hydroxyalkyl and 5-6 membered heterocyclyl comprising 1 heteroatom that is 0.
Embodiment 32. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 27 and 31, wherein RA is selected from the list consisting of C1-C6alkyl, C1-C6alkylene-O-C1-C 6alkyl, C1-C6haloalkyl, C(=O)-O-C1-C6alkyl, C1- Czhydroxyalkyl, 3-6 membered heteroatom comprising 1 heteroatom that is 0, halo, O-C1-C6alkyl, C3-C6cycloalkyl, cyano and O-C1-C6alkylene-O-C1-C 6alkyl.
Embodiment 32a. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 32, wherein RA is selected from the list consisting of CH3, CH2CH2OCH3, OCH2CH3, CHF2, C(=O)-O-CH3, CH2OH, 5 membered heteroatom comprising heteroatom that is 0, 6 membered heteroatom comprising 1 heteroatom that is 0, CH2OCH3, OCH3, Cl, C3cycloalkyl, CF3, cyano, OCH2CH2OCH3 and OCH2CH3.
Embodiment 33. A compound selected from any one of 1) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 3) 2'-((3-(difluoromethyl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF 4) methyl 4-((7'-((1 R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1 H-pyrazole-3-carboxylate; ) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1 H-pyrazol-5-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 6) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(hydroxymethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7) 7'-((1 R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 8) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydrofuran-3-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 9) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydro-2H-pyran-2-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 11) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((2-(methoxymethyl)-1 H-imidazol-5- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 12) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methoxy-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 13) 2'-((3-chloro-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 14) 2'-((3-cyclopropyl-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(trifluoromethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 16) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1-(2-methoxyethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 17) 7'-(3-hydroxycycloheptyl)-2'-((3-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF 18) 7'-((1 R,3R)-3-hydroxycycloheptyl)-2'-((3-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 19) 2'-((3-chloro-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycycloheptyl)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-2'-yl)amino)-1 H-pyrazole-3-carbonitrile; 21) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(methoxymethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 22) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-methoxyethoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 23) 2'-((3-ethoxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; or a pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 33a. A compound selected from any one of: 24) 2'-((3-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 2'-((3-(((3S,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 26) 2'-((3-(((3R,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 27) 2'-((3-(((3S,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 28) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyridin-3-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 29) 2'-((3-(3,3-difluorocyclobutoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 2'-((3-(3,3-difluorocyclobutoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF 31) 2'-((5'-(difluoromethyl)-1 -methyl-1 H, 1 'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 32) 2'-((3-((S)-2,2-difluorocyclopropyl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 33) 2'-((3-((S)-2,2-difluorocyclopropyl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 34) 2'-((1'-(difluoromethyl)-1 H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; ) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-methyl-1 H-pyrazol-4-yl)oxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 36) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-ylethynyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 37) 2'-((1 ',5'-dimethyl-1 H, 1 'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 38) 2'-((3-(cyclopropylmethoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 39) 2'-((3-(2-fluoroethoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 40) 2'-((3-cyclobutoxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 41) 2'-((3-(2,2-difluoroethoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 42) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-hydroxyethoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 43) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-methyl-1 H-pyrazol-3-yl)methoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 44) 2'-((3-(2,2-difluoro-3-methoxypropoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF 45) 2'-((3-((1 -fluorocyclopropyl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 46) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)oxy)-1 H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 47) 2'-((3-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 48) 2'-((3-((3-fluorooxetan-3-yl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 49) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(methoxy-d3)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 50) 2'-((3-(((3R,4R)-4-fluoro-1 -methylpyrrolidin-3-yl)oxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 51) 2'-((3-(((3S,4S)-4-fluoro-1 -methylpyrrolidin-3-yl)oxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 52) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(methylthio)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 53) 2'-((3-((2-acetyl-2-azaspiro[3.3]heptan-6-yl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 54) 2'-((3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 55) 2'-((3-cyclopropoxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 56) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(2,2,2-trifluoroethoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 57)2'-((5'-chloro-1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 58) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(prop-1-yn-1-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF 59) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-4-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 60) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-2-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 61) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 62) 2'-((1'-(difluoromethyl)-5'-methyl-1 H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 63) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3-yl)oxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 64) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyrazin-3-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 65) 2'-((3-(((1 r,3R)-3-hydroxy-3-methylcyclobutyl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)- 3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 66) 2'-((3-(((R)-1,4-dioxan-2-yl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 67) 1-(((4-((7'-((1 R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1 H-pyrazol-3-yl)oxy)methyl)cyclopropane-1-carbonitrile; 68) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-((methylthio)methyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 69) 2'-((3-((S)-2,2-difluorocyclopropoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 70) 2'-((3-((R)-2,2-difluorocyclopropoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 71) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3-yl)methoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 72) 7’-((1 R,3R)-3-hydroxycyclohexyl)-2 ’-((3-(((S)-tetrahydrofuran-3-yl)methoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5 ’-pyrrolo[2,3-d]pyrimidin]-6 ’(7’H)-one; PAT059456 FF 73) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1 H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 74) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-((tetrahydro-2H-pyran-4-yl)oxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 75) 2'-((3-((-4-fluorotetrahydrofuran-3-yl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 76) 2'-((3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 77) 2'-((3-hydroxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one.; 78) 7’-((1 R,3R)-3-hydroxycyclohexyl)-2 ’-((3-(((S)-tetrahydrofuran-3-yl)oxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5 ’-pyrrolo[2,3-d]pyrimidin]-6 ’(7’H)-one; 79) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-1 H,1'H-[3,3'-bipyrazol]-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 80) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-1 H,1'H-[3,4'-bipyrazol]-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 81) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyrimidin-3-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 82) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-((1 r,3R)-3-methoxycyclobutoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 83) 2'-((3-(1,3,4-oxadiazol-2-yl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 84) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-5'-(trifluoromethyl)-1 H,1'H-[3,4'-bipyrazol]-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 85) 2'-((3-(1 -(fluoromethyl)cyclopropoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; or a pharmaceutically acceptable salt and/or tautomer thereof.
PAT059456 FF Embodiment 34. The compound according to Embodiment 1, wherein the compound is ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 35. The compound according to Embodiment 1, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 35a. The compound according to Embodiment 1, wherein the compound , ora pharmaceutically acceptable salt and/or tautomer thereof. is Embodiment 36. The compound according to Embodiment 1, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 36a. The compound according to Embodiment 1, wherein the compound or a pharmaceutically acceptable salt and/or tautomer thereof. is PAT059456 FF Embodiment 37. The compound according to Embodiment 1, wherein the compound is or a pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 37a. The compound according to Embodiment 1, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 38. The compound according to Embodiment 1, wherein the compound is or a pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 38a. The compound according to Embodiment 1, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 39. The compound according to Embodiment 1, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
PAT059456 FF Embodiment 39a. The compound according to Embodiment 1, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment 40. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding Embodiments and one or more pharmaceutically acceptable carriers.
Embodiment 41. A combination comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 39a, and one or more therapeutically active agents.
Embodiment 42. A method of modulating CDK2 activity in a subject comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments to 39a.
Embodiment 43. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 39a.
Embodiment 44. A compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 39a for use as a medicament.
Embodiment 45. A compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 39a for use in the treatment of cancer.
Embodiment 46. Use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 39a in the treatment of cancer.
Embodiment 47. Use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments 1 to 39a in the manufacture of a medicament for the treatment of cancer.
Embodiment 48. The method according to Embodiment 43, the compound for use according to Embodiment 45, or the use according to Embodiment 46 or Embodiment 47, wherein the cancer PAT059456 FF is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
Embodiment 49. The method according to Embodiment 43 or Embodiment 48, the compound for use according to Embodiment 45 or Embodiment 48, or the use according to any one of Embodiments 46 to 48, wherein the cancer is a cyclin E amplified cancer.
Further Embodiments of the Invention are defined below in Embodiments A to LL: Embodiment A. A compound according to formula (I), (I); wherein: Y1 is a bond or CH2 (e.g. Y1 is a bond); Y2 is a bond, 0, NR5 or CR6R7 (e.g. Y2 is a bond); R1 and R2 are each independently selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl, or R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl (e.g. Rand R2 join together to form C3-C4cycloalkyl, e.g. R1 and R2 join together to form C3cycloalkyl); each R3 is independently selected from the group consisting of hydroxyl, halo, C1-C6alkyl and C1- Cshaloalkyl; R4 is selected from the group consisting of H, halo, C1-C6alkyl and C1-C6haloalkyl (e.g. R4 is H); R5 is selected from the group consisting of H, C1-C6alkyl, C(=O)-C1-C6alkyl orC(=O)-O-C1-C 6alkyl; R6 and R7 join together to form, together with the carbon atom to which they are mutually attached, a C3-C6cycloalkyl or a 3-6 membered heterocyclyl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein said C3-C6cycloalkyl or 3-6 membered heterocyclyl is substituted with 0-3 substituents R8; each R8 is independently selected from the group consisting of C1-C6alkyl, C(=O)C1-C6alkyl, halo, C1-C6haloalkyl, S-C1-C6alkyl, SO-C1-C6alkyl, SO2-C1-C6alkyl, cyano, hydroxyl, or wherein two Rsubstituents on the same ring atom join together to form =0.
PAT059456 FF n is 0 to 3 (e.g. n is 1, e.g. n is 1 and R3 is hydroxyl); m is 1 to 5 (e.g. m is 4); is a 5 membered heteroaryl selected from the group consisting of 1) X ,2) wherein X is selected from O, NH and S; Aeach RA is independently *L1-X1, wherein * indicates the point of attachment to W, each L1 is independently selected from bond, 0, S, SO, SO2, C=C, C(=0), *C(=O)-O**, C1-C6alkylene, C1- Cshaloalkylene, *O-C1-C6alkylene**, *O-C1-C6haloalkylene**, *O-C1-C6hydroxyalkylene**, C1- C6alkylene-O-C1-C 6alkylene, *O-C3-C6cycloalkylene**, *0-3-6 membered heterocyclylene**, 01- Czhydroxyalkylene, C3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising heteroatom which is O), O-C1-C6alkylene-O, *O-C1-C6alkylene-O-C3-C 6cycloalkylene** and *O- C1-C6alkylene-O-3-6 membered heterocyclylene**, wherein * indicates the point of attachment to A )-V, and ** indicates the point of attachment to X1; and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C(=O)-C1- C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl substituted by 0-3 R8 groups, O-C1-C6alkyl, S-C1-C6alkyl, S(O)-C1-C6alkyl, S(O)2-C1-C6alkyl, N(C1-C6alkyl) 2, C(=O)N(C1-C6alkyl) 2, C1-C6hydroxyalkyl, 3-membered heterocyclyl (e.g. comprising 1 or 2 heteroatoms independently selected from O, N and S) substituted by 0-3 R8 groups, 5-10 membered heteroaryl (e.g. 5, 6, 9 or 10 membered heteroaryl) comprising 1-4 heteroatoms independently selected from O, N and S substituted by 0-3 R8 groups, 5-10 membered partially saturated heterocyclyl comprising 1 to 4 heteroatoms independently selected from the group consisting of O, N and S substituted by 0-3 R8 groups, 7- PAT059456 FF membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from 0, N and S substituted by 0-3 R8 groups and C7-C10spirocycloalkyl substituted by 0-3 R8 groups; or two RA substituents located on adjacent ring atoms join together to form with said adjacent ring atoms a 4 to 6 membered heterocyclyl comprising 1 to 3 heteroatoms independently selected from N, O and S, with the proviso that at least one heteroatom is N; or a pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment B. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment A, wherein Y1 is a bond.
Embodiment C. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment A or Embodiment B, wherein Y2 is a bond.
Embodiment D. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to C, wherein m is 4.
Embodiment E. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to D, wherein n is 1 to 3, e.g. n is 1.
Embodiment F. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment E, wherein at least one R3 is OH.
Embodiment G. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment A, wherein the compound of formula (I) is a compound of formula (la): (la), wherein R1, R2, R3, R4 and are as defined in Embodiment A.Embodiment Ga. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment G, wherein the compound of formula (la) is a compound of formula (la- I): PAT059456 FF -OH (la-l), wherein R3 and are as defined in Embodiment A.
Embodiment H. The compound or pharmaceutically acceptable salt and/or tautomerthereof according to Embodiment A, wherein the compound of formula (I) is a compound offormula (lb): (lb), wherein R1, R2, R3, R4 and are as defined in Embodiment A.
Embodiment Ha. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment H, wherein the compound of formula (lb) is a compound of formula (lb- I): (Ib-I), wherein R3 and are as defined in Embodiment A.
Embodiment !.The compound or pharmaceutically acceptable salt and/or tautomer thereof according Embodiment A, wherein the compound of formula (I) is a compound of formula (Ic): PAT059456 FF ( A )(Ic), wherein R1, R2, R3, R4 and W are as defined in Embodiment A.
Embodiment la. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment I, wherein the compound of formula (Ic) is a compound of formula (Ic- I): are as defined in Embodiment A.
Embodiment J. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment 1, wherein the compound of formula (I) is a compound offormula (Id): 0(Id), wherein R1, R2, R4 and are as defined in Embodiment A.
Embodiment Ja. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment J, wherein the compound of formula (Id) is a compound of formula (Id- I): PAT059456 FF (Id-I), wherein is as defined in Embodiment A.
Embodiment K. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to Ja, wherein R1 and R2 join together to form C3-C4cycloalkyl or C3-C4cyclohaloalkyl.
Embodiment L. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment K, wherein R1 and R2 join together to form C3-C4cycloalkyl.
Embodiment M. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment L, wherein R1 and R2 join together to form C3cycloalkyl.
Embodiment N. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to M, wherein R4 is H.
Embodiment O. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to N, wherein X is NH.
Embodiment P. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to 0, wherein V-V is selected from the group consisting of R" and H Embodiment Q. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment P, wherein Embodiment R. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment Q, wherein RA is selected from a) halo, PAT059456 FF b) cyano, c) C1-C6alkyl, d) C1-C6haloalkyl, e) C1-C6hydroxyalkyl, f) O-C1-C6alkyl, g) C(=O)-O-C1-C6alkyl, b) C1-C6alkylene-O-C1-C 6alkyl, i) O-C1-C6alkylene-O-C1-C 6alkyl, j) C3-C6cycloalkyl substituted by 0-3 R8 groups, k) 5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, and S substituted by 0-3 R8 groups, I) 5-10 membered partially saturated heterocyclyl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, m) O-C3-C6cycloalkyl substituted by 0-3 R8 groups, n) C=C-5-10 membered heteroaryl comprising 1 -4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, 0) S-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N,O and S substituted by 0-3 R8 groups, p) C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, q) O-C1-C6haloalkyl, r) O-C1-C6alkylene-N(C1-C 6alkyl)2, s) O-C1-C6hydroxyalkylene-O-C1-C 6alkyl, t) O-C1-C6alkylene-C3-C 6cycloalkyl substituted by 0-3 R8 groups, u) O-C1-C6alkylene-3-6 membered heterocyclyl comprising 1 or 2 heteroatomsindependently selected from O, N and S substituted by 0-3 R8 groups, PAT059456 FF v) O-C1-C6alkylene-C(=O)-N(C1-C 6alkyl)2, w) C1-C6alkylene-5-10 membered partially saturated heterocyclyl comprising 1-4heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, x) O-C1-C6alkylene-7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatomsindependently selected from 0, N and S substituted by 0-3 R8 groups, y) O-C1-C6alkylene-S(O)2-C1-C 6alkyl, z) O-C1-C6hydroxyalkyl, aa) O-C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independentlyselected from N, O and S substituted by 0-3 R8 groups, bb) 0-5-10 membered heteroaryl comprising 1 -4 heteroatoms independently selected from N, O and S substituted by 0-3 R8 groups, cc) 0-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from 0, N and S substituted by 0-3 R8 groups, dd) CEC-C3-C6cycloalkyl substituted by 0-3 R8 groups, ee) S-C1-C6haloalkyl, ff) O-C1-C6alkylene-O-3-6 membered heterocyclyl comprising 1 or 2 heteroatomsindependently selected from O, N and S substituted by 0-3 R8 groups gg) and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S substituted by 0-3 R8 groups.
Embodiment S. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment R, wherein each R8 is independently selected from the group consisting of halo (e.g. fluoro), C1-C6alkyl (e.g. methyl), hydroxyl, cyano, S(O2)-C1-C6alkyl (e.g. S(02)CH3), C(=O)-C1-C6alkyl (e.g. C(=O)CH3), O-C1-C6alkyl (e.g. OCH3) and C1-C6haloalkyl (e.g. C1 haloalkyl, e.g. CHF2), or wherein two R8 substituents on the same ring atom join together to form =0.
PAT059456 FF Embodiment T. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to S, wherein H and RA is CH3,OCH3 orOCH2CH3 Embodiment U. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to R, wherein each L1 is independently selected from bond, 0, C(=O), *C(=O)-O**, C1-C6alkylene, C1-C6haloalkylene, *O-C1-C6alkylene**, C1- C6alkylene-O-C1-C 6alkylene, C1-C6hydroxyalkylene, C3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising 1 heteroatom which is 0) and O-C1-C6alkylene-O, wherein( A )*i ndicates the point of attachment to , and ** indicates the point of attachment to X1; and each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, O-C1-C6alkyl, C1-C6hydroxyalkyl and 3-6 membered heterocyclyl (e.g. comprising 1 heteroatom that is 0).
Embodiment Ua. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment U, wherein each L1 is independently selected from bond, 0, C(=0), *C(=O)-O**, C1-C2alkylene, Cihaloalkylene, *O-C1-C2alkylene**, C1-C2alkylene-O- Cialkylene, C1-hydroxyalkylene, C3cycloalkylene, 5-6 membered heterocyclylene comprising Aheteroatom which is 0 and O-C2alkylene-O, wherein *indicates the point of attachment to W, and ** indicates the point of attachment to X1.
Embodiment Ub. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment U or Embodiment Ua, wherein each X1 is independently selected from H, halo, cyano, hydroxyl, C1-C2alkyl (e.g. Cialkyl), C1 haloalkyl, C3cycloalkyl, O-C1- C2alkyl, C1 hydroxyalkyl and 5-6 membered heterocyclyl comprising 1 heteroatom that is 0.
Embodiment V. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to R or Embodiment U, wherein RA is selected from the list consisting of C1-C6alkyl, C1-C6alkylene-O-C1-C 6alkyl, C1-C6haloalkyl, C(=O)-O-C1- C6alkyl, C1-C6hydroxyalkyl, 3-6 membered heteroatom comprising 1 heteroatom that is O, halo, O-C1-C6alkyl, C3-C6cycloalkyl, cyano and O-C1-C6alkylene-O-C1-C 6alkyl.
PAT059456 FF Embodiment Va. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to Embodiment V, wherein RA is selected from the list consisting of CH3, OCH2CH3, CH2CH2OCH3, CHF2, C(=O)-O-CH3, CH2OH, 5 membered heteroatom comprising heteroatom that is 0, 6 membered heteroatom comprising 1 heteroatom that is 0, CH2OCH3, OCH3, Cl, C3cycloalkyl, CF3, cyano, OCH2CH2OCH3 and OCH2CH3.
Embodiment W. A compound selected from any one of: 1) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;2) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1-(2-methoxyethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;3) 2'-((3-(difluoromethyl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;4) methyl 4-((7'-((1 R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1 H-pyrazole-3-carboxylate;5) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(hydroxymethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;6) 7'-((1 R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;7) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydrofuran-3-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;8) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;9) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydro-2H-pyran-2-yl)-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;10) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methoxy-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;11) 2'-((3-chloro-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;12) 2'-((3-cyclopropyl-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;13) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(trifluoromethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456 FF 14) 4-((7'-((1 R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1 H-pyrazole-3-carbonitrile;15) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(methoxymethyl)-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;16) 7'-((1 R,3R)-3-hydroxycycloheptyl)-2'-((3-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;17) 7'-((1 R,3R)-3-hydroxycycloheptyl)-2'-((3-methoxy-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;18) 2'-((3-chloro-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycycloheptyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one;19) 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-methoxyethoxy)-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; and20) 2'-((3-ethoxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; or a pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment X. The compound according to Embodiment A, wherein the compound is or a pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment Y. The compound according to Embodiment A, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
PAT059456 FF Embodiment Z The compound according to Embodiment A, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment AA. The compound according to Embodiment A, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment BB. The compound according to Embodiment A, wherein the compound is , ora pharmaceutically acceptable salt and/or tautomer thereof.
Embodiment CC. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB, and one or more pharmaceutically acceptable carriers.
Embodiment DD. A combination comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB, and one or more therapeutically active agents.
Embodiment EE. A method of modulating CDK2 activity in a subject comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB.
Embodiment FF. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB.
PAT059456 FF Embodiment GG. A compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB for use as a medicament.
Embodiment HH. A compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB for use in the treatment of cancer.
Embodiment II. Use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB in the treatment of cancer.
Embodiment JJ. Use of the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of Embodiments A to BB in the manufacture of a medicament for the treatment of cancer.
Embodiment KK. The method according to Embodiment FF, the compound for use according to Embodiment HH, or the use according to Embodiment II or Embodiment JJ, wherein the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
Embodiment LL. The method according to Embodiment FF or Embodiment KK, the compound for use according to Embodiment HH or Embodiment KK, or the use according to any one of Embodiments II to KK, wherein the cancer is a cyclin E amplified cancer.
Definitions For the purpose of interpreting this specification, the following definitions will apply unless specified otherwise and when appropriate, terms used in the singular will also include the plural and vice versa. It must be noted that as used herein and in the appended claims, the singular forms "a", "an" and "the" include the plural unless the context clearly dictates otherwise. Thus, for example, reference to "the compound" includes reference to one or more compounds, and so forth.
As used herein, the term "substituent " refers to a radical group which replaces a hydrogen atom in a given molecule. In groups such as H , a hydrogen atom is (necessarily) shown explicitly in the structure on a heteroatom. The substituent (in this case, RA) can be replace any PAT059456 FF As used herein, the term "alkyl " refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, and which is attached to the rest of the molecule by a single bond. For instance, C1-C6alkyl contains from 1 to carbon atoms. Examples of C1-C6alkyl include, but are not limited to, methyl (Me), ethyl (Et), n- propyl, 1-methylethyl (iso-propyl), n-butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, 2- methylpentyl, 3-methylpentyl, 2,3-dimethylbutyl and 2,2-dimethylbutyl.
As used herein, the term "halogen ", "halo ", "hal ", etc. refers to fluorine, chlorine, bromine or iodine. Halogen-substituted groups and moieties, such as alkyl substituted by halogen (haloalkyl) can be mono-, poly- or per-halogenated.
As used herein, the term "haloalkyl " refers to an alkyl radical as defined herein, wherein one or more of the hydrogen atoms of said alkyl has been replaced with a halogen atom. Particularly said one or more halogen atom(s) are each fluorine atom(s), in which case the "haloalkyl " is a "fluoroalkyl ". For instance, C1-C6haloalkyl contains from 1 to 6 carbon atoms (and 1 or more halogen atoms).
As used herein, the term "hydroxyalkyl " refers to an alkyl radical as defined herein, wherein one or more of the hydrogen atoms of said alkyl has been replaced with a hydroxyl group. For instance, C1-C6hydroxyalkyl contains from 1 to 6 carbon atoms (and 1 or more hydroxyl groups).
As used herein, the term "alkylene " refers to a straight-chain or branched divalent radical of an alkyl group. For instance, "C1-C4alkylene " contains from 1 to 4 carbon atoms e.g., -CH2-, - CH2CH2-, -CH2CH2CH2-, -CH(CH3)2-, -CH2CH(CH3)CH2-.
PAT059456 FF Likewise, as used herein, the term "haloalkylene" refers to a straight-chain or branched divalent radical of a haloalkyl group.
As used herein, the term "cycloalkyl " refers to a saturated carbocyclic ring radical. C3-C6cycloalkyl for instance, is any such ring radical containing 3 to 6 carbon atoms, and is particularly monocyclic i.e. cyclobutyl, cyclopentyl and cyclohexyl. However, the cycloalkyl (e.g. C3-C6cycloalkyl) can also be a fused (e.g. 5 v ) or bridged (e.g. ’ ) bicyclic ring system.
The term "cycloalkylene " refers to a divalent radical of a cycloalkyl group.
As used herein, the term "cyclohaloalkyl " refers to a cycloalkyl radical as defined herein, wherein one or more of the hydrogen atoms of said cycloalkyl has been replaced with a halogen atom. Particularly said one or more halogen atom(s) are each fluorine atom(s), in which case the "cyclohaloalkyl " is a "cyclofluoroalkyl ". As with cycloalkyls, a cyclohaloalkyl can be a fused or bridged bicyclic ring system.
As used herein, the term "heterocyclyl", "heterocycle ", "heterocyclic " etc. refers to a heterocyclic radical that is saturated or partially unsaturated but not aromatic, and can be a monocyclic or a polycyclic ring, including a fused or bridged bicyclic ring system. Particularly, however, the heterocyclyl is a monocyclic ring. A heterocyclyl contains at least one non-carbon atom as a ring member, typically nitrogen, oxygen or sulfur unless otherwise specified, the remaining ring atoms therefore being carbon. Preferably the number of heteroatoms in the heterocyclyl is from 1 to 3, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. Where a heterocyclyl contains S as a heteroatom, the S can be in the form of S, SO orSO 2 (in other words, the oxygen atoms bonded to the sulphur do not constitute substitutions). For example, the term "4-6 membered heterocyclyl comprising 1 heteroatom selected from the group consisting of O, N and S" refers to a ring radical containing 4 to 6 ring atoms comprising 1 heteroatom (either 0, N, orS [the latter including S, SO and SO2]), with the remaining ring atoms being carbon.
The term "heterocyclylene" refers to a divalent radical of a heterocyclyl group.
PAT059456 FF As used herein, the term "O-alkyl" refers to an alkyl radical as defined herein, which is attached to the rest of the molecule via an O linker. An example is OCH3.
As used herein, the term "O-haloalky! " refers to a haloalkyl radical as defined herein, which is attached to the rest of the molecule via an O linker. An example is OCF3.
As used herein, the term "alkylene-O-alkyl" refers to an alkyl radical as defined herein, wherein one of the hydrogen atoms of said alkyl radical has been replaced with -O-alkylene- (attached to the alkyl radical through the oxygen). An example is "C1alkylene-O-C1-alkyl ", i.e. -CH2-O-CH3.
The term "5-10 membered heteroaryl " is a monocyclic or bicyclic aromatic ring radical containing to 10 ring atoms (e.g. 9 or 10 ring atoms in a bicyclic aromatic ring radical) which, unless otherwise stated, comprises 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur in the ring radical.
The term "5 membered heteroaryl " is a monocyclic aromatic ring radical which, unless otherwise stated, comprises 1,2 or 3 heteroatoms (preferably 2) individually selected from nitrogen, oxygen and sulfur (which can be in the form of S, SO orSO 2, particularly S) in the ring radical. Preferably, at least one of the heteroatoms in the 5 membered heteroaryl is nitrogen. Preferably, there are two heteroatoms in the 5 membered heteroaryl, at least one of which is nitrogen. Most preferably, there are two heteroatoms in the 5 membered heteroaryl, both of which are nitrogen.
As used herein, the term "partially saturated heterocycly!" is intended to include partially saturated monocyclic, bicyclic or polycyclic heterocyclyls containing one or more heteroatoms selected O, N, and S (S where present may be in the form of S, SO or SO2). Representative examples are imidazolinyl, indolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, dihydrobenzopyranyl, dihydropyridooxazinyl, dihydrobenzodioxinyl (e.g., 2,3-dihydrobenzo[b][1,4]dioxinyl), benzodioxolyl (e.g., benzo[d][1,3]dioxole), dihydrobenzooxazinyl (e.g., 3,4-dihydro-2H- benzo[b][1,4]oxazine), tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydroimidazo[4,5- c]pyridyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinoxalinyl, and the like. The term "5- to 10-membered partially saturated heterocycly!" is to be construed accordingly.
As used herein, the term "spiroheterocycly!", refers to ring system comprising a first carbocyclic or heterocyclic ring comprising from 3 to 6 ring atoms wherein two of the substituents on a carbon PAT059456 FF ring atom in said first carbocyclic or heterocyclic ring join together to form a second carbocyclic or heterocyclic ring comprising from 3 to 6 ring atoms, with the proviso that at least one of the first and second rings is a heterocyclic ring comprising one or more heteroatoms selected from the group consisting of 0, N and S (the latter can be in the form of S, SO or SO2), particularly selected from the group consisting of O and N. Particularly, the spiroheterocyclyl is saturated. The term 7- membered spiroheterocyclyl, as used herein means that the total number of ring atoms in the first carbocyclic or heterocyclic ring and the second carbocyclic or heterocyclic ring is from 7 to 9.I—For instance, the spiroheterocyclyl 8 is a 7 membered spiroheterocyclyl, as thereare 7 ring atoms present. As will be appreciated by the skilled person, a "spiroheterocyclyl " is a mono-radical, whereas a "spiroheterocyclylene" is a di-radical (analogous to alkyl and alkylene).
As used herein, the term "spirocycloalkyl " refers to a ring system comprising a first carbocyclic ring comprising from 3 to 6 ring carbon atoms, wherein two of the substituents on a carbon ring atom in said first carbocyclic ring join together to form a second carbocyclic ring comprising from to 6 ring carbon atoms. Particularly, the spirocycloalkyl is saturated. The term 6-8 membered spirocycloalkyl, as used herein means that the total number of carbon ring atoms in the first carbocyclic ring and the second carbocyclic ring is from 7 to 8. As will be appreciated by the skilled person a "spirocycloalkylene " is a di-radical equivalent to a "spirocycloalkyl ".
The term "two RA substituents located on adjacent ring atoms join together to form with said adjacent ring atoms a 4 to 6 membered heterocycly!" as used herein refers to (taking the example n /~rakA NHof R ) heterocycles such as '■—/ (in this example, a 6 membered heterocyclecontaining 2 heteroatoms which are both N).
Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible stereoisomers or as mixtures thereof, for example as pure optical isomers, or as stereoisomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms. The present invention is meant to include all such possible stereoisomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms. Optically active (R)- and (S)- stereoisomers may be prepared using chiral synthons PAT059456 FF or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included. Many compounds of the invention exhibit tautomerism. For instance can tautomerize to hn'Ntautomeric forms are within the scope of the claimed invention.
As used herein, the terms "salt " or "salts " refers to an acid addition or base addition salt of a compound of the present invention. "Salts " include in particular "pharmaceutical acceptable salts ". The term "pharmaceutically acceptable salts " refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. When both a basic group and an acid group are present in the same molecule, the compounds of the present invention may also form internal salts, e.g., zwitterionic molecules.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
PAT059456 FF Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
In another aspect, the present invention provides compounds of the present invention in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate trifenatate, trifluoroacetate or xinafoate salt form.
In another aspect, the present invention provides compounds of the present invention in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate trifenatate, trifluoroacetate or xinafoate salt form.
In another aspect, the present invention provides compounds according to any one of embodiments 1 to 39a, in sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, copper, isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine or tromethamine salt form.
Any formula given herein is also intended to represent unlabelled forms as well as isotopically labelled forms of the compounds. Isotopically labelled compounds have structures depicted by the formulae given herein except that one or more atoms are replaced by an atom having a PAT059456 FF selected atomic mass or mass number. Isotopes that can be incorporated into compounds of the invention include, for example, isotopes of hydrogen.
Further, incorporation of certain isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index or tolerability. It is understood that deuterium in this context is regarded as a substituent of a compound of the present invention. The concentration of deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted as being deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). It should be understood that the term "isotopic enrichment factor " can be applied to any isotope in the same manner as described for deuterium.
Other examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 3H, 11C, 130, 140, 1؛n, 18F, 31P, 32P, 35s, 36Cl, 123I, 124I, 125I respectively. Accordingly it should be understood that the invention includes compounds that incorporate one or more of any of the aforementioned isotopes, including for example, radioactive isotopes, such as 3H and 14C, or those into which non-radioactive isotopes, such as 2H and 13C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed. 100 PAT059456 FF PHARMACEUTICAL COMPOSITIONAs used herein, the term "pharmaceutical composition " refers to a compound of the invention, or a pharmaceutically acceptable salt and/or tautomer thereof, together with at least one pharmaceutically acceptable carrier, in a form suitable for oral or parenteral administration.
As used herein, the term "pharmaceutically acceptable carrier" refers to a substance useful in the preparation or use of a pharmaceutical composition and includes, for example, suitable diluents, solvents, dispersion media, surfactants, antioxidants, preservatives, isotonic agents, buffering agents, emulsifiers, absorption delaying agents, salts, drug stabilizers, binders, excipients, disintegration agents, lubricants, wetting agents, sweetening agents, flavoring agents, dyes, and combinations thereof, as would be known to those skilled in the art (see, for example, Remington The Science and Practice of Pharmacy, 22nd Ed. Pharmaceutical Press, 2013, pp. 1049-1070).
The term "a therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "a therapeutically effective amount " refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by CDK2, or (ii) associated with CDK2 activity, or (iii) characterized by activity (normal or abnormal) of CDK2; or (2) reduce or inhibit the activity of CDK2; or (3) reduce or inhibit the expression of CDK2. In another non-limiting embodiment, the term "a therapeutically effective amount " refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective in at least partially reducing or inhibiting the activity of CDK2; or at least partially reducing or inhibiting the expression of CDK2.
As used herein, the term "subject " refers to primates (e.g., humans, male orfemale), dogs, rabbits, guinea pigs, pigs, rats and mice. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
As used herein, the term "inhibit ", "inhibition" or "inhibiting " refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process. 101 PAT059456 FF As used herein, the term "treat ", "treating" or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the development of the disease or at least one of the clinical symptoms thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those which may not be discernible to the patient.
As used herein, the term "prevent ", "preventing " or "prevention " of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.
As used herein, a subject is "in need of " a treatment if such subject would benefit biologically, medically, or in quality of life from such treatment.
As used herein, the term "a", "an ", "the " and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as ") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (/?)-, (S)- or (R,S)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
Accordingly, as used herein a compound of the present invention can be in the form of one of the possible stereoisomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) stereoisomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization. 102 PAT059456 FF Any resulting racemates of compounds of the present invention or of intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O, 0 '-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor- 10-sulfonic acid. Racemic compounds of the present invention or racemic intermediates can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as ") provided herein is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
The compounds of the present application can be prepared by those skilled in the art of organic synthesis using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled chemist in light of the teachings herein.
The compounds of Formula (I) may be prepared by methods as set forth in the following synthetic reaction schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis as described for example in Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons: New York, 1999 or Protecting Groups, 3rd edition, Thieme, Stuttgart, 2004. Protective groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
Those skilled in the art will recognize if a stereocentre exists in the compounds disclosed herein. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994). 103 PAT059456 FF Compounds of the present disclosure can be synthesized by following the steps outlined in Scheme 1. Starting materials are either commercially available or made by known procedures in the reported literature or as illustrated.
The invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure material. Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art.
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, ora pharmaceutically acceptable salt and/or tautomer thereof, and a pharmaceutically acceptable carrier. In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration (e.g. by injection, infusion, transdermal or topical administration), and rectal administration. Topical administration may also pertain to inhalation or intranasal application. The pharmaceutical compositions of the present invention can be made up in a solid form (including, without limitation, capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including, without limitation, solutions, suspensions or emulsions). Tablets may be either film coated or enteric coated according to methods known in the art. Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of: a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and e) absorbents, colorants, flavors and sweeteners. 104 PAT059456 FF METHODS OF USE OF THE INVENTIONThe compounds of formula (I), in free form or in pharmaceutically acceptable salt form and/or tautomeric form, exhibit valuable pharmacological properties, for example CDK2 modulating properties, for example as indicated in in vitro tests as provided in the next sections, and are therefore indicated for therapy or for use as research chemicals, e.g. as tool compounds.
Compounds of the invention may be useful in the treatment, or prevention of cancer. In an embodiment, the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
Thus, as a further aspect, the present invention provides the use of a compound of formula (I), (in particular according to any one of embodiments 1 to 39a), or a pharmaceutically acceptable salt and/or tautomer thereof, in therapy. In a further embodiment, the therapy is treatment of a disease, disorder or condition which may be treated by inhibition of CDK2. In another embodiment, the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
Thus, as a further aspect, the present invention provides a compound of formula (I), (in particular according to any one of embodiments 1 to 39a), or a pharmaceutically acceptable salt and/or tautomer thereof, for use in therapy. In a further embodiment, the therapy is selected from a disease which may be treated by inhibition of CDK2. In another embodiment, the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
In another aspect, the invention provides a method of treating, or preventing a disease which is treated by inhibiting CDK2 comprising administration of a therapeutically effective amount of a compound of any one of formula (I) (in particular according to any one of embodiments 1 to 39a), or a pharmaceutically acceptable salt and/or tautomer thereof. In a further embodiment, the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
Thus, as a further aspect, the present invention provides the use of a compound of any one of formula (I) (in particular according to any one of embodiments 1 to 39a), or a pharmaceutically acceptable salt and/or tautomer thereof, for the manufacture of a medicament. In a further embodiment, the medicament is for treatment, or prevention of a disease, which may be treated 105 PAT059456 FF by inhibition of CDK2. In another embodiment, the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
The pharmaceutical composition or combination of the present invention may, for example, be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
COMBINATION PRODUCT AND COMBINATION THERAPY OF THE INVENTION"Combination " refers to either a fixed combination in one dosage unit form, or a combined administration where a compound of the present invention and a combination partner (e.g. another drug as explained below, also referred to as "therapeutic agent " or "co-agent ") may be administered independently at the same time or separately within time intervals, especially where these time intervals allow for the combination partners to have a cooperative, e.g. synergistic effect. The single components may be packaged in a kit or separately. One or both of the components (e.g. powders or liquids) may be reconstituted or diluted to a desired dose prior to administration. The terms "co-administration " or "combined administration " or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The term "pharmaceutical combination " as used herein means a product that results from the mixing or combining of more than one therapeutic agent and includes both fixed and non- fixed combinations of the therapeutic agents. The term "fixed combination " means that the therapeutic agents, e.g. a compound of the present invention and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non- fixed combination " means that the therapeutic agents, e.g. a compound of the present invention and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the 106 PAT059456 FF patient. The latter also applies to cocktail therapy, e.g. the administration of three or more therapeutic agents.
The term "pharmaceutical combination " as used herein refers to either a fixed combination in one dosage unit form, or non-fixed combination or a kit of parts for the combined administration where two or more therapeutic agents may be administered independently at the same time or separately within time intervals, especially where these time intervals allow for the combination partners to have a cooperative, e.g. synergistic effect.
The term "combination therapy" refers to the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients. Alternatively, such administration encompasses co-administration in multiple, or in separate containers (e.g. tablets, capsules, powders, and liquids) for each active ingredient. Powders and/or liquids may be reconstituted or diluted to a desired dose prior to administration. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
The compounds of the present invention may be administered either simultaneously with, or before, or after, one or more other therapeutic agent. The compounds of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents. A therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the invention.
Thus, in another aspect, the invention provides a combination, in particular a pharmaceutical combination, comprising (e.g. a therapeutically effective amount of) a compound of formula (I) in particular according to any one of embodiments 1 to 39a), or a pharmaceutically acceptable salt and/or tautomer thereof, and one or more other therapeutically active agents.
In one embodiment, the invention provides a product comprising a compound of formula (I) in particular according to any one of embodiments 1 to 39a), or a pharmaceutically acceptable salt 107 PAT059456 FF and/or tautomer thereof, and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
In one embodiment, the therapy is the treatment, or prevention of a disease or condition mediated by CDK2. Products provided as a combined preparation include a composition comprising a compound of formula (I) a pharmaceutically acceptable salt and/or tautomer thereof, and the other therapeutic agent(s) together in the same pharmaceutical composition, ora compound of formula (I) or a pharmaceutically acceptable salt and/or tautomer thereof, and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
In one embodiment, the invention provides a pharmaceutical combination comprising a compound of formula (I) (in particular according to any one of embodiments 1 to 39a), ora pharmaceutically acceptable salt and/or tautomer thereof, and another therapeutic agent(s). Optionally, the pharmaceutical combination may comprise a pharmaceutically acceptable carrier, as described above.
In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) (in particular according to any one of embodiments 1 to 39a), or a pharmaceutically acceptable salt and/or tautomer thereof. In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
EXAMPLES The disclosure is further illustrated by the following examples and synthetic methods, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
The compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples. All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesise the compounds of the present invention are either commercially available or can be produced by 108 PAT059456 FF organic synthesis methods known to one of ordinary skill in the art. In all of the methods it is understood that protecting groups for sensitive or reactive groups may be employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (2014) Protective Groups in Organic Synthesis, Sth edition, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. Unless otherwise noted, reagents and solvents were used as received from commercial suppliers.
The chemical names were generated using ChemDraw Professional v19.1.2.36 from PerkinElmer.
Temperatures are given in degrees Celsius. As used herein, unless specified otherwise, the term "room temperature " or "ambient temperature " means a temperature of from 15°C to 30°C, such as from 20°C to 30°C, such as from 20°C to 25°C. If not mentioned otherwise, all evaporations are performed under reduced pressure, typically between about 15 mm Hg and 100 mm Hg (= - 133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesize the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art.
In the following general methods, Y1, Y2, m, n, R1, R2, R3, R4 and are as previously definedin the above embodiments, or limited to designations in the Schemes. PG is a suitable protecting group. Unless otherwise stated, starting materials are either commercially available or are prepared by known methods.
LIST OF ABBREVIATIONS DIPEA (N,N-diisopropylethylamie)Boc (tert-butyl carbamate)IPA (isopropyl alcohol)NBS (N-bromosuccinimde)TEA (Triethylamine) 109 PAT059456 FF AcOH (Acetic Acid)DMF (N,N-dimethylformamide)NaH (Sodium hydride)ACN (Acetonitrile)THF (Tetrahydrofuran)TBDMSCI (tertbutyldimethylsilyl chloride)tBuOH (tert-butyl alcohol)SFC (Supercritical fluid chromatography)SEM (2-(Trimethylsilyl)ethoxymethyl)MeOH (Methanol)DIBAL-H (Diisobutylaluminum hydride)m-CPBA (meta-chloroperoxybenzoic acid)NaOtBu (Sodium tert-butoxide)NaOAc (Sodium acetate)NaBH4 (Sodium borohydride)NH4CI (ammonium chloride)Mel (Methyliodide)CS2CO3 (Cesium Carbonate)EtOH (Ethanol)DMS (Dimethyl sulfate)AC2O (Acetic anhydride)Zn (Zinc) General synthetic schemes The examples were prepared as shown in Scheme 1 (5 membered rings) or Scheme 2 (membered rings). 110 PAT059456 FF Scheme 1 where Y1 is a bond 111 PAT059456 FF Scheme 2 R3 protected with TBS Intermediate 1 112 PAT059456 FF Experimental details of Intermediate! Step-1: Synthesis of (1R,3R)-3-((2-chloro-5-iodopyrimidin-4-yl)amino)cyclohexan-1-ol:To a stirred solution of (1R,3R)-3-aminocyclohexan-1-ol hydrochloride (60 g, 397.3 mmol) and DIPEA (183 mb, 993.25 mmol) in isopropanol (300 ml), was added 2,4-dichloro-5-iodopyrimidine (108 g, 397.3 mmol) at room temperature and stirred for 16h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the solvent was removed under reduced pressure to give the crude product. The crude compound was purified by column chromatography by using silica gel (100-2mesh), eluting with 0-40% ethyl acetate in pet-etherto give (1R,3R)-3-((2-chloro-5-iodopyrimidin-4- yl)amino)cyclohexan-1-ol (113 g, 81% yield, regio-isomeric mixture; 82% and 15% isomers) as pale yellow solid. LC-MSm/z [M+H]+ = 353.98, 1H NMR (400 MHz, DMSO-d6)6 = 8.28-8.40 (m, 1H), 6.58 (d, J= 8.4 Hz, 1H), 4.50-4.51 (m, 1H), 4.25-4.30 (m, 1H), 3.90-4.20 (m, 1H), 1.71-1.80 (m, 4H), 1.20-1.70 (m, 5H).
Step-2: Synthesis of (1R,3R)-3-((2-chloro-5-((trimethylsilyl)ethynyl)pyrimidin-4- yl)amino)cyclohexan-1-ol:To a degassed solution of (1R,3R)-3-((2-chloro-5-iodopyrimidin-4- yl)amino)cyclohexan-1-ol (56.5 g, 160.5 mmol; 82% and 15% isomers), Cui (3.04 g, 16.0 mmol), triethyl amine (115 mL, 800 mmol) and Pd(PPh3)4 (1.84 g, 1.60 mmol) in dry THF (560 mL), was added trimethylsilyl acetylene (22.7 mL, 160.5 mmol) and heated at 55 °C for4h. The progress of the reaction was monitored by TLC & LCMS. After completion of the reaction, the reaction mass was filtered through plug of eelite, the filtrate was concentrated under reduced pressure to give the crude product. The crude compound was purified by column chromatography using silica gel (100-200 mesh), eluting with 0-20% ethyl acetate in pet-etherto give (1R,3R)-3-((2-chloro-5-((trimethylsilyl)ethynyl)pyrimidin-4- yl)amino)cyclohexan-1-ol (35 g, 68%) as pale yellow solid. LC-MSm/z [M+H]+ = 325.66, 1H NMR (400 MHz, DMSO-d6)6 = 8.16 (s, 1H), 6.48 (d, J = 8.0 Hz, 1H), 4.55 (d, J = 2.80 Hz, 1H), 4.25-4.40 (m, 1H), 3.90-4.0 (m, 1H), 1.61-1.85 (m, 4H), 1.30-1.60 (m, 4H), 0.26 (s, 9H).
Step-3: Synthesis of (1R,3R)-3-(2-chloro-7H-pyrrolo[2,3-d] pyrimidin-7-yl) cyclohexan-1-ol:To a stirred solution of (1R,3R)-3-((2-chloro-5-((trimethylsilyl)ethynyl)pyrimidin-4-yl)amino)cyclohexan-1-ol (g, 136.2 mmol) in acetonitrile (2,200 mL), was added C52CO3 (22.1 g, 68.1 mmol) and heated at 75 °C for h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered, the filtrate was concentrated under reduced pressure to give crude product. The crude compound was purified by column chromatography using silica gel (100-200 mesh), eluting with 0-50% ethyl acetate in pet-etherto give (1R,3R)-3-(2-chloro-7H-pyrrolo[2,3-d] pyrimidin-7-yl) cyclohexan-1-ol ( 113 PAT059456 FF g, 85% yield) as pale yellow solid; LC-MSm/z [M+H]+ = 252.17, 1H NMR (400 MHz, DMSO-d6)6 = 8.(s, 1H), 7.82 (d, J = 3.6 Hz, 1H), 6.70 (d, J = 3.6 Hz, 1H), 4.75 (d, J = 2.8 Hz, 1H), 4.15 (d, J = 2.4 Hz, 1H), 2.01-2.11 (m, 1H), 1.40-1.99 (m, 7H).
Step-4: Synthesis of 7-((1R,3R)-3-((tert-butyldimethylsilyl) oxy)cyclohexyl)-2-chloro-7H-pyrrolo[2,3- d]pyrimidine:To a stirred solution of (1R,3R)-3-(2-chloro-7H-pyrrolo[2,3-d] pyrimidin-7-yl) cyclohexan-1- ol (20 g, 79.68 mmol) and imidazole (10.8 g, 159.3 mmol) in DMF (200 mL), was added TBDMS-CI (18 g, 159.3 mmol) at room temperature and stirred for 16h. Progress of the reaction was monitored by TLC and LCMS. After, 16h, the reaction mass was quenched with ice-cold water (50 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with ice-cold water (2 x 60 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure. The crude compound was purified by column chromatography using silica gel (100-200 mesh), eluting with 0-50% ethyl acetate in pet-etherto give 7-((1R,3R)-3-((tert-butyldimethylsilyl) oxy)cyclohexyl)-2-chloro-7H-pyrrolo[2,3- d]pyrimidine (29 g, 96% yield) as brown gummy liquid. LC-MSm/z [M+H]+ =366.24, 1H NMR (400 MHz, DMSO-d6)6 = 8.88 (s, 1H), 7.79 (d, J = 3.6 Hz, 1H), 6.68 (d, J = 3.6 Hz, 1H), 4.95-5.10 (m, 1H), 4.27 (s, 1H), 1.96-2.05 (m, 1H), 1.80-1.95 (m, 4H), 1.64 (d, J = 8.0 Hz, 2H), 1.45-1.55 (m, 1H), 0.90-0.98 (m, 9H), 0.01-0.50 (m, 6H), Step-5: Synthesis of 5,5-dibromo-7-((1R,3R)-3-((tert-butyldimethylsilyl) oxy)cyclohexyl)-2-chloro- 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one: To a stirred solution of 7-((1R,3R)-3-((tert-butyldimethylsilyl) oxy)cyclohexyl)-2-chloro-7H-pyrrolo[2,3-d]pyrimidine (50 g, 136.9 mmol) in t-BuOH: H2O (600 mL, 4:1), was added NBS (73 g, 410.9 mmol) at room temperature and stirred for 4h. Progress of the reaction was monitored by TLC & LCMS. After completion of the reaction. The reaction mass was quenched with water (100 mL), extracted with MTBE (3 x 300 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to get the crude 5,5-dibromo-7-((1R,3R)-3-((tert-butyldimethylsilyl) oxy)cyclohexyl)-2-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one (73 g crude) as pale yellow semi- solid. The crude product was used as such for next step without further purification. LC-MSm/z [M+H]+ = 540.21 Step-6: Synthesis of 7-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2-chloro-5,7-dihydro-6H- pyrrolo[2,3-d]pyrimidin-6-one:To a stirred solution of 5,5-dibromo-7-((1R,3R)-3-((tert-butyldimethylsilyl) oxy)cyclohexyl)-2-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one (73g crude, 135.4 mmol) in AcOH (730 mL), was added Zn dust (44 g, 677.1 mmol) at room temperature and stirred for 1h. Progress of the reaction was monitored by TLC & LCMS. After completion of the reaction, the reaction mass was filtered through celite pad, the filtrate was diluted with ethyl acetate (500 mL) and washed with water (100 mL), the 114 PAT059456 FF organic layer was dried over Na2SO4, concentrated under reduced pressure to get the crude product. The crude product was purified by using column chromatography (silica gel, 100-200 mesh), eluting with 0-30% ethyl acetate: pet ether to give 7-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2-chloro-5,7-dihydro- 6H-pyrrolo[2,3-d]pyrimidin-6-one (33 g, 63% yield after 2 steps) as brown gummy liquid. LC-MS m/z [M+H]+ = 382.29, 1H NMR (400 MHz, DMSO-d6)6 = 8.25 (s, 1H), 4.58-4.68 (m, 1H), 4.26 (s, 1H), 3.63 (s, 2H), 2.30-2.40 (m, 1H), 2.10-2.21 (m, 1H), 1.55-1.80 (m, 5H), 1.45-1.50 (m, 1H), 0.91 (s, 9H), 0.01-0.(m, 6H).
Step-7: Synthesis of 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'- chlorospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one:To a stirred solution of 7-((1R,3R)- 3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one (11g, 28.87 mmol) and dibromoethane (7.4 mb, 86.61 mmol) in dry DMF (110 mb), was added NaH (60%, 3.4 g, 86.61 mmol) portion wise at room temperature and stirred for 4h. Progress of the reaction was monitored by TLC & LCMS. After completion of the reaction, the reaction was quenched sat.NH4CI, extracted with MTBE (3 x 100 mb). The organic layer was dried over Na2SO4, concentrated under reduced pressure to get the crude product. The crude product was purified by column chromatography (silica gel, 100-2mesh), eluting with 0-15% ethyl acetate in pet ether to give 7'-((1R,3R)-3-((tert- butyldimethylsilyl)oxy)cyclohexyl)-2'-chlorospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (g, 85% yield) as dark brown gummy liquid. LC-MSm/z [M+H]+ = 408.31, 1H NMR (400 MHz, DMSO-d6)= 8.16 (s, 1H), 4.65-4.75 (m, 1H), 4.26 (s, 1H), 3.58-3.62 (m, 1H), 2.30-2.42 (m, 1H), 2.15-2.25 (m, 1H), 1.81-1.91 (m, 2H), 1.55-1.80 (m, 7H), 1.55-1.80 (m, 7H), 0.91 (s, 9H), 1.39-1.49 (m, 1H), 0.04 (s, 6H).
Intermediate 2 was made using the method to generate intermediate 1, but starting from 115 PAT059456 FF Example 1 Synthesis of /N״N.■"OH(7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one).
Trans racemic THF, 50،C, IhStep-58%Peak-2 Step-1: Synthesis of 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((1-methyl-1H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (compound-2): Procedure:To a degassed solution of 7'-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'- chlorospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (trans-racemic) (0.5 g, 1.70 mmol), 1- methyl-1H-pyrazol-4-amine (0.25 g, 2.55 mmol) and NaO ؛Bu (0.24 g, 2.55 mmol) in dry THF (10 ml), was added Brettphospd-G3 (0.15 g, 0.17 mmol) under argon atmosphere and stirred at 50°C for 1h. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was filtered through celite pad, the filtrate was concentrated under reduced pressure to afford crude compound. The crude was purified by column chromatography (silica gel, 230-400 mesh), eluting with 0-5% methanol in DCM to give 7'-3-hydroxycyclohexyl)-2'-((1-methyl-1 H-pyrazol-4-yl)amino)spiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (trans-racemic) (0.35 g, 58% yield) as brown solid. LC-MS m/z [M+H]+ = 355.26, 1H NMR (400 MHz, DMSO-d6)6 = 9.35 (s, 1H), 7.87 (s, 1H), 7.86 (s, 1H), 7.48 (s, 1H), 4.65-4.(m, 1H), 4.60 (s, 1H), 4.13 (s, 1H), 3.79 (s, 3H), 2.20-2.35 (m, 1H), 1.52-1.85 (m, 7H), 1.35-1.50 (m, 3H).
Step-2: SFC separation7'-3-hydroxycyclohexyl)-2'-((1-methyl-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (trans-racemic) (0.35 g, 0.98 mmol) was subjected to SFC separation in methanol as co-solvent. After completion of the separation, the solvent of peak-2 was distilled off to give 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1-methyl-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (0.136 g, 38%) as white solid. LC- MSm/z [M+H]+ = 355.30, 1H NMR (400 MHz, DMSO-d6)6 = 9.35 (s, 1H), 7.87 (s, 1H), 7.85 (s, 1H), 7.(s, 1H), 4.55-4.80 (m, 2H), 4.13 (s, 1H), 3.79 (s, 3H), 2.40-2.50 (m, 1H), 2.20-2.35 (m, 1H), 1.51-1.85 (m, 7H), 1.35-1.50 (m, 3H). 116 BrettphosPd-G3, PAT059456 FF Example 2 (7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1 H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one).
N™NH NO2 DMF, 0o C-RT N—NStep-1 SEM70% Pd/CMeOH Step-95%N~NSEM 3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-methyl-4- nitro-1H-pyrazole (1 g, 7.86 mmol) and C52CO3 (5.12 g, 15.75 mmol) in DMF (10 ml), was added SEM-CI (2.09 mL, 11.80 mmol) at 0 °C and then stirred at room temperature for 2h. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was quenched with ice-cold water and extracted into ethyl acetate (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated under reduced pressure to afford crude compound. The crude was purified by column chromatography (silica gel, 100-200 mesh), eluting with 0-10% ethyl acetate in pet ether to give 3-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.43 g, 70% yield) as colorless liquid. 1H NMR (400 MHz, DMSO-d6)6 = 8.03 (s, 1H), 8.32 (s, 1H), 5.58 (s, 1H), 5.44 (s, 2H), 3.58-3.68 (m, 4H), 2.70 (s, 2H), 2.49 (s, 3H), 0.85-0.93 (m, 4H), 0.0-0.04 (m, 9H).
Step-2: Synthesis of 53-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.43 g, 5.55 mmol) in MeOH (15 ml), was added Pd/C (0.2 g) at room temperature and stirred at hydrogen balloon pressure for6h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, the reaction mass was filtered through celite pad, the filtrate was concentrated under reduced pressure and chased with toluene to afford crude 3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (1.2 g, 95% yield) as pale red solid. The crude product was used as such for next step without further purification. 1H NMR (400 MHz, DMSO-d6)6 = 6.90- 7.038 (m, 1H), 5.21 (s, 1H), 5.11 (s, 1H), 3.68 (s, 2H), 3.38-3.45 (m, 2H), 1.90-2.10 (m, 3H), 0.79 (t, J = 8.4 Hz, 2H), -0.05-0.04 (m, 9H). 117 PAT059456 FF Stepi: 7'-((1 R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((3-methyl-1 -((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6‘(7‘H)-one:To a degassed solution of 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)- 2'-chlorospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (30 g, 73.52 mmol) and 3-methy-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (18.2 g, 80.87 mmol) in dry THF (450 mL), was added NaOtBu (10.8 g, 110.28 mmol) and BrettphospdG3(2.0 g, 2.2 mmol), reaction mass was degassed with argon for 5 min and the reaction mass was stirred at room temperature for 1 h . Progress of the reaction was monitored by TLC and LCMS. After completion of reaction, the reaction mass was filtered, the filtrate was concentrated under reduced pressure to give crude compound. The crude compound was purified by Sepa- Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-etherto give 7'-((1R,3R)-3- ((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one. The obtained 7'-((1 R,3R)-3-((tert- butyldimethylsilyl)oxy)cyclohexyl)-2'-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one was dissolved in DCM and stirred with Si-Thiourea (Palladium scavenger) for 3hrs and flitered through celite pad. The filtrate was concentrated under reduced pressure to provide target compound as brown colour gummy solid (40 g, 90% yield).
LC-MS m/z:[M+H]+=599.77 Step2: 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one: To a stirred solution of 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (50 g, 83.48 mmol) in methanol (5mL), was added 4M HCI in dioxane (250 mL) at room temperature and stirred at 50 °C for 4 h. Progress of the reaction was monitored by TLC & LCMS. After completion of the reaction, reaction mass was concentrated under reduced pressure. The crude product was basified with aq. NaHCO3 and extracted with ethyl acetate (3 x200 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to get the crude compound. The crude product was washed with DCM: MTBE (10V, 1:4) and filtered. The obtained solid was dissolved in 50% MeCN in water and concentrated under reduced pressure to give 7'- ((1R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- 118 PAT059456 FF d]pyrimidin]-6'(7'H)-one as off white solid (21 g, 71% yield). LC-MS m/z:[M+H]+=355.2 (96.47%) 1H NMR (400 MHz, DMSO-de) 6 = 12.27 - 12.18 (m, 1H), 8.59-8.54 (m, 1H), 7.81-7.55 (m, 2H), 4.66 (brs, 1H), 4.(br s, 1H), 4.08 (br s, 1H), 2.49 (s, 3H), 2.25-2.14 (m, 4H), 1.79-1.35 (m, 8H).
Example 3 DMF, 0o C-RT Step-1 92% MeOHSEM Ste P2־ 80% Step-1: Synthesis of 3-(difluoromethyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-(difluoromethyl)-4-nitro-1H-pyrazole (1.5 g, 9.21 mmol) and C52CO3 (5.9 g, 18.mmol) in DMF (15 mb), was added SEM-CI (2.5 mb, 13.81 mmol) at 0° C and then stirred at room temperature for 2h. The progress of the reaction was monitored by TbC and bCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 30 mb). The organic layer was washed with ice-cold water (2x10 mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 3-(difluoromethyl)-4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (2.5 g, 92% yield) as colourless liquid. 1H NMR (400 MHz, DMSO-d6)6 = 9.26 (s, 1H), 8.53 (s, 1H), 7.22-7.75 (m, 3H), 5.56 (s, 4H), 3.60-3.68 (m, 7H), 0.80-0.93 (m, 8H), 0.01-0.03 (m, 6H).
Step-2: Synthesis of 3-(difluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (Intermediate-4):To a parr-shaker containing 3-(difluoromethyl)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (2.5 g, 8.53 mmol) in methanol (25 mb), was added Pd/C (10%, 0.25 g) and stirred at room temperature at 80 psi hydrogen pressure for 2h. Progress of the reaction was monitored by TbC. After completion of reaction, reaction mass was filtered through plug of celite, the filtrate was concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-20% ethyl acetate in pet-etherto give 3-(difluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (1.8 g, 80% yield) as pale orange liquid. 1H NMR (400 MHz, DMSO-d6)6 = 6.78-7.30 (m, 3H), 5.25-5.35 (m, 2H), 4.(br-s, 2H), 3.40-3.52 (m, 3H), 0.75-0.85 (m, 3H), -0.09-0.10 (m, 11H). 119 PAT059456 FF F 7Coupling to Intermediate 1 and deprotection of SEM group to form N-NH ((3-(difluoromethyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1, 5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-oneperthe method described in Example 2.
Example 4 7Synthesis of N-NH (methyl 4-((7'-((1 R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carboxylate).
Methyl 4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carboxylate: To a stirring solution of 4-((7'- ((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'- yl)amino)-1H-pyrazole-3-carbonitrile (0.25 g, 0.65 mmol) in methanol (2.5 ml), was added 4M HCI in 1,4- dioxne (1.5 mL) at 0 °C and then stirred at 50 °C for 2h. The progress of the reaction was monitored by TLC & LCMS. After completion of reaction, the reaction mass was concentrated under reduced pressure, basified with sat. NaHCO3 and extracted with ethyl acetate (3x10 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to afford crude compound. The crude was purified by Prep. HPLC (column: YMC triart (250*19mm) 5u), Buffer A: 10 MM ABC Buffer B: acetonitrile, mobile phase conditions (% of B): 0/20,2/20,15/60,20/60,20.1/100,24/100,24.1/20,28/20 flow-19 mL APMS-022 to give methyl 4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carboxylate (15 mg, 6% yield) as off white solid. 120 PAT059456 FF LC-MSm/z [M+H]+ = 399.29, 1H NMR (400 MHz, DMSO-d6)6 = 13.54 (br-s, 1H), 8.57 (br-s, 1H), 8.27 (s, 1H), 7.98 (s, 1H), 4.65-4.78 (m, 1H), 4.65 (d, J = 2.4 Hz, 1H),4.13 (s, 1H), 3.88 (s, 3H), 2.42-2.52 (m, 1H), 2.20-2.35 (m, 1H), 1.55-1.82 (m, 7H), 1.38-1.55 (m, 3H).
Example 5 (7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1 H-pyrazol-5- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one). -methvl-3-nitro-1-((2-(trimethvlsilvl)ethoxv)methvl)-1H-pyrazole:To a stirred solution of 5-methyl-3- nitro-1H-pyrazole (2 g, 15.73 mmol) and C52CO3 (10.25 g, 31.47 mmol) in DMF (20 ml), was added SEM- Cl (4.14 mL, 23.60 mmol) at 0 °C and then stirred at room temperature for 2h. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was quenched with ice-cold water and extracted into ethyl acetate (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated under reduced pressure to afford crude compound. The crude was purified by column chromatography (silica gel, 100-200 mesh), eluting with 0-10% ethyl acetate in pet ether to give 5- methyl-3-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (3 g, 75% yield) as pale yellow liquid. 1H NMR (400 MHz, CDCIa)6 = 6.92 (s, 1H), 5.81 (s, 2H), 3.62 (dd, J = 7.2, 8.8 Hz, 2H), 2.33 (s, 3H), 0.91 (t, 3H, J = 8.0 Hz, 2H), 0.01 (s, 9H). -methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-amine:To a stirred solution of 5-methyl-3- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (3 g, 11.65 mmol) in MeOH (30 ml), was added Pd/C (0.43 g) at room temperature and stirred at 80 psi H2 pressure for 2h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, the reaction mass was filtered through celite pad, the filtrate was concentrated under reduced pressure and chased with toluene to afford crude 5- methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-amine (2.1 g, 80.7% yield) as pale red liquid. The crude product was used as such for next step without further purification. LC-MS m/z [M+H]+ = 228.42. 121 PAT059456 FF Synthesis of rac7'-((1 R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((5-methyl-1 -((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6‘(7‘H)-one: To a degassed solution of 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-chlorospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (0.g, 1.22 mmol), 5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-amine (0.33 g, 1.47 mmol) and NaO؛Bu (0.17 g, 1.83 mmol) in dry THF (10 ml), was added Brettphospd-G3 (0.1 g, 0.12 mmol) at room temperature and stirred for 2h. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was filtered through celite pad, the filtrate was concentrated under reduced pressure to afford crude compound. The crude was purified by column chromatography (silica gel, 100-2mesh), eluting with 0-30% ethyl acetate in pet ether to give 7'-((1R,3R)-3-((tert- butyldimethylsilyl)oxy)cyclohexyl)-2'-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (0.57 g, 81% yield) as pale brown solid. LC-MS m/z [M+H]+ = 599.5 (21%+22%, positional isomers). 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((5-methyl-1H-pyrazol-3-yl)amino)spiro[cyclopropane-1,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one:To a stirring solution of 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (0.57 g, 0.95 mmol, 69% purity) in methanol (5 ml), was added 4M HCI in 1,4-dioxne (2.85 mL) at 0 °C and then stirred at 50 °C for 2h. The 122 PAT059456 FF progress of the reaction was monitored by TLC & LCMS. After completion of reaction, the reaction mass was concentrated under reduced pressure, basified with sat. NaHCO3 and extracted with ethyl acetate (x 10 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to afford crude compound. The crude was purified by Prep. HPLC (column XB 19*150), Buffer A: ABC Buffer B: Acetonitrile, mobile phase conditions (% of B): 0/20,2/20,8/30,11/30 flow-30ml/min dac to give 7'- ((1R,3R)-3-hydroxycyclohexyl)-2'-((5-methyl-1H-pyrazol-3-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6'(7'H)-one (50 mg, 15% yield) as off white solid. LC-MSm/z [M+H]+ = 355.30 (97.54%), 1H NMR (400 MHz, DMSO-d6)6 =11.79 (br-s, 1H), 9.45 (br-s, 1H), 7.86 (s, 1H), 6.34 (br-s, 1H), 4.63-4.(m, 1H), 4.57 (s, 1H), 4.11 (s, 1H), 2.50-2.60 (m, 1H), 2.25-2.38 (m, 1H), 2.19 (s, 3H), 1.51-1.85 (m, 7H), 1.35-1.50 (m, 3H).
Example 6 Methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate:To a stirred solution of methyl 4-nitro-1H-pyrazole-3-carboxylate (2 g, 11.69 mmol) and C52CO3 (7.6 g, 23.39 mmol) in DMF (mL), was added SEM-CI (3.2 mL, 17.54 mmol) at 0° C and then stirred at room temperature for 2h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with ice-cold water (2x10 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-etherto give methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole- 3-carboxylate (3.2 g, 91% yield) as colourless liquid. 1H NMR (400 MHz, DMSO-d6)6 = 9.18 (s, 1H), 8.(s, 1H), 5.60 (s, 2H), 5.51 (s, 2H), 3.97 (s, 3H), 3.89 (s, 3H), 3.50-3.64 (m, 4H), 0.80-0.90 (m, 4H), -0.05- 0.01 (m, 9H). (4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol:To a stirred solution of methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (1.5 g, 4.97 mmol) in dry THF (15 ml) was added DIBAH (14.93 ml, 14.93 mmol) drop wise at -30°C, then reaction mass was raised to room temperature and stirred for 5h. The progress of the reaction was monitored TLC & LCMS. After completion of the reaction, quenched with 1N HCI and extracted with ethyl acetate (3 x 30 mL). The organic layer was dried over Na2SO4, concentrated to give crude compound. The crude compound was purified by Sepa- 123 DIBAL-H PAT059456 FF Bean using silica gel (230-400 mesh), eluting with 0-50% ethyl acetate in pet-etherto give (4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (0.5 g, 36% yield) as pale brown liquid. 1H NMR (400 MHz, CDCI)6 = 8.32 (s, 1H), 5.41 (s, 2H), 4.93 (d, J = 5.6 Hz, 2H), 3.64 (t, J = 8.4 Hz, 2H), 2.83 (br- s, 1H), 0.95 (t, J = 8.4 Hz, 2H), -0.08-0.01 (m, 9H). 4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol:To a stirring solution of (4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (0.46 g, 8.53 mmol) in methanol (10 mb), was added Pd/C (10%, 0.1 g) and stirred at room temperature under hydrogen balloon pressure for 2 h. Progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was filtered through plug ofcelite, the filtrate was concentrated under reduced pressure to give the crude 4-amino-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (0.25 g, 62% yield) as pale green liquid. The crude product used as such without further purification. 1H NMR (400 MHz, CDCIa)6 = 7.14 (s, 1H), 5.(s, 2H), 4.74 (s, 2H), 3.50-3.60 (m, 2H), 0.88-1.0 (m, 2H), -0.01-0.05 (m, 9H).
Coupling to Intermediate 1 and deprotection of SEM group to form 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(hydroxymethyl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one as per the method described in Example 2.
Example 7 (7'-((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl- 1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one). 124 PAT059456 FF Ethyl 1-(4-chloro-2-(methylthio)pyrimidin-5-yl)cyclopropane-1-carboxylate:To a stirring solution of (commercially sourced) ethyl 2-(4-chloro-2-(methylthio)pyrimidin-5-yl)acetate (9 g, 36.48 mmol) and dibromoethane (15.7 mL, 182.40 mmol) in dry DMF, was added NaH (60%, 7.2 g, 182.4 mmol) portion wise at room temperature and stirred for 2h. The progress of the reaction was monitored by TLC & LCMS. After completion of reaction, the reaction mass was quenched with ice-cold water, extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with ice-cold water (2x10 mL) and brine solution (10 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to afford crude compound. The crude was purified by flash column chromatography (230-400 g silica gel), eluting with 0- 10% ethyl acetate in pet ether to give ethyl 1-(4-chloro-2-(methylthio)pyrimidin-5-yl)cyclopropane-1- carboxylate (5.6 g, 56% yield) as pale yellow liquid. LC-MSm/z [M+H]+ =279.03, 1H NMR (400 MHz, DMSO-d6)6 = 8.62 (s, 1H), 4.05 (q, J = 6.8 Hz, 2H), 2.54 (s, 3H), 1.55-1.60 (m, 2H), 1.32-1.38 (m, 2H), 1.(t, J= 6.8 Hz, 3H).
Ethyl 1-(4-chloro-2-(methylsulfonyl)pyrimidin-5-yl)cyclopropane-1-carboxylate;To a stirring solution of ethyl 1-(4-chloro-2-(methylthio)pyrimidin-5-yl)cyclopropane-1-carboxylate (5.6 g, 20.53) in DCM (84 ml), was added m-CPBA (15.18 g, 61.59 mmol) portion wise at 0 °C and then stirred at room temperature for 2h. The progress of the reaction was monitored by TLC & LCMS. After completion of reaction, the reaction mass was quenched with sat.NaHCO3, extracted with DCM (2 x 100 mL), dried over Na2SO4, concentrated under reduced pressure to afford crude compound. The crude was purified by flash column chromatography (230-400 g silica gel), eluting with 0-20% ethyl acetate in pet ether to give Ethyl 1-(4-chloro-2- (methylsulfonyl)pyrimidin-5-yl)cyclopropane-1-carboxylate (5.8 g, 93% yield) as white solid. LC-MS m/z [M+H]+ = 305.09, 1H NMR (400 MHz, DMSO-d6)6 = 9.10 (s, 1H), 4.08 (q, J = 6.8 Hz, 2H), 3.46 (s, 3H), 1.65-1.70 (m, 2H), 1.45-1.52 (m, 2H), 1.1 (t, J = 6.8 Hz, 3H).
Ethyl1-(4-chloro-2-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)pyrimidin- 5-yl)cyclopropane-1-carboxylate:To a stirring solution of Ethyl 1-(4-chloro-2-(methylsulfonyl)pyrimidin- 5-yl)cyclopropane-1-carboxylate (6.5 g, 21.42 mmol) and N-(3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-4-yl)formamide (5.47 g, 21.42 mmol) in dry THF (65 mL), was added NaH (60%, 1.02 g, 25.mmol) portion wise at room temperature and heated at 50 °C for 4h. The progress of the reaction was 125 NaH,DMF, RT PAT059456 FF monitored for by TLC & LCMS. After completion of reaction, the reaction mass was quenched with ice-cold water, extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over Na2SO4, concentrated under reduced pressure to afford crude compound. The crude was purified by flash column chromatography (230-400 g silica gel), eluting with 0-20% ethyl acetate in pet ether to give ethyl 1-(4-chloro- 2-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)cyclopro pane-1- carboxylate (7 g, 68% yield) as brown gummy liquid. LC-MS m/z [M+HJ+ =452.34, 1H NMR (400 MHz, DMSO-d6)6 = 9.36 (s, 1H), 8.36 (s, 1H), 8.01 (s, 1H), 5.32 (s, 2H), 4.08 (q, J = 7.2 Hz, 2H), 3.55 (t, J = 8.Hz, 2H),2.17 (s, 3H), 1.52-1.62 (m, 2H), 1.25-1.35 (m,2H), 1.14 (t, J = 7.2 Hz, 3H), 0.86 (t, J = 8.0 Hz, 3H), 0.01-0.0 (s, 9H).
Peak-2 3-amino-5,5-dimethylcyclohex-2-en-1-one:In to a two neck round bottom flask rquipped with dean-stark apparatus containing 5,5-dimethylcyclohexane-1,3-dione (5 g, 35.66 mmol) in toluene (100 ml), were added acetic acid (0.9 mL, 16.05 mmol) and NH4OAc (5.5g, 71.32 mmol), stirred at 110 °C for 12h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, the reaction mass was quenched with sat. Na2CO3 (10 mL) and 1N NaOH (10 mL) and extracted with DCM (10 x 20 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to afford crude 3-amino-5,5- dimethylcyclohex-2-en-1-one (3.5 g, 71% yield) as pale yellow solid. The crude product was used as such for next step without further purification. 1H NMR (400 MHz, DMSO-d6)6 = 6.71 (br-s, 2H), 4.89 (s, 1H), 2.12 (s, 2H), 1.90 (s, 2H), 0.96 (s, 6H). -amino-3,3-dimethylcyclohexan-1-ol:To a stirred solution of 3-amino-5,5-dimethylcyclohex-2-en-1-one (4 g, 28.23 mmol) in ethanol (40 ml), was added 20% NaOH (1.2 mL) and Raney-Ni (3.6 g) and stirred at 100 psi hydrogen pressure for 48h The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, the reaction mass was filtered through celite pad, the filtrate was concentrated under reduced pressure and chased with toluene to afford crude 5-amino-3,3-dimethylcyclohexan-1-ol (3 g, 73% 126 PAT059456 FF yield) as brown liquid. The crude product was used as such for next step without further purification. 1H NMR (400 MHz, CDCI3) 6 = 4.35-4.52 (brs, 1H), 4.20-4.28 (m, 1H), 3.68-3.74 (m, 2H), 3.20-3.30 (m, 1H), 2.17 (d, J = 8.4 Hz, 4H), 1.88-2.0 (m, 2H), 1.20-1.70 (m, 22H).
Tert-butyl ((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl) carbamate:To a stirred solution of tert-butyl ((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl) carbamate (10 g, 69.81 mmol) in dioxane (50 ml), and water (50 mb), were added NaHCO3 (5.8 g, 69.81 mmol) and (B0c)2O (19.2 mb, 83.78 mmol) and stirred at room temperature 2h. The progress of the reaction was monitored by TbC and bCMS. After completion of reaction, the reaction mass was quenched with sat. NaCI and extracted with DCM (3x 100 mb). The organic layer was dried over Na2SO4, concentrated under reduced pressure to afford crude compound. The crude was purified by column chromatography (silica gel, 100-200 mesh), eluting with 0-40% ethyl acetate in pet ether to give tert-butyl ((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl) carbamate (3.5 g, 17% yield) as pale yellow liquid. 1H NMR (400 MHz, CDCI3) 6 = 4.38 (br-s, 1H), 4.19 (s, 1H), 3.98 (br-s, 1H), 1.92-2.02 (m, 1H), 1.68-1.75 (m, 2H), 1.50-1.55 (m, 2H), 1.40-1.49 (m, 10H), 1.30-1.40 (m, 2H), 1.15 (s, 3H), 1.02-1.(m, 1H), 0.90-0.98 (m, 4H). (1R,5R)-5-amino-3,3-dimethylcyclohexan-1-ol hydrochloride:To a stirred solution of compound-4A(g, 12.34 mmol) in 1,4-dioxane (15 ml), was 4M HCI in dioxane (15 mb) at room temperature and stirred 2h. The progress of the reaction was monitored by TbC and bCMS. After completion of reaction, the solvent was removed under reduced pressure, triturated with diethyl ether, decanted and dried under reduced pressure to afford crude (1R,5R)-5-amino-3,3-dimethylcyclohexan-1-ol hydrochloride (1.6 g, 59% yield) as off white solid. The crude product was used as such for next step without further purification. LC-MS m/z [M+H]+ = 144.29.
Rac7'-((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6‘(7‘H)-one:To a stirred solution of (1R,5R)-5-amino-3,3-dimethylcyclohexan-1-ol hydrochloride (0.6 g, 3.32 mmol) and DIPEA (1.2 mb, 6.65 mmol) in ethanol (20 mb), was added ethyl 1- (4-chloro-2-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)pyrimidin-5- yl)cyclopropane-1-carboxylate (1g, 2.21 mmol) and irradiated under microwave radiation at 150 °C for4h. After completion of reaction, the solvent was removed under reduced pressure to give crude SnAr adduct, which was dissolved in acetonitrile (10 mb) and added C52CO3 (0.29g, 0.89 mmol) and heated at 75°C for 6h. Progress of the reaction was monitored by bCMS. After completion of reaction, the reaction mass was filtered, the filtrate was concentrated to give crude compound. The crude product was purified by column chromatography (silica gel, 100-200 mesh), eluting with 0-70% ethyl acetate in pet ether to give rac7'- 127 PAT059456 FF ((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one(0.3 g, 27% yield after 2 steps) as pale yellow liquid. LC-MS m/z[M+H]+ = 513.47.
Rac7'-((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one:To a stirred solution of rac7'- ((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one(0.3 g, 0.58 mmol) in MeOH (1.5 ml), was added 4M HCI in dioxane (1.5 mL) and heated at 50° C for 3h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, the reaction mass concentrated, basified with aq.NaHCO3 and extracted with ethyl acetate, the organic layer was dried over Na2SO4, concentrated under reduced pressure to afford crude compound. The crude was purified by Prep. HPLC (Buffer A: 10 mm abc, Buffer B:- ACN solubility:- ACN-THF-water mobile phase conditions (% of B):- 0/30,2/30,10/55,15/55,15.01/100,18/100,18.01/30,21/30 flow-10 ml/min anl-mcl-prep-014 column: XB c- 18(19*250mm) Sum buffer) to give trans-rac7'-((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl- 1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (70 mg, 32% yield) as off white solid. LC-MS m/z [M+H]+ = 383.43 7'-((1R,5R)-5-hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one:trans-racemic 7'-((1R,5R)-5- hydroxy-3,3-dimethylcyclohexyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrro Io [2,3- d]pyrimidin]-6'(7'H)-one (70 mg) was subjected to SFC separation in methanol as co-solvent. After completion of the separation, the solvent of peak-1 was distilled off to give 7'-((1R,5R)-5-hydroxy-3,3- dimethylcyclohexyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one (22 mg) as off white solid. LC-MSm/z [M+H]+ = 383.43, 1H NMR (400 MHz, DMSO-d6)6 = 12.15 (br-s, 1H), 8.55 (s, 1H), 7.82 (s, 1H), 7.62 (s, 1H), 4.82 (t, J= 12.4 Hz, 1H), 4.54 (s, 1H), 4.10 (s, 1H), 2.38-2.48 (m, 1H), 2.10-2.35 (m, 4H), 1.40-1.70 (m, 6H), 1.20-1.38 (m, 2H), 1.23 (s, 3H), 0.85 (s, 3H). 128 PAT059456 FF Example 8 SEM NO2 60.7% til % Procedure:To a degassed solution of 3-chloro-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.g, 2.88 mmol) and 2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.85 g, 4.32 mmol) in dioxane (6 ml) and H2O (2ml) was added K2CO3 (1g, 7.20 mmol) and PdCI2(dppf).DCM (0.235g 0.2mmol), the reaction mass was closed under argon atmosphere and stirred at 100 °C for 16h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered; the filtrate was concentrated under reduced pressure to give crude compound. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-20% ethyl acetate in pet-ether to give 3-(2,5-dihydrofuran-3-yl)-4-nitro-1-((2 (trimethylsilyl)ethoxy)methyl)-1H-pyrazole. (0.6g, 60.7% yield) as yellow solid. LC-MSm/z: [M+H]+ = 312.35 1H NMR (400 MHz, CHLOROFORM-d) 6 = 8.30 - 8.15 (m, 1H), 7.15 - 7.06 (m, 1H), 5.46 - 5.36 (m, 2H), 5.06 - 4.84 (m, 4H), 3.73 - 3.58 (m, 2H), 1.- 0.82 (m, 2H), 0.07 - -0.09 (m, 11H) 3-(tetrahydrofuran-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a parr-shaker containing 3-(2,5-dihydrofuran-3-yl)-4-nitro-1-((2 (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (600mg, 1.mmol) in methanol (6 mL), was added Pd/C (10%, 0.180 g) and stirred at room temperature at 80 psi hydrogen pressure for2h. The progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was filtered through plug of celite, the filtrate was concentrated under reduced pressure to give the crude product 3-(tetrahydrofuran-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.g crude, 91% yield) as brown oil. LC-MS m/z:[M+H]+ = 284.48 1H NMR (400 MHz, DMSO-d6) 6 = 7.12 - 6.96 (m, 1H),5.17-5.08 (m, 2H), 4.03-3.35 (m, 12H), 2.21 -1.96 (m, 3H), 1.79-1.71 (m, 1H), 0.86-0.(m, 3H), 0.06--0.17 (m, 12H). 129 PAT059456 FF Coupling to Intermediate 1 and deprotection of SEM group to form 7'-((1R,3R)-3-hydroxycyclohexyl)-2'- ((3-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)- as per the method described in Example 2.
Example 9 Synthesis of (7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one). 82% Step-1: Synthesis of tert-butyl 3-((diphenylmethylene)amino)-6,7-dihydropyrazolo[1,5-a]pyrazine- 5(4H)-carboxylate (Compound-3): Tert-butyl 3-((diphenylmethylene)amino)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate:To a stirred solution of tert-butyl 3-bromo-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (0.5 g, 1.65mmol), diphenylmethanimine(0.447 g, 2.47 mmol) in THF (5 mb) was added NaOt-Bu (0.32 g, 3.mmol). The reaction mixture was purged by N2 gas for 15 min and then was added BrettPhosPdG3 (0.15 g, 0.165 mmol), purged for 2 min. The resulting reaction mixture was irradiated in microwave at 70 °C for 1h. 130 PAT059456 FF The progress of the reaction monitored by TLC and LCMS. After completion of reaction, reaction mass was passed through celite pad and the pad was washed with 10% MeOH in DCM (10 mL). The filtrate was washed with brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0- 30% ethyl acetate in pet-ether to give tert-butyl 3-((diphenylmethylene)amino)-6,7-dihydropyrazolo[1 ,5- a]pyrazine-5(4H)-carboxylate (0.6 g, 82% yield) as yellow solid. LC-MS m/z: [M+H]+ =403.53 (91%) 1H NMR (400 MHz, CHLOROFORM-d) 6 = 7.76 - 7.74 (m, 2H), 7.50 - 7.22 (m, 8H), 6.02 (s, 1H), 4.79 (s, 2H), 4.07 - 3.8 (m, 4H), 1.57- 1.49 (m, 9H).
Tert-butyl 3-amino-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate:To a stirred solution of tert- butyl 3-((diphenylmethylene)amino)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (0.6 g, 1.mmol) in methanol (6 mL), was added NaOAc (0.37 g, 4.47 mmol), followed by NH2OH.HCI (0.42 g, 5.mmol) and the resulting reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was filtered and the filtrate was evaporated under reduced pressure to afford crude. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% MeOH in DCM to give tert-butyl 3-amino- 6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (0.27 g, 57% yield) as brown oil. LC-MS m/z: [M+H]+ = 239.13 1H NMR (400 MHz, DMSO-d6) 6 = 6.920 (s, 1H), 4.41 (s, 2H), 3.94 - 3.92 (m, 2H), 3.78 - 3.(m, 2H), 3.17 (s, 2H), 1.906 (s, 3H), 1.44 (s, 9H).
Tert-butyl 3-((7'-((1 R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate:To adegassed solution of 2'-chloro-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6'(7'H)-one (0.17 g, 0.578 mmol) and tert-butyl 3-amino-6,7-dihydropyrazolo[1,5-a]pyrazine- 5(4H)-carboxylate (0.2 g, 0.868 mmol) in dry THF (2 mL), was added NaO/-Bu (85 mg, 0.868 mmol) and BrettphosPdG3 (53 mg, 0.057 mmol), the reaction mass was closed under argon atmosphere and irradiated in microwave at 60 °C for 1h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered through celite pad; the filtrate was concentrated under reduced pressure to give crude compound. The crude compound was purified by 131 PAT059456 FF Sepa-Bean using silica gel (230-400 mesh), eluting with 0-5% MeOH in DCM to give tert-butyl 3-((7'- ((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'- yl)amino)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (0.2 g, 72% yield, 89% purity) as brown solid. LC-MS m/z: [M+H]+ = 496.36. 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydrofuran-3-yl)-1 H-pyrazol-4-yl) amino) spiro[cyclopropane-1,5‘-pyrrolo[2,3-d]pyrimidin]-6‘(7‘H)-one (S0-EE-PYZF): To a stirred solution of trans-racemic-tert-butyl 3-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'- dihydrospiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-6,7-dihydropyrazolo[1,5-a]pyrazine- 5(4H)-carboxylate (0.2 g, 0.4 mmol) in methanol (2 mb), was added 4M HCI in dioxane (2 mb) at 0° C and stirred at RT for 2h. Progress of the reaction was monitored by TbC & bCMS. After completion of reaction, reaction mass was diluted with ethyl acetate and concentrated under reduced pressure. The crude product was submitted for prep HPbC purification. CObUMN:-XB BUFFER A: ABC BUFFER B: ACETONITRIbE, MOBIbE PHASE CONDITIONS (% OF B):-0/10,2/10,10/30 FbOW-20Mb ANb-MCb5;PREP-017 Diluent: ACN+THF+WATER Temperature: - Ambient The pure fractions obtained were evaporated under reduced pressure, lyophilized to give (78.7 mg, 48 % yield) as white solid. LC-MS m/z: [M+H]+=396.22 (96.27%) 1H NMR (400 MHz, DMSO-d6) 6 = 8.707 (s, 1H), 7.80 (s, 1H), 7.53 (s, 1H), 4.75-4.58 (m, 2H), 4.12-4.(m, 1H), 3.92 (t, J = 5.4 Hz, 2H), 3.85 - 3.76 (m, 2H), 3.13 - 3.01 (m, 2H), 2.46 - 2.30 (m, 1H), 2.29 - 2.(m, 1H), 1.763- 1.516 (m, 10H).
Example 10 % Procedure:To a degassed solution of 3-chloro-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.g, 3.61 mmol) and 2-(3,4-dihydro-2H-pyran-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.1 g, 5.41 mmol) in dioxane (6mb) and H2O (2ml) was added K2CO3 (1.49g, 10.83 mmol) and PdCI2(dppf).DCM (0.294g 0.361 mmol), the reaction mass was closed under argon atmosphere and stirred at 100 °C for 16h. The progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, the reaction 132 PAT059456 FF mass was filtered; the filtrate was concentrated under reduced pressure to give crude compound. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-20% ethyl acetate in pet-ether to give 3-(3,4-dihydro-2H-pyran-6-yl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (0.36g, 30% yield) as pale yellow oil. LC-MS m/z: [M+H]+=326.43 Step-2: Synthesis of 3-(tetrahydro-2H-pyran-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine (Compound-4): % Pd/C SEM 3-(tetrahydro-2H-pyran-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a parr- shaker containing 3-(3,4-dihydro-2H-pyran-6-yl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (0.360 g, 1.107 mmol) in methanol (7 mb), was added Pd/C (10%, 0.15 g) and stirred at room temperature at 80 psi hydrogen pressure for 2h. The progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was filtered through plug of celite, the filtrate was concentrated under reduced pressure to give the crude product 3-(tetrahydro-2H-pyran-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-4-amine (0.265 g crude, 80% yield) as pale yellow oil. LC-MS m/z: [M+H]+=298.19 Coupling to Intermediate 1 and deprotection of SEM group to form 7'-((1R,3R)-3-hydroxycyclohexyl)-2'- ((3-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one as per the method described in Example 2.
Example 11 133 PAT059456 FF h2so4, hno350-60 °C, Step-26.6%DMF, RT, 3h, Step-85% SEM-CI, Cs 2CO3NaBH4. MeOH.°C-RT,2hStep-346% NaH.MelDMF.RTStep-66% nh2Fe/ NH4CIEtOH, H20,50 "CStep-572% Ethyl 5-nitro-1H-imidazole-2-carboxylate:To a stirred solution of ethyl 1H-imidazole-2-carboxylate (8 g, 57.14 mmol) in H2SO4 (35ml) was added HNO3 (35 mL) dropwise at 0° C and then stirred at 50-60 °C for 3h. The progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with ice/water mixture, the precipitated crystals are collected by suction filtration and washed with 1500 ml of ice-water to give Ethyl 5-nitro-1H-imidazole-2-carboxylate (2.8 g, 26.6% yield) as white solid. LC-MS m/z: [M+H]+= 186.27 (98%).
Ethyl 5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate:To a stirred solution of Ethyl 5-nitro-1H-imidazole-2-carboxylate (2.4 g, 12.96 mmol) and C52CO3 (8.42 g, 25.92mmol) in DMF (mL), was added SEM-CI (3.44 mL, 19.44 mmol) at 0° C and then stirred at room temperature for 4h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mL). The organic layer was washed with ice-cold water (2 x 200 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give Ethyl 5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole- 2-carboxylate (3.5 g, 85% yield) as pale yellow liquid. 1H NMR (400 MHz, DMSO-de) 6 = 8.046 (s, 1H), 5.827 (m, 2H), 4.482 - 4.428 (m, 2H), 3.665 - 3.623 (m, 2H), 2.945 - 2.872 (s, 1H), 1.448-1.413 (t, J = 7.Hz, 3H), 0.993 - 0.951 (m, 2H), 0.013 - -0.13 (s, 9H) 134 PAT059456 FF (5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)methanol:To a stirred solution of Ethyl 5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate (3.5 g, 11.09 mmol) in methanol (35ml) was added NaBH4 (0.839g 22.194mmol). Then stirred the reaction mixture for2h at RT, reaction progress monitored by TLC and LC-MS , after completion of reaction , reaction mass was quenched with sat.NH4CI solution and extracted with ethyl acetate (2 x200 mL). The organic layer was washed with ice- cold water (2 x 200 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-30% ethyl acetate in pet-etherto give (5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2- yl)methanol (1.4 g, 46% yield) as pale yellow liquid. LC-MS m/z:[M+H]+= 274.37 (89%) 1H NMR (4MHz, CHLOROFORM-d) 6 = 7.863 (s, 1H), 5.592 - 5.458 (s, 2H), 4.855 - 4.765 (d, 2H), 3.633 - 3.592 (m, 2H), 2.793(br s, 2H), 0.994 - 0.953 (m, 2H), 0.029 (m, 9H) 2-(methoxymethyl)-5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-imidazole:To a stirred solution of (5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)methanol (1.4 g, 5.12 mmol) in THF (14 mL), was added NaH (409mg 10.24mmol) and Mel (1.09g 7.68 mmol) at 0 ° C and stirred at RT for 1h. The progress of the reaction was monitored by TLC & LCMS. After completion of reaction, reaction mass was quenched with sat.NH4CI solution and extracted with ethyl acetate (2 x 200 mL). The organic layer was washed with ice-cold water (2 x 200 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-20% ethyl acetate in pet-ether to give 2-(methoxymethyl)-5-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1 H-imidazole (0.630 g, 66% yield) as pale yellow liquid. LC-MS m/z: [M+H]+= 288.23 (96%) 1H NMR (400 MHz, CHLOROFORM-d) 6 = 7.874 (s, 1H), 5.420 (s, 2H), 4.601 (s, 2H), 3.5- 3.548 (m, 2H), 3.376 (s, 3H), 0.967 - 0.926(m, 2H), 0.08 - -0.006 (s, 9H) 2-(methoxymethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-amine:To a round-bottom flask containing 2-(methoxymethyl)-5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-imidazole (400 mg 1.3mmol) in ethanol (4ml) and water (4ml), was added Fe (770.3 mg, 13.93 mmol) and NH4CI (749.4 mg 13.mmol) then stirred at 50 °C for 2h. The progress of the reaction was monitored by TLC. The reaction mass was filtered through eelite pad and washed with 10% MeOH in DCM (200ml); the filtrate concentrated under reduced pressure to give the crude product, the crude product was diluted with DCM (50ml) and filtered through glass funnel, the filtrate concentrated under reduced pressure to give 2-(methoxymethyl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-amine as brown colour oil (260 mg crude, 72% yield). The crude compound was directly used for next step LC-MS m/z:[M+H]+= 258.53 135 PAT059456 FF 0Coupling to Intermediate 1 and deprotection of SEM group to form / ((1R,3R)-3-hydroxycyclohexyl)-2'-((2-(methoxymethyl)-1H-imidazol-5-yl)amino)spiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one) as per the method described in Example 2.
Example 12: Synthesis of (7'-(3-hydroxycyclohexyl)-2'-((3-methoxy-1H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one). no2SEM-Ci. Cs 2CO3 ,MDMF, RT, 3h,Step-175% sem—nno2 Pd/C, MeOHStep-76%sem-n ךnh2 3-methoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-methoxy- 4-nitro-1H-pyrazole (5 g, 34.96 mmol) and C52CO3 (22.7 g, 69.92 mmol) in DMF (50 mb), was added SEM- CI (9.3 mb, 52.44 mmol) at 0 ° C and then stirred at room temperature for 3h. The progress of the reaction was monitored by TbC and bCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mb). The organic layer was washed with ice-cold water (x 500 mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 3-methoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (7.2 g, 75% yield) as colourless liquid. LC-MS m/z:[M+H]+=274.37 (78%)1H NMR (400 MHz, CHbOROFORM-d) 6 = 8.14(s, 1H), 5.32 (s, 2H), 4.04 (s, 3H), 3.67 - 3.61 (m, 2H), 1.01 - 0.85 (m, 2H), 0.22 - -0.18 (m, 9H). 136 PAT059456 FF 3-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a parr-shaker containing 3- methoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (7.2 g, 28.5 mmol) in methanol (72 mL), was added Pd/C (10%, 0.72 g) and stirred at room temperature at 80 psi hydrogen pressure for 1h. The progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was filtered through plug ofcelite and washed with 10% MeOH in DCM, the filtrates were concentrated under reduced pressure to give the crude product 3-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (4.g, 76% yield) as brown liquid. LC-MS m/z:[M+H]+=243.21 (90%)1H NMR (400 MHz, CHLOROFORM-d) = 7.04 (s, 1H), 5.16 - 5.09 (m, 2H), 3.97 - 3.88 (m, 3H), 3.56 - 3.43 (m, 2H), 2.81 - 2.59 (m, 2H), 0.99 - 0.(m,2H), 0.12--0.05 (m, 9H). 2 OTBS Step ؛ 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((3-methoxy-1-((2- Step (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6‘(7‘H)-one:To a degassed solution of 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)- 2'-((3-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (10 g, 24.5 mmol) and 3-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-4-amine (8.9 g, 36.7 mmol) in dry THF (200 mL), was added NaOt-Bu (3.5g, 36.75 mmol) and BrettphosPdG3 (2.21 g, 2.45 mmol), the reaction mass was closed under argon atmosphere and stirred at room temperature for 4h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered; the filtrate was concentrated under reduced pressure to give crude compound. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-ether to give 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((3- methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6'(7'H)-one. The obtained was dissolved in DCM and stirred with Si-Thiourea (Palladium scavenger) for 3h and filtered through celite pad. The filtrate was concentrated under reduced pressure to give 7'-((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((3-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one (10.2 g, 68% yield) as brown gummy solid. LC-MS m/z:[M+H]+=615.43; 1H NMR (400 MHz, CHLOROFORM-d) 6 = 7.97 (s, 1H), 7.63 (s, 1H), 6.65 - 6.53 (m, 1H), 5.40 - 5.11 (m, 2H), 4.05 - 3.98 (m, 3H), 3.64-3.49 (m, 2H), 2.67-2.25 (m, 1H), 1.89-1.21 (m, 9H), 1.03 -0.78 (m, 9H), 0.02--0.05 (m, 9H). 137 PAT059456 FF Step-2: 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-methoxy-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one:To a stirred solution of 7'- ((1R,3R)-3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-2'-((3-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (10.2g, 16.5 mmol) in methanol (102 mb), was added 4M HCI in dioxane (153 mb) at 0° C and stirred at 50 °C for 16h. The progress of the reaction was monitored by TbC & bCMS. After completion of reaction, reaction mass was diluted with ethyl acetate and concentrated under reduced pressure. The crude product was basified with aq. NaHCO3 and extracted with ethyl acetate (3 x 200 mb). The organic layer was dried over Na2SO4, concentrated under reduced pressure to get the crude compound. The crude product was purified by trituration with 5% MeOH in DCM to give 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-methoxy-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (3.3 g, 53 % yield) as off white solid. LC-MS m/z:[M+H]+=371.38, 1H NMR (400 MHz, DMSO-de) 6 = 11.71 - 11.51 (s, 1H), 8.19 (s, 1H), 7.(s, 1H), 7.647-7.643 (d, 1H), 4.649-4.619 (m, 1H), 4.52 (d, J = 2.8 Hz, 1H), 4.06 (brs, 1H), 3.78 (s, 3H), 2.35-2.10 (m, 1H), 1.83 -1.19 (m, 10H).
Example 13: Fe/NH4CI,SEM-n'Step-90% EtOH, H2O, 50 °CStep-278.6% 3-chloro-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-chloro-4- nitro-1H-pyrazole (3.0 g 20.4 mmol) and C52CO3 (13.26 g, 40.8mmol) in DMF (30 ml), was added SEM-CI (5.4 ml 30.61 mmol) at 0° C and then stirred at room temperature for2h. The progress of the reaction was monitored by TbC and bCMS. The reaction was quenched with ice-cold water (100 mb) and extracted with ethyl acetate (2 x 200 mb). The organic layer was washed with ice-cold water (2 x 100 mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 3-chloro-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as pale yellow oil (5.2 g, 90% yield). 1H NMR (400 MHz, CHbOROFORM-d) 6 = 8.33 - 8.19 (m, 1H), 5.53 (s, 1H), 5.52 - 5.39 (m, 2H), 3.67 - 3.(m, 2H), 0.97 - 0.91 (m, 2H), 0.02 - -0.01 (m, 9H) 138 PAT059456 FF 3-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-chloro-4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (2.5 g 9.02 mmol) in ethanol (10V) and water (10V) was added NH4CI (4.78 g, 90.25 mmol) followed by Fe (5.03g, 90.25 mmol) and the reaction mixture was stirred at 50 °C for 1h. The progress of the reaction was monitored by TLC. The reaction mass was filtered through plug ofcelite and washed with 10% MeOH in DCM; the filtrate was washed with water (50 mL) and extracted with 10% MeOH in DCM concentrated under reduced pressure to give 3-chloro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine as brown gummy solid (2.0 g, 78.66% yield). LC-MS m/z: [M+H]+=248.11 (87%) 1H NMR (400 MHz, DMSO-d6) 6 = 7.40 - 7.20 (m, 1H), 5.31 - 5.27 (m, 2H), 5.22 (s, 1H), 4.14 (brs, 2H), 3.54 - 3.48 (m, 2H), 0.91 - 0.82 (m, 2H), 0.08 - -0.13 (m, 9H) Coupling to Intermediate 1 and deprotection of SEM group to form 2'-((3-chloro-1H-pyrazol-4-yl)amino)-7'- ((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one as per the method described in Example 2.
Example 14: Fe/NH4CI, SEM-n׳K DMF, RT, 3hStep-89% . EtOH, h2o,60°c n02 step-92% 3-cyclopropyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3- cyclopropyl-4-nitro-1H-pyrazole (3.0 g 19.6 mmol) and C52CO3 (12.74g 39.2mmol) in DMF (30ml), was added SEM-CI (5.1 ml 29.4mmol) at 0° C and then stirred at room temperature for 2h. The progress of the reaction was monitored by TLC and LCMS. The reaction was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mL). The organic layer was washed with ice-cold water (2 x1 00 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 3-cyclopropyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as colourless liquid (4.9 g, 89% 139 PAT059456 FF yield). LC-MSm/z: was not ionizing, 1H NMR (400 MHz, CDCI3, 298 K) 6 (ppm) = 8.23-8.06 (m, 1H), 5.55- 5.30 (m, 2H), 3.68 - 3.57 (m, 2H), 2.64 - 2.02 (m, 1H), 1.24-1.03 (m, 4H), 1.02 - 0.92 (m, 2H), 0.05 (s, 9H) 3-cyclopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a Parr-shaker containing 3- cyclopropyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (2.0 g 7.067 mmol) in Ethanol (20ml) and water (20ml), was added Fe (1.97g 35.3mmol) and NH4CI (1.88g 35.3 mmol) then stirred at 60 °C for 2h. The progress of the reaction was monitored by TLC. The reaction mass was filtered through eelite pad and washed with 10% MeOH in DCM (200ml); the filtrate was washed with water (50 ml) and extracted with 10% MeOH in DCM The organic layers was concentrated under reduced pressure to give the crude product 3-cyclopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine as brown colour oil (1.65 g, 92% yield). The crude compound was directly used for next step LC-MS m/z:[M+H]+=254.21 1H NMR (4MHz, DMSO-d6) 6 = 7.12-6.93 (m, 1H), 5.35-5.15 (m, 2H), 4.072 (brs, 2H), 3.52-3.41 (m, 2H), 1.78-1.(m, 1H), 0.82-0.75 (m, 4H), 0.67-0.64 (m, 2H), 0.01- -0.03 (s, 9H).
Coupling to Intermediate 1 and deprotection of SEM group to form 2'-((3-cyclopropyl-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one as per the method described in Example 2.
Example 15: SEM-CI, Cs ?CO3DMF, RT, 3h ״־Step-1NO297% % Pd/CMeOH, RT Step-2 NH288% 4-nitro-3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4- nitro-3-(trifluoromethyl)-1H-pyrazole (3.0 g 16.56 mmol) and C52CO3 (10.7g 33.13mmol) in DMF (30ml), was added SEM-CI (4.4ml 24.85mmol) at 0° C and then stirred at room temperature for 3h. The progress of the reaction was monitored by TLC and LCMS. The reaction was quenched with ice-cold water and 140 PAT059456 FF extracted with ethyl acetate (2 x200 mL). The organic layer was washed with ice-cold water (2 x 100 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 4-nitro-3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as a colour less liquid (5.0 g, 97% yield). LC-MSm/z: was not ionizing, 1H NMR (400 MHz, DMSO-d6) 6 = 9.36 - 8.61 (m, 1H), 5.74 - 5.56 (m, 2H), 3.65-3.61 (m, 2H), 0.89-0.84 (2H), 0.05-0.01 (m, 9H) 3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a Parr-shaker containing 4-nitro-3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (3.0 g 9.64 mmol) in methanol (30 mL), was added Pd/C (10%, 0.3 g) and the reaction mixture was stirred at room temperature with 80 psi hydrogen pressure for 2h. The progress of the reaction was monitored by TLC. The reaction mass was filtered through eelite pad and washed with 10% MeOH in DCM (200 mL); the filtrate was concentrated under reduced pressure to give the crude product 3-(trifluoromethyl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine as a pale yellow liquid (2.4 g (crude), 88% yield). This crude compound was directly used for next step. LC-MS m/z: [M+H]+=282.18 (92%), 1H NMR (400 MHz, DMSO-d6) 6 = 7.33 - 7.14 (m, 1H), 5.32-5.29 (m, 2H), 4.69-4.31 (m, 2H), 3.54-3.42 (m, 2H), 0.83-0.79 (m, 2H), 0.0- -0.065 (m, 9H).
Coupling to Intermediate 1 and deprotection of SEM group to form 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(trifluoromethyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one as per the method described in Example 2. 141 PAT059456 FF Example 16: HN '"OHN-N (7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1 -(2-methoxyethyl)-1 H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one) was made using the method ofNH2 N-NN b n-nExample 1, using / (commercially available) instead of ' Example 17: (7'-(3-hydroxycycloheptyl)-2'-((3-methyl-1 H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one) was made using the method of Example 2, but using Intermediate 2 rather than Intermediate 1. 142 PAT059456 FF Example 17 Alternative Synthesis: tons-racemic 3-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cycloheptan-1-one:To a stirred solution of 2-chloro-7H- pyrrolo[2,3-d]pyrimidine (10 g, 65.11 mmol) and K2CO3 (13.5 g, 97.69 mmol) in toluene (100 ml), was added cyclohept-2-en-1-one (21.4 g, 195.40 mmol) and heated at 85OC for 16h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered through plug of eelite, the filtrate was concentrated under reduced pressure to give the crude product. The crude compound was purified by column chromatography using silica gel (100-200 mesh), eluting with 0-40% ethyl acetate in pet-ether to give 3-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cycloheptan-1-one (13.3 g, 78%) as pale yellow solid. LC-MSm/z [M+H]+ = 264.31, 1H NMR (400 MHz, CDCIa)6 = 8.79 (m, 1H), 7.23 (d, J = 3.6 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 5.05-5.15 (m, 1H), 3.22 (dd, J = 11.2, 15.0 Hz, 1H), 2.85- 2.92 (m, 1H), 2.62-2.72 (m, 1H), 2.02-2.30 (m, 4H), 1.70-1.82 (m, 2H). 3-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cycloheptan-1-ol(racemate, diasteromeric mixture): To a stirred solution of 3-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cycloheptan-1-one (10 g, 38.02 mmol) in dry THF (100 mL), was added L-selectride (57 mL, 57.03 mmol) at -78 °C and stirred at same temperature for 2h. The progress of the reaction was monitored by TLC & LCMS. After completion of the reaction, the reaction mass was quenched with sat. NH4CI (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over Na2SO4, concentrated under reduced pressure. The crude compound was purified by column chromatography using silica gel (100-200 mesh), eluting with 0-50% ethyl acetate in pet-ether to give 3-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cycloheptan-1-ol (64% trans) & (15% cis) (8.5 g, 84% yield as mixture of cis-trans isomers) as pale yellow solid. LC-MS m/z [M+H]+ = 266.39 ,5-dibromo-2-chloro-7-(3-hydroxycycloheptyl)-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one (racemate, diasteromeric mixture): To a stirred solution of 3-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-7- 143 PAT059456 FF yl)cycloheptan-1-ol (8.5 g, 23.28 mmol) in tert-butanol (85 mL) and water (17 mL), was added NBS (12.g, 69.86 mmol) at room temperature and stirred to 3h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was diluted with water (50 mL) and extracted with ethyl acetate (3 x 75 mL), the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to give crude 5,5-dibromo-2-chloro-7-(3-hydroxycycloheptyl)-5,7-dihydro-6H- pyrrolo[2,3-d]pyrimidin-6-one (14.5 g crude, mixture of cis-trans isomers) as brown gummy liquid. The crude compound used as such for next step without further purification. 2-chloro-7-(3-hydroxycycloheptyl)-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one(racemate, diasteromeric mixture): To a stirred solution of 5,5-dibromo-2-chloro-7-(3-hydroxycycloheptyl)-5,7-dihydro- 6H-pyrrolo[2,3-d]pyrimidin-6-one (14g crude, 31.85 mmol) in AcOH (140 mL) was added Zinc-dust (10 g, 159.27 mmol) at room temperature and stirred for 1h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered through celite-pad, filtrate was concentrated under reduced pressure. The crude was diluted with ethyl acetate (300 mL) and washed with water (2 x 50 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure. The crude compound was purified by column chromatography using silica gel (230-400 mesh), eluting with 0- 50% ethyl acetate in pet-ether to give 2-chloro-7-(3-hydroxycycloheptyl)-5,7-dihydro-6H-pyrrolo[2,3- d]pyrimidin-6-one (77% cis) and (10% trans) (4.5 g, 68% yield after two steps) as brown colour solid. LC- MSm/z [M+H]+ =282.33 2'-chloro-7'-(3-hydroxycycloheptyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (Racemate, diastereomeric mixture): To a stirred solution of 2-chloro-7-(3-hydroxycycloheptyl)-5,7-dihydro- 6H-pyrrolo[2,3-d]pyrimidin-6-one (3 g, 10.64 mmol) and dibromoethane (4.6 mL, 53.24 mmol) in dry DMF (30 mL), was added NaH (60%, 2.1 g, 53.24 mmol) portion wise at room temperature and stirred for 3h. Progress of the reaction was monitored by TLC & LCMS. After completion of the reaction, the reaction was quenched with ice-cold water (10 mL), extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with ice-cold water (2x10 mL), dried over Na2SO4, concentrated under reduced pressure to get the crude product. The crude product was purified by column chromatography (silica gel, 230-400 mesh), eluting with 0-70% ethyl acetate in pet ether to give 2'-chloro-7'-(3-hydroxycycloheptyl)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (79% trans) & (13% cis) (2.2 g, 67% yield) as pale brown solid. LC-MS m/z [M+H]+= 308.21,1H NMR(400 MHz, CDCIa) 6 = 7.78-7.84 (m, 1H), 4.79-4.89 (m, 1H), 4.29 (s, 1H), 2.62-2.72 (m, 1H), 2.27-2.42 (m, 1H), 1.93-2.08 (m, 2H), 1.70-1.90 (m, 7H), 1.55-1.70 (m, 3H), 1.42- 1.58 (m, 1H). 144 PAT059456 FF 7'-(3-hydroxycycloheptyl)-2'-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one(Racemate, diastereo meric mixture): To a degassed solution of 2'-chloro-7'-(3-hydroxycycloheptyl)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6'(7'H)-one (0.35 g, 1.14 mmol) and 3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol- 4-amine (0.31 g, 1.36 mmol) in dry THF (4 mL), was added NaOtBu (0.16 g, 1.71 mmol) and BrettphosPdG(0.10 g, 0.11 mmol), the reaction mass was closed under argon atmosphere and stirred at room temperature for 2h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered; the filtrate was concentrated under reduced pressure to give crude compound. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-70% ethyl acetate in pet-ether to give 7'-(3-hydroxycycloheptyl)-2'-((3-methyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one (0.35 g, 53% yield) as pale yellow liquid. LC-MS m/z [M+H]+ = 499.67 & 499.57. 7'-(3-hydroxycycloheptyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6'(7'H)-one(trans-racemic); To a stirred solution of 7'-(3-hydroxycycloheptyl)-2'-((3-methyl- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one (0.3 g, 0.60 mmol) in methanol (1.5 mL), was added 4M HCI in dioxane (1.5 mL) at 0° C and stirred at 50 °C for 3h. Progress of the reaction was monitored by TLC & LCMS. After completion of reaction, reaction mass was concentrated under reduced pressure. The crude product was basified with aq. NaHCOand extracted with 5% MeOH in DCM (3x15 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to get the crude compound. The crude product was purified by Prep. HPLC (Column: YMC trial C18 Buffer A: 10 mm ABC Buffer B:- ACN solubility:- ACN-THF-water mobile phase conditions (% of B):- 0/35,2/50,12/60,12.01/100,16/100,16.01/35,20/35 flow-20/min) to give 7'-(3- hydroxycycloheptyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one (peak-2, 40 mg, trans-isomer) as off white solid. LC-MSm/z [M+H]+ = 369.43, 1H NMR (400 MHz, DMSO-d6)6 = 11.50-12.80 (br-s, 1H), 8.54 (br-s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 4.68-4.80 (m, 1H), 4.49 (s, 1H), 3.98 (s, 1H), 2.50-2.62 (m, 1H), 2.10-2.20 (m, 3H), 2.20-2.28 (m, 1H), 1.60-1.80 (m, 6H), 1.55- 1.64 (m, 3H), 1.40-1.54 (m, 3H), 1.30-1.40 (m, 1H). 7'-((1R,3R)-3-hydroxycycloheptyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one:Trans-racemic 7'-(3-hydroxycycloheptyl)-2'-((3-methyl-1H-pyrazol- 4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one (30 mg) was subjected to SFC separation (Chiralpak IC, 65% CO2, 35% (30 mM methanolic ammonia in methanol as co-solvent). After completion of the separation, the solvent of peak-1 was distilled off to give 7'-((1R,3R)-3- hydroxycycloheptyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one (0.136 g, 38%) as white solid. LC-MSm/z [M+H]+ = 369.40, 1H NMR (400 MHz, DMSO-d6)6 145 PAT059456 FF = 12.09 (br-s, 1H), 8.54 (s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 4.68-4.78 (m, 1H), 4.49 (s, 1H), 3.98 (s, 1H), 2.50-2.60 (m, 1H), 2.10-2.25 (m, 4H), 1.63-1.82 (m, 5H), 1.56-1.62 (m, 3H), 1.41-1.55 (m, 3H), 1.30-1.(m, 1H).
Example 18: (7'-((1 R,3R)-3-hydroxycycloheptyl)-2'-((3-methoxy-1 H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one) was made using the method of Example 12, but using Intermediate 2 rather than Intermediate 1.
NH2 Alternatively, the route of Example 17 alternative synthesis can be used, but using SEM instead of SEM Example 19: (2'-((3-ch loro-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycycloheptyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one) was made using the method of Example 13, but using Intermediate 2 rather than Intermediate 1.
PAT059456 FF NH2 Alternatively, the route of Example 17 alternative synthesis can be used, but usingNH2SEM instead of SEM Example 20: NO?no2 nh2SEM-CI, Cs 2CO3 Pd/CDMF, 0o C-RT Step-89% N—N MeOH, RT SEM Step-73%N™NSEM 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbonitrile:To a stirred solution of 4-nitro- 1H-pyrazole-3-carbonitrile (3g, 21.70 mmol) and C52CO3 (14.1 g, 43.40 mmol) in DMF (150 mb), was added SEM-CI (5.7 mb, 32.60 mmol) at 0° C and then stirred at room temperature for 3 h. The progress of the reaction was monitored by TbC. After completion of the reaction, the reaction was quenched with ice-cold water and extracted with ethyl acetate (2 x 50 mb). The organic layer was washed with ice-cold water (2 x mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbonitrile as pale yellow liquid (5.2 g, 89% yield). 1H NMR (400 MHz, CDCIa)6 = 8.40 (s, 1H), 5.52 (s, 2H), 3.62-3.72 (m, 2H), 0.92-1.(m, 2H), 0.00-0.05 (m, 9H). 4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbonitrile:To a Parr-shaker containing 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbonitrile (2g, 7.46 mmol) in methanol (20 mb), was added Pd/C (0.2g) and the reaction mass was stirred at room temperature with 80 psi hydrogen pressure for 2 h. Progress of the reaction was monitored by TbC. After completion of the reaction, the reaction mass was filtered through plug of celite, the filtrate was concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-20% ethyl acetate in pet-ether to give 4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole-3-carbonitrile as pale brown sloid (1.3 g, 73% yield). LC-MSm/z [M+H]+ = 239.48, 1H NMR (400 147 PAT059456 FF MHz, DMSO-d6)6 = 7.35 (s, 1H), 5.31 (s, 2H), 4.82 (s, 2H), 4.50 (t, J = 8.0 Hz, 2H), 0.82 (t, J = 8.0 Hz, 2H), -0.08-0.0 (m, 9H).
Coupling to Intermediate 1 and deprotection of SEM group to form 4-((7'-((1R,3R)-3-hydroxycyclohexyl)- 6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carbonitrile as per the method described in Example 2.
Example 21: 0 ^2U A SEM-CI, Cs•W 7N~NH Methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate:To a stirred solution of methyl 4-nitro-1H-pyrazole-3-carboxylate (2 g, 11.69 mmol) and C52CO3 (7.6 g, 23.39 mmol) in DMF (20 mb), was added SEM-CI (3.2 mb, 17.54 mmol) at 0° C and then stirred at room temperature for 2h. The progress of the reaction was monitored by TbC and bCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 30 mb). The organic layer was washed with ice-cold water (2x10 mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-etherto give methyl 4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (3.2 g, 91% yield) as colourless liquid. 1H NMR (400 MHz, DMSO-d6)6 = 9.18 (s, 1H), 8.46 (s, 1H), 5.60 (s, 2H), 5.51 (s, 2H), 3.97 (s, 3H), 3.89 (s, 3H), 3.50-3.64 (m, 4H), 0.80-0.90 (m, 4H), -0.05-0.01 (m, 9H). (4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol:To a stirred solution of methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (1.2 g, 3.98 mmol) in dry THF (12 ml) was added Dibal-H (12 ml, 15.80 mmol) drop wise at -30°C, then reaction mass was raised to room temperature and stirred for 3h. The progress of the reaction was monitored TbC & bCMS. After completion of the reaction, quenched with 1N HCI and extracted with ethyl acetate (3 x 30 mb). The organic layer was 148 PAT059456 FF dried over Na2S04, concentrated to give crude compound. The crude compound was purified by Sepa- Bean using silica gel (230-400 mesh), eluting with 0-50% ethyl acetate in pet-ether to give (4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (0.45 g, 41% yield) as pale orange liquid. 1H NMR (400 MHz, CDCI3)6 = 8.32 (s, 1H), 5.42 (s, 2H), 4.93 (d, J = 6.8 Hz, 2H), 3.60-3.68 (m, 2H), 2.82 (t, J = 6.Hz, 1H), 0.92-0.98 (m, 2H), -0.06-0.05 (m, 9H). 3-(methoxymethyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of (4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (0.4 g, 1.46 mmol) in dry THF (15 ml) was added NaH (60%, 0.09g, 3.65 mmol) at 0°C and stirred for 30 min. After, dimethyl sulfate (0.16 mL, 1.75 mmol) was added and stirred at 50°C for4h. The progress of the reaction was monitored TLC & LCMS. After completion of the reaction, quenched with water and extracted with ethyl acetate (3 x 30 mL). The organic layer was dried over Na2SO4, concentrated to give crude compound. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-ether to give 3-(methoxymethyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.35 g, 83% yield) as pale brown liquid. 1H NMR (400 MHz, CDCIa)6 = 8.33 (s, 1H), 5.44 (s, 2H), 4.81 (s, 2H), 3.64 (t, J = 8.0 Hz, 2H), 3.51 (s, 3H), 0.94 (t, J = 8.0 Hz, 2H), -0.09-0.02 (m, 9H). 3-(methoxymethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirring solution of 3-(methoxymethyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.35 g, 1.21 mmol) in methanol (6 mL), was added Pd/C (10%, 0.1 g) and stirred at room temperature under hydrogen balloon pressure for 2h. Progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was filtered through plug of eelite, the filtrate was concentrated under reduced pressure to give the crude 3- (methoxymethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.23 g, 73% yield) as pale green liquid. The crude product used as such without further purification. 1H NMR (400 MHz, CDCI)6 = 7.14 (s, 1H), 5.29 (s, 2H), 4.55 (s, 2H), 3.53 (t, J = 8.0 Hz, 2H), 3.92 (s, 3H), 0.92 (t, J = 8.0 Hz, 2H), -0.01-0.08 (m, 9H).
Coupling to Intermediate 1 and deprotection of SEM group to form 7'-((1R,3R)-3-hydroxycyclohexyl)-2'- ((3-(methoxymethyl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one as per the method described in Example 2. 149 PAT059456 FF Example 22: HOPyridine, Ac 2O°C Step-81% 3 /"O " ' MeOH/NaOH~ P ؛® K2CO3, DMF =O SStep-2 / 78%85% H2SO4,HNO3Step-55%(Crude) SEM-ClCs 2CO3, DMFStep-64%(Crude)N-NxSEM Pd/C, MeOH, H2Step-83%(Crude) 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one:To a stirred solution of 1H-pyrazol-3-ol (5 g, 59.5mmol) in pyridine (26 mb) was added Ac2O (5.9 ml, 62.05mmol) in 9 mb of pyridine at 95 °C over 30 min. The reaction mass was stirred under argon atmosphere at 95°C for 3.5hs. Progress of the reaction was monitored by TbC and LCMS. After completion of the reaction, the reaction mass was concentrated under reduced pressure to give crude compound. The crude compound was purified by trituration with methanol (15 mb) and filtered through Buchner funnel and washed with methanol and dried to give 1-(3-hydroxy-1H-pyrazol- 1-yl)ethan-1-one (6.1g, 81% yield) as off white solid. LC-MS m/z:[M+H]+ = 127.00 1H NMR (400 MHz, DMSO-d6) 6 = 10.956 (s, 1H), 8.132-8.125 (d, J=2.8HZ, 1H), 6.012-6.005 (d, J=2.8HZ, 1H), 2.507 (s, 3H). 1-(3-(2-methoxyethoxy)-1H-pyrazol-1-yl)ethan-1-one:To a degassed solution of 1-(3-hydroxy-1H- pyrazol-1-yl)ethan-1-one (2g, 15.87 mmol) and 1-bromo-2-methoxyethane (2.28 g, 16.66 mmol) in DMF(20mb), was added K2CO3 (3.28g, 23.8mmol), the reaction mass was stirred under argon atmosphere at 850C for2h. Progress of the reaction was monitored by TbC and LCMS. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mb). The organic layer was washed with ice-cold water (2 x 500 mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-30% ethyl acetate in pet-ether to give 1-(3-(2-methoxyethoxy)-1H- pyrazol-1-yl)ethan-1-one (2.5g, 85% yield) as pale yellow liquid. LC-MS m/z: [M+H]+ = 185.31 1H NMR (400 MHz, CDCI3) 6 = 8.054-8.046 (d, J=3.3HZ, 1H), 6.007-6.000 (d, J=3.3HZ, 1H), 4.414 (m, 2H), 3.757- 3.727 (m, 2H), 3.44 (s, 3H), 2.594 (s, 3H). 150 PAT059456 FF 3-(2-methoxyethoxy)-1H-pyrazole:To a degassed solution of 1-(3-(2-methoxyethoxy)-1H-pyrazol-1- yl)ethan-1-one (2.5g, 13.58mmol) in MeOH(17.5ml), was added 8M NaOH(6.8ml, 135.8mmol) solution, the reaction mass was closed under argon atmosphere and stirred at 50 °C for 1h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mL). The organic layer was washed with ice-cold water (2 x 500 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude 3-(2- methoxyethoxy)-1H-pyrazole (1.5g crude, 78% yield) as pale yellow solid. LC-MS m/z:[M+H]+ =143.(82%purity) 1H NMR (400 MHz, CDCL3) 6 = 9.169(brs, 1H), 7.357-7.351 (d, J=2.4HZ, 1H), 5.772-5.7(d, J=2.4HZ, 1H), 4.344-4.321 (m, 2H), 3.752-3.728 (m, 2H), 3.441 (s, 3H). 3-(2-methoxyethoxy)-4-nitro-1H-pyrazole:To a solution of 3-(2-methoxyethoxy)-1H-pyrazole (1.5g, 10.56mmol) in H2SO4(6 mL, 4 V), was added HNO3 (1.5 mL, 1V), and the reaction mass was stirred under argon atmosphere at 50 °C for 3h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mL). The organic layer was washed with ice-cold water (2 x 500 mL), dried over Na2SOand concentrated under reduced pressure to give the crude 3-(2-methoxyethoxy)-4-nitro-1H-pyrazole (1.1g crude, 55% yield) as yellow solid. LC-MS m/z: [M+H]+ =188.32 (76%) 3-(2-methoxyethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-(2-methoxyethoxy)-4-nitro-1H-pyrazole (1.1g, 5.88mmol) and C52CO3 (3.44 g, 10.58mmol) in DMF (mL), was added SEM-CI (1.55 mL, 8.82mmol) at 0° C and then stirred at room temperature for 3h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mL). The organic layer was washed with ice-cold water (2 x 500 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-40% ethyl acetate in pet-ether to give 3-(2-methoxyethoxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.2g, 64% yield) as Pale yellow colour liquid. LC-MS m/z: [M+H]+ =318.48 3-(2-methoxyethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a parr-shaker containing 3-(2-methoxyethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.2 g, 3.78mmol) in methanol (24 mL), was added Pd/C (10%, 120mg) and stirred at room temperature at 80 psi hydrogen pressure for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, reaction 151 PAT059456 FF mass was filtered through eelite pad and washed with 10% MeOH in DCM, the filtrates were concentrated under reduced pressure to give the crude product 3-(2-methoxyethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-4-amine ( 900 mg crude, 83% yield) as brown liquid. LC-MS m/z: [M+H]+= 288.08 Coupling to Intermediate 1 and deprotection of SEM group to form 7'-((1R,3R)-3-hydroxycyclohexyl)-2'- ((3-(2-methoxyethoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one as per the method described in Example 2.
Example 23: seM-CI, Cs 2CO3nN J ،Pd/C, MeOH SEM-N N• DMF, RT, 3hStep-185%NO2Step-46%nh2 3-ethoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-ethoxy-4- nitro-1H-pyrazole (900mg, 5.73 mmol) and C52CO3 (3.7 g, 11.46mmol) in DMF (9 mb), was added SEM-CI (1.51 mb, 8.59 mmol) at 0° C and then stirred at room temperature for4h. The progress of the reaction was monitored byTbC and bCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mb). The organic layer was washed with ice-cold water (2 x 5mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 3-ethoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.4 g, 85% yield) as Pale yellow colour liquid.
LC-MS m/z:not ionizing (78%)1H NMR (400 MHz, CHbOROFORM-d) 6 = 8.136 (s, 1H), 5.245(s, 2H), 4.410- 4.392 (m, 2H), 3.365 - 3.609 (m, 2H), 1.485 - 1.450 (t, J=6.8 HZ, 3H), 0.961-0.919 (m, 2H), 0.036- 0.011 (s, 9H). 3-ethoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a parr-shaker containing 3- ethoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (500 g, 1.74mmol) in methanol (5 mb), was added Pd/C (10%, 50mg) and stirred at room temperature at 80 psi hydrogen pressure for 1h. Progress of the reaction was monitored by TbC. After completion of reaction, reaction mass was filtered through celite 152 PAT059456 FF pad and washed with 10% MeOH in DCM, the filtrates were concentrated under reduced pressure to give the crude product3-ethoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (210 mg, 46% yield) as brown liquid. LC-MS m/z: [M+H]+= 258.45 Coupling to Intermediate 1 and deprotection of SEM group to form 2'-((3-ethoxy-1H-pyrazol-4-yl)amino)- 7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one as per the method described in Example 2.
Example 24: Step-354%MeOHStep-484% (Cis racemate)-4-fluorotetrahydrofuran-3-yl 4-nitrobenzoate:To a stirred solution of PPh3 (11.53 g, 35.34 mmol) and DIAD (7.1 g, 35.34 mmol) in THF (100 mb) at RT was added a mixture of (Trans- racemate)-4-fluorotetrahydrofuran-3-ol (2.5 g, 23.56 mmol) and 4-nitrobenzoic acid (5.90 g, 35.34 mmol) dissolved in THF (10 mb). The reaction mixture was stirred at RT for 16h. The progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, the reaction mixture was evaporated under vacuum to afford crude compound. The crude compound was purified by Sepa-Bean using silica gel (100- 200 mesh), by eluting with 15-20% ethyl acetate in pet-ether and evaporated to give (Cis-racemate)-4- fluorotetrahydrofuran-3-yl 4-nitrobenzoate (5.0 g, 83% yield) as an Off-white solid. 1H NMR (400 MHz, CDCI3) 6 =8.29-8.33 (m, 2H), 8.24-8.27 (m, 2H), 4.80-5.10 (m, 2H), 4.01-4.25 (m, 4H).
(Cis racemate)-4-fluorotetrahydrofuran-3-ol:To a stirred solution of (Cis racemate)-4- fluorotetrahydrofuran-3-yl 4-nitrobenzoate (5.0 g, 19.59 mmol) in MeOH (250mb) at RT was added K2CO(13.54 g, 97.96 mmol). The reaction mixture was stirred at RT under argon atmosphere for2h. The progress of the reaction was monitored by TbC. After completion of the reaction, the reaction mixture was filtered and filtrate was evaporated under reduced pressure to give crude compound. The crude compound was purified by Sepa-Bean using silica gel (100-200 mesh), eluting with 50% ethyl acetate in pet-ether to give 153 PAT059456 FF (Cis-racemate)-4-fluorotetrahydrofuran-3-ol. (1.3 g, 52% yield over 2 steps) as a Pale brown syrup. 1H NMR (400 MHz, CDCh) 6= 4.95-5.10 (m, 1H), 4.28-4.41 (m, 1H), 3.95-4.11 (m, 4H), 2.237 (br-s, 1H).
(Trans-racemate) 3-((-4-fluorotetrahydrofuran-3-yl) oxy)-4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazole:To a stirring solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (300 mg, 1.15 mmol), (Cis-Racemate))-4-fluorotetrahydrofuran-3-olin Toluene (6 mb) was added CMBP at RT. The reaction mixture was subjected to heat at 100 °C in a microwave for 1h. The progress of the reaction was monitored by TLC. After completion of reaction, reaction mixture was evaporated under reduced pressure to give the crude compound. The crude compound was purified by Sepa-Bean using silica gel (100-200 mesh), eluting with 25% ethyl acetate in pet-ether to give Trans-racemate 3-((-4- fluorotetrahydrofuran-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (220 mg, 54% yield) as a Pale yellow solid. LC-MS m/z [M+H]+ = 348.45 Trans-racemate 3-((-4-fluorotetrahydrofuran-3-yl) oxy)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H- pyrazol-4-amine:To a stirred solution of Trans-racemate 3-((-4-fluorotetrahydrofuran-3-yl)oxy)-4-nitro-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.3 g, 3.47 mmol) in Methanol (26 mL), was added 10% Pd/C (40%w/w, 520 mg) at RT and stirred under hydrogen balloon pressure for4h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was filtered through plug of eelite, the filtrate was evaporated under reduced pressure to give Trans-racemate 3-((-4- fluorotetrahydrofuran-3-yl) oxy)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-4-amine (1.0 g, 84% yield) as a Pale pink syrup. The crude product used as such without further purification. LC-MSm/z [M+H]+ = 318.17 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM followed by chiral SFC provided for Peak 1 2'-((3-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4- yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 154 PAT059456 FF Example 25: Peak 2 from SFC in example 24 resulted in 2'-((3-(((3S,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4- yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 26: Synthesis of Cis-Racemate 3-((-4-fluorotetrahydrofuran-3-yl) oxy)-4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-3-ol (1.0 g, 3.85 mmol), (trans-racemate)-4-fluorotetrahydrofuran-3-ol (0.613 g, 5.78 mmol) and (Tributylphosphoranylidene) acetonitrile (1.86 g, 7.72 mmol) in Toluene (15 mb) at RT. The reaction mixture was subjected to microwave irradiation at 100 °C for 3h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was evaporated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (100-200 mesh), eluting with 30-40% ethyl acetate in pet-ether to give Cis-Racemate 3-((-4-fluorotetrahydrofuran-3-yl)oxy)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (900 mg, 27% yield) as a Pale brown syrup. LC-MS m/z [M+H]+ = 348.19.
Cis-Racemate 3-((-4-fluorotetrahydrofuran-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole: To a stirred solution of Cis-Racemate 3-(-4-fluorotetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.9 g, 2.59 mmol) in MeOH (9.0 mb) was added 10% Pd/C (40%w/w, 0.36 g) and stirred at RT under hydrogen balloon pressure for 2h. The progress of the reaction was monitored by TbC. After completion of reaction, reaction mass was filtered through plug of celite, the filtrate was evaporated under reduced pressure to give the crude compound. The crude compound was purified by Sepa-Bean using silica gel (100-200 mesh), eluting with 40-50% ethyl acetate 155 PAT059456 FF in pet-ether to give Cis-Racemate 3-((-4-fluorotetrahydrofuran-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.3 g) as a Pale brown syrup. LC-MS m/z [M+H]+ = 318.52 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM followedby chiral SFC provided for Peak 1 2'-((3-(((3R,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4- yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 27: Peak 2 from SFC in example 26 provided for2'-((3-(((3S,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol- 4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 28: Fe, NH4CIPd(dppf)CI 2 DCM.NaOt-Bu, 90 °C, 4hStep-142% N—N Eton, H2OSEM 80 °C, 2hStep-65% 3-(4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-yl) pyrazolo[1,5-a] pyridine:To a stirred solution of 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.1 g, 2.97 mmol), 3-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine (0.729 g, 2.97 mmol) in Toluene: H2O (20 mb: 156 PAT059456 FF 2 mL) at RT was added NaOt-Bu (0.715 g, 7.42 mmol). The reaction mixture was degassed with argon for min, Pd(dppf)CI2.DCM (0.243 g, 0.297 mmol) was added and then stirred at 90°C for 4h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was concentrated under reduced pressure to give crude compound. The crude compound was purified by Sepa- Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-etherto give 3-(4-nitro-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridine (0.45 g, 42% yield) as a Pale yellow solid. LC-MS m/z [M+H]+ = 360.16 3-(pyrazolo[1,5-a]pyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirring solution of 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridine (350 mg, 0.974 mmol) in Ethanol: H2O (3.5 mL: 0.7 mL) was added Fe powder (0.272 g, 4.87 mmol), NH4CI (0.26 g 0.487 mmol) at RT. The reaction mixture was stirred at 80 °C for 2h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was filtered through plug ofcelite, the filtrate was concentrated under reduced pressure to give the crude compound. The crude compound was purified by Sepa-Bean using silica gel (100-200 mesh), eluting with 40-45% ethyl acetate in pet-ether pure fractions to give 3-(pyrazolo[1,5-a]pyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine (0.21 g, 65% yield) as a Pale brown solid. LC-MS m/z [M+H]+ = 330.21 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyridin-3-yl)-1 H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 29: NO2HO10% Pd/CN~nSEMCMBP. Toluene, 100 °C, MW, 1hStep-141% F™FSEM Step-2 157 PAT059456 FF 3-(3,3-difluorocyclobutoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirring solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (5.0 g, 19.3 mmol), 3,3- difluorocyclobutan-1-ol (2.08 g, 19.3 mmol) in Toluene (50 mL) was added CMBP at RT. The reaction mixture was subjected to heat at 100 °C in a microwave for 1h. The progress of the reaction was monitored by TLC. After completion of reaction, reaction mixture was evaporated under reduced pressure to give the crude compound. The crude compound was purified by Sepa-Bean using silica gel (100-200 mesh), eluting with 0-10% ethyl acetate in pet-ether to give 3-(3,3-difluorocyclobutoxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (2.8 g, 41% yield) as a Pale brown liquid. 1H NMR (400 MHz, CDCI) 6 =8.15 (s, 1H), 5.24 (s, 2H), 4.97-5.00 (m, 1H), 3.60-3.65 (m, 2H), 3.06-3.16 (m, 2H), 2.80-2.(m, 2H), 0.91-0.98 (m, 2H), 0.07 (s, 9H). 3-(3,3-difluorocyclobutoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirring solution of 3-(3,3-difluorocyclobutoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (2.8 g, 8.0mmol) in Methanol (28 mL), was added 1% Pd/C (10%, 280 mg) and stirred at RT under hydrogen balloon pressure for 2h. The progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was filtered through plug ofcelite, the filtrate was concentrated under reduced pressure to give the 3-(3,3-difluorocyclobutoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine(2.5 g) as a Pale brown liquid, proceeded to next step without further purification. 1H NMR (400 MHz, CDCI) 6 =7.001 (s, 1H), 5.107 (s, 2H), 3.46-3.51 (m, 2H), 3.05-3.06 (m, 2H), 2.71-2.77 (m, 4H), 0.85-0.90 (m, 2H), 0.001 (s, 9H).
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 2'-((3-(3,3-difluorocyclobutoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 158 PAT059456 FF Example 30 % Pd/CCMBP, Toluene.MW, 100 °C, 1hStep-165% N-n MeOH, Hz , RT,16hSEM Step-2 3-((3,3-difluorocyclopentyl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (1.000 g, 3.856 mmol), 3,3- difluorocyclopentan-1-ol (470.8 mg, 3.856 mmol) in Toluene (10.00 mL) was added 2-(tributyl-l5- phosphaneylidene) acetonitrile (CMBP) (1.861 g, 7.712 mmol). The reaction was subjected to heating at 100 °C for 1h in micro-wave. The progress of the reaction was monitored by TLC and LCMS. The reaction mass was evaporated under reduced pressure to give crude compound, which was purified by column usingsilica gel (100-200 mesh), compound was eluted with 30-35% ethyl acetate in pet-ether to give 3-((3,3-difluorocyclopentyl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as a Colour less liquid (920 mg, 65% yield). 1H NMR (400 MHz, CDCIa)6 = 8.147 (s, 1H), 5.20-5.30 (m, 3H), 3.60- 3.68 (m, 2H), 2.58-2.61 (m, 1H), 2.10-2.50 (m, 5H), 0.90-0.95 (m, 2H), 0.002 (s, 9H). 3-((3,3-difluorocyclopentyl) oxy)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-4-amine:To a stirred solution 3-((3,3-difluorocyclopentyl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (920.0 mg, 1.0, 2.531 mmol) in MeOH (10.00 mL) was added 10% Pd/C (360.0 mg, 40% w/w). The reaction mixture was stirred under H2 atmosphere (90 psi) at RT for2h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, reaction mass was filtered through ceilite pad. The filtrate was evaporated under reduced pressure to give 3-((3,3-difluorocyclopentyl) oxy)-1-((2- (trimethylsilyl) ethoxy) methyl)-1H-pyrazol-4-amineas a Brown color liquid (820 mg). LC-MSm/z [M+H] + = 334.13 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 2'-((3-(3,3-difluorocyclobutoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 31 159 PAT059456 FF ;bMEtOH, H2U, 80 °C Step-1 DASTDCM, -78°C, RT, 6hStep-262%SEM % Pd/CStep-3SEM 1'-methyl-4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H,1'H-[3,4'-bipyrazole]-5'-carbaldehyde: To a degassed solution of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-5- carbaldehyde (1.0 g, 4.23 mmol), 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.56 g, 4.23 mmol) in EtOH (4.0 mb), H2O (1.0 mb) was added CsF (1.28 g, 8.47 mmol) at RT. To reaction mixture Pd(PPh3)4 (342 mg, 0.296 mmol) was added and stirred under argon atmosphere at 80 °C for 16h. The progress of the reaction was monitored by TLC and bCMS. After completion of the reaction, the reaction mass filtered on celite bed and filtrate was evaporated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-20% ethyl acetate in pet-etherto give T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazole]-5'- carbaldehyde (270 mg, 18% yield) as a Pale brown liquid. LC-MS m/z [M+H]+ = 352.54. '-(difluoromethyl)-1'-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole:To a stirred solution of T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazole]-5'- carbaldehyde (0.42 g, 1.19 mmol) in DCM (8.4 mb) at -78 °C was added DAST (0. ml, 0.47 mmol) drop wise. The reaction mixture was raised to RT and stirred for6h. The progress of the reaction was monitored by TbC. After completion of reaction, reaction mass quenched with saturated NaHCO3 solution, extracted with DCM and evaporated under reduced pressure to give the crude compound. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-20% ethyl acetate in pet-etherto give 5'-(difluoromethyl)-T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole (2mg, 62% yield) as a Brown liquid. LC-MS m/z [M+H]+ = 374.53. '-(difluoromethyl)-1'-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine:To a stirring solution of 5'-(difluoromethyl)-T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'- bipyrazole (0.28 g, 0.749 mmol) in MeOH (10 mb), was added 10% Pd/C (40%w/w, 112 mg) and stirred at RT under hydrogen balloon pressure for 5h. The progress of the reaction was monitored by TbC. After completion of reaction, reaction mass was filtered through plug of celite, filtrate was evaporated under reduced pressure to give 5'-(difluoromethyl)-T-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'- bipyrazol]-4-amine (0.230 g) as a Pale brown syrup, which was used to next step without further purification. LC-MSm/z [M+H]+ = 344.25 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 2'-((5'-(difluoromethyl)-T-methyl-1H,TH-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3- 160 PAT059456 FF hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 32 ^■'bf3k ■ n°2 Pd(dppf)CI 2 DCM. KaPO4 _1,4-Dioxane, H2O; 90 °C. 16h SEIStep-354% %Pd-CMeOH, RT, 16hStep-3SEM 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-3-vinyl-1H-pyrazole:To a stirred solution of 3-iodo-4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (5.000 g, 13.54 mmol), Potassium vinyl-trifluoroborate (2.177 g, 16.25 mmol) in 1,4-Dioxane (90.00 mb) was added K3PO4 (7.186 g, 33.85 mmol) and H2O (mb) and purged the reaction mass with argon for 5 min. Pd(dppf)CI2.DCM (1.106 g, 1.354 mmol) was added and purged the reaction mass with argon for 5 min. The reaction mixture was heated to 90 °C and stirred for 16h. The progress of the reaction was monitored by bC-MS. After completion of the reaction, reaction mixture was filtered through cellite pad and filtrate was evaporated under reduced pressure to give crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0- 20% ethyl acetate in pet-etherto give 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-3-vinyl-1H-pyrazole as a Pale yellow liquid (2.0 g, 54% yield). 1H NMR(400 MHz, CDCh)6 = 8.12 (s, 1H), 7.11-7.18 (m, 1H), 6.24- 6.28 (m, 1H), 5.93-5.97 (m, 1H), 5.47 (s, 2H), 3.70-3.74 (m, 2H), 0.91-0.95 (m, 2H), 0.01 (s, 9H). 3-(2,2-difluorocyclopropyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-3-vinyl-1H-pyrazole (2.000 g, 7.424 mmol) in THF (40.00 mb) at 0 °C was added Nai (71.27 mg, 2.970 mmol), followed by TMSCF3 (22.3 mb, 148.5 mmol). The reaction was stirred at 60 °C for 48h.The progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, the reaction mass was quenched water (30), extracted the compound with ethyl acetate (2 x 40 mb). The organic layer was dried over Na2SO4, evaporated under reduced pressure to give crude compound. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 15-30% ethyl acetate in pet-ether to give 3-(2,2-difluorocyclopropyl)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole as an Off-white solid (1.1 g, 41% yield). 1H NMR (400 MHz, CDCh)6 = 8.12 (s, 1H), 5.42-5.66 (m, 2H), 3.61-3.66 (m, 2H), 2.82-2.88 (m, 1H), 2.17-2.18 (m, 1H), 2.02- 2.06 (m, 1H), 0.87-0.95 (m, 2H), 0.008 (s, 9H). 161 PAT059456 FF 3-(2,2-difluorocyclopropyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-(2,2-difluorocyclopropyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (1.000 g, 3.131 mmol) in MeOH (30.00 mL) was added 10%Pd-C (400.0 mg, 40% w/w). The reaction mixture was stirred under H2 (90 psi) at room temperature for 16h. The progress of the reaction was monitored by TLCand LCMS. After completion of the reaction, reaction mixture was filtered through ceilite bed, filtrate was evaporated under reduced pressure to give 3-(2,2-difluorocyclopropyl)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-4-amine as an Off-white solid (900 mg), forwarded to next step with out further purification. LC-MSm/z [M+H]+ =290.38 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM followed by chiral SFC provided for peak 1 provided for,OH2'-((3-((S)-2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 33 Peak 2 from SFC in example 32 provided forOH2'-((3-((S)-2,2-difluorocyclopropyl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 162 PAT059456 FF Example 34 % T-(difluoromethyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole:To a stirred solution of 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.0 g, 4.mmol) in 1,4-Dioxane (10.00 mL) was added 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.96 g, 5.327 mmol), K3PO4(2.17 g, 10.24 mmol), H2O (2.0 mL) and degassed with the Nitrogen for 5 min. Tetrakis (473.5 mg, 409.8 mmol) was added to the reaction mixture and again degassed with nitrogen for min at RT and then stirred at 90 °C for 3h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, the mixture was filtered through ceilite bed, then filtrate was concentrated under reduced pressure to get crude compound. The crude was purified by column using 100-200 silica gel, compound was eluted with 50% ethyl acetate in pet-ether to give 1'-(difluoromethyl)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H,1'H-3,4'-bipyrazole as an Off-white solid (440 mg, 30% yield). LC-MS m/z [M+H] + = 360.40 T-(difluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine:To a stirred solution of T-(difluoromethyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole (440 mg, 1.224 mmol) in MeOH (10 mL) was added 10% Pd/C (130.3 mg). The reaction mixture was stirred under H2 (70 psi) at room temperature for 16h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, reaction mixture was filtered through ceilite bed. The filtrate was concentrated under reduced pressure to get crude compound, which was purified by column using 100- 200 silica gel compound was eluted with 60% ethyl acetate in pet-etherto give 1'-(difluoromethyl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H,1'H-[3,4'-bipyrazol]-4-amine as a brown colour solid (290 mg, 72% yield). LC-MSm/z [M+H]+ = 330.31. 163 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((1'-(difluoro methyl)-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 35 w /N—N Rd (OAc)2, Cs 2CO3,Toulene,I 80 °C, 6hStep-82% 3-((1-methyl-1H-pyrazol-4-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1 g, 2.708 mmol) in Toluene (10 mb) was added 1-methyl-1H-pyrazol-4-ol (1.79 g, 2.709 mmol), C52CO3 (1.324 g, 4.06 mmol) and degassed with the Nitrogen for 5 min. To this 5-(di(adamantan-1-yl) phosphaneyl)-1',3',5'-triphenyl- 1'H-1,4'-bipyrazole (35.90 mg, 54.17 pmol), Hexakis(acetate) tripalladium(ll) (18.24 mg, 27.08 pmol) was added and stirred at 80 °C for 16h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was evaporated under reduced pressure to get crude compound. The crude was purified by column chromatography using 100-200 silica gel, compound was eluted with 40% ethyl acetate in pet- ether to give 3-((1-methyl-1H-pyrazol-4-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as an Off-white solid (700 mg, 76% yield). LC-MS m/z [M+H] + = 340.37 (82%). 3-((1-methyl-1H-pyrazol-4-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: :To a stirred solution of 3-((1 -methyl- 1 H-pyrazol-4-yl)oxy)-4-nitro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H- pyrazole (600 mg, 1.768 mmol) in EtOH (10 mb), H2O (2.5 mb) at 0 °C was added NH4CI (472 mg, 8.8mmol), Fe (493.6 mg, 8.838 mmol). The reaction mixture was stirred at 80 °C for 2h. The progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, filtered through a plug of ciliate bed, filtrate was evaporated under reduced pressure to give crude compound, which was purified by column chromatography using 100-200 silica gel, compound eluted with 80% ethyl acetate in pet-etherto give 3-((1-methyl-1H-pyrazol-4-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amineas a Brown liquid (200 mg, 37%). bC-MS m/z [M+H] + = 310.18 164 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for /7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-((1 -methyl- 1 H-pyrazol-4-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 36 3-(pyridin-3-ylethynyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To a stirred solution of 3- iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (600 mg, 1.76 mmol), 3-ethynylpyridine (2mg, 2.65 mmol) in DMF (5.0 mb) was added Et3N (6.0 mb), followed by Cui (67.37 mg, 0.36 mmol) andwas degassed with the Nitrogen for 5 min. To this Pd(PPh3)2CI2 (124.1 mg, 6.9 pmol) was added and again degassed with nitrogen for 3 min. The reaction mixture was stirred at 50 °C for 8h. The progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, the reaction mixture was filtered on celite pad, washed with ethyl acetate. The organic layer was washed with the brine solution and dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crudecompound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 50-80% ethyl acetate in pet-etherto give 3-(pyridin-3-ylethynyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amineas an Pink gum biquid (300 mg, 16.6 % yield). LC-MS m/z [M+H]+ = 314.46. 165 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-ylethynyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 37 Fe powder /N-NK3PO4, Dioxane H2O, 90 °C, 161■ Step-32% NH4CI, EtOH Step-277% T,5'-dimethyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,1'H-3,4'-bipyrazole:To a stirred solution of 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (500 mg, 1.35 mmol) and 1,5-dimethyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (360 mg,1.62 mmol), Potassium phosphate, tribasic (718.6 mg, 3.385 mmol) in 1,4-Dioxane (9.000 mb) and water (1.000 L)was degassed with the Nitrogen for 5min. 1,1'Bis(diphenylphosphino)ferrocene] dichloropalladium (II) Complex with Dichloromethane (110.6 mg, 135.4 pmol) was added to the reaction mixture and again degassed with nitrogen for 3 min. The reaction mixture was stirred at 90 °C for 16h. After completion of the reaction, the reaction mixture was filtered on celite pad, washed with ethyl acetate. The organic layer was washed with the brine solution and dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20- 30% ethyl acetate in pet-etherto give T,5'-dimethyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'- bipyrazole as an Pale yellow Liquid (250 mg, 32% yield). LC-MS m/z [M+H]+ = 338.45 T,5'-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine: To a stirredsolution of T,5'-dimethyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole (250 mg, 0.mmol) in Ethanol (2,500 mL) and water (2,500 mL), was added NH4CI (198 mg, 3.70 pmol), Fe powder (207 mg, 3.70 mmol) at RT. The mixture was heated to 60 °C and stirred for4h. The progress of the reaction was monitored by LC-MS. After completion of reaction, reaction mass was concentrated under reduced pressure to get the crude compound. The crude compound was purified by Sepa-Bean using silica gel (230- 400 mesh), eluting with 20-30% ethyl acetate in pet-ether to give 1',5'-dimethyl-1-((2- 166 PAT059456 FF (trimethylsilyl)ethoxy)methyl)-1H,1'H-[3,4'-bipyrazol]-4-amine as an Pink colour Liquid (170 mg, 77% yield). LC-MSm/z [M+H] + = 308.2 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((1 ',5'-dimethyl-1 H,1 'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1 R,3R)- 3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 38 N™Nx 75% 3-(cyclopropylmethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (1.0 g, 3.85 mmol) and (bromomethyl)cyclopropane (1.04 g, 7.712 mmol) in DMF (10 mL) at RT was added C52CO3 (3.141 g, 9.6mmol) and stirred for 3h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, quenched with ice water (30 mL) and extracted with ethyl acetate (2x50 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 5-10% ethyl acetate in pet-etherto give 3-(cyclopropylmethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as a Pale yellow liquid (1.1 g, 81% yield). LC-MS m/z [M+H]+ = 314.42 3-(cyclopropylmethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To a stirredsolution of 3-(cyclopropylmethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1 g, 3.19 mmol) in Methanol (30 ml) was added 10% Pd/C (300 mg) at room temperature and stirred the reaction mixture under H2 atmosphere in Parr shaker for 5h. The Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug ofcelite, the filtrate was evaporated under reduced pressure to give 3-(cyclopropylmethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine as a Pink liquid (0.9 g, 75 % yield). LC-MS m/z [M+H] + = 284.46 167 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 2'-((3-(cyclopropylmethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 39 Cs2CO3, DMFStep-1 % Pd/CMeOHStep-79% 3-(2-fluoroethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (15.0 g, 57.83 mmol) and 1-fluoro-2-iodoethane (20.12 g, 115.68 mmol) in DMF (150 mb), was added C52CO3 (47.113 g, 144.60 mmol) at RT and stirred for 6h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, quenched with ice water (100 mL) and extracted with ethyl acetate (3 x50 ml). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 5-10% ethyl acetate in pet-etherto give 3-(2-fluoroethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (15 g, 83.61% yield) as an Off-white solid. 1H NMR (400 MHz, CDCIa)6 = 8.16 (s, 1H), 5.25 (s, 2H), 4.78-4.(m, 2H), 4.75-4.77 (m, 1H), 4.61-4.65 (m, 1H), 4.55-4.58 (m, 1H), 3.60-3.65 (m, 2H), 0.92-0.97 (m, 2H), 0.011 (s, 9H). 3-(2-fluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3- (2-fluoroethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (15 g, 49.119 mmol) in MeOH (1ml) was added 10% Pd/C (3.0 g, 20% w/w) at RT. The reaction mixture was stirred under H2 atmosphere in Parr shaker for 5h. The Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite, filtrate was concentrated under reduced pressure to give 3-(2-fluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amineas a Pink liquid (12.5 g, 79.% yield). 1H NMR (400 MHz, CDCIa)6 = 7.03 (s, 1H), 5.13 (s, 2H), 4.68-4.82 (m, 2H), 4.42-4.51 (m, 2H), 3.49-3.53 (m, 2H), 2.77 (br-s, 2H), 0.88-0.92 (m, 2H), 0.00 (s, 9H). 168 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-(2-fluoroethoxy)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one.
Example 40 CMBP Toluene, 100°CStep-154% EtOH, HStep-54% Fe/NH4CI, 3-cyclobutoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole: To a stirred solution of 4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (600.0 mg, 2.31 mmol) was taken in toluene (6 mb) was added CMBP (1.1 g, 1.23 mb, 4.62 mmol) and cyclobutanol (250.2 mg, 3.47 mmol), Then stirred the reaction mixture for 4 hours at 100 °C, Reaction progress was monitored by bC-MS. bC-MS showed desired product formation. Reaction mixture was quenched with water and extracted with ethyl acetate (2 x 1ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give compound-3 (520.0 mg, 54 %, 76% Purity). bC-MS m/z [M+H]+ = 314. 3-cyclobutoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To s stirred solution of 3- cyclobutoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-pyrazole (100.0 mg, 0.31 mmol) was taken in Ethanol (1 mb) and water (1 mb) was added ammonium chloride (85.33 mg, 1.59 mmol) and iron (89.mg, 1.59 mmol), Then stirred the reaction mixture for 4 hour at 60 °C, Reaction progress was monitored by bC-MS & TbC. bC-MS showed desired product formation, TbC showed completion of starting material. Reaction mixture was filtered through celite pad & washed with 10% MeoH in DCM (250 ml), separated the organic layers and concentrated under reduced vacuum pressure to give crude product, this crude product again dried over sodium sulphate filtered and washed with DCM (50 ml) concentrated under reduced 169 PAT059456 FF vacuum pressure to give crude product 3-cyclobutoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine (85.00 mg, 54 %) as pale brown oil. LC-MS m/z [M+H]+ = 284.33 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 2'-((3-cyclobutoxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 41 DMF,60°C Step-77% K2CO3 N-NH H2SO4,HNO:Step-32%55% N—NH SEM-Cl Step-4 977%10% Pd/C,MeOH,RTStep-5 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one:To a degassed solution of 1-(3-hydroxy-1H-pyrazol-1- yl)ethan-1-one (3g, 23.8mmol) and 1,1-difluoro-2-iodoethane (6.8 g, 35.71mmol) in DMF (30mL), was added C52CO3 (19.3g, 59.5 mmol), the reaction mass was closed under argon atmosphere and stirred at 60°C for 2h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 200 mL). The organic layer was washed with ice-cold water (2 x 500 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-30% ethyl acetate in pet-ether to give 1-(3-(2,2-difluoroethoxy)-1H- pyrazol-1-yl)ethan-1-one. (3.5g, 77% yield) as pale yellow liquid. LC-MS m/z [M+H]+ = 190.98 3-(2,2-difluoroethoxy)-1H-pyrazole:To a degassed solution of 1-(3-(2,2-difluoroethoxy)-1H-pyrazol-1- yl)ethan-1-one (4.2g, 22.1mmol) was taken in MeOH (42 ml), was added K2CO3 (4.57, 33.15mmol), the 170 PAT059456 FF reaction mass was closed under argon atmosphere and stirred at 50°C for 1h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered through Buchner funnel and washed with 10% MeOH in DCM (200ml), the filtrates were concentrated under vacuum pressure to give the crude product. 3-(2,2-difluoroethoxy)-1H-pyrazole (3.1g crude,) as pale yellow solid. LC-MSm/z [M+H]+ = 149.13 3-(2,2-difluoroethoxy)-4-nitro-1H-pyrazole:To a degassed solution of 3-(2,2-difluoroethoxy)-1H- pyrazole (3.5g, 23.6mmol) was taken in H2SO4(14ml 4vol), was added HNO3(3.5ml, 1vol), the reaction mass was closed under argon atmosphere and stirred at 50°C for 3h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was quenched with ice- cold water and extracted with ethyl acetate (2 x200 mL). The organic layer was washed with ice-cold water (2 x 500 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product 3- (2,2-difluoroethoxy)-4-nitro-1H-pyrazole (1.5g crude, 32% yield) as yellow solid. LC-MS m/z [M+H]+ = 194.20 3-(2,2-difluoroethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-(2,2-difluoroethoxy)-4-nitro-1H-pyrazole (1g, 5.18mmol) and C52CO3 (3.36 g, 10.36mmol) in DMF (mL), was added SEM-CI (1.37 mL, 87.77mmol) at 0° C and then stirred at room temperature for 3h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was quenched with ice-cold, water and extracted with ethyl acetate (2 x200 mL). The organic layer was washed with ice-cold water (2 x 500 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-40% ethyl acetate in pet-ether to give 3-(2,2-difluoroethoxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.3g, 77% yield) as pale yellow colour liquid. LC-MS m/z [M+H]+ = 324.34 3-(2,2-difluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a parr-shaker containing 3-(2,2-difluoroethoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (500 mg, 1.5mmol) in methanol (10 mL), was added Pd/C (10%, 50mg) and stirred at room temperature at 80 psi hydrogen pressure for 1h. Progress of the reaction was monitored by TLC. After completion of reaction, reaction mass was filtered through eelite pad and washed with 10% MeOH in DCM, the filtrates were concentrated under reduced pressure to give the crude product 3-(2,2-difluoroethoxy)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (350 mg crude,) as brown liquid. LC-MSm/z: [M+H]+= 295.37 171 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for FNNH",OH2'-((3-(2,2-difluoroethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 42 HON~N TBSOK2CO: Step-18% K2CO3** TRsn'MeOH,50°CStep-2 .0-H2SO4,HNO3N-NH Step-3 SEM-C!DMF,Cs2CO3, Step-425% Fe, NH4C=,Eton, H2O,60°CStep-5 1-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-1H-pyrazol-1-yl)ethan-1-one:To a degassed solution of 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one (6g, 47.6 mmol) and (2-bromoethoxy)(tert-butyl)dimethylsilane (12.46 g, 52.3mmol) in DMF(30mb), was added K2CO3 (9.8g, 71.4mmol), the reaction mass was closed under argon atmosphere and stirred at 80°C for 4h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x200 mb). The organic layer was washed with ice-cold water (2 x200 mb), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-30% ethyl acetate in pet-ether to give 1-(3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-1H-pyrazol-1-yl)ethan-1-one. (2.5g, 18% yield) as pale yellow liquid. LC-MS m/z [M+H]+ = 285.27 3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-1H-pyrazole:To a degassed solution of 1-(3-(2-((tert- butyldimethylsilyl)oxy)ethoxy)-1H-pyrazol-1-yl)ethan-1-one (2.2g, 7.746 mmol) was taken in MeOH (22 ml), was added K2CO3 (11.6g, 11.61 mmol), the reaction mass was closed under argon atmosphere and stirred at 50°C for 1h. Progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, the reaction mass was filtered through Buchner funnel and washed with 10% MeOH in DCM (200ml) the 172 PAT059456 FF filtrates were concentrated under vacuum pressure to give the crude product 3-(2-((tert- butyldimethylsilyl)oxy)ethoxy)-1H-pyrazole (1.55g crude) as pale yellow solid. LC-MS m/z [M+H]+ = 243.42 2-((4-nitro-1H-pyrazol-3-yl)oxy)ethan-1-ol: To a degassed solution of 3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-1H-pyrazole (600mg, 2.479mmol) was taken in H2SO4(2.4ml 4vol), was added HNO3(0.6ml, 1vol), the reaction mass was closed under argon atmosphere and stirred at 50°C for 3h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 50 mL). The organic layer was washed with ice-cold water (2 x 100 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product 2-((4-nitro-1H-pyrazol-3-yl)oxy)ethan-1-ol (400 mg crude,) as pale yellow liquid. LC-MSm/z [M+H]+ = 174.03 2-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)ethan-1-ol:To a stirred solution of 2-((4-nitro-1H-pyrazol-3-yl)oxy)ethan-1-ol (400 mg, 2.312 mmol) and C52CO3 (1.502 g, 4.624mmol) in DMF (10 mL), was added SEM-CI (0.61 mL, 3.468 mmol) at 0° C and then stirred at room temperature for 16h. The progress of the reaction was monitored by TLC and LCMS. After completion of reaction, reaction mass was quenched with ice-cold water and extracted with ethyl acetate (2 x 100 mL). The organic layer was washed with ice-cold water (2 x 200 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-40% ethyl acetate in pet-ether to give 2-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-3-yl)oxy)ethan-1-ol (180mg, 25% yield) as Pale yellow colour liquid. LC-MS m/z [M+H]+ = 304.12 2-((4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)ethan-1-ol:To a stirred solution of Compound-7(180 mg 0.594 mmol) in ethanol (10V) and water (10V) was added NH4CI (317.1 mg, 5.mmol) followed by Fe (331.4g, 5.94 mmol) and the reaction mixture was stirred at 60 °C for 1h. The progress of the reaction was monitored by TLC. The reaction mass was filtered through plug of celite and washed with 10% MeOH in DCM; the filtrate was washed with water (50 mL) and extracted with 10% MeOH in DCM concentrated under reduced pressure to give Compound-8as brown gummy liquid (169 mg, crude). LC- MSm/z [M+H]+ = 274.19 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-hydroxyethoxy)-1 H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 173 PAT059456 FF Example 43 ؛ NO ( Br ______N' dcm n/ "z cs,co,,dmfStep-1 *Step-238% 33% Fe/NH4CIEton, h20Step-28% 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol:To stirred solution of (1-methylpyrazol-3- yl) methanol (1.000 g, 1 Eq, 8.918 mmol) in DCM (100.0 mL) was added Triphenylphosphine (3.977 g, 3.359 mL, 15.16 mmol) and carbontetrabromide (5.324 g, 1.68 mL, 16.05 mmol) , Then stirred the reaction mixture for 3 hour at RT, Reaction progress was monitored by LC-MS and TLC. LC-MS showed desired product formation. Reaction mixture was quenched with water (25ml) and extracted with ethyl acetate (2x50ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (24 g), eluting with a gradient of 15-30% EtOAc in petether, collected the pure fractions and concentrated under reduced vacuum pressure to give 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (900.0 mg, 38.91 %) as a yellow oil. LC-MS m/z [M+H]+ = 176.91 3-((1-methyl-1H-pyrazol-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-ol (600.0 mg, 2.314 mmol) in DMF (3.000 mL) was added Cesium carbonate (1.885 g, 462.8 pL, 5.784 mmol) and 3-(bromomethyl)- 1-methyl-1H-pyrazole (688.4 mg, 3.933 mmol) Then stirred the reaction mixture for 3 hour at RT. Reaction progress was monitored by LC-MS. LC-MS showed desired product formation. Reaction mixture was quenched with cold water (100ml) and extracted with ethyl acetate (2x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give 3-((1- methyl-1H-pyrazol-3-yl) methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (550.0 mg, 33.%) as brown gummy solid. LC-MS m/z [M+H]+ = 353.47. 3-((1-methyl-1H-pyrazol-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To stirred solution of 3-((1-methyl-1 H-pyrazol-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy) methyl)-1 H- pyrazole (500.0 mg, 1.415 mmol) in Ethanol (5,000 mL) and water (5,000 mL) and was added Ammonium chloride (378.3 mg, 262.9 pL 7.073 mmol) and Iron (395.0 mg, 50.3 pL, 7.073 mmol) Then stirred the reaction mixture for 3 hour at 50 °C Reaction progress was monitored by LC-MS and TLC. LC-MS showed desired product formation. Reaction mixture was filtered through celite pad washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give crude product. The crude material was washed with DCM to remove ammonium chloride which remains as solid and desired compound is soluble in DCM is collected and concentrated under reduced vacuum pressure to give3-((1- 174 PAT059456 FF methyl-1H-pyrazol-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (300.0 mg, 28.38%) as brown gummy solid. LC-MS m/z [M+H]+ = 323.47 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided HN N 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-methyl-1H- pyrazol-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 44 2,2-difluoro-3-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)propan-1-ol:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (300.0 mg, 1.157 mmol) in Toluene (9.000 mb), CMBP (558.4 mg, 612 pb, 2.314 mmol) and 2,2-Difluoropropane-1,3-diol (194.5 mg, 1.735 mmol) is added, then stirred the reaction mixture for 16 hour at 100 °C. Reaction progress was monitored by TLC and LC-MS. TLC and LC-MS shows desired product formation. Reaction mixture was quenched with water (50 ml) and extracted with ethyl acetate (2x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 21.2 % EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give 2,2-difluoro-3-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)propan-1-ol (300.0 mg, %) as light brown liquid. LC-MS m/z [M+H]+ = 354.38 3-(2,2-difluoro-3-methoxypropoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole:To stirred solution of 2,2-difluoro-3-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol- 3-yl)oxy)propan-1-ol (250.00 mg, 707.41 pmol) in THF (3.250 mL) and Sodium hydride (43.91 mg, 1.06mmol)is added at0°C and after 15 minutes Methyl iodide (200.82 mg, 1.4148 mmol)is added, Then stirred the reaction mixture for 1 hour at RT, Reaction progress was monitored by TLC and LC-MS. LC-MS showed desired product formation .Reaction mixture was quenched with ice water (100ml) and extracted with ethyl 175 PAT059456 FF acetate (2x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (g), eluting with a gradient of 20-22% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give 3-(2,2-difluoro-3-methoxypropoxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (240.0 mg, 83 %) as light brown gummy liquid. LC-MS m/z [M+H]+ = 368.42 3-(2,2-difluoro-3-methoxypropoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: Tostirred solution of 3-(2,2-difluoro-3-methoxypropoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole (240.0 mg, 653.2 pmol) was taken in Methanol (2.500 mb) and Pd/c (69.51 mg, 65.32 pmol) was added and H2 gas is passed through bladder at 5 psi pressure, then stirred the reaction mixture for 4 hours at RT Reaction progress was monitored by LC-MS and TLC. LC-MS showed desired product formation. Reaction mixture was filtered through eelite pad and washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give 3-(2,2-difluoro-3-methoxypropoxy)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (150.0 mg, 34 %).as brown gummy solid. LC-MS m/z [M+H]+ = 338.42 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-(2,2-difluoro-3-methoxypropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 45 no2 / N-Np-TsCI, Et 3N,F OH DMAPFe/NH4CDCM,RT Step-55%DMF, 50°C Step-67%EtOH, h20,50°cStep-349% (l-fluorocyclopropyl)methyl 4-methylbenzenesulfonate: To a stirred solution of (1-fluorocyclopropyl)methanol (1.000 g, 11.10 mmol) in DCM (10.000 mL), Triethylamine (7.73 mL, 55.49 176 PAT059456 FF mmol) was added and DMAP (271.2 mg, 2.220 mmol), p-Toluenesulfonyl chloride (3.174 g, 16.65 mmol) is added at 0°C, then stirred the reaction mixture for 3 hours at RT, Reaction progress was monitored by LC-MS and TLC. TLC showed completion of SM-1. (No LC-MS ionization.) Reaction mixture was quenched with NaHCO3 solution(100ml) and extracted with ethyl acetate (2 x 100ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product.The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give (l-fluorocyclopropyl)methyl 4-methylbenzenesulfonate (1.500 g, 55.33 %) as white solid. LC-MS m/z [M+H]+ = 245.38 3-((1-fluorocyclopropyl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3-ol (1.000 g, 3.856 mmol) in DMF (5.500 mL) was added Cesium carbonate (3.141 g, 9.640 mmol) and (l-fluorocyclopropyl)methyl 4- methylbenzenesulfonate (1.413 g, 5.784 mmol) , then stirred the reaction mixture for 2 hour at 50 °C, Reaction progress was monitored by LC-MS and TLC. LC-MS showed desired product formation. Reaction mixture was quenched with cold water (100 ml) and extracted with ethyl acetate (2x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (24 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give 3- ((1-fluorocyclopropyl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.000 g, 67 %,) as colourless gummy liquid. LC-MS m/z [M+H]+ = 332.2 3-((1-fluorocyclopropyl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-((1-fluorocyclopropyl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (700.0 mg, 2.112 mmol) in Ethanol (7.000 mL) and Water (7.000 mL) and Ammonium chloride (564.9 mg, 10.56 mmol) and Iron (589.8 mg, 10.56 mmol) Then stirred the reaction mixture for 3 hour at 50 °C. Reaction progress was monitored by LC-MS and TLC. LC-MS and TLC showed desired product formation. Reaction mixture was filtered through eelite pad and washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give crude product. The crude material was washed with DCM to remove ammonium chloride which remains as solid and desired compound is soluble in DCM is collected and concentrated under reduced vacuum pressure to give3-((1- fluorocyclopropyl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (600.0 mg, 49 %) as brown gummy solid. LC-MS m/z [M+H]+ = 302.2 177 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-((1-fluorocyclopropyl)methoxy)-1H-pyrazol-4-yl)amino)-7'- ((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 46 N-N 'SE OHתBooCMBPToiuene,100°CStep-170% NO__—___N—i N-N BCM: 0°C-RTBoc" SEM Stop-2؟ , Fe/NH4Cl .EtOH,H20,60°CStep-4SEM 54% tert-butyl 3-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)azetidine-1- carboxylate:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (500.0 mg, 1.928 mmol) in Toluene (5.000 mb), CMBP (930.7 mg, 1.02 mb, 3.856 mmol) and tert-butyl 3- hydroxyazetidine-1-carboxylate (500.9 mg, 2.892 mmol) is added, Then stirred the reaction mixture for hour at 100 °C. Reaction progress was monitored by, TbC and bC-MS. TbC and bC-MS shows no proper ionization but TbC Shows desired product formation. Reaction mixture was quenched with NaHCO3 (1ml) and extracted with ethyl acetate (2x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre- packed silica gel column (12 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give tert-butyl 3-((4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)azetidine-1-carboxylate (700.0 mg, 70 %) as light brown liquid. LC-MSm/z [M+H]+ = 414.53 3-(azetidin-3-yloxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of tert-butyl 3-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)azetidine-1-carboxylate (700.00 mg, 1.68 mmol) in DCM (7.000 mb) was added TFA (1.400 mb) and then stirred the reaction mixture for 1 hour at RT, Reaction progress was monitored by bC-MS. bC-MS showed desired product formation.Reaction mixture was quenched with Cold sat. NAHCO3 solution(100ml) and extracted with 10% MeOH IN DCM (2x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give 3-(azetidin-3-yloxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (440.0 mg, 79 %) as colorless gummy solid. bC-MS m/z [M+H]+ = 314.53 178 PAT059456 FF 4-nitro-3-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)oxy)-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole: To a stirred solution of 3-(azetidin-3-yloxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (440.mg, 1 Eq, 1.3994 mmol) in EtOH (8.800 mb) was Sodium bicarbonate (470.3 mg, 218 pb, 4 Eq, 5.59mmol) and 2,2,2-trifluoroethyl trifluoro meth an esulfonate (649.60 mg, 2 Eq, 2.7988 mmol) was added at 00C, Then stirred the reaction mixture for 16 hourat80 °C, Reaction progress was monitored by TLC AND LC-MS. LC-MS showed desired product formation. Reaction mixture was quenched with water (25 ml) and extracted with DCM (1x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give 4-nitro-3-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)oxy)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (400.0 mg, 67 %) as brown gummy solid. LC-MS m/z [M+H]+ = 396.44 3-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To stirred solution of 4-nitro-3-(oxetan-3-ylmethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (450.0 mg, 1.366 mmol) as taken in Ethanol (4.500 mb) and Water (4.500 mb) and wasadded Ammonium chloride (365.3 mg, 6.830 mmol) and Iron (381.5 mg, 6.830 mmol) Then stirred the reaction mixture for 3 hour at 50 °C Reaction progress was monitored by bC-MS and TbC. bC-MS showed desired product formation. Reaction mixture was filtered through celite pad and washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give crude. The crude material was washed with DCM to remove ammonium chloride which remains as solid and desired compound is soluble in DCM is collected and concentrated under reduced vacuum pressure to give 3-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (330.0 mg, 54 %) as light pink solid. LC-MS m/z [M+H]+ = 366.53 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1 -(2,2,2- trifluoroethyl)azetidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one 179 PAT059456 FF Example 47 EtOH, H20,60°CStep-274% Fe/NH4CI, XSEM 3-(4-nitro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3-yl)-5,6-dihydro-4H-pyrrolo[1,2- b]pyrazole:To stirred solution of 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (500.mg, 1.3542 mmol) in1,4-Dioxane (4.500 mb), Water (0.500 mb) and degassed with nitrogen and Potassium phosphate, tribasic (718.59 mg, 3.3854 mmol) and [1,1- Bis(diphenylphosphino)ferrocene]dichloropalladium(ll)ComplexWith Dichloromethane (110.59 mg, 135.umol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole (475.54 mg, 2.0313 mmol), Then stirred the reaction mixture for 16 hours at 90 °C. Reaction progress was monitored by bC-MS. bC-MS showed desired product formation. Reaction mixture was filtered through celite pad and washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole (250.0 mg, 42 %) as brown gummy liquid. bC-MS m/z [M+H]+ = 350.24 3-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine:To stirred solution of 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-5,6-dihydro- 4H-pyrrolo[1,2-b]pyrazole (250.0 mg, 715.4 umol) was taken in Ethanol (2.500 mb) and Water (1.250 mb) and Ammonium chloride (191.3 mg, 3.577 mmol) and Iron (199.8 mg, 3.577 mmol) was added. Then stirred the reaction mixture for3 hour at 50 °C Reaction progress was monitored by bC-MS and TbC. bC-MS showed desired product formation. Reaction mixture was filtered through celite pad and washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give crude product. The crude material was washed with DCM to remove ammonium chloride which remains as solid and desired compound is soluble in DCM is collected and concentrated under reduced vacuum pressure to give 3-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-4- amine (170.0 mg, 74.38 %) as brown gummy solid. LC-MS m/z [M+H]+ = 320.22 180 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H-pyrazol-4- yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 48 HO 3-((3-fluorooxetan-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To the stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (500.0 mg, 1.928 mmol) in Toluene (15.00 mb), CMBP (930.7 mg, 1.02 mb, 3.856 mmol) and (3-fluorooxetan-3-yl)methanol (306.mg, 2.892 mmol) is added, Then stirred the reaction mixture for 5 hours at 100°C. Reaction progress was monitored by TbC and bC-MS. TbC and bC-MS shows desired product formation. Reaction mixture was quenched with NaHCO3 (25 ml) and extracted with ethyl acetate (2x50ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 21.2 % EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give 3-((3-fluorooxetan-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (550.0 mg, 65 %) as light yellow gummy solid. bC-MS m/z [M+H]+ = 348.42 3-((3-fluorooxetan-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To sstirred solution of 3-((3-fluorooxetan-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (550.0 mg, 1.583 mmol) in EtOH (5.500 mb) and Water (5.500 mb) and Ammonium chloride (423.4 mg, 7.915 mmol) and Iron (442.1 mg, 7.915 mmol) was added. Then stirred the reaction mixture for 3 hours at °C. Reaction progress was monitored by bC-MS and TbC. bC-MS showed desired product formation. Reaction mixture was filtered through eelite pad and washed with 10% MEOH in DCM and filtrate is 181 PAT059456 FF collected and concentrated under reduced vacuum pressure to give crude product. The crude material was washed with DCM to remove ammonium chloride which remains as solid and desired compound is soluble in DCM is collected and concentrated under reduced vacuum pressure to give 3-((3-fluorooxetan-3- yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (400.0 mg, 44 %) as brown gummy solid. LC-MS m/z [M+H]+ = 318.42 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-((3-fluorooxetan-3-yl)methoxy)-1H-pyrazol-4-yl)amino)- 7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 49 HONO2DCs 2CO3, 7N״NxFe/NH 4CI SEMDMF.RTStep-1؟׳ 64 H20, EtOH, 60’ Step-48% 3-(methoxy-d3)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (600.0 mg, 2.314 mmol) in DMF (6.000 mb) was added Cesium carbonate (1.885 g, 5.784 mmol) and iodomethane-d3 (670.7 mg, 4.627 mmol), Then stirred the reaction mixture for 3 hours at RT. Reaction progress was monitored by LC-MS. LC-MS showed desired product formation. Reaction mixture was quenched with cold water (100ml) and filtered through Buchner funnel and washed with DCM to afford 3-(methoxy-d3)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole (550.0 mg, 64.93 %) as brown solid. LC-MS m/z [M+H]+ = 277.38 3-(methoxy-d3)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3- (methoxy-d3)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (500.0 mg, 1.809 mmol) in Ethanol (5,000 mL) and Water (5,000 mL) and was added Ammonium chloride (483.8 mg, 9.046 mmol) and Iron (505.2 mg, 9.046 mmol). Then stirred the reaction mixture for 3 hours at 50 °C Reaction progress was monitored by LC-MS and TLC. LC-MS showed desired product formation. Reaction mixture was filtered through celite pad washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give crude product. The crude material was washed with DCM to remove ammonium chloride which remains as solid and desired compound is soluble in DCM is collected and concentrated 182 PAT059456 FF under reduced vacuum pressure to give.3-(methoxy-d3)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine (300.0 mg, 43.29 %) as brown gummy solid. LC-MS m/z [M+H]+ = 247.38 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(methoxy-d3)-1H-pyrazol- 4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 50 paraformaldehydeSTAB, AcOHMeOH, RTSiep-539% tert-butyl 3-fluoro-4-hydroxypyrrolidine-1-carboxylate:To stirred solution of tert-butyl 6-oxa-3-aza- bicyclo[3.1.0]hexane-3-carboxylate (4.000 g, 21.60 mmol) in Triethyl ammonium Fluoride (5.222 g, 5.3 mb, 32.39 mmol), Then stirred the reaction mixture for 16 hour at 120°C. Reaction progress was monitored by TLC. TLC showed desired product formation. Reaction mixture was quenched with Sat.NAHCO3 solution (125 ml) and stirred for 1 hr. and extracted with 20% IPA in DCM (2 x 200mL), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give tert-butyl 3-fluoro-4-hydroxypyrrolidine-1-carboxylate (3.600 g, 81.22 %) as black gummy liquid. LC-MS m/z [M+H]+ = 414. tert-butyl 3-fluoro-4-((4-nitro-1H-pyrazol-3-yl)oxy)pyrrolidine-1-carboxylate:To stirred solution of tert- butyl 3-fluoro-4-hydroxypyrrolidine-1-carboxylate (3.500 g, 17.05 mmol) in THF (30 ml) and Sodium hydride (818.6 mg, 0.68 mL, 20.46 mmol) was added at 0°C and in another RB flask. 1,4-dinitro-1H-pyrazole (2.6g, 17.05 mmol) is dissolved in 90 ml THF at -78°C, then the alkoxide solution is transferred directly to SM- RB flask and then stirred the reaction mixture for 1 hour at -78°C. Reaction progress was monitored by TLC and LC-MS. LC-MS showed desired product formation. Reaction mixture was quenched with Sat.NH4CI soln. (50ml) and extracted with ethyl acetate (2x1 00ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 28-32% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give tert-butyl 3-fluoro-4- 183 PAT059456 FF ((4-nitro-1H-pyrazol-3-yl)oxy)pyrrolidine-1-carboxylate (1.500 g, 424 %) as light yellow liquid. LC-MS m/z [M+H]+ = 261.52 (M-56) tert-butyl 3-fluoro-4-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)pyrrolidine-1- carboxylate:To stirred solution oftert-butyl 3-fluoro-4-((4-nitro-1H-pyrazol-3-yl)oxy)pyrrolidine-1- carboxylate (1.500 g, 4.742 mmol) in DMF (7.000 mb), Cesium carbonate (3.090 g, 9.485 mmol) is added atO°C and 2-(Chloromethoxyethyl)trimethyl silane (1.186 g, 1.26 mb, 7.114 mmol) was added Then stirred the reaction mixture for 1 hour at RT, Reaction progress was monitored by TbC and bC-MS. bC-MS showed desired product formation. Reaction mixture was quenched with cold water (50ml) and extracted with ethyl acetate (2x1 00ml), combined the organic layers and dried over sodium sulphate, filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi-Sep pre-packed silica gel column (g), eluting with a gradient of 25-28% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give tert-butyl 3-fluoro-4-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-3-yl)oxy)pyrrolidine-1-carboxylate (1.500 g, 363 %) as light yellow gummy solid. LC-MS m/z [M+H]+ = 447.24 3-((4-fluoropyrrolidin-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To stirred solution of 3-fluoro-4-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)pyrrolidine-1- carboxylate (1.500 g, 3.359 mmol) in DCM (15.00 mb) and TFA (296 mg, 0.200 mb, 2.60 mmol) was added and then stirred the reaction mixture for 1 hour at RT, Reaction progress was monitored by TbC and bC-MS. bC-MS showed desired product formation. Reaction mixture was quenched with Cold sat. NaHCO3 solution(100ml) and extracted with 10% MEOH IN DCM (2x100ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give 3-((4- fluoropyrrolidin-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (900.0 mg, 62 %, 80% Purity) as light yellow gummy solid. LC-MS m/z [M+H]+ = 347.53 3-((4-fluoro-1-methylpyrrolidin-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3-((4-fluoropyrrolidin-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (900.00 mg, 2.5979 mmol) in Methanol (18.000 mb), Paraformaldehyde (780.2 mg, 25.979 mmol), Acetic acid (156.0 mg, 149.3 pb, 2.5979 mmol) is added at 0°C and after 1 hour Sodium triacetoxyborohydride (1.6518 g, 7.7938 mmol) was added, then stirred the reaction mixture for 16 hours at RT, Reaction progress was monitored by bC-MS. bC-MS showed desired product formation. Reaction mixture was quenched with water (50ml) and extracted with DCM(2x100ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by sepabean chromatography through a Redi- Sep pre-packed silica gel column (12 g), eluting with a gradient of 45-55% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to give desired product 3-((4-fluoro-1- 184 PAT059456 FF methylpyrrolidin-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (270.0 mg, 39 %, 87% Purity) LC-MS m/z(M+H)+: 361.24 3-((4-fluoro-1-methylpyrrolidin-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To stirred solution of 3-((4-fluoro-1-methylpyrrolidin-3-yl)oxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazole (200.00 mg, 554.85 pmol) has taken in Methanol (2.000 mL) and Pd/C (118.09 mg, 110.pmol) was added and H2 gas is passed through bladder at 5 psi pressure, then stirred the reaction mixture for 2 hours at RT Reaction progress was monitored by TLC and LC-MS and TLC. TLC and LC-MS showed desired product formation. Reaction mixture was filtered through celite pad and washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give 3-((4-fluoro-1- methylpyrrolidin-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (170.0 mg, 52 %) as light brown gummy solid. LC-MS m/z [M+H]+ = 331.24 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM followed Nby chiral SFC provided for Peak 1 / 2'-((3-(((3R,4R)-4-fluoro-1-methylpyrrolidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 51 Peak 2 from chiral SFC in example 50 provided for /fluoro-1-methylpyrrolidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 2'-((3-(((3S,4S)-4- 185 PAT059456 FF Example 52 1.0 M in THE sFe, NH4Cl N-NEtOH, H20Step-2 3-(methylthio)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To the stirred solution of 4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1g, 4.11 mmol) in THF (20.00 mL) LiHMDS 1.0 M in THF (6.16 mL, 6.16 mmol) was added at -78 °C and 1,2-dimethyldisulfane (580.6 mg, 6.16 mmol) is added, Then stirred the reaction mixture for 2 hour at RT. Reaction progress was monitored by TLC and LC-MS. TLC and LC-MS shows desired product formation. Reaction mixture was quenched with NH4CI (25 ml) and extracted with ethyl acetate (2x50ml), combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give 3-(methylthio)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (550.0 mg) as light yellow gummy solid. LC-MS m/z [M+H]+ = 289.42 3-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution 3- (methylthio)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (300.0 mg, 1.04 mmol) in EtOH (3.mL) and Water (3.00 mL) and Ammonium chloride (277 mg, 5.18 mmol) and Iron (289 mg, 5.18 mmol) was added. Then stirred the reaction mixture for 3 hours at 50 °C. Reaction progress was monitored by LC-MS and TLC. LC-MS showed desired product formation. Reaction mixture was filtered through celite pad and washed with 10% MEOH in DCM and filtrate is collected and concentrated under reduced vacuum pressure to give crude product. The crude material was washed with DCM to remove ammonium chloride which remains as solid and desired compound is soluble in DCM is collected and concentrated under reduced vacuum pressure to 3-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (270.0 mg) as Yellowish brown gummy solid. LC-MS m/z(M+H)+: 259.42 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(methylthio)-1H-pyrazol-4- yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 186 PAT059456 FF Example 53 *״ ^N.tolune, 100 °C, 4h SEM-NStep-179% A020, TLADCM, 0 °C to RT 1 h SEM-NStep-365% tert-butyl 6-(((4-nitro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2- azaspiro[3.3]heptane-2-carboxylate:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-3-ol (800.0 mg, 3.085 mmol) in toluene (1 mb) was added tert-butyl 6-(hydroxymethyl)-2- azaspiro[3.3]heptane-2-carboxylate (1.052 g, 4.627 mmol) followed by CMBP (1.65 mb, 1.5 Eq, 4.6mmol) at RT and the resulting reaction mixture was stirred at 100 °C for 4 hour. The reaction progress was monitored by TbC and bCMS. On completion, the reaction mixture was diluted with water (10 mb) and extracted with ethyl acetate (2 x 20 mb). Combined organic layers was washed with brine (5 mb), dried over sodium sulphate, filtered and evaporated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by SepaBean chromatography through a RediSep pre-packed silica gel column (24 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to afford tert-butyl 6-(((4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3-yl)oxy)methyl)-2-azaspiro[3.3]heptane-2-carboxylate (1.2 g, 79.07 % yield) as a pale yellow oil. LC-MS m/z [M+H]+ = 469.54 6-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2-azaspiro[3.3]heptane: To a stirred solution of tert-butyl 6-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)oxy)methyl)-2-azaspiro[3.3]heptane-2-carboxylate (600 mg, 1.2803 mmol) in DCM (12 mb) was added TFA (1.2 mb) at 0 °C and the resulting reaction mixture was stirred at RT for 2 hours. The reaction progress was monitored by TbC and bCMS. On completion, the reaction mixture was quenched with sat. NaHCO3 solution (10 mb) and extracted with DCM (2 x 20 mb). The combined organic layer was washed with brine (10 mb), dried over sodium sulphate, filtered and evaporated under reduced vacuum pressure to 187 DCM, 0 °C to RT, 2hStep-278% PAT059456 FF give 6-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2-azaspiro[3.3]heptane (450 mg, 78.04 % yield) as a yellow oil. LC-MS m/z [M+H]+ = 369.45 1-(6-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2- azaspiro[3.3]heptan-2-yl)ethan-1-one: To a stirred solution of 6-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2-azaspiro[3.3]heptane (500 mg, 1.3568 mmol) in DCM (7 mL) was added TEA (0.6 mb, 4.07 mmol) followed by acetic anhydride (0.2 mb, 1.5 Eq, 2.03mmol) at 0 °C and the resulting reaction mixture was stirred at RT for 1 hour. The reaction progress was monitored by TLC and bCMS. On completion, the reaction mixture was diluted with water (10 mb) and extracted with DCM (2 x 20 mb). The combined the organic layer was washed with brine (5 mb), dried over sodium sulphate, filtered and concentrated under reduced vacuum pressure to afford 1-(6-(((4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2-azaspiro[3.3]heptan-2-yl)ethan-1-one (4mg, 65.44% yield) as a yellow oil. LC-MS m/z [M+H]+ = 411.47 1-(6-(((4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2- azaspiro[3.3]heptan-2-yl)ethan-1-one: To a stirred solution of 1-(6-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2-azaspiro[3.3]heptan-2-yl)ethan-1-one (4mg, 1.0961 mmol) in ethanol (4.5 mb) and water (4.5 mb) was added ammonium chloride (295 mg, 5.48mmol) followed by iron (306 mg, 5.4805 mmol) at RT and the resulting reaction mixture was stirred at °C for 1 hour. The reaction progress was monitored by TbC and bCMS. On completion, the reaction mixture was passed through celite pad and pad was washed with 10% MeOH in DCM (5 mb). Filtrate was diluted with water (5 mb), extracted with DCM (2x10 mb), washed with brine (5 mb), dried over sodium sulfate and evaporated under reduced vacuum pressure to afford 1-(6-(((4-amino-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-2-azaspiro[3.3]heptan-2-yl)ethan-1-one (4mg, 61.22 % yield) as a brown oil. LC-MS m/z [M+H]+ = 381.54 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for N-NH ---/ 2'-((3-((2-acetyl-2-azaspiro[3.3]heptan-6-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3- d]pyrimidin]-6'(7'H)-one 188 PAT059456 FF Example 54 CMBPTolune, RT, 16hStep-171% Fe, NH4CIEtOH, water, °C,2hStep-245% 3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole: To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (400 mg, 1.5424 mmol) in toluene (4.0 mb) was added (2-oxaspiro[3.3]heptan-6-yl)methanol (336 mg, 2.6220 mmol) followed by CMBP (0.8 mb, 3.0848 mmol) and the resulting reaction mixture was stirred at RT for 16 hour. The reaction progress was monitored by TbC and bCMS. On completion, the reaction mixture was diluted with water (5 ml) and extracted with ethyl acetate (2x10 mb). The combined organic layer was washed with brine (5 mb), dried over sodium sulphate, filtered and concentrated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by Sepabean chromatography through a RediSep pre-packed silica gel column (24 g), eluting with a gradient of 0-50% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to afford Compound-3(480 mg, 71.11 % yield) as a pale yellow oil. LC-MSm/z [M+H]+ = 370. 3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To a stirred solution of 3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazole (480 mg, 1.299 mmol) in ethanol (5 mb) and water (5 mb) was added ammonium chloride (3mg, 6.495 mmol) followed by iron (363 mg, 6.495 mmol) at RT and the resulting reaction mixture was stirred at 60 °C for 2 hours. The reaction progress was monitored by TbC and bCMS. After completion of reaction, all volatiles were evaporated in vacuo, the residue obtained was dissolved in dichloromethane (10 mb), filtered and filtrate was evaporated in vacuum to afford 3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-1 -((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (400 mg, 44.70 % yield. LC-MS m/z [M+H]+ = 340.43 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-1H-pyrazol- 4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 189 PAT059456 FF Example 55 2^*ohHN'^ TFAA, KNO3 ^'N'^ NaH HN'^ / SEM-CI, CS2CO3SLM'N-N f Fa. NH4CI DMF, 0 °C to RT, 2h ؛ EtOH, wate2h ؛ °؟ 60 ? Step-3 NO’ Ep ؛ 48 % S48% of 4-nitro-1H-pyrazole (2.5 g, 22.11 mmol) in DCM (25 ( DCM, 0 °C NO2 toRT, 16h Step-170% THF, 0 °CNO2 to RT, 4hStep-17% To a stirred no2 solution 1.4-dinitro-1H-i mb) was added potassium nitrate (6.7 g, 66.32 mmol) followed by TFAA (12.5 mb, 88.44 mmol) at 0 °C and the resulting reaction mixture was stirred at RT for 16 hours. The reaction progress was monitored by TLC and LCMS. On completion, the reaction mixture was cooled to 0 °C, quenched with water (50 mb) and extracted with DCM (2 x25 mb). The combined organic layer was washed with brine (15 mb), dried over Na2SO4and evaporated under reduced pressure to afford 1,4-dinitro-1H-pyrazole (2.5 g, 70.10 % yield). 1H NMR (400 MHz, CdCI3)6 = 9.035 (d, 8.0 Hz), 8.182 (d, 8.0 Hz). 3-cyclopropoxy-4-nitro-1H-pyrazole:To a stirred solution of 1,4-dinitro-1H-pyrazole (0.62 mb, 9.mmol) in THF (2.3 mb) was added NaH (1.3 g, 31.63 mmol) at 0 °C, stirred for 10 minutes. This suspension was added in the stirred solution of cyclopropanol (2.3 g, 14.55 mmol) in THF (2.3 mb) at -78 °C and the resulting reaction mixture was stirred at RT for 1 hour. The reaction progress was monitored by TbC and bCMS. The reaction mixture was diluted cold water (20 mb) and extracted with EtOAc (2 x 20 mb), dried over sodium sulfate, evaporated under reduced pressure to afford crude. The crude material was absorbed onto a plug of silica gel and purified by Sepabean chromatography through a RediSep pre-packed silica gel column (24 g), eluting with a gradient of 0-70% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to afford 3-cyclopropoxy-4-nitro-1H-pyrazole (0.55 g, 17.47% yield) as a yellow solid. LC-MS m/z [M+H]+ = 170.07. 3-cyclopropoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 3- cyclopropoxy-4-nitro-1H-pyrazole (550 mg, 3.252 mmol) in/V,/V-dimethylformamide (5.5 mb) was added cesium carbonate (1.6 g, 4.878 mmol) followed by SEM-CI (0.7 mb, 3.902 mmol) at 0 °C and the resulting reaction mixture was stirred at RT for 2 hour. The reaction progress was monitored by TbC and bCMS. After completion of reaction, the reaction mixture was diluted with cold water (5 mb) and extracted with EtOAc (2 x 20 mb). The combined organic layer was washed with brine (5 mb), dried over Na2SO4 and evaporated under reduced pressure to afford crude. The crude material was absorbed onto a plug of silica gel and purified by Sepabean chromatography through a RediSep pre-packed silica gel column (12 g), eluting with a gradient of 0-20% EtOAc in pet ether, collected pure fractions and concentrated under reduced vacuum pressure to afford 3-cyclopropoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.3 g, 48.14% yield) as a brown solid. LC-MS m/z [M+H]+ = 300.23. 190 PAT059456 FF 3-cyclopropoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3- cyclopropoxy-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (350 mg, 1.169 mmol) in ethanol (3.mL) and water (3.5 mL) was added ammonium chloride (315 mg, 5.845 mmol) followed by iron (326 mg, 5.845 mmol) at RT and the resulting reaction mixture was stirred at 60 °C for 1 hour. The reaction progress was monitored by TLC and LCMS. After completion of reaction, all volatiles were evaporated in vacuo, the residue obtained was dissolved in dichloromethane (5 mL), filtered and filtrate was evaporated in vacuo to afford 3-cyclopropoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.3 g, 48.14% yield) as a brown solid. LC-MS m/z [M+H]+ = 270.28 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-cyclopropoxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 56 1-(4-hydroxy-1H-pyrazol-1-yl)ethan-1-one:To a stirred solution of 1 H-pyrazol-4-ol(10.0 g, 118.mmol) in pyridine (35 mL) was added acetic anhydride (12 mL, 127.34 mmol) in pyridine (35 mL) at RT and the resulting reaction mixture was stirred at 90 °C for 4 hours. The reaction progress was monitored by TLC and LCMS. On completion, all volatiles were evaporated under reduced pressure to afford crude. The crude was washed with diethyl ether (100 mL) and filtered to obtain 1-(4-hydroxy-1H-pyrazol-1-yl)ethan-1-one (g, 78.21% yield) as pale yellow solid. LC-MS m/z [M+H]+ = 126.97 3-(2,2,2-trifluoroethoxy)-1H-pyrazole:To a stirred solution of 1-(4-hydroxy-1H-pyrazol-1-yl)ethan-1-one (3.0 g, 23.79 mmol) in DMF (30 mL) was added K2CO3 (6.6 g, 47.58 mmol) followed by trifluoromethyliodide (3.5 mL, 35.68 mmol) at RT and the resulting reaction mixture was stirred at °C for 16 hours. The reaction progress was monitored by TLC and LCMS. On completion, the reaction mixture was diluted with cold water (50 mL), extracted with EtOAc (2 x 50 mL), washed with brine (30 mL), 191 PAT059456 FF dried over sodium sulphate and evaporated under reduced vacuum pressure to afford 3-(2,2,2- trifluoroethoxy)-1H-pyrazole (1.5 g, 19.34% yield) as yellow solid. LC-MS m/z [M+H]+ = 167.15 4-nitro-3-(2,2,2-trifluoroethoxy)-1H-pyrazole:To a stirred solution of 3-(2,2,2-trifluoroethoxy)-1H- pyrazole (1.5 g, 9.03 mmol) in cone. H2SO4 (4.5 mL) was added cone. HNO3 (1.5 mL) dropwise at 0 °C and the resulting reaction mixture was stirred at 60 °C for 1 hour. The reaction progress was monitored by TLC and LCMS. On completion, the reaction mixture was poured on crushed ice, pale yellow solid separated was filtered, washed with n-pentane (10 mb) to afford 4-nitro-3-(2,2,2-trifluoroethoxy)-1H-pyrazole (1.5 g, 33.05% yield) as pale yellow solid. LC-MS m/z [M+H]+ = 210.11 4-nitro-3-(2,2,2-trifluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-3-(2,2,2-trifluoroethoxy)-1H-pyrazole (1.5 g, 7.11 mmol) in DMF (15 mb) was added cesium carbonate (4.7 g, 10.66 mmol) followed by SEM-CI (1.9 mb, 10.66 mmol) atO °C and the resulting reaction mixture was stirred at RT for 1 hour. The reaction progress was monitored by TbC and bCMS. On completion, the reaction mixture was diluted with cold water (50 mb), extracted with EtOAc (2 x 50 mb), washed with brine (20 mb), dried over sodium sulfate and evaporated under reduced vacuum pressure to afford crude. The crude compound was purified by SepaBean using silica gel (100-200 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 4-nitro-3-(2,2,2-trifluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazole (0.7 g, 29% yield) as a yellow oil. LC-MS m/z [M+H]+ = 342.55 3-(2,2,2-trifluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 4-nitro-3-(2,2,2-trifluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (300 mg, 0.8mmol) in ethanol (2 mb) and water (3 mb) was added 10% Pd/C (90 mg, 30% w/w) and the resulting reaction mixture was stirred at RT under hydrogen balloon pressure for 6 hours. The reaction progress was monitored by TbC and bCMS. After completion of reaction, the reaction mixture was passed through eelite pad and pad was washed with MeOH (10 mb). Filtrate was evaporated under reduced pressure to afford 3-(2,2,2-trifluoroethoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.3 g, 76.74% yield) as a brown solid. LC-MS m/z [M+H]+ = 312.07 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(2,2,2-trifluoroethoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 192 PAT059456 FF Example 57 2M LDA in THF SEM THF, -78 °C to RT, 2hStep-120% (Ad) 2BuP, Pd(OAc), K2cd 3, t-BuCOOHDMF, 120 °C, 12hStep-233% O2N-_^n-SEM EtOH, water, °C, 4hStep-3 Fe, NH4CI 62% -chloro-4-iodo-1-methyl-1H-pyrazole:To a stirred solution of 4-iodo-1-methyl-1H-pyrazole (1 g, 1 Eq, 48.08 mmol) in THF (10 mb) was added 2M LDA in THF (48 mL, 2 eq 96.2 mmol) at -78 °C, stirred for minutes and then was added hexachloroethane (1.4 g, 1 Eq, 57.7 mmol) and the resulting reaction mixture was stirred at RT for 2 hours. The reaction progress was monitored by TLC and LCMS. On completion, the reaction mixture was cooled to 0 °C, quenched with saturated NH4CI solution (150 mL) and extracted with EtOAc (2 x 150 mL). The combined organic layer was washed with brine (100 mL), dried over Na2SO4and evaporated under reduced pressure to afford crude. The crude material was absorbed onto a plug of silica gel and purified by Sepabean chromatography through a RediSep pre-packed silica gel column (120 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to afford 5-chloro-4-iodo-1-methyl-1H-pyrazole (3.5 g, 19.52% yield) as a yellow oil. LC-MSm/z [M+H]+ = 243.10 '-chloro-T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,1'H-3,4'-bipyrazole:To a stirred solution of 5-chloro-4-iodo-1-methyl-1H-pyrazole (1 g, 1 Eq, 4.12 mmol) in DMF (20 mL) was added 4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.5 g, 1.2 Eq, 6.19 mmol) followed by K2CO3 (1.43 g, 2.Eq, 10.31 mmol), (Ad)2BuP (0.148 g, 0.1 Eq, 0.412 mmol), Pd(OAc)2 (0.046 g, 0.05 Eq, 0.206 mmol) and t-BuCOOH (0.210 g, 0.05 Eq, 0.206 mmol) at RT and the resulting reaction mixture was stirred at 120 °C for 12 hours. The reaction progress was monitored by TLC and LCMS. The reaction mixture was diluted cold water (20 mL) and extracted with EtOAc (2 x 20 mL), dried over sodium sulfate, evaporated under reduced pressure to afford crude. The crude material was absorbed onto a plug of silica gel and purified by Sepabean chromatography through a RediSep pre-packed silica gel column (24 g), eluting with a gradient of 0-50% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to afford 5'-chloro-T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole (0.55 g, 33.33% yield) as a yellow solid. LC-MS m/z [M+H]+ = 358.47 '-chloro-T-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,1'H-[3,4'-bipyrazol]-4-amine:To a stirred solution of 5'-chloro-T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole (500 mg, Eq, 1.40 mmol) in ethanol (5 mL) and water (3.5 mL) was added ammonium chloride (375 mg, 5 Eq, 6. 193 PAT059456 FF mmol) followed by iron (391 mg, 5 Eq, 6.99 mmol) at RT and the resulting reaction mixture was stirred at °C for 4 hours. The reaction progress was monitored by TLC and LCMS. After completion of reaction, all volatiles were evaporated in vacuum, the residue obtained was dissolved in dichloromethane (15 mL), filtered and filtrate was evaporated in vacuum to afford 5'-chloro-1'-methyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H,1'H-[3,4'-bipyrazol]-4-amine (0.4 g, 61.69% yield) as a brown oil. LC-MS m/z [M+H]+ = 328.50 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((5'-chloro-1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 58 N-NHSEM-CI, Cs 2CO3DMF. 0°C-RT, 3hStep-85% no2 N-NTHF, -78°C no2< Fe, NH4CIN-N EtOH ׳ H2°50° ׳CSEM Step-381% nh2 N-NSEM Propyne, tetrakisDMF. 55c C, 5hStep-436%I 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole: To a stirred solution of 4-nitro-1H-pyrazole (5g, 44.21 mmol) and C52CO3 (28.7 g, 88.49 mmol) in DMF (50 mL), was added SEM-CI (11.5 mL, 66.37 mmol) at 0° C and stirred at room temperature for 3h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was washed with ice-cold water, dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230- 400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazole as colorless liquid (8 g, 85% yield). 1H NMR (400 MHz, CDCI)6 = 8.31 (s, 1H), 8.08-8.14 (m, 1H), 5.45 (s, 2H), 3.59-3.69 (m, 2H), 0.90-1.0 (m, 2H), 0.00-0.05 (m, 9H). 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (10 g, 46.94 mmol) in dry THF (100 mL), was added LiHMDS (mL) at -78°C and stirred for 1h at same temperature. After 1h, Iodine (10g, 78.85 mmol) was added at - 78°C and stirred for 1h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with sat. NH4CI, extracted with ethyl acetate. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was 194 PAT059456 FF purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-etherto give 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as pale yellow liquid (10 g, 58% yield). 1H NMR (400 MHz, CDCIa)6 = 8.26 (s, 1H), 5.61 (s, 2H), 3.62-3.69 (m, 2H), 0.90-0.99 (m, 2H), 0.00-0.05 (m, 9H). 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-iodo-4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (3g, 8.13 mmol) in ethanol (30 mb) and water (30 mb), were added NH4CI (4.30 g, 81.30 mmol) and iron powder (4.71 g, 81.30 mmol) at room temperature and then stirred at 50 °C for 3h. Progress of the reaction was monitored by TbC. After, completion of the reaction, the reaction mass was filtered through plug ofcelite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-etherto give 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol- 4-amine as pale brown liquid (2.5 g, 91% yield). 1H NMR (400 MHz, CDCI)6 = 7.15-7.28 (m, 1H), 5.31- 5.40 (m, 2H), 3.49-3.59 (m, 2H), 2.80 (br-s, 2H), 0.88-0.92 (m, 2H), -0.03-0.02 (m, 9H). 3-(prop-1-yn-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a degassed stirring solution of 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (2 g, 5.89 mmol) in DMF (40 mb), were added Cui (0.22 g, 1.17 mmol), triethyl amine (16 mb, 18V) and tetrakis (0.6 g, 0.58 mmol) and degassed for10 min. After, propyne (15.7 mb, 11.79 mmol, 3% in heptane) was added and heated at 55OC for 5h. Progress of the reaction was monitored by TbC & bCMS. After completion of the reaction, the reaction mass was filtered through celite plug, washed with ethyl acetate. The ethyl acetate layer was washed with ice-cold water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude product was purified by Sepa-Bean using silica gel (230-4mesh), eluting with 0-40% ethyl acetate in pet-ether to give 3-(prop-1-yn-1-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine as brown gummy liquid (0.5 g, 36% yield). LC-MSm/z [M+H]+ = 252.13, 1H NMR (400 MHz, CDCIa)6 = 7.19 (s, 1H), 5.39 (s, 2H), 3.58-3.64 (m, 2H), 3.05-3.(br-s, 2H), 3.17 (s, 3H), 0.90-0.96 (m, 2H), -0.08-0.02 (m, 9H).
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(prop-1-yn-1-yl)-1H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 195 PAT059456 FF Example 59 Pd(OAc') 2K2CO3, (Ad) 2BuPPivalic acid, DMF120 °C, 6hStep-138.48% NH4CL FeEtOH:H 2O °C,2hStep-232.9% 4-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine:To a stirred solution of 4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (500 mg, 1.92 mmol) and 4-bromopyridine (592.9 mg, 2.mmol) in DMF (5 mb), was added K2CO3 (799.3 mg 5.78 mmol), Bis (1-adamantyl-butyl-phosphane (69.mg, 0.19 mmol) and Pivalic acid (98.45 mg, 0.96 mmol) ) at 25° C and stirred at 120°C for6h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was diluted with water and extracted with ethyl acetate. The organic layer was washed with ice-cold water, dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-40% ethyl acetate in pet-etherto give 4-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine as pale yellow liquid (300 mg, 38.48% yield). LC-MS m/z [M+H]+ =321.43 3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 4-(4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine (300 mg, 0.93 mmol) in ethanol (3 mL) and water (3 mL), were added NH4CI (500.8 mg, 9.36 mmol) and iron powder (522.9 mg, 9.363 mmol) at room temperature and then stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (200 mg, 32.9% yield) as brown liquid LC-MSm/z [M+H]+ =291.39.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-4-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 196 PAT059456 FF Example 60 Pivalic acidDMF, 120°C, 6hStep-127.84% Pd(OAc) K2CO3,(Ad) 2BuPNH4Cl, FeEtOH:H ?O °C,2hStep-224% 2-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine:To a stirred solution of 4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (500 mg, 2.05 mmol) and 2-bromopyridine (487.0 mg, 3.mmol) in DMF (5 mb), was added K2CO3 (851.9 mg 6.16 mmol), Bis (1-adamantyl-butyl-phosphane (73.mg, 0.20 mmol) and Pivalic acid (104.9 mg 0.12 mmol) at 25° C and stirred at 120°C for 6h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was diluted with water and extracted with ethyl acetate. The organic layer was washed with ice-cold water, dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-ether to give 2-(4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine (300 mg, 27.84% yield) as pale yellow liquid. LC-MSm/z [M+H]+ =321.43 3-(pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 2-(4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine (300 mg, 0.93 mmol) in ethanol (3 ml) and water (3 m1), were added NH4CI (500.8 mg, 9.363 mmol) and iron powder (522.9 mg, 9.363 mmol) at room temperature and then stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 3-(pyridin-2-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (200 mg, 24 % yield) as brown liquid. LC-MSm/z [M+H]+ = 291.43.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-2-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 197 PAT059456 FF Example 61 Pd(OAc)2K2CO3, (Ad) 2BuPPivalic aicd,DMF, 120°C, 6hStep-57% NH4CI, FeEtOH:H 2O C, 2hStep-74% 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine:To a stirred solution of 4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (500 mg, 2.055 mmol) and 3-bromopyridine (487.0 mg, 3.082 mmol) in DMF (5 mb), was added K2CO3 (851.9 mg 6.164 mmol), Bis (1-adamantyl-butyl-phosphane (73.67 mg, 0.20 mmol) and Pivalic acid 104.9 mg 0.102 mmol) ) at 25° C and stirred at 120°C for 6h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was diluted with water and extracted with ethyl acetate. The organic layer was washed with ice-cold water, dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-etherto give 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine (400 mg, 57.77% yield) as pale yellow liquid. LC-MS m/z [M+H]+ = 321.34. 3-(pyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-(4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridine (400 mg, 1.248 mmol) in ethanol (4 ml) and water (4 m1), were added NH4CI (667.7 mg, 12.48 mmol) and iron powder (697.2 mg, 12.48 mmol) at room temperature and then stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 3-(pyridin-3-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (300 mg, 74.78 % yield) as brown liquid. LC-MSm/z [M+H]+ =291.43.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 198 PAT059456 FF Example 62 NO2 / N־NFe, NH4ClEtOH, H2O60°C,2h SEM59% 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-iodo-4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (5 g, 13.54 mmol) in ethanol (50 ml) and water (50 m1), were added NH4CI (7.243 g, 135.4 mmol) and iron powder (7.563 g, 135.4 mmol) and stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (3.0 g, 59 % yield) as brown liquid. LC-MSm/z [M+H]+ = 340.30. 1-(difluoromethyl)-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole:To a stirred solution of 5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (10.0 g, 48.06 mmol) and sodium 2-chloro-2,2-difluoroacetate (8.9 g, 58.38 mmol) in ACN (100 mL), was added 18-Crown-6 (2.5g 9.61 mmol), and stirred at room temperature for 24h. Progress of the reaction was monitored by TLC/LCMS. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 5-10% ethyl acetate in pet-ether to give 1-(difluoromethyl)-5-methyl-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1 H-pyrazole (7.0 g, 77% yield) as colour less liquid. LC-MS m/z [M+H]+ = 259.32, T-(difluoromethyl)-5'-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine: To a degassed solution of 1-(difluoromethyl)-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- pyrazole (1 g, 2.94 mmol), 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (912.9 mg, 3.mmol) and K3PO4 (1.567 g 7.36 mmol) in 1,4-Dioxane (9 mL) and Water (1 mL) was added Pd(dppf)CI2.DCM (240.7 mg, 0.29 mmol) stirred at 90°C for 5h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered, diluted with ethyl acetate (20 mL) and washed with water (2 x 30 mL). The organic layer was dried over Na2SO4, concentrated under 199 PAT059456 FF reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 30-40% EtOAc in pet ether to give 1'-(difluoromethyl)-5'-methyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H,1'H-[3,4'-bipyrazol]-4-amine (500 mg, 43.03% yield) as brown colour gummy solid. LC-MS m/z [M+H]+ = 344.15.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((1'-(difluoromethyl)-5'-methyl-1H,1'H-[3,4'-bipyrazol]-4- yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 63 Step-176.75% 54.59% (R)-4-nitro-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole: To astirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (1.0 g, 3.85 mmol) and (S)- tetrahydrofuran-3-ol (509.6 mg, 5.78 mmol) in toluene (30 mb), was added CMBP(1.861g 7.71 mmol) and stirred at 90°C for 4h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-ether to give (R)-4-nitro-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.0 g, 76.75% yield) as pale yellow liquid. LC-MS m/z [M+H]+ = 330.49.
(R)-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of R)-4-nitro-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (1.0 g, 3.03 mmol) in ethanol (10 ml) and water (10 m1), were added NH4CI (1.62 g, 30.36 mmol) and iron powder (1.69 mg, 30.36 mmol) and stirred at 60 °C for2h. Progress of the reaction was monitored by TLC. 200 PAT059456 FF After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of (R)-3-((tetrahydrofuran-3-yl)oxy)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (900 mg, 54.59 % yield) as brown liquid. LC-MS m/z [M+H]+ = 300.50 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3- yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 64 /Ax Pd(OAc)2 / K2co 3. (Ad) 2BuPN״N --------------- :-------NH4CI, FePivalic acid, DMF120°C, 16hStep-53% SEM 60°C, 2hStep-61% 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrazine:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (400 mg, 1.64 mmol) and 3- bromopyrazolo[1,5-a]pyrazine (488.3 mg, 2.46 mmol) in DMF (4 mb), was added K2CO3 (681.5 mg 4.mmol), Bis (1-adamantyl-butyl-phosphane (58.94 mg, 0.16 mmol) and Pivalic acid (83.94 mg 0.88 mmol) at 25° C and stirred at 120°C for 16h. TLC monitored the progress of the reaction. After completion of the reaction, the reaction was diluted with water and extracted with ethyl acetate. The organic layer was washed with ice-cold water, dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 30-40% ethyl acetate in pet-ether to give 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyrazine (400 mg, 53.08% yield) as pale yellow liquid. LC-MS m/z [M+H]+ = 361.54 201 PAT059456 FF 3-(pyrazolo[1,5-a]pyrazin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrazine (400 mg, 1.11 mmol) in ethanol (4 ml) and water (4 m1), were added NH4CI (593.6 mg, 11.10 mmol) and iron powder (619.8 mg, 11.10 mmol) at room temperature and then stirred at 60 °C for2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate (20 mL) and washed with water (2 x 30 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 3- (pyrazolo[1,5-a]pyrazin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-4-amine (300 mg, 61.46% yield) as brown liquid. LC-MS m/z [M+H]+ =331.51 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for HN N-NH"OH7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 65 HOToluene, rt, Step-66.1%Step-2 Step-379.54% '־ ' 83.98% Fe/NH4CIEtOH, H2O, 60°C, 2hStep 4 3-((3,3-dimethoxycyclobutyl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (500 mg, 1.92 mmol) and (3,3- dimethoxycyclobutyl)methanol (563.7 mg, 3.85 mmol) in toluene (15 mL), was added Cyanomethylene)tributylphosphorane (698.0 mg 2.89 mmol) and stirred at room temperature for 16h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-etherto give 3-((3,3- dimethoxycyclobutyl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (510 mg, 66.11% yield) as brown gummy liquid. 1H NMR (400 MHz, DMSO-d6)6 = 8.139 (s, 1H), 5.246 (s, 2H), 4.347 (d, J 202 PAT059456 FF = 7.2 Hz, 2H), 3.63 (t, J =8.0 Hz 2H), 3.1575(d, J = 6.8 Hz, 6H), 2.40-2.345 (m, 1H), 2.029-2.012(111, 2H), 2.004-1.996(111, 2H), 0.949-0.9281(111, 2H),0.101 (s, 9H). 3-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)cyclobutan-1-one:To a stirred solution of 3-((3,3-dimethoxycyclobutyl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole (500 mg, 1.29 mmol) in methanol (2.5 mL) and water (1.5 mL) was added p-TSA (1.22 g 6.mmol), at 0° C and stirred at room temperature for 5h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was diluted with water and extracted with ethyl acetate. The organic layer was washed with ice-cold water, dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 10-20% ethyl acetate in pet-ether to give 3-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-3-yl)oxy)methyl)cyclobutan-1-one (370 mg, 83.98% yield) as pale yellow liquid. 1H NMR (400 MHz, DMSO-d6)6 = 8.161 (s, 1H), 5.258 (s, 2H), 4.475 (d, J = 2.8 Hz, 2H), 3.656-3.614 (m, 2H), 3.288-3.207 (m, 2H), 3.071-3.001 (m, 3H), 0.912-1.012 (m, 2H) ,0.101 (s, 9H). 1-methyl-3-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)cyclobutan-1- ol: To a stirred solution of 3-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)cyclobutan-1-one (360 mg, 1.05 mmol) in THF (5.4 ml) was added CH3MgBr (593.6 mg, 11.10 mmol) at-78°C and then stirred at same temperature 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was quenched with NH4CI solution & extracted with ethyl acetate. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 1-methyl-3-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)oxy)methyl)cyclobutan-1-ol (300 mg, 79.59% yield) as brown liquid. 3-(((4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-1-methylcyclobutan- 1-01:To a stirred solution of 1-methyl-3-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)oxy)methyl)cyclobutan-1-ol (300 mg, 0.83 mmol) in ethanol (3.5 ml) and water (3.5 m1), were added NH4CI (448.9 mg, 8.392 mmol) and iron powder (468.7 mg, 8.392 mmol) and stirred at60°C for2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was filtered through plug ofcelite, the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 3- (((4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)-1-methylcyclobutan-1-ol (2mg, 30.21% yield) as brown liquid. LC-MS m/z [M+H]+ = 328.19 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided , 2'-((3-(((1 r,3R)-3-hydroxy-3-methylcyclobutyl)methoxy)-1 H- 203 PAT059456 FF pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 66 NO2 N-NxCMBP SEMToluene, 90°C, 4hStep-173% Eton, h20SEM 60 =c 2hN־Nx SEMStep-45% (R)-3-((1,4-dioxan-2-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (500 mg, 1.92 mmol) and (R)-(1,4- dioxan-2-yl)methanol (341.6mg, 2.89mmol) in Toluene (15.0mL), was added (Cyanomethylene)tributylphosphorane (930.7 mg 3.85 mmol)C and stirred at 90°C for4h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-etherto give (R)-3-((1,4-dioxan-2-yl)methoxy)- 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (600 mg, 73.69% yield) as pale yellow liquid. LC- MSm/z [M+H]+ = 360.23 (R)-3-((1,4-dioxan-2-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To astirred solution of (R)-3-((1,4-dioxan-2-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (600 mg, 1.66 mmol) in ethanol (6 ml) and water (6 ml), were added NH4CI (892.9 mg, 16.69 mmol) and iron powder (932.3 mg, 16.69 mmol) and stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of (R)-3-((1,4-dioxan-2-yl)methoxy)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (500 mg, 45% yield) as brown liquid. LC-MSm/z [M+H]+ = 330.31. 204 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-(((R)-1,4-dioxan-2-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'- ((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 67 27% NH4CI, FeEton, h60°C, 2hStep-248% 1-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)cyclopropane-1- carbonitrile:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (500 mg, 1.92 mmol) and 1-(hydroxymethyl)cyclopropane-1-carbonitrile (280.9 mg, 2.89 mmol) in toluene (15 mb), was added (Cyanomethylene) tributylphosphorane (930.7 mg 3.85 mmol) and stirred at 60°C for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-ether to give 1-(((4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3-yl)oxy)methyl)cyclopropane-1-carbonitrile (300 mg, 27.74% yield) as pale yellow liquid. 1H NMR (400 MHz, CDCI3)6 = 8.150 (s, 1H), 5.241 (s, 2H), 4.348(s, 2H), 3.634-3.592(m, 2H), 1.435-1.403 (m, 2H), 1.225-1.193 (m, 2H), 0.958-0.9517 (m, 2H). 1-(((4-amino-1 -((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)cyclopropane-1- carbonitrile:To a stirred solution of 1-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)oxy)methyl)cyclopropane-1-carbonitrile (300 mg, 0.88 mmol) in ethanol (3 ml) and water (3 m1), were added NH4CI (474.1 mg, 8.86 mmol) and iron powder (495.1 mg, 8.864 mmol) and stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 1-(((4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)cyclopropane-1- carbonitrile (200 mg, 48% yield) as brown liquid. LC-MS m/z [M+H]+ = 309.45. 205 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 1 -(((4-((71)).׳ R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazol-3- yl)oxy)methyl)cyclopropane-1-carbonitrile Example 68 NOMeO2C>J.SEM-CICS2CO3MeO 2C. DIBAL-H N-NHDMF, rt, 2h Step-52% 11 / N-NSEM DCM, 0°C-n Step-368%SEM % NaSMe----------------------a p ACN 0°C-RTFe, NH4CiEtOH;H 2O 60°C, 2hStep-571% methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate: To a stirredsuspension of methyl 4-nitro-1H-pyrazole-3-carboxylate (15 g, 87.66 mmol) and C52CO3 (42.7 g, 105.mmol) in DMF (150 mL), was added SEM-CI (22.38 ml, 105.19 mmol) at 0° C and stirred at 25°C for 2h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was diluted with, water and extracted with EtOAc. The organic layer dried over Na2SO4 and concentrated under reduced pressure to get the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in pet-ether to give methyl 4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (13.56 g, 52 % yield) as pale yellow liquid. 1H NMR (400 MHz, CDCI3, Mixture of regioisomers)6 = 8.348 (s, 1H), 8.076 (s, 1H), 5.629 (s, 2H), 5.5(s, 2H), 4.0175 (d, J = 3.8 Hz, 5H), 3.687-3.468 (m, 2H), 3.603-561 (m, 2H), 1.005-0.890 (m, 4H), 0.452- 0.19 (m, 12H). 206 THF -10*0-11, 3 hStep-232% MsCI, DIPEA PAT059456 FF (4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol:To a stirred solution of methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (13.56 g, 44.99 mmol) in THF (135.ml), was added DIBAL-H (89.9 mL, 89.989 mmol) at -10°C and then stirred at 25OC for 3 h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with aq.NH4CI and extracted with ethyl acetate. The organic layer was washed with water, dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 20-30% ethyl acetate in Pet-etherto give (4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (4.2 g, 32.7% yield) as Pale red liquid. LC- MSm/z [M+H]+ =274.19. (4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl methanesulfonate:To a stirred solution of (4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (4.2 g, 15.36 mmol) and DIPEA (3.47 mL, 19.96 mmol) in DCM (20 ml) was added Mesyl chloride (1.33 mL, 17.20 mmol) at 0°C and then stirred at room temperature for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give (4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl methanesulfonate (3.6 g, 67.92% yield) as brown liquid. The crude product was used as such for next step without further purification. 1H NMR (400 MHz, DMSO-d6)6 = 8.319 (s, 1H), 7.80-8.04 (m, 2H), 5.424 (s, 1H), 4.875 (s, 1H), 3.673-3.616 (m, 2H), 0.962- 0.920 (m, 1H), 0.000 (s, 9H). 3-((methylthio)methyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of (4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl methanesulfonate (3.6 g, 10.mmol) in acetonitrile (36 ml) was added 20% NaSMe (7.2 mL) at 0°C and then stirred at room temperature for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was concentrated, diluted with ethyl acetate (30 mL) and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give 3-((methylthio)methyl)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (2 g, 64.5% yield) as brown liquid. The crude product was used as such for next step, without further purification. LC-MS m/z [M+H]+ = 304.13. 3-((methylthio)methyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-((methylthio)methyl)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (800 mg, 2.63 mmol) in ethanol (8 ml) and water (8 m1), were added NH4CI (1.397 g, 26.36 mmol) and iron powder (1.44 g, 26.mmol) and stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give 3-((methylthio)methyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (500 mg, 71.42% yield) as pale red liquid. The crude product was used as such for next step without further purification. LC-MS m/z [M+H]+ =274.31. 207 PAT059456 FF As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((methylthio)methyl)-1H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 69 40 °C,3h Step-64% hno3, h2so4THF, 0 °C-RT, 30min Step-225% SEMCI, t-BuOKCs 2CO3, ACN, °C, 6h Step-30% Hydrogen tetra(but-1 -yl) ammonium sulphateNaOHJouleneRT, 1h Step-54%SEM TMSCF3, Na!THF, 60 °C, 16hStep-523%SEM % Pd/CMeOH, H2 (90psi), RT, 16h Step-6 4-nitro-1H-pyrazol-3-ol:H2SO4 (300 mb, 5.629 mol) was cooled to -10 °C and added 1 H-pyrazol-3-ol (1g, 1.204 mol), followed by HNO3(100 mb, 1.95 mol). The mixture was stirred at 40 °C for3h. The progress of the reaction was monitored by TbC and bCMS. The reaction mixture was quenched with ice cold water (200 mb), precipitation was observed. Filtered the precipitated solid and dried under vacuum to get the crude compound. The crude was purified by manual column using 100-200 silica gel compound was eluted with 100% ethyl acetate to give4-nitro-1H-pyrazol-3-ol as a Pale-yellow solid. (99 g, 64% yield). LC-MSm/z [M+H] + = 130.16 Synthesis of 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-ol:To a stirred solution of 4- nitro-1H-pyrazol-3-ol (50 g, 387.4 mmol) in THF (500 mb) at 0 °C was added t-BuOK (21.73 g, 193.mmol), followed by SEM-CI (61.7 mb, 348.6 mmol). The reaction mixture was stirred at RT for 30 min. The progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, the reaction mixture was quenched with water (100 mb) and extracted with ethyl acetate (4 x200 mb). The combined organic layer was dried over sodium sulphate, filtered and evaporated under reduced pressure 208 PAT059456 FF to give crude product. The crude was purified by column using 100-200 silica gel, compound was eluted with 30% ethyl acetate in pet-ethertogive 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H- pyrazol-3-ol as a Yellow solid (30 g, 25% yield). 1H NMR (400 MHz, CDCIa)6 = 8.229 (br-s, 1H), 8.1(s, 1H), 5.29 (s, 2H), 3.64-3.68 (m, 2H), 0.92-0.96 (m, 2H), -0.00 (s, 9H). 3-(2-bromoethoxy)-4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-ol (10 g, 38.6 mmol) in ACN (150 mL) at 0 °C was added C52CO3 (31.4 g, 96.4 mmol), 1,2-dibromoethane (10.9 g, 57.8 mmol). The reaction mixture was stirred at 90 °C for 6h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, reaction mixture was filtered through ceilite pad, filtrate was evaporated under reduced pressure to give crude compound, which was purifiedby Sepa-Bean using silica gel (230-4mesh), eluting with 15-20% ethyl acetate in pet-etherto give 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)- 1H-pyrazol-3-ol as an Off-white solid (5.1 g, 30% yield). LC-MS m/z [M+H] + = 366.34. 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-3-(vinyloxy)-1H-pyrazole:To a stirred solution of 4-nitro- 1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-ol (4.1 g, 11.19 mmol) in Toluene (82 mL) at 0 °C was added 50% NaOH solution (22.5 mL), Hydrogen tetra(but-l-yl) ammonium sulphate (3.801 g, 11.19 mmol). The reaction mixture was stirred at RT for 1h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (2 x 50mL). The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure to give crude product, which was purifiedby Sepa-Bean using silica gel (230-4mesh), compound was eluted with 25-30% ethyl acetate in pet-ethertogive 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-3-(vinyloxy)-1H-pyrazole as an Off-white solid (2.0 g, 54% yield). 1H NMR (400 MHz, CDCI) 6 = 8.185 (s, 1H), 7.12-7.25 (m, 1H), 5.27 (s, 2H), 5.07-5.11 (m, 1H), 4.63-4.66 (m, 1H), 3.61-3.(m, 2H), 0.92-0.96 (m, 2H), -0.00 (s, 9H). 3-(2,2-difluorocyclopropoxy)-4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-3-(vinyloxy)-1H-pyrazole (550 mg, 1.92 mmol) in THF (5.5 mL) at 0 °C was added Nai (144 mg, 0.964 mmol), TMSCF3(5.69 mL 38.54mmol). The reaction mixture was stirred at 60 °C for 16h. The progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (2x10 mL). The organic layer was dried over sodium sulphate, filtered and evaporated under reduced pressure to give crude product. The crude was purified by column using 100-200 silica gel, compound was eluted with 25-30% ethyl acetate in pet-etherto give 3-(2,2-difluorocyclopropoxy)-4- nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazole as an Off-white solid (150 mg, 23% yield). 3-(2,2-difluorocyclopropoxy)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-(2,2-difluorocyclopropoxy)-4-nitro-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazole (670 mg, 209 PAT059456 FF 2.0 mmol) in MeOH (10 mL) was added 10%Pd/C (200 mg, 30%). The reaction mixture was stirred under H2 (90psi) at room temperature for 16h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was filtered through ceilite pad; filtrate was evaporated under reduced pressure to give 3-(2,2-difluorocyclopropoxy)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-4-amine as a Brownliquid (550 mg). LC-MS m/z [M+H]+ = 306.16■ As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM followed by chiral SFC provided for Peak 1,difluorocyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 70 Peak 2 from Chiral SFC in example 69 provided fordifluorocyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1 ,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 71 4-nitro-3-((tetrahydrofuran-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (1 g, 3.85 mmol) and 210 RF- PAT059456 FF (tetrahydrofuran-3-yl)methanol (0.59 g, 5.78 mmol) in dry toluene (20 mL), was added CMBP (1.86 g, 7.mmol) and stirred at room temperature for 16h . Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was diluted with ethyl acetate, washed with water and brine solution. The organic layer was dried over Na2SO4, concentrated under reduced pressure to give crude compound. The crude compound was purified by flash column chromatography (24 g, silica gel column), eluting with 0-30% ethyl acetate in pet-ether to give 4-nitro-3-((tetrahydrofuran-3-yl)methoxy)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.7 g, 44% yield) as pale yellow liquid. LC-MS m/z [M+H]+ = 344.43 3-((tetrahydrofuran-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 4-nitro-3-((tetrahydrofuran-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.65 g, 1.89 mmol) in methanol (10 mL), was added Pd/C (0.2 g, 1.89 mmol) and stirred under hydrogen balloon pressure at room temperature for 3h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered, filtrate was concentrated under reduced pressure to give crude 3-((tetrahydrofuran-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine (0.45 g, 75% yield) as maroon liquid. 1H NMR (400 MHz, DMSO-d6)6 = 7.082 (s, 1H), 5.087 (s, 2H), 4.100-3.973 (m, 2H), 3.805-3.756(m, 2H), 3.706-3.669 (m, 1H), 3.589-3.568 (m, 2H), 3.576-3.499 (m, 2H), 2.689-2.554 (m, 1H), 2.005-1.954 (m, 1 H),1.677-1.685 (m, 1H), 0.855-0.815(m, 2H), 0.000(s, 9H).
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM followed 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3- d]pyrimidin]-6'(7'H)-one Example 72 Peak 2 from Chiral SFC of example 71 affordedhydroxycyclohexyl)-2 ’-((3-(((S)-tetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5’-pyrrolo[2,3-d]pyrimidin]-6 ’(7’H)-one 211 by chiral SFC afforded Peak 1, 7’-((1R,3R)-3- PAT059456 FF Example 73 NH2 3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine: To a degassed solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine (0.2 g, 0.802 mmol) in DMF (4 mL), were added 3-iodo-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.22 g, 0.66 mmol), K3PO4 (0.35 g, 1.67 mmol) and Pd(dppf)CI2.DCM (0.054 g, 0.06 mmol), stirred at 90°C for 16h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was concentrated under reduced pressure to give crude compound. The crude compound was purified by flash column chromatography (g, silica gel column), eluting with 0-5% MeOH in DCM to give 3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin- 3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.2 g, 42% yield) as pale brown solid. LC-MS m/z [M+H]+ = 334.46 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(4,5,6,7- tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3- dlpyrimidinl-6'(7'H)-one 212 N־N PAT059456 FF Example 74 W /N-N C82CO2 40%SEM 50°C, 2h55% 4-nitro-3-((tetrahydro-2H-pyran-4-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (1 g, 3.85 mmol) and 4- bromotetrahydro-2H-pyran (0.95 g, 5.78 mmol) in DMF (15 mb), was added Cs2CO3 (3 g, 2.38 mmol) and stirred at 80°C for 16 hours. Progress of the reaction was monitored by TLC & LCMS, after completion of the reaction, the reaction mass was diluted with ice-cold water and extracted with ethyl acetate. The organic layer was dried on NaSO4, concentrated under reduced pressure to get crude. The crude product was purified by the flash column chromatography (24 g, silica column), eluted with 0-30% EtOAc in pet ether to give 4-nitro-3-((tetrahydro-2H-pyran-4-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (0.6 g, 40.7%) as a pale-yellow solid. LC-MS m/z [M+H]+ = 344.18 3-((tetrahydro-2H-pyran-4-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To astirred solution of 4-nitro-3-((tetrahydro-2H-pyran-4-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (0.6 g, 1.74 mmol) in ethanol (5 mL), water (5 mL), were added iron powder (0.48 g, 8.73 mmol) and NH4CI (0.46 g, 8.73 mmol) and stirred at 50°C for 2 hours. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was diluted with EtOAc and filtered on celite pad, washed with water and brine solution. The organic layer was dried over Na2SO4, concentrated under vacuum. The crude was purified by flash column chromatography (12 g silica column), eluting with 0-50% EtOAc in pet- ether to give 3-((tetrahydro-2H-pyran-4-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.g, 55 %) as a brown liquid. LC-MS m/z [M+H]+ = 314.23 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((tetrahydro-2H-pyran-4- yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 213 PAT059456 FF Example 75 Step-48% pyridine, r.t, 6hStep-229%DMF, 80°C, 16hStep-338% Cis-RacemateTHF, rt, 3fStep-480%81% 4-(hydroxymethyl)tetrahydrofuran-3-ol:To a stirred solution of NaBH4 (6.56 g, 173.5 mmol) in ethanol (20 mL), was added methyl 4-oxotetrahydrofuran-3-carboxylate (5 g, 34.69 mmol) as a solution in ethanol (20 mb) at -30 °C. The resulting reaction mass was stirred at -30 °C for 30 min and then allowed to stir at room temperature for16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was acidified with 1N aq HCI. All the solvents were evaporated under vacuum. Solid was triturated with 10% MeOH in DCM and decanted. The decanted portions were concentrated under vacuum to get crude product. The crude product was purified by the flash column chromatography (40g, silica column), eluting with 0-5% MeOH in DCM to get 4-(hydroxymethyl)tetrahydrofuran-3-ol (2 g, 48% yield) as a pale-yellow semi-solid. 1H NMR (400 MHz, CDCI3) 6 = 4.53 (s, 1H), 4.32 (brs, 2H), 4.09-4.(m, 2H), 3.71-3.94(m, 16H), 2.87 (m, 1H), 2.22-2.75 (m, 8H). (4-hydroxytetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate:To a stirred solution of 4- (hydroxymethyl)tetrahydrofuran-3-ol (2.7 g, 22.86 mmol) in pyridine (27.00 mL) was added p-TsCI (4.7g, 25.14 mmol) and stirred at room temperature for 6h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was diluted with ethyl acetate washed with water. Combined organic layers were dried over, Na2SO4, concentrated under vacuum to get crude. The crude product was purified by the flash column chromatography (24 g, silica column), eluted with 0-5% MeOH in DCM. to get (4-hydroxytetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate (1.8 g, 29 %) as a colourless semi-solid. LC-MS m/z [M+H]+ = 273.20 4-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)tetrahydrofuran-3-ol:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (1.6 g, 6.208 mmol) and (4- hydroxytetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate (1.69 g, 6.208 mmol) in DMF (30.000 mL) 214 PAT059456 FF was added C52CO3 (4 g, 12.42 mmol) and stirred at 80 °C for 16h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was quenched with ice-cold water, extracted with ethyl acetate. The organic layer was dried over Na2SO4, concentrated under reduced pressure to get crude. The crude product was purified by the flash column chromatography (24 g, silica column), eluted with 0-60% EtOAc in pet ethee to give 4-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-3-yl)oxy)methyl)tetrahydrofuran-3-ol (800 mg, 38% yield) as off white solid. LC-MS m/z [M+H]+ = 360.46 3-(((4-fluorotetrahydrofuran-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole: To a stirred solution of 4-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)oxy)methyl)tetrahydrofuran-3-ol (1 g, 2.782 mmol) in THF (10 mL), were added PBSF (1.26 g, 4.1mmol) as a solution in THF (1 mL), 1-methyl-1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine (0.64 g 4.17 mmol) and stirred at room temperature for 3h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was concentrated under vacuum to get crude. The crude product was purified by the flash column chromatography (24 g, silica column), eluted with 0- 30% EtOAc in pet ether to give 3-((-4-fluorotetrahydrofuran-3-yl)methoxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (800 mg, 80 %,) as a colourless solid. LC-MS m/z [M+H]+ = 362.48 3-((-4-fluorotetrahydrofuran-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To a stirred solution of 3-((-4-fluorotetrahydrofuran-3-yl)methoxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.8 g, 2.21 mmol) in EtOH (1 mL) and water (1 mL) were added Iron powder (0.61 g, 11.06 mmol), NH4CI (0.59 g, 11.06 mmol) and stirred at 50 °C for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was diluted with EtOAc and filtered on celite pad, washed with EtOAc. The filtrate was concentrated under vacuum to get the crude. The crude product was purified by the flash column chromatography (12 g silica column) eluted with 0-50% EtOAc in pet ether to give cis-racemate 3-((-4-fluorotetrahydrofuran-3-yl)methoxy)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.6 g, 81% yield) as a yellow semi-solid. LC-MS m/z [M+H]+ = 332.48 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-((-4-fluorotetrahydrofuran-3-yl)methoxy)- 1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 215 for cis-racemate PAT059456 FF Example 76 PCC16h ؛، DCM. 0°C-rStep-138%MeOH, rt 2h Step -** 77% 4-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)methyl)dihydrofuran-3(2H)-one: a stirred solution of 4-(((4-nitro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3- yl)oxy)methyl)tetrahydrofuran-3-ol (2 g, 5.56 mmol) in DCM (30: mL) was added PCC (1.79 g, 8.mmol) at 0 °C and then stirred at room temperature for 16h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was diluted with water and extracted with DCM. The combined organic layers were dried over Na2SO4, concentrated under reduced pressure to get crude. The crude product was purified by the flash column chromatography (40 g, silica gel column), eluted with 0-30% EtOAc in pet ether to get the pure 4-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3- yl)oxy)methyl)dihydrofuran-3(2H)-one (1.2 g, 38.67 % yield) as colourless semi-solid. LC-MS m/z [M+H]+ = 358. 3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole:To a stirred solution of 4-(((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3- yl)oxy)methyl)dihydrofuran-3(2H)-one (1.1 g, 3.07 mmol) in DCM (20 mb) was added DAST (2.48 g, 15.mmol) at 0 °C, and then stirred at room temperature for 16h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was diluted with Ice-cold aq. NaHCO3, extracted with DCM. The organic layer was dried over Na2SO4, concentrated under reduced pressure to get crude product. The crude product was purified by the flash column chromatography (24 g, silica column), eluted with 0-40% EtOAc in pet ether to get (R)-3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.5 g, 43 % yield) as a colourless semi-solid. LC-MS m/z [M+H]+ = 380.46. 3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4- amine: To a stirred solution of (R)-3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.4 g, 1.05 mmol) in methanol (8 mL) was added Pd-C (0.22 g, 1.26 mmol) and stirred at room temperature for2h under hydrogen bladder pressure. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was diluted with MeOH and filtered on celite pad, the filtrate was concentrated under reduced pressure to get the crude product. The crude product was purified by the flash column chromatography (12 g, silica column), eluted with 0-5% MeOH in DCM to get the (R)-3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-1-((2- 216 PAT059456 FF (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (280 mg, 77% yield) as pale yellow semi-solid. LC-MS m/z [M+H]+ = 350.46 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-1H-pyrazol- 4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 77 Fe/NH4CIEtOH, H2OStep-186.6% To a stirred solution of 4-nitro-3-((2-(trimethylsilyl)ethoxy)methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazole (1.0 g, 2.567 mmol) in ethanol (10 ml) and water (10 m1), were added NH4CI (1.373 g, 25.mmol) and iron powder (1.434 g, 25.67 mmol) at room temperature and then stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug ofcelite; the filtrate was concentrated, diluted with ethyl acetate (20 mL) and washed with water (2 x 30 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of 3-((2-(trimethylsilyl) ethoxy) methoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-4-amine as brown liquid (800.0 mg, 86.67 % yield). 1H NMR (400 MHz, CDCIa) 6 = 7.05 (br-s, 1H), 5.32-5.42 (br-s, 2H), 5.12 (br-s, 2H), 3.47-3.82 (m, 5H), 2.82 (br-s, 1H), 0.86-0.98 (m, 4H), 0.0 (s, 18H).
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 2'-((3-hydroxy-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one.
Example 78 217 PAT059456 FF (S)-4-nitro-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole: To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (600.0 mg, 2.31 mmol) in toluene (ml) was added (R)-tetrahydrofuran-3-ol (305.8 mg, 3.47 mmol) and CMBP (7.243 g, 135.4 mmol) at room temperature and then stirred at 80 °C for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was diluted with, water (20 mL) and extracted with Ethyl acetate (2 x 30 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 25-30% EtOAc in pet ether to give (S)-4-nitro-3-((tetrahydrofuran-3-yl)oxy)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole as brown colour gummy solid (600 mg, 74% yield). LC-MS m/z [M+H]+ = 330.46.
(S)-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To astirred solution of (S)-4-nitro-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (500.0 mg, 1.51 mmol) in ethanol (6 ml) and water (6 m1), were added NH4CI (811.9 mg, 15.1 mmol) and iron powder (847.7 mg, 15.1 mmol) at room temperature and then stirred at 60 °C for 2h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate (20 mL) and washed with water (2 x mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of (S)-3-((tetrahydrofuran-3-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-4-amine as brown liquid (350.0 mg, 28 % yield). LC-MS m/z [M+H]+ = 300.50.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided N tCJi ,JL / °HNAfT N, 0 (XXj N-NH •—/ '0Hfor O 7’-((1 R,3R)-3-hydroxycyclohexyl)-2 ’-((3-(((S)-tetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5 ’-pyrrolo[2,3-d]pyrimidin]-6 ’(7’H)-one Example 79 218 PAT059456 FF K3PO4, Pd(dppf)CI ؟ NDioxane:H 2O, 100 °C, 6hStep-30% T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,3'-bipyrazole:To a degassed solution of 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.500 g,4 063 mmol), 1-methyl-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.268 g,6.094 mmol) and K3PO4(2.156 g,10.mmol) in 1,4-Dioxane (15 mL) and Water (3 mL) was added Pd(dppf)CI2.DCM (331.8 mg,406.3 umol) stirred at 90°C for 5h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mass was filtered, diluted with ethyl acetate (20 mL) and washed with water (2 x 30 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 60-70% EtOAc in pet ether to give T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,3'-bipyrazole as brown colour gummy solid (450 mg, 30% yield). LC-MS m/z [M+H] + = 324.2.
T-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,3'-bipyrazol]-4-amine:To a stirred solution of T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,3'-bipyrazole (450.0 mg,1.391 mmol) in ethanol (4.5 ml) and water (4.5 m1), were added NH4CI (744.2 mg,13.91 mmol) and iron powder (777.mg,13.91 mmol) at room temperature and then stirred at 50 °C for 3h. Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate (20 mL) and washed with water (2 x 30 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of T- methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,3'-bipyrazol]-4-amine as brown liquid (300.0 mg, % yield). LC-MSm/z [M+H]+ = 294.31.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((1 '-methyl- 1 H,TH-[3,3'- bipyrazol]-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 80 219 PAT059456 FF N—N Dioxane:H 2O, 100 °C, 6hSEM Step-68%N~NSEMEtOHStep-83%SEM T-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine: To a degassedsolution of 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.0 g,2.71 mmol), 1-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (676 mg, 3.25 mmol) and Na2CO3 (574 mg,5.mmol) in ACN (30 mb) and Water (5 mb) was added Pd(dppf)CI2.DCM (198.0 mg,0.27 mmol) stirred at 90°C for 16h. Progress of the reaction was monitored by TbC and bCMS. After completion of the reaction, the reaction mass was filtered, diluted with ethyl acetate (20 mb) and washed with water (2 x 30 mb). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 40-50% EtOAc in pet ether to give T-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine as brown colour gummy solid (600 mg, 68% yield). LC-MS m/z [M+H] + = 323.4.
T-methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-3,4'-bipyrazole:To a stirred solution of T-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine (600.0 mg, 1.85 mmol) in ethanol (6.0 ml) and water (6.0 m1), were added NH4CI (947.3 mg, 18.57 mmol) and iron powder (984.mg, 18.57 mmol) at room temperature and then stirred at 50 °C for 3h. Progress of the reaction was monitored by TbC. After, completion of the reaction, the reaction mass was filtered through plug of celite; the filtrate was concentrated, diluted with ethyl acetate (20 mb) and washed with water (2 x 30 mb). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product of T- methyl-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,1'H-3,4'-bipyrazole as brown liquid (450.0 mg, 83 % yield). LC-MSm/z [M+H]+ = 293.4.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-1H,1'H-[3,4'- bipyrazol]-4-yl)amino)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 81 220 PAT059456 FF pivaiic acid, DMF Step-12(5% EtOH:H 2O.°CStep-98% 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine:To a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1 g, 4.12 mmol) in DMF (20 mb) was added 3-bromopyrazolo[1,5-a]pyrimidine (1.5 g, 6.19 mmol) followed by K2CO3(1.43 g, 10.31 mmol), (Ad)2BuP (0.148 g, 0.412 mmol) and pivalic acid (0.210 g, 0.206 mmol) at RT, purged with nitrogen gas to minutes and was added Pd(OAc)2 (0.046 g, 0.206 mmol) and the resulting reaction mixture was stirred at 120 °C for 12 hours. The reaction progress was monitored by TLC and LCMS. The reaction mixture was diluted cold water and extracted with EtOAc, dried over sodium sulfate, evaporated under reduced pressure to afford crude. The crude material was absorbed onto a plug of silica gel and purified by Sepabean chromatography through a RediSep pre-packed silica gel column (24 g), eluting with a gradient of 0-50% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to afford 3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine (0.4 g, 25.65% yield) as a yellow oil. LC-MS m/z [M+H]+ =361.18. 3-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To astirred solution of 3-(4-nitro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3-yl)pyrazolo[1,5- a]pyrimidine(300 mg, 0.832 mmol) in ethanol (3 mL) and water (3 mL) was added ammonium chloride (232 mg, 4.16 mmol) followed by iron (223 mg, 4.16 mmol) at RT and the resulting reaction mixture was stirred at 50 °C for 2 hours. The reaction progress was monitored by TLC and LCMS. After completion of reaction, all volatiles were evaporated in vacuo, the residue obtained was dissolved in dichloromethane, filtered and filtrate was evaporated in vacuo to afford 3-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.35 g, 98% yield) as a brown oil. LC-MSm/z [M+H]+ = 331.45.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 7'-((1 R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1 ,5- a]pyrimidin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 82 221 K2CO؟, (Ad) 2BuP, Pd(OAc) ? PAT059456 FF NaBH 4————————————MeOHOC-RTStep-148% NaH, MeiTHF OC-RTStep-249% CMBPtoluene, RTStep-465% MeOH Step-3 NH4CI, FeEtOH:H 2O °CStep-551% 64% Pd/CPd(OH) 2, (1s,3s)-3-(benzyloxy)cyclobutan-1-ol:To a stirred solution of 3-(benzyloxy)cyclobutan-1-one (5 g, 28.mmol) in MeOH (50 mb) was added NaBH4 (1.6 g, 42.56 mmol) at 0 °C and the resulting reaction mixture was stirred at RT for 2 hours. The reaction progress was monitored by TLC and LCMS. On completion, the reaction mixture was cooled to 0 °C, quenched with sat. NH4CI solution , extracted with EtOAc, washed with brine, dried over sodium sulfate and evaporated under reduced vacuum pressure to afford (1s,3s)-3- (benzyloxy)cyclobutan-1-ol (4 g, 48 % yield) as a pale yellow oil. 1H NMR (CDCIs):6 = 7.37-7.25 (m, 5H), 4.41 (s, 2H), 3.91-3.89 (m, 1H), 3.66-3.59 (m, 1H), 2.75-2.67 (m, 2H), 1.97-1.89 (m, 2H). (((1s,3s)-3-methoxycyclobutoxy)methyl)benzene: To a stirred solution of(1s,3s)-3-(benzyloxy)cyclobutan-1-ol (4 g, 22.44 mmol) in THF (40 mL) was added NaH (1.35 g, 60% w/w, 33.mmol) at 0 °C, stirred for 10 minutes and was added Mel (2.1 mL, 33.66 mmol) and the resulting reaction mixture was stirred at RT for 2 hours. The reaction progress was monitored by TLC and LCMS. On completion, the reaction mixture was quenched with ice cold water (100 mL), extracted with EtOAc (2 x 100 mL), washed with brine (50 mL), dried over sodium sulfate and evaporated under reduced vacuum pressure to afford (((1s,3s)-3-methoxycyclobutoxy)methyl)benzene (3.5 g, 49 % yield) as a pale yellow oil. 1H NMR (CDCIs):6 = 7.36-7.25 (m, 5H), 4.42 (s, 2H), 3.71-3.64 (m, 1H), 3.53-3.46 (m, 1H), 3.23 (s, 3H), 2.66-2.59 (m, 2H), 1.97-1.89 (m, 2H). (1s,3s)-3-methoxycyclobutan-1-ol:To a solution of (((1s,3s)-3-methoxycyclobutoxy)methyl)benzene (3.5 g, 1.93 mmol) in MeOH (35 mL) was added Pd/C (1.4 g, 40% w/w) followed by Pd(OH)2 (0.35 g, 10% w/w) in parr shaker and the resulting reaction mixture was stirred at RT under hydrogenation pressure (psi) for 12 hours. The reaction progress was monitored by TLC. On completion, the reaction mixture was 222 PAT059456 FF passed through celite pad and the pad was washed with MeOH (30 mL). Filtrate was dried over sodium sulphate, filtered and evaporated under reduced vacuum pressure to afford (1s,3s)-3- methoxycyclobutan-1-ol(1.7 g, 64 % yield) as a pale yellow oil. 1H NMR (CdCIs):6 = 4.98 (d, J = 6.8 Hz, 1H), 3.68-3.66 (m, 1H), 3.36-3.32 (obs, 1H), 3.09 (s, 3H), 2.53-2.47 (m, 2H), 1.67-1.61 (m, 2H). 3-((1r,3r)-3-methoxycyclobutoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-ol (500 mg, 1.93 mmol) in toluene (1 mL) was added (1s,3s)-3-methoxycyclobutan-1-ol (0.36 g, 3.47 mmol) followed by CMBP (mL, 3.86 mmol) and the resulting reaction mixture was stirred at RT for 12 hours. The reaction progress was monitored by TLC and LCMS. On completion, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate. Combined organic layers was washed with brine, dried over sodium sulphate, filtered and evaporated under reduced vacuum pressure to give crude product. The crude material was absorbed onto a plug of silica gel and purified by SepaBean chromatography through a RediSep pre-packed silica gel column (24 g), eluting with a gradient of 0-30% EtOAc in pet ether, collected the pure fractions and concentrated under reduced vacuum pressure to afford 3-((1r,3r)-3-methoxycyclobutoxy)-4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole (0.45 g, 65 % yield) as a pale yellow oil. LC-MS m/z [M+H]+ = 344.21 [M+H]+ 3-((1r,3r)-3-methoxycyclobutoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine: To astirred solution of 3-((1 r,3r)-3-methoxycyclobutoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (400 mg, 1.16 mmol) in ethanol (4 mL) and water (4 mL) was added ammonium chloride (311 mg, 5.mmol) followed by iron (325 mg, 5.82 mmol) and the resulting reaction mixture was stirred at 50 °C for hours. The reaction progress was monitored by TLC and LCMS. After completion of reaction, all volatiles were evaporated in vacuo, the residue obtained was dissolved in dichloromethane (15 mL), filtered and filtrate was evaporated in vacuo to afford 3-((1r,3r)-3-methoxycyclobutoxy)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (0.3 g, 51% yield) as a brown oil. LC-MSm/z [M+H]+ = 314.21 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided for 'XO< 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1r,3R)-3-methoxycyclobutoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 83 223 PAT059456 FF SEM-CI, NaHTHF, 11, 16hStep-157% NH2NH2.H2OEtOH, 100°C, 12hStep-245% AcOH100°C,3hStep-368% MeOH, rt, 6hStep-55% Pd/C methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate:To a stirred solution of methyl 4-nitro-1H-pyrazole-3-carboxylate (3 g, 17.53 mmol) and NaH (0.54 g, 23.99 mmol) in THF (mL) was added SEM-CI (3.5 g, 21.03 mmol) at 0 °C and then stirred at room temperature for 16h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, concentrated under reduced pressure. The crude product was purified by the flash column chromatography (40 g, silica gel column), eluted with 0-30% EtOAc in pet ether to get the pure methyl 4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (3 g, 57 % yield) as pale yellow liquid. LC-MSm/z [M+H]+ = 302.17 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbohydrazide: To a sealed tubecontaining stirred solution of methyl 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (2 g, 6.63 mmol) in ethanol (30 mL) was added hydrazine hydrate (0.66 g, 13.27 mmol) and stirred at 100°C for 12h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, concentrated under reduced pressure to get crude product. The crude product was purified by the flash column chromatography (24 g, silica column), eluted with 0-100% EtOAc in pet ether to get 4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbohydrazide (0.9 g, 45% yield) as a colourless liquid. LC- MS m/z [M+H]+ = 302.17 2-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazole:To a sealed tube containing a stirred solution of 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbohydrazide (g, 3.38 mmol) in acetic acid (2.5 mL) was added triethoxymethane (5 mL) and stirred at 100°C for 3h. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was 224 PAT059456 FF concentrated under reduced pressure to get the crude product. The crude product was purified by the flash column chromatography (24 g, silica column), eluted with 0-80% ethyl acetate in pet-etherto get the 2-(4- nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazole (0.75 g, 68% yield) as colourless gummy liquid. LC-MS m/z [M+H]+ = 312.07. 3-(1,3,4-oxadiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 2-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazole (0.8 g, 2.56 mmol) in methanol (8 mb) was added Pd-C (0.32 g) and stirred at room temperature for 6h under hydrogen bladder pressure. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was diluted with MeOH and filtered on celite pad, the filtrate was concentrated under reduced pressure to get 3-(1,3,4-oxadiazol-2-yl)-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-4-amine (0.4 g, 55% yield) as pale violet liquid. LC-MS m/z [M+H]+ = 282.13.
As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided 2'-((3-(1,3,4-oxadiazol-2-yl)-1 H-pyrazol-4-yl)amino)-7'-((1 R,3R)-3- hydroxycyclohexyl)spiro[cyclopro pane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Example 84 N—NH 225 PAT059456 FF Step-514.74% 4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole:To a stirred solution of 4-nitro-1H-pyrazole (5g, 44.21 mmol) and C52CO3 (28.7 g, 88.49 mmol) in DMF (50 mL), was added SEM-CI (11.5 mb, 66.mmol) at 0° C and stirred at room temperature for 3h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was quenched with ice-cold water and extracted with ethyl acetate (2 x50 mL). The organic layer was washed with ice-cold water (2x10 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-10% ethyl acetate in pet-etherto give 4-nitro-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazoleas colorless liquid (8 g, 85% yield). 1H NMR (400 MHz, CDCh)6 = 8.31 (s, 1H), 8.08-8.14 (m, 1H), 5.45 (s, 2H), 3.59-3.69 (m, 2H), 0.90-1.0 (m, 2H), 0.00-0.05 (m, 9H). 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole:To a stirred solution of 4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (10 g, 46.94 mmol) in dry THF (100 mL), was added LiHMDS (mL) at -78 °C and stirred for 1h at the same temperature. After 1h, Iodine (10 g, 78.85 mmol) was added at -78°C and stirred for 1h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was quenched with sat. NH4CI, extracted with ethyl acetate (2 x 100 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-ether to give 3-iodo-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazoleaspale yellow liquid (10 g, 58% yield). 1H NMR (400 MHz, CDCIa)6 = 8.26 (s, 1H), 5.61 (s, 2H), 3.62-3.69 (m, 2H), 0.90-0.(m, 2H), 0.00-0.05 (m, 9H). 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-iodo-4-nitro- 1-((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrazole (3 g, 8.13 mmol) in ethanol (30 mL) and water (30 mL), were added NH4CI (4.30 g, 81.30 mmol) and iron powder (4.71 g, 81.30 mmol) at room temperature and then stirred at 50 °C for 3h. The Progress of the reaction was monitored by TLC. After, completion of the reaction, the reaction mass was filtered through plug of celite, the filtrate was concentrated, diluted with ethyl acetate (100 mL) and washed with water (2 x 50 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure to give the crude product. The crude compound was purified by 226 PAT059456 FF Sepa-Bean using silica gel (230-400 mesh), eluting with 0-30% ethyl acetate in pet-etherto give 3-iodo-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amineas Pale brown liquid (2.5 g, 91% yield). 1H NMR (400 MHz, CDCIa)6 = 7.15-7.28 (m, 1H), 5.31-5.40 (m, 2H), 3.49-3.59 (m, 2H), 2.80 (br-s, 2H), 0.88-0.92 (m, 2H), -0.03-0.02 (m, 9H). 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)-1H-pyrazole:To a stirred solution of 4-bromo-1-methyl-5-(trifluoromethyl)-1H-pyrazole (500 mg, 5.155 mmol) and BisPin (720.8 mg, 2.838 mmol) in Toluene (14.40 mL) was added PdCI2(PP3)2 (76.63 mg 0.109 mmol) at 25OC and stirred for 15 minutes at 150°C. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mass was cooled to 25°C and filtered over celite then rinsed with ethylacetate. The filtrated was concentrated under reduced pressure to give the crude product 1-methyl-4-(4,4,5,5- tetramethyl- 1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)-1H-pyrazole (720.0 mg, 44.51 % yield). LC-MS m/z [M+H]+ =277.42 T-methyl-5'-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H,TH-[3,4'-bipyrazol]-4-amine: To a stirred solution of 3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (500 mg, 1.4mmol) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)-1H-pyrazole (488.3 mg, 1.474 mmol) and Potassium phosphate tribasic (782.1 mg, 3.685 mmol) in 1,4-Dioxane (4.5 mL) and Water (0.5 mL) was added Pd(dppf)CI2.DCM complex (120.4 mg, 0.147 mmol at 25°C and then stirred at 90 °C for 16h. Progress ofthe reaction was monitored by TLC. After, completion ofthe reaction, the reaction mass was diluted with water and extracted with ethyl acetate (2x15 mL). The organic layer was washed with ice-cold water (2x10 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product. The crude compound was purified by Sepa-Bean using silica gel (230-400 mesh), eluting with 50- 70% ethyl acetate in pet-ether to give T-methyl-5'-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H,1'H-[3,4'-bipyrazol]-4-amineas white color solid (250 mg, 14.74 % yield). LC-MS m/z [M+H]+ = 362.50 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided F ؛ Ffor F 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-5'-(trifluoromethyl)-1H,TH-[3,4'-bipyrazol]-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one 227 PAT059456 FF Example 85 SEM-CI Cs 2CO3DMF Step-2LiOH _MeOH. H2OStep-390% NO2BH3.DMS PBSF؛ MTBD.THF n~N thfStep-4 SEM Step-585% 46% Fe. NH4CIEtOH, H2OStep-644% methyl 1-((4-nitro-1H-pyrazol-3-yl)oxy)cyclopropane-1-carboxylate:To a stirred solution of methyl 1- hydroxycyclopropane-1-carboxylate (3 g, 25.84 mmol) in THF (30 mL) was added sodium hydride (1.0g, 25.84 mmol) and stirred for 30 minutes at 0 °C, this reaction mixture was added to a stirred solution of 1,4-dinitro-1H-pyrazole (4.1 g, 25.84 mmol) in THF (120 mL) at -78 °C. The resulting reaction mixture was stirred at same temperature foe 1 hour. The reaction progress was monitored by LCMS & TLC. LC-MS showed desired product formation. The reaction mixture was quenched with sat. NH4CI solution and extracted with ethyl acetate, combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude product was purified by the SepaBean column chromatography and eluted with 20-35% EtOAc in pet ether. All pure fractions were collected and concentrated to get the methyl 1-((4-nitro-1H-pyrazol-3-yl)oxy)cyclopropane-1-carboxylate (g, 13 % yield) as off white solid. LC-MS m/z [M+H]+ = 228.28 methyl 1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)cyclopropane-1- carboxylate:To a stirred solution of methyl 1-((4-nitro-1H-pyrazol-3-yl)oxy)cyclopropane-1-carboxylate (900 mg, 3.96 mmol) was taken in DMF (9 mL) was added cesium carbonate (2.6 g, 7.92 mmol) and SEM- Cl (991 mg, 1 mL, 5.94 mmol) dropwise at 0 °C. The resulting reaction mixture was stirred for 2 hours at °C, The reaction progress was monitored by LC-MS & TLC. LC-MS showed desired product formation. The reaction mixture was quenched with water and extracted with ethyl acetate, combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude product was purified by the SepaBean column chromatography and eluted with 10-20% EtOAc in pet ether. All pure fractions were collected and concentrated to get the pure compound of methyl 1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)cyclopropane-1-carboxylate (1.3 g, % yield) as a pale yellow oil. LC-MS m/z [M+H]+ = 300.12 228 PAT059456 FF methyl 1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)cyclopropane-1- carboxylate:To a stirred solution of methyl 1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)oxy)cyclopropane-1-carboxylate (1.1 g, 3.077 mmol) was taken in methanol (11 mL), THF (11 mL) and water (6 mL) was added LiOH (0.22 g, 9.232 mmol). Then stirred the reaction mixture for 3 hour at 27 °C, Reaction progress was monitored by LC-MS. LC-MS showed desired product formation. The reaction mixture was concentrated under reduced vacuum pressure to give crude product and acidified with 1N HCI solution and extracted with ethyl acetate, combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give 1-((4-nitro-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)cyclopropane-1-carboxylic acid (910 mg, 67 % yield) as pale yellow gummy liquid. LC-MS m/z [M+H]+ = 343.45 (1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)cyclopropyl)methanol:To a stirred solution of 1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)cyclopropane-1- carboxylic acid (900.0 mg, 2.621 mmol) was taken in THF (15 mL) was added BH3.DMS (2.6 mL, 2M, 5.2mmol) dropwise at 0 °C. The resulting reaction mixture was stirred for 3 hours at 65 °C. Reaction progress was monitored by LCMS. The reaction mixture was quenched with methanol & concentrated under reduced vacuum pressure to give crude product. The crude product was purified by the Sepabean column chromatography and eluted with 40-70% EtOAc in pet ether. All pure fractions were collected and concentrated to get (1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3- yl)oxy)cyclopropyl)methanol (750 mg, 85 % yield) as an off white solid. LC-MS m/z [M+H]+ = 330.18 3-(1-(fluoromethyl)cyclopropoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole: To astirred solution of (1-((4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)oxy)cyclopropyl)methanol (300 mg, 910.66 umol) was taken in THF (9 mL) was added PBSF (0.24 mL, 1.366 mmol) in THF (3 mL) dropwise at 0 °C & MTBD (210 mg, 1.3660 mmol), Then stirred the reaction mixture for 3 hour at 0 °C, Reaction progress was monitored by LC-MS. The reaction mixture was quenched with water and extracted with DCM, combined the organic layers and dried over sodium sulphate filtered and concentrated under reduced vacuum pressure to give crude product. The crude product was purified by the Sepabean column chromatography and eluted with 10-30% EtOAc in pet ether. All pure fractions were collected and concentrated to get 3-(1-(fluoromethyl)cyclopropoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1 H- pyrazole (140 mg, 46 % yield) as a white solid. LC-MS m/z [M+H]+ = 332.48 3-(1-(fluoromethyl)cyclopropoxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine:To a stirred solution of 3-(1-(fluoromethyl)cyclopropoxy)-4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (140 mg, 422.42 umol) was taken in ethanol (1.4 mL) and water (1.4 mL) was added iron (118 mg, 2.mmol) and ammonium chloride (113 mg, 2.1121 mmol). The resulting reaction mixture was stirred for hours at 50 °C. The reaction progress was monitored by LCMS & TLC. The reaction mixture was filtered through celite pad & washed with 10% MeoH in DCM, dried over sodium sulphate, filtered and concentrated under reduced vacuum pressure to give 3-(1-(fluoromethyl)cyclopropoxy)-1-((2- 229 PAT059456 FF (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (120 mg, 44 % yield) as pale orange oil. LC-MS m/z [M+H]+ = 302.23 As per the method described in Example 2, coupling to Intermediate 1 and deprotection of SEM provided ((1 R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one Structure Data /jf >0 LC-MSm/z [M+H]+ = 355.30, 1H NMR (400 MHz, DMSO- d6)6 = 9.35 (s, 1H), 7.87 (s, 1H), 7.85 (s, 1H), 7.48 (s, 1H),HN^N^N V )uoN—N (Example 1) 4.55-4.80 (m, 2H), 4.13 (s, 1H), 3.79 (s, 3H), 2.40-2.50 (m,1H), 2.20-2.35 (m, 1H), 1.51-1.85 (m, 7H), 1.35-1.50 (m, 3H).
T || >0 LC-MSm/z [M+H]+ = 355.27, 1H NMR (400 MHz, DMSO- de)5 = 12.17 (br-s, 1H), HN^N^N 8.57 (br-s, 1H), 7.81 (s, 1H), 7.68 (s, 1H), 4.60-4.75 (m,׳ V. /,"OHN-NH un (Example 2)1H), 4.54 (s, 1H), 4.08 (s, 1H), 3.17 (d, J = 5.2 Hz, 2H), 2.40-2.50 (m, 1H), 2.10-2.30 (m, 4H), 1.50-1.82 (m, 7H), 1.30-1.50 (m, 3H).
LC-MSm/z [M+H]+ = 391.34, 1H NMR (400 MHz, DMSO- de)5 = 13.11 (s, 1H), 8.82 (s, 1H), 8.04 (s, 1H), 7.87 (s, 1H), 7.17 (t, J = 54 Hz,I 1 /-- ץOH /"׳ ؟ / F^^wN-NH (Example 3) 1H), 4.62-4.75 (m, 1H), 4.56 (d, J = 2.8 Hz, 1H), 4.09 (s, 1H), 2.42-2.50 (m, 1H), 2.15-2.28 (m, 1H), 1.50-1.82 (m, 7H), 1.45-1.50 (m, 2H), 1.38 (t, J = 12.8 Hz, 1H). 230 PAT059456 FF O> hn^n^nLa 3A 7 ?־״OHN״NH " (Example 4) LC-MSm/z [M+H]+ = 399.29, 1H NMR (400 MHz, DMSO- de)6 = 13.54 (br-s, 1H), 8.57 (br-s, 1H), 8.27 (s, 1H), 7.(s, 1H), 4.65-4.78 (m, 1H), 4.65 (d, J = 2.4 Hz, 1H), 4.13 (s, 1H), 3.88 (s, 3H), 2.42-2.52 (m, 1H), 2.20-2.35 (m, 1H), 1.55-1.82 (m, 7H), 1.38-1.55 (m, 3H). n־^VL a XA0HN N N LC-MSm/z [M+H]+ = 355.30, 1H NMR (400 MHz, DMSO- de)6 =11.79 (br-s, 1H), 9.45 (br-s, 1H), 7.86 (s, 1H), 6.34(br-s, 1H), 4.63-4.73 (m, 1H), 4.57 (s, 1H), 4.11 (s, 1H),hnA (nA V/״oh (Example 5) 2.50-2.60 (m, 1H), 2.25-2.38 (m, 1H), 2.19 (s, 3H), 1.51- 1.85 (m, 7H), 1.35-1.50 (m, 3H). n^Y>==o HN n ׳ץ LC-MSm/z [M+H]+ = 371.30, 1H NMR (400 MHz, DMSO- de)6 = 12.34 (s, 1H), 8.51 (s, 1H), 7.85 (s, 2H), 5.12 (br-s, V-/ ،0HN NH (Example1H), 4.45-4.75 (m, 4H), 4.10 (s, 1H), 2.52-2.62 (m, 1H), 2.15-2.30 (m, 1H), 1.51-1.85 (m, 7H), 1.32-1.50 (m, 3H).6) nzVJl /L )=0HN^N N LC-MSm/z [M+H]+ = 383.43, 1H NMR (400 MHz, DMSO- de)6 = 12.15 (br-s, 1H), 8.55 (s, 1H), 7.82 (s, 1H), 7.62 (s, 1H), 4.82 (t, J= 12.4 Hz, 1H), 4.54 (s, 1H), 4.10 (s, 1H), N-NH "OH/ (Example 7)2.38-2.48 (m, 1H), 2.10-2.35 (m, 4H), 1.40-1.70 (m, 6H), 1.20-1.38 (m, 2H), 1.23 (s, 3H), 0.85 (s, 3H).
H'N3na ’1 !1 A A0 LC-MS m/z:[M+H]+ =411.19 (99%) 1H NMR (400 MHz, DMSO-de)6 = 12.459 - 12.353 (m, 1H), 8.600 (br s, 2H), 7.802 (m, 1H), 7.216 - 6.90 (m, 1H), 4.77 - 4.38 (m, 2H),rA N NJ H 14.20-4.01 (m, 1H), 3.95 (t, J = 7.6 Hz, 1H), 3.85 (brd, J =O O"0HA_Z (Example 8)5.6 Hz, 1H), 3.78 -3.68 (m,1H), 3.62 (brs, 1H), 3.56 - 3.(m, 1H), 2.45-2.30 (m, 1H), 2.25-2.10 (m, 3H), 2.09 - 1.97 (m, 1H), 1.81 - 1.56 (m, 9H). 231 PAT059456 FF 1 עHN N^N!tV-^ (AN~kl^ V /־"OHN NH—/ (Example 9) LC-MS m/z:[M+H]+=396.22 (96.27%) 1H NMR (400 MHz, DMSO-d6)6 = 8.707 (s, 1H), 7.80 (s, 1H), 7.53 (s, 1H), 4.75 - 4.58 (m, 2H), 4.12 - 4.03 (m, 1H), 3.92 (t, J = 5.4 Hz, 2H), 3.85 - 3.76 (m, 2H), 3.13 - 3.01 (m, 2H), 2.46 - 2.(m, 1H), 2.29-2.13 (m, 1H), 1.763- 1.516 (m, 10H).
N-//T jl /=/--qI /"~Z m X V /״OHN™NH —-•־׳(Example 10) LC-MSm/z: [M+H]+=425.22 (97%); 1H NMR (400 MHz, DMSO-d6)6 = 12.52 - 12.43 (m, 1H), 8.53 - 8.47 (m, 1H), 8.16 - 7.99 (m, 1H), 7.87-7.65 (m, 1H), 4.82 - 4.45 (m, 3H), 4.31 - 3.99 (m, 2H), 3.68 - 3.45 (m, 1H), 2.74 - 2.(m, 1H), 2.36-2.05 (m, 1H), 1.92 - 1.18 (m, 16H).
HN^N^N HN' p ( —0h 0/ (Example 11) LC-MS m/z[M+H]+ =385.32 (99%) 1H NMR (400 MHz, DMSO-d6)6 = 11.97 - 11.78 (m, 1H), 9.37 (s, 1H), 7.88 (s, 1H), 7.19 (s, 1H), 4.73 - 4.67 (m, 1H), 4.57 - 4.54 (m, 1H), 4.32 (s, 2H), 4.18 - 4.00 (m, 1H), 3.27(m, 3H), 2.71 - 2.(m, 1H), 2.40 - 2.24 (m, 1H), 1.87 - 1.36 (m, 10H).
Y £ /=0 -pA f ־ n־־nh vy 0H (Example12) LC-MS m/z:[M+H]+=371.38 (98%) 1H NMR (400 MHz, DMSO-d6)5 = 11.71 -11.51 (s, 1H), 8.19 (s, 1H), 7.78 (s, 1H), 7.647-7.643 (d, 1H), 4.649-4.619 (m, 1H), 4.52 (d, J = 2.8 Hz, 1H), 4.06 (brs, 1H), 3.78 (s, 3H), 2.35-2.10 (m, 1H), 1.83-1.19 (m, 10H).
Y '° ؟، civ / /,,,OHN־״NH ' A (Example 13) LC-MS m/z:[M+H]+=375.27 (98%) 1H NMR (400 MHz, DMSO-d6, 298 K)6 (ppm) = 13.02- 12.52 (m, 1H), 8.62 - 8.43 (m, 2H), 7.98 - 7.76 (m, 2H), 4.74 - 4.43 (m, 2H), 4.(br s, 1H), 2.49 - 2.52 (m, 1H), 2.35 - 1.99 (m, 1H), 1.84 - 1.14 (m, 11H). 232 PAT059456 FF NZ^r" V-n1! J 7=°HN^N^1! •--0HN״NH (Example14) LC-MS m/z:[M+H]+=381.35 (98%), 1H NMR (400 MHz, DMSO-d6, 298 K)6 (ppm) = 12.22 - 11.99 (m, 1H), 8.71 - 8.38 (m, 1H), 7.93 - 7.43 (m, 2H), 4.74 - 4.44 (m, 2H), 4.- 3.91 (m, 1H), 2.50- 1.84 (m, 3H), 1.84 -1.16 (m, 12H), 0.86- 0.60 (m, 4H) A>° VF A / "AF/vT 7 /"'OHN־־NH (Example LC-MSm/z: [M+H]+=409.30 (95%), 1H NMR (400 MHz, DMSO-d6: 298 K)6 (ppm) = 13.479 (s, 1H), 8.547 (s, 1H), 8.024 (s, 1H), 7.816 (s, 1H), 4.631 -4.525 (m, 2H), 4.0(brs, 1H), 2.457-2.392 (m, 1H), 2.159-2.136 (m, 1H), 1.77 - 1.11 (m, 10H).15) N^V"^JL fHN /' NA ex n-n VV^oh LC-MSm/z [M+H]+ = 399.34, 1H NMR (400 MHz, DMSO- d6)6 = 9.36 (s, 1H), 7.88-7.90 (m, 2H), 7.52 (s, 1H), 4.(t, J= 12.4 Hz, 1H), 4.59 (s, 1H), 4.18 (t, J = 5.6 Hz, 2H), 4.12 (s, 1H), 3.65 (t, J = 5.6 Hz, 2H), 3.22 (s, 3H), 2.45- 2.50 (m, 1H), 2.20-2.35 (m, 1H), 1.52-1.85 (m, 7H), 1.38- 1.50 (m, 3H)./ (Example 16) XV/o V-OHN־־NH ^V (Example 17) LC-MSm/z [M+H]+ = 369.40, 1H NMR (400 MHz, DMSO-d6) = 12.09 (br-s, 1H), 8.54 (s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 4.68-4.78 (m, 1H), 4.49 (s, 1H), 3.98 (s, 1H), 2.50-2.60 (m, 1H), 2.10-2.25 (m, 4H), 1.63-1.82 (m, 5H), 1.56-1.62 (m, 3H), 1.41-1.55 (m, 3H), 1.30-1.50 (m, 1H).
N-::Xr/ '؛ THN^N^־־"^/0־~XS "OHN-NH ־X^V (Example LC-MSm/z [M+H]+ = 385.37, 1H NMR (400 MHz, DMSO- de)6 = 11.63 (s, 1H), 8.16 (s, 1H), 7.78 (s, 1H), 7.67 (s, 1H), 4.64-4.73 (m, 1H), 4.47 (s, 1H), 3.97 (s, 1H), 3.79 (s, 3H), 2.50-2.60 (m, 1H), 2.12-2.28 (m, 1H), 1.52-1.80 (m, 8H), 1.52-1.30 (m, 4H).18) 233 PAT059456 FF aX^0 HN N N< 1n u / )״,OhN™NH A-V (Example 19) LC-MSm/z [M+H]+ = 389.13, 1H NMR (400 MHz, DMSO- de)6 = 12.86 (s, 1H), 8.53 (s, 1H), 7.92 (s, 1H), 7.82 (s, 1H), 4.68-4.75 (m, 1H), 4.48 (d, J = 3.2 Hz, 1H), 3.97 (s, 1H), 2.50-2.60 (m, 1H), 2.12-2.25 (m, 1H), 1.55-1.80 (m, 8H), 1.42-1.54 (m, 3H), 1.28-1.40 (m, 1H).
HN^N '~־־Nt J.^7 /OHN—NH """־־" LC-MSm/z [M+H]+ = 366.24, 1H NMR (400 MHz, DMSO-de) = 13.71 (br-s, 1H), 9.34 (s, 1H), 8.05 (s, 1H), 7.89 (s, 1H), 4.62-4.72 (m, 1H), 4.55 (d, J = 2.4 Hz, 1H), 4.08 (s, 1H), 2.42-2.52 (m, 1H), 2.12-2.26 (m, 1H), 1.30-1.82 (m, 10H).
(Example 20) j| | 7=0 V/^°hN—NH '"־׳—'(Example 21) LC-MSm/z [M+H]+ = 385.49, 1H NMR (400 MHz, DMSO-de) = 12.55 (br-s, 1H), 8.58 (br-s, 1H), 7.82-7.94 (m, 2H), 4.63- 4.73(m, 1H), 4.56 (d, J = 2.4 Hz, 1H), 4.48 (s, 2H), 4.09 (s, 1H), 3.22 (s, 3H), 2.45-2.55 (m, 1H), 2.15-2.28 (m, 1H), 1.51-1.84 (m, 7H), 1.32-1.50 (m, 3H).
II J 7=0HN^N^N LC-MSm/z: [M+H]+=415.20 (99%) 1H NMR (400 MHz, DMSO-de)6 = 11.673 (br s, 1 H),8.117 (s, 1H), 7.795(s, 1H), 7.665(s, 1H), 4.658 - 4.598 (m, 1H), 4.530 (br s, 1H), 4.220-־ ^ 0 ־־־ ^C-NH ''0H (Example 22) 4.196 (m, 2H), 4.066 (brs, 1H), 3.629 - 3.605 (m, 2H), 3.3(s, 3H), 2.510 (s, 1H), 2.328 - 2.179 (m, 1H), 1.756 - 1.5(m, 9H), 1.480-1.337 (m, 1H).
°HN^N^No^Ax <"^~y / /•״OHN™NH '-־-—/ u (Example 23) LC-MS m/z:[M+H]+=385.33 (97%) 1H NMR (400 MHz, DMSO-de)6 = 11.615 (brs, 1H), 8.105 (s, 1H), 7.788(s, 1H), 7.638 (s, 1H), 4.6.52-4.591 (m, 1H), 4.533 (brs, 1H), 4.174- 4.121 (m, 2H), 4.06 (brs, 1H), 2.497(s, 1H), 2.235 - 2.209(m, 1H), 1.755 - 1.462 (m, 9H), 1.454 - 1.281 (m, 4H). 234 PAT059456 FF ••־׳■؟،׳> NA JL X0״HN^Ir ־N(.
NH "--V ״ J N ،CT (Example 24) LC-MSm/z [M+H]+ = 445.28, Chiral HPLC: 98.61% (Rt= 7.70), 1H NMR (400 MHz, DMSO-d6)6 = 11.85 (s, 1H), 8.(br-s, 1H), 7.808 (s, 1H), 7.733-7.737 (m, 1H), 5.26-5.39 (m, 1H), 5.07-5.12 (m, 1H), 4.54-4.67 (m, 1H), 4.542-4.549 (d, J = 2.8 Hz, 1H), 4.10-4.14 (m, 1H), 4.07-4.10 (m, 1H), 3.81- 3.97 (m, 3H), 2.40-2.45 (m, 1H), 2.15-2.25 (m, 1H), 1.30- 1.75 (m, 10H). 11 1 >0HN^N^N~^N^NH Vv^ 0"־H J NNH ؟ (Example 25) LC-MSm/z [M+H]+ = 445.28, Chiral HPLC: 96.58% (Rt= 9.32), 1H NMR (400 MHz, DMSO-d6)6 = 11.85 (s, 1H), 8.(br-s, 1H), 7.808 (s, 1H), 7.733-7.737 (m, 1H), 5.26-5.39 (m, 1H), 5.07-5.12 (m, 1H), 4.54-4.67 (m, 1H), 4.542-4.549 (d, J = 2.8 Hz, 1H), 4.10-4.14 (m, 1H), 4.07-4.10 (m, 1H), 3.81- 3.97 (m, 3H), 2.40-2.45 (m, 1H), 2.15-2.25 (m, 1H), 1.30- 1.75 (m, 10H). j] 1 7=0HN^n'^NF 1 /—. / ؛oh /■״ / v /־־־ר"، J N--NH CT (Example 26) LC-MSm/z [M+H]+= 445.28, Chiral HPLC: 99.98% (Rt= 3.97), 1H NMR (400 MHz, DMSO-d6)6 = 11.803 (s, 1H), 8.191 (s, 1H), 7.802 (s, 1H), 7.707 (s, 1H), 5.29-5.43 (m, 1H), 5.02-5.08 (m, 1H), 4.58-4.70 (m, 1H), 4.533-4.539 (d, J = 2.4 Hz, 1H), 4.05-4.11 (m, 1H), 4.011-4.017 (m, 1H), 3.91-3.95 (m, 1H), 3.70-3.74 (m, 1H), 2.41-2.45 (m, 1H), 2.16-2.25 (m, 1H), 1.23-1.80 (m, 10H).
S'^rXo HN^N^NFH°~X X"0h ( N-NH ^-Vb' (Example 27) LC-MSm/z [M+H]+= 445.24, Chiral HPLC: 99.52% (Rt=5.14), 1HNMR (400 MHz, DMSO-d6)6 = 11.803 (s, 1H), 8.191 (s, 1H), 7.802 (s, 1H), 7.707 (s, 1H), 5.29-5.43 (m, 1H), 5.02-5.08 (m, 1H), 4.58-4.70 (m, 1H), 4.533-4.539 (d, J = 2.4 Hz, 1H), 4.05-4.11 (m, 1H), 4.011-4.017 (m, 1H), 3.91-3.95 (m, 1H), 3.70-3.74 (m, 1H), 2.41-2.45 (m, 1H), 2.16-2.25 (m, 1H), 1.23-1.80 (m, 10H). 235 PAT059456 FF jN= ، V / ITj Uh VV"°h (Example 28) LC-MSm/z [M+H]+ = 457.32, 1H NMR (400 MHz, DMSO-de) = 12.71-12.88 (br-s, 1H, rotamers), 8.59-8.65 (m, 2H), 8.08-8.20 (m, 2H), 7.63-7.80 (m, 2H), 7.26-7.29 (m, 1H), 6.90-6.93 (m, 1H), 4.43-4.60 (m, 2H), 3.70-4.15 (m, 1H), 1.85-2.30 (m, 2H), 1.15-1.75 (m, 10H). jTX^ 0 / ؟׳، orf N-NH "OHF"/F (Example 29) LC-MSm/z [M+H]+ = 447.26, 1H NMR (400 MHz, DMSO-de) = 1HNMR (400 MHz, DMSO-de)6 = 11.78 (s, 1H), 8.(br-s, 1H), 7.802 (s, 1H), 7.69-7.70 (m, 1H), 4.78-4.90 (m, 1H), 4.58-4.70 (m, 1H), 4.535-4.542 (d, J=2.8 Hz, 1H), 4.05- 4.11 (m, 1H), 3.00-3.107 (m, 2H), 2.65-2.80 (m, 2H), 2.40- 2.45 (m, 1H), 2.15-2.28 (m, 1H), 1.30-1.85 (m, 10H).
I i >Q HN^N^N zY-A O-h ، J N™NH ^—ZF f (Example 30) LC-MSm/z [M+H]+ = 461.29, 1H NMR (400 MHz, DMSO- de)0 = 11.72 (s, 1H), 8.19 (br-s, 1H), 7.805 (br-s, 1H), 7.702- 7.706 (m, 1H), 5.0-5.08 (m, 1H), 4.60-4.70 (m, 1H), 4.537- 4.544 (d, J=2.8 Hz, 1H), 4.05-4.10 (m, 1H), 2.55-2.61 (m, 2H), 2.025-2.35 (m, 6H), 1.45-1.80 (m, 9H), 1.28-1.41 (m, 1H). fY>°N- HN^N^N X/ A / 20Hp-Y N״NH '—zF (Example 31) LC-MSm/z [M+H]+ = 471.26, 1H NMR (400 MHz, DMSO-de) = 12.89 (s, 1H), 8.49 (br-s, 1H), 7.76-7.83 (m, 2H), 7.42- 7.69 (m, 2H), 4.50-4.57 (m, 2H), 3.95-4.05 (m, 1H), 3.96 (s, 3H), 2.31-2.35 (m, 1H), 1.98-2.15 (m, 1H), 1.41-1.75 (m, 9H), 1.15-1.35 (m, 1H). 236 PAT059456 FF j 1 00HN^N^N ؟ n-nh VV "oh (Example 32) LC-MSm/z [M+H]+ = 417.23, Chiral HPLC: 99.81 % (Rt: 2.min), 1H NMR (400 MHz, DMSO-de)6 = 11.47 (s, 1H), 8.(br-s, 1H), 7.60-7.89 (m, 2H), 4.65-4.70 (m, 1H), 4.552- 4.558 (d, J=2.4 Hz, 1H), 4.05-4.15 (m, 1H), 3.03-3.108 (m, 1H), 2.451-2.456 (m, 1H), 2.15-2.25 (m, 1H), 1.85-2.01 (m, 2H), 1.51-1.85 (m, 7H), 1.45-1.50 (m, 2H), 1.31-1.41 (m, 1H). njA X hn^n^n0"™N-NH OH (Example 33) LC-MSm/z [M+H] + = 417.23, Chiral HPLC: 99.01% (Rt: 4.21 min), 1H NMR (400 MHz, DMSO-de)6 = 11.47 (s, 1H), 8.87 (br-s, 1H), 7.60-7.89 (m, 2H), 4.65-4.70 (m, 1H), 4.552- 4.558 (d, J=2.4 Hz, 1H), 4.05-4.15 (m, 1H), 3.03-3.108 (m, 1H), 2.451-2.456 (m, 1H), 2.15-2.25 (m, 1H), 1.85-2.01 (m, 2H), 1.51-1.85 (m, 7H), 1.45-1.50 (m, 2H), 1.31-1.41 (m, 1H). c / JI J z^ 0F 0 HN 'N'' ^(A» / /,,'OHN-NH ^-V (Example 34) LC-MSm/z [M+H]+ = 457.23. 1H NMR (400 MHz, DMSO- de)6 = 12.78-12.84 (br-s, 1H, rotamers), 8.66 (br-s, 1H), 8.36 (s, 1H), 7.69-8.0 (m, 4H), 4.49-4.58 (m, 2H), 3.99 (s, 1H), 2.32-2.33 (m, 1H), 2.03-2.05 (m, 1H), 1.45-1.70 (m, 9H), 1.15-1.31 (m, 1H). n'^^x _JI / °HN^N^N *A^A )0N J N-NH ،-Z'n (Example 35) LC-MSm/z [M+H]+ = 437.25, 1H NMR (400 MHz, DMSO- de)6 = 11.98 (s, 1H), 8.44 (s, 1H), 7.80 (s, 1H), 7.760-7.7(m, 1H), 7.34 (s, 1H), 4.55-4.70 (m, 1H), 4.51-4.52 (d, J=2.Hz, 1H), 4.029 (br-s, 1H), 3.75 (s, 3H), 2.41-2.50 (m, 1H), 2.15-2.25 (m, 1H), 1.45-1.75 (m, 9H), 1.28-1.40 (m, 1H).
A ؟ ? O-^jY /״,ohN-NH LC-MS m/z [M+H]+ =441.90, 1H NMR (400 MHz, DMSO- de)6 = 13.08-13.25 (br-s, 1H, rotamers), 9.00-9.17 (br-s, 1H, rotamers), 8.74 (br-s, 1H), 8.56-8.57 (m, 1H), 8.08 (br-s, 1H), 7.95-7.98 (m, 1H), 7.90 (s, 1H), 7.44-7.47 (m, 1H), 4.66-4.72 (m, 1H), 4.562-4.568 (d, J=2.4 Hz, 1H), 4.05-4.15 237 PAT059456 FF (Example 36) (m, 1H), 2.49-2.501 (m, 1H), 2.21-2.25 (m, 1H), 1.23-1.(m, 10H).
A'V'V.,< נ !וV HN^N nn (Example 37) LC-MSm/z [M+H] + = 435.50, 1H NMR (400 MHz, DMSO- de)6 =12.57 (br-s, 1H), 8.25 (br-s, 1H), 7.75 (br-s, 1H), 7.(s, 1H), 4.50-4.58 (m, 2H), 3.98-4.05 (m, 1H), 3.72 (s, 3H), 2.39 (s, 3H), 2.02-2.11 (m, 2H), 1.40-1.80 (m, 9H), 1.20-1.(m, 1H).
!! X / HN^N^N ~"z Y / /"OHN-NH (Example 38) LC-MSm/z [M+H]+ = 440.26, 1H NMR (400 MHz, DMSO-d6) = 11.61 (s, 1H), 8.10 (s, 1H), 7.79 (s, 1H), 7.64 (s, 1H), 4.62-4.70 (m, 1H), 4.52-4.53 (d, J=2.4 Hz, 1H), 4.058 (br-s, 1H), 3.91-3.93 (m, 2H), 2.41-2.50 (m, 1H), 2.15-2.25 (m, 1H), 1.25-1.75 (m, 10H), 1.28-1.40 (m, 1H), 1.15-1.25 (m, 2H), 0.49-0.53 (m, 2H), 0.25-0.30 (m, 2H). jqX° r''"^ / POLF N~NH un (Example 39) LC-MSm/z [M+H]+ = 440.26, 1H NMR (400 MHz, DMSO-d6) = 11.72 (s, 1H), 8.17 (s, 1H), 7.67 (s, 1H), 4.63-4.77 (m, 3H), 4.52-4.526 (d, J=2.4 Hz, 1H), 4.29-4.38 (m, 2H), 4.(br-s, 1H), 2.46-2.49 (m, 1H), 2.20-2.32 (m, 1H), 1.70-1.(m, 1H), 1.51-1.65 (m, 6H), 1.41-1.45 (m, 2H), 1.25-1.38 (m, 1H) A XHN N Nץ ץ( w / OLI | N-NH V—/ U (Example 40) LC-MSm/z: [M+H]+=411.31 1H NMR(400 MHz, DMSO-d) 6 = 11.613 (s, 1H),8.104(br s, 1H) 7.792 (s, 1H), 7.760- 7.637 (s, 1H),4.833- 4.815(m, 1H), 4.657- 4.626(1, J=12.Hz 1H),4.532-4.526 (d 1H), 4.1 (br s 1H), 2.497-2.328 (m 1H) 2.324-2.319 (m 1H), 2.312-2.305 (m 1H), 2.074-2.0(m 2H), 1.757-1.462 (m 11H), 1.494-1.462 (m 1H) 238 PAT059456 FF j JL / HN^N^NF 1 K-ך / סי^׳^ c/""~ • ' /'"OHF N_NH <_/ (Example 41) LC-MSm/z: [M+H]+=421.29 1H NMR (400 MHz, DMSO-de ) 6 = 11.853(s, 1H),8.276(br 5 1H) 7.793 (s 1H), 7.696 (s, 1H),6.491-6.482(1 J=4.8 Hz 1H), 4.624- 4.595(1, J=11.6 Hz 1H),4.528(S 1H),4.410-4.432 (m 2H),4.063(5 1H), 2.497 (s 1H),2.217-2.190 (m 1H), 1.753-1.507 (m 9H), 1.482-1.3(m1H) jj .± / 0HN^N^N Uh U/"On ؛ ^ HO (Example 42) LC-MSm/z: [M+H]+= 401.21 1H NMR (400 MHz, DMSO-d) 6 = 11.622(5, 1H),8.264(br s 1H) 7.824 (5 1H), 7.727 (5, 1H),4.878-4.864 (1 J=5.6 Hz 1H), 4.688- 4.658(1, J=12 Hz H),4.554-4.547(d J=2.8 Hz 1H), 4.126-4.083 (m 3H),3.686- 3.647(m 2H), 2.467 (m 1H),2.328-2.1810 (m 1H), 1.803- 1.737 (m 1H), 1.704-1.486 (m 6H),1.470-1.462 (m 2H), 1.453-1443 (m 1H) °HN^N^'N""NO^/°־-xA) ( גN W / ‘OHN -NH x—' (Example 43) LC-MSm/z: [M+H]+=451.41 1H NMR(400 MHz, DMSO-d) 6 = 11.7 (5, 1H),8.152(5, 1H) 7.782 (5, 1H), 7.676-7.673(d, J=1.2Hz 1H)7.621-7.615(d, J=2.4Hz 1H) 6.524(5, 1H), 6.286-6.273(1 J=3.2Hz 1H), 5.062 (5 2H), 4.620 (1, 1H),4.531-4.524(d J=2.8 1H),4.072 (5 1H),3.808(3H),2.497-2.492 (m 1H),2.333-2.323 (m1H), 1.753-1.4(m 12H) T h 7=0HN^N^N /^0Ls Ll™ / N-NH t-v (Example 44) LC-MSm/z: [M+H]+=464.24 1H NMR(400 MHz, DMSO-d6 ) = 11.843 (s,1H), 8.431(5, 1H) 7.816 (5, 1H), 7.741(5, 1H), 4.682-4.651 (1, J=12.4 1H),4.545(br 5 1H),4.431-4.399 (J=13.6Hz 2H),3.240(5 3H),2.492 (m 1H),2.337-2.3(m1H), 1.761-1.460 (m 9H) n/55Vv_.Jl / 0 A F I )—,v / OHn-nh 1—z (Example 45) LC-MSm/z: [M+H]+=429.24 1H NMR(400 MHz, DMSO-d6 ) = 11.719 (s,1H), 8.155(br 5, 1H),7.796 (5, 1H), 7.667(5, 1H), 4.658-4.627 (1, J=12.4 1 H),4.529-4.522(d J=28Hz 1H),4.421-4.364 (d J=22.8Hz 2H),4.064(br 5 1H), 2.455 (m 1H) ,2.323-2.231 (m 1H) 1.780-1.464 (m 9H), 1.356-1.3(m 1H), 1.091-1.075 (m2H), 0.8-0.6 (m 2H) 239 PAT059456 FF JI X >°HN N' ^/A1—1 X V /"OHN-NHr 3^^./ (Example 46) LC-MSm/z: [M+H]+=494.24 1H NMR(400 MHz, DMSO-d6 ) = 11.717 (s,1H), 8.231 (s, 1H),7.798 (s, 1H), 7.672(5, 1H), 4.954-4.897 (m 1 H),4.657-4.533(m 2H),4.064(5 1H),3.787- 3.766, (t J=6.8Hz 2H) ,3.318-3.240(m 4H) ,2.492(m 1H) , 2.332-2.319(m 1H) 1.758-1.506(m 9H), 1.492-1.481 (m 1H), 3/ N ^V v.... II 1 )^0 LC-MSm/z: [M+H]+=447.52 1H NMR(400 MHz, DMSO-d6 )= 12.62 (5,1 H), 8.356 (5, 1H),7.760 (5, 1H), 7.607(5, d/Jx o ״™ (Example 47) 1H),7.515 (5 1H) 4.570-4.491 (m 2H),4.084-4.020(m 3H), 2.951-2.905 (t 2H), 2.530-2.510 (m 2H), 2.501-2.497 (m 1H), 2.328-2.108 (m 1H), 1.908-1.420 (m 9H), 1.355-1.2(m 1H) HN^N^N LC-MSm/z: [M+H]+=445.42 1H NMR(400 MHz, DMSO-d6 ) = 11.796 (5,1 H), 8.303 (5,1H),7.805 (5,1H), 7.713 (5,1H), 4.722-4.487 (m 7H), 4.072 (br 5 1H), 2.493-2.451 (m 1H) N—NH 2.251-2.161 (m 1H), 1.790-1.337 (m 12 H) (Example 48) N^Vx ~JI X 0HN^N^N / A / /־"OHD 'D N־־־NH V LC-MSm/z: [M+H]+=494.24 1H NMR(400 MHz, DMSO-d6 ) = 11.632 (s,1H), 8.185 (5, 1H),7.782 (5, 1H), 7.645- 7.641(d, J=1.6Hz 1H), 4.649-4.618 (t J=12.4 1H), 4.526- 4.520 (d J=2.4Hz 1H), 4.064 (br 5 1H),2.505-2.457 (m 1H), 2.263-2.177 (m 1H), 1.786-1.459 (m 9H), 1.361-1.236 (m 1H)(Example 49) rY>°HN^N^N LC-MSm/z(M+H) +:458.241H NMR(400 MHz, DMSO-d6) = 11.79 (5, 1H), 8.24 (5, 1H), 7.80 (5, 1H), 7.70 (5, 1H), 5.00-5.18 (m, 1H), 4.99-4.92 (m, 1H), 4.66-4.60 (m, 1H),F Ax /—'( f nX O"0H / 4.54 (brs, 1H), 4.06 (5,1H), 3.18-3.16 (m, 1H), 2.82-2.65 (m, 2H), 2.49-2.42 (obs, 1H), 2.40-2.37 (m, 1H), 2.31-2.12 (m, 4H), 1.61-1.49 (m, 9H), 1.47-1.45 (m, 2H), 240 PAT059456 FF (Example 50) T J )=0o A /^־A/-V 'A / C /־"OH ( J N-NH vvhr (Example 51) LC-MSm/z(M+H) +:458.24 1H NMR(400 MHz, DMSO-de) = 11.80 (s, 1H), 8.26 (s, 1H), 7.80 (s, 1H), 7.71 (s, 1H), 5.01-5.22 (m, 1H), 4.97-4.96 (m, 1H), 4.63-4.60 (m, 1H), 4.54-4.53 (brs, 1H), 4.06 (s, 1H), 3.31-3.16 (m, 1H), 2.86- 2.67 (m, 2H), 2.50-2.42 (obs, 1H), 2.40-2.37 (m, 1H), 2.41- 2.12 (m, 4H), 1.81-1.49 (m, 9H), 1.47-1.20 (m, 2H), JOC^ ° A ץ ؟׳، sM Ju V / "OH N~NH —-י/ (Example 52) LC-MSm/z(M + H)+:387.24 1H NMR (400 MHz, DMSO-d6 )6 = 12.94-12.75 (m, 1H), 8.35-8.19 (m, 1H), 7.85-7.72 (m, 2H), 4.68-4.65 (m, 1H), 4.54 (brs, 1H), 4.(s, 1H), 2.49-2.45 (obs, 1H), 2.34 (s, 3H), 2.25-2.19 (m, 1H), 1.80-1.45 (m, 9H).
!A b, 0H N-NH v —/ (Example 53) LCMS: 508.37 [M+H]+ (90% purity). 1H NMR (400MHz, DMSO-d6)6 = 11.64 (brs, 1H), 8.11 (s, 1H), 7.79 (s, 1H), 7.70-7.63 (m, 1H), 4.53 (brs, 1H), 4.07-3.94 (m, 5H), 3.77- 3.68 (m, 2H), 2.56-2.42 (obs, 2H), 2.25-2.20 (m, 3H), 2.01- 1.97 (m, 2H), 1.69-1.32 (m, 13H).
JI /L / HN^N^^ °0vY /0־V^A (A/--v A / /־"OHN-NH (Example 54) LCMS:467.38 [M+H]+ (97%)1H NMR (400 MHz, DMSO-d6) = 11.63 (brs, 1H), 8.08 (s, 1H), 7.79 (s, 1H), 7.62 (s, 1H), 4.65-4.53 (m, 1H), 4.51 (brs, 1H), 4.42 (s, 2H), 4.05-3.98 (m, 3H), 2.44-2.42 (obs, 2H), 2.29-2.19 (m, 3H), 2.00-1.95 (m, 2H), 1.75-1.43 (m, 9H), 1.33-1.30 (m, 2H). 241 PAT059456 FF 11 A ■ HN^N^N) V ؟׳ 0<-־f '' ' /',׳OHv N-NH ^-V u (Example 55) LC-MS:397.33 [M+H]+ (99%)1H NMR (400 MHz, DMSO-de) = 11.71 (brs, 1H), 8.14 (brs, 1H), 7.78 (s, 1H), 7.67 (s, 1H), 4.65-4.54 (m, 1H), 4.53 (brs, 1H), 4.06-4.01 (m, 2H), 2.49- 2.46 (obs, 1H), 2.35-2.21 (m, 1H), 1.85-1.42 (m, 9H), 1.40- 1.31 (m, 1H), 0.68-0.58 (m, 4H). || 1 /=OHN^N^NC-o r N-NH —' (Example 56) LC-MS:439.32 [M+H]+ (99% Purity). 1H NMR (400 MHz, DMSO-de)6 = 11.94 (brs, 1H), 8.32 (s, 1H), 7.79 (s, 1H), 7.70 (s, 1H), 4.79-4.72 (m, 2H), 4.65-4.52 (m, 2H), 4.06 (brs, 1H), 2.46-2.42 (obs, 1H), 2.24-2.15 (m, 1H), 1.78-1.46 (m, 9H), 1.34-1.31 (m, 1H).
JL JL / 0״ HN N NCX'0H0| N5h (Example 57) LC-MS:455.24 [M+H]+ (98%)1H NMR (400 MHz, DMSO-de) = 12.75 (brs, 1H), 8.37 (s, 1H), 7.85-7.64 (m, 3H), 4.65- 4.50 (m, 2H), 4.03 (s, 1H), 3.80 (s, 3H), 4.456-4.451 (obs, 1H), 2.11-2.10 (m, 1H), 1.72-1.45 (m, 9H), 1.31-1.23 (m, 1H). 11 / ° "׳OH N—-NH — (Example 58) LC-MSm/z [M+H]+ = 379.25, 1H NMR (400 MHz, DMSO- de)6 = 12.77 (br-s, 1H), 8.20-8.65 (br-s, 1H), 7.75-8.00 (m, 2H), 4.62-4.72 (m, 1H), 4.56 (d, J = 1.4 Hz, 1H), 4.09 (s, 1H), 2.45-2.52 (m, 1H), 2.18-2.30 (m, 1H), 2.07 (s, 3H), 1.45-1.82 (m, 9H), 1.32-1.44 (m, 1H). 0 <= ן ||z>~^ HN N CXa hA—h Coh (Example 59) LC-MSm/z [M+H]+ = 418.28, 1H NMR (400 MHz, DMSO-de)6 = 13.07-13.42 (m, 1H), 8.45-8.85 (m, 3H), 7.58-7.90 (m, 4H), 4.43-4.62 (m, 2H), 3.95 (s, 1H), 1.88-2.32 (m, 2H), 1.5-1.22 (m, 4H), 1.12-1.(m, 6H). 242 PAT059456 FF 0 < ו 11 sAyS Q...oh N-NH v—z (Example 60) LC-MSm/z [M+H]+ = 418.22, 1H NMR (400 MHz, DMSO- de)6 = 13.06 (br-s, 1H), 10.37 (br-s, 1H), 8.67 (d, J = 4.Hz, 1H), 8.32 (s, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.96 (s, 1H), 7.88-7.95 (m, 1H), 7.32-7.37 (m, 1H) 4.70-4.82 (m, 1H), 4.(d, J = 2.4 Hz, 1H), 4.16 (s, 1H), 2.50-2.60 (m, 1H), 2.25- 2.40 (m, 1H), 1.58-1.92 (m, 7H), 1.40-1.60 (m, 3H).
J Z^0/r- HN^N^NAXA O'״OH N-NH (Example 61) LC-MSm/z [M+H]+ = 418.24, 1H NMR (400 MHz, DMSO- de)6 = 12.87 (br-s, 1H), 8.92 (d, J = 1.2 Hz, 1H), 8.65 (s, 1H), 8.45 (dd, J = 1.6, 4.8 Hz, 1H), 8.05-8.10 (m, 1H), 7.(s, 1H), 7.40 (dd, J = 4.8, 7.6 Hz, 1H), 4.40-4.62 (m, 2H), 3.96 (br-s, 1H), 2.15-2.35 (m ,1H), 1.88-2.10 (m, 1H), 1.38- 1.75 (m, 9H), 1.10-1.30 (m, 1H).
Yo R N- HN^N^NW b- (Example 62) LC-MSm/z [M+H]+ = 471.30, 1H NMR (400 MHz, DMSO- de)6 = 12.80 (s, 1H), 8.50 (s, 1H), 7.64-7.98 (m, 4H), 4.48- 4.65 (m, 2H), 3.98-4.10 (m, 1H), 2.57 (s, 2H), 2.30-2.40 (m, 1H), 1.98-2.20 (m, 1H), 1.40-1.78 (m, 9H), 1.18-1.38 (m, 1H).
Y %،״ N=v N ؛° ، 1 ™נ __/"׳OH (Example 63) LC-MSm/z [M+H]+ = 427.31, 1H NMR (400 MHz, DMSO-de) = 11.69 (s, 1H), 8.16 (s, 1H), 7.80 (s, 1H), 7.68 (d, J = 1.Hz, 1H), 5.09-5.15 (m, 1H), 4.63 (t, J = 11.6 Hz, 1H), 4.(d, J = 2.4 Hz, 1H), 4.06 (s, 1H), 3.77-3.85 (m, 3H), 3.68- 3.74 (m, 1H), 2.42-2.52 (m, 1H), 2.01-2.28 (m, 3H), 1.40- 1.82 (m, 9H), 1.20-1.40 (m, 1H). jO^° N HN N N(Aoh /־״ n T A ، V< ,Z N-NH —vN LC-MSm/z [M+H]+ = 458.31, 1H NMR (400 MHz, DMSO- de)6 = 12.92-13.11 (m, 1H), 9.27-9.56 (m, 1H), 8.70-8.(m, 2H), 8.19-8.36 (m, 1H), 7.63-7.96 (m, 3H), 4.38-4.62 (m, 2H), 3.70-4.02 (m, 1H), 1.78-2.30 (m, 2H), 1.04-1.72 (m, 10H). 243 PAT059456 FF (Example 64) V>; HN N N (A N-NH ،-/ '0H (Example 65) LC-MSm/z [M+H]+ = 455.33, 1H NMR (400 MHz, DMSO-de)6 = 11.61 (s, 1H), 8.10 (s, 1H), 7.80 (s, 1H), 7.66 (d, J = 1.2 Hz, 1H), 4.85 (s, 1H), 4.(t, J = 12.4 Hz, 1H), 4.54 (d, J = 2.8 Hz, 1H), 4.05 (d, J = 6.4 Hz, 1H), 2.42-2.52 (m, 1H), 2.12-2.38 (m, 2H), 1.95-2.(m, 2H), 1.42-1.82 (m, 11H), 1.28-1.40 (m, 1H), 1.21 (s, 3H). !ר^°^.0^ HN N N N-NH VV';CH (Example 66) LC-MSm/z [M+H]+ = 457.31, 1H NMR (400 MHz, DMSO-de)6 = 11.69 (s, 1H), 8.24 (s, 1H), 7.80 (s, 1H), 7.69 (d, J = 1.6Hz, 1H), 4.58-4.70 (m, 1H), 4.53 (d, J = 2.8 Hz, 1H), 4.01-4.12 (m, 3H), 3.72-3.90 (m, 3H), 3.54-3.68 (m, 2H), 3.42-3.52 (m, 1H), 3.30-3.40 (m, 1H), 2.42-2.52 (m, 1H), 2.15-2.30 (m, 1H), 1.42-1.82 (m, 9H), 1.28-1.41 (m, 1H). rY>o HN^N^NGH 0roh (Example 67) LC-MSm/z [M+H]+ = 436.35, 1H NMR (400 MHz, DMSO- de)6 = 11.77 (s, 1H), 8.22 (s, 1H), 7.80 (s, 1H), 7.68 (s, 1H), 4.63 (t, J= 11.6 Hz, 1H), 4.53 (d, J = 2.4 Hz, 1H), 4.13 (s, 2H), 4.07 (s, 1H), 2.45-2.52 (m, 1H), 2.15-2.28 (m, 1H), 1.40-1.80 (m, 9H), 1.28-1.40 (m, 3H), 1.14-1.27 (m, 2H). jTY^o HN^N^N "V''0HN-NH ^-V (Example 68) LC-MSm/z [M+H]+ = 401.30, 1H NMR (400 MHz, DMSO- de)6 = 12.40 (br-s, 1H),8.69(s, 1H), 7.80-8.04 (m,2H),4.(t, J= 12.4 Hz, 1H), 4.57 (s, 1H), 4.10 (s, 1H), 3.81 (s, 2H), 2.45-2.52 (m, 1H), 2.16-2.30 (m, 1H), 1.97 (s, 3H), 1.32-1.(m, 10H). 244 PAT059456 FF T /=0 ^°-A o F^V N-NH VV"OH (Example 69) LC-MSm/z [M+H]+ = 433.24, 1H NMR (400 MHz, DMSO-d6)6 = 11.91 (br-s, 1H), 8.29 (s, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 4.42-4.72 (m, 3H), 4.07 (s, 1H), 2.40-2.52 (m, 1H), 2.12-2.30 (m, 1H), 1.90-2.00 (m, 1H), 1.28-1.80 (m, 11H).
XX>HN^N^N / /(؟׳، FfA-7־' Y / /־״OH׳ N-NH — (Example 70) LC-MSm/z [M+H]+ = 433.37, 1H NMR (400 MHz, DMSO-d6)6 = 11.90 (br-s, 1H), 8.29 (s, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 4.42-4.70 (m, 3H), 4.07 (s, 1H), 2.40-2.52 (m, 1H), 2.15-2.29 (m, 1H), 1.90-2.01 (m, 1H), 1.28-1.82 (m, 11H).
T ji /=HN^N^N 0(3X^°xS V )-OH N~NH '-V U (Example 71) LC-MSm/z [M+H]+ = 441.26, 1H NMR (400 MHz, DMSO- de)6 = 11.66 (s, 1H), 8.19 (s, 1H), 7.79 (s, 1H), 7.67 (d, J = 1.2 Hz, 1H), 4.58-4.70 (m, 1H), 4.52-4.56 (m, 1H), 4.03-4.(m, 2H), 3.97-4.02 (m, 1H), 3.68-3.75 (m, 2H), 3.59-3.66 (m, 1H), 3.50-3.56 (m, 1H), 2.58-2.68 (m, 1H), 2.42-2.50 (m, 1H), 2.15-2.26 (m, 1H), 1.90-2.01 (m, 1H), 1.40-1.80 (m, 10H), 1.28-1.39 (m, 1H).
XX^0 HN^N^NcO ״״/ v2)״ohN—NH ’־־—/ (Example 72) LC-MSm/z [M+H]+ = 441.26, 1H NMR (400 MHz, DMSO-de)6 = 11.66 (s, 1H), 8.19 (s, 1H), 7.79 (s, 1H), 7.67 (s, 1H), 4.58-4.70 (m, 1H), 4.53 (d, J = 2.4 Hz, 1H), 4.03-4.10 (m, 2H), 3.96-4.02 (m, 1H), 3.69- 3.75 (m, 2H), 3.59-3.66 (m, 1H), 3.50-3.55 (m, 1H), 2.59- 2.69 (m, 1H), 2.42-2.50 (m, 1H), 2.15-2.28 (m, 1H), 1.90- 2.01 (m, 1H), 1.41-1.80 (m, 10H), 1.28-1.40 (m, 1H). jl /V / HN^N^N kn/ oh /־״ / ץ fVI N-NH v—7 (Example 73) LC-MSm/z [M+H]+ = 461.36, 1H NMR (400 MHz, DMSO-de)6 = 8.31 (s, 1H), 7.76 (s, 1H), 7.67 (s, 1H), 7.52 (s, 1H), 4.40-4.70 (m, 2H), 3.98-4.10 (m, 3H), 2.82-2.90 (m, 2H), 2.30-2.45 (m, 1H), 2.02-2.30 (m, 1H), 1.90-1.99 (m, 2H), 1.40-1.80 (m, 11H), 1.18-1.32 (m, 1H). 245 PAT059456 FF fY^o (» 1 /'"OH( N״NHO-V (Example 74) LC-MSm/z [M+H]+ = 441.31, 1H NMR (400 MHz, DMSO-d6)6 = 11.67 (s, 1H), 8.15 (s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 4.58-4.72 (m, 2H), 4.54 (s, 1H), 4.07 (s, 1H), 3.82-3.90 (m, 2H), 3.36-3.48 (m, 2H), 2.45-2.52 (m, 1H), 2.15-2.28 (m, 1H), 1.92-2.02 (m, 2H), 1.40-1.82 (m, 11H), 1.28-1.41 (m, 1H).
H >=0 O״™ (Example 75) LC-MSm/z [M+H]+ = 459.30, 1H NMR (400 MHz, DMSO-d6)6 = 11.69 (s, 1H), 8.25 (s, 1H), 7.81 (s, 1H), 7.70 (s, 1H), 5.38-5.62 (m, 1H), 4.59-4.(m, 1H), 4.54 (s, 1H), 4.30-4.38 (m, 1H), 4.12-4.20 (m, 1H), 4.18 (s, 1H), 3.80-3.99 (m, 3H), 3.52-3.60 (m, 1H), 2.70-2.(m, 1H), 2.42-2.50 (m, 1H), 2.15-2.29 (m, 1H), 1.40-1.80 (m, 9H), 1.28-1.40 (m, 1H). j 1 >0F F HN^N^NO'- (Example 766) LC-MSm/z [M+H]+ = 477.35, 1H NMR (400 MHz, DMSO-d6)6 = 11.75 (s, 1H), 8.23 (s, 1H), 7.80 (s, 1H), 7.70 (d, J = 1.2 Hz, 1H), 4.59-4.70 (m, 1H), 4.54 (d, J = 2.78 Hz, 1H), 4.30-4.38 (m, 1H), 4.12-4.(m, 2H), 4.07 (s, 1H), 3.92-4.02 (m, 1H), 3.80-3.91 (m, 2H), 2.96-3.10 (m, 1H), 2.42-2.50 (m, 1H), 2.15-2.28 (m, 1H), 1.28-1.82 (m, 10H).
. A ؛ N'XII 1 /^OHN^N^NHO^zAs Z0H ?'׳، / N™NH ---- z (Example 77) LC-MSm/z [M+H]+ = 357.48, 1H NMR (400 MHz, DMSO- d6)6 = 11.5 (br-s, 1H), 9.32 (br-s, 1H), 7.80 (br-s, 1H), 7.(br-s, 1H), 4.57-4.70 (m, 1H), 4.09 (s, 1H), 2.45-2.52 (m, 1H), 2.18-2.30 (m, 1H), 1.64-1.76 (m, 6H), 1.51-1.56 (m, 3H), 1.34-1.41 (m, 1H). 246 PAT059456 FF N'^TXJi JL '°HN^N^N, (.0 J N-Nh v—/ (Example 78) LC-MSm/z [M+H]+ = 427.25, 1H NMR (400 MHz, DMSO- d6)6 = 11.69 (br-s, 1H), 8.15 (br-s, 1H), 7.79 (br-s, 1H), 7.(d, J= 1.6 Hz,1H), 5.12 (d, J = 5.6 Hz, 1H), 4.52-4.68 (m, 1H), 4.02-4.1 (br-s, 1H), 3.78-3.85 (m, 3H), 3.68-3.75 (m, 1H), 2.42-2.5 (m, 1H), 2.12-2.25 (m, 2H),1.98-2.05 (m,1H), 1.42-1.78 (m,9H),1.25-1.4(m,1H). 11 1 >=0X-N H/N *t N™NH '—/ U (Example 79) LC-MSm/z [M+H]+ = 421.60, 1H NMR (400 MHz, DMSO- d6)6 = 12.69-13.08 (d, J=156Hz, 1H), 8.85-9.24 (d, J=156Hz, 1H), 8.13-8.20 (d, J=28Hz ,1H), 7.91-7.94 (d, J=12Hz, 1H), 7.79-7.81 (d, J = 8 Hz, 1H), 6.52-6.63 (d, J=Hz, 1H), 4.60-4.74 (m, 2H), 4.15 (br-s, 1H), 3.95 (s, 3H), 2.54-2.57 (m, 1H), 2.28-2.37 (m, 1 H),1.66-1.93 (m, 10H). fX^° hm^N^N/ 1 nN «—nT / V /,,׳OHn~nh (Example 80) LC-MSm/z [M+H]+ = 421.60, 1H NMR (400 MHz, DMSO- d6)6 = 12.54-12.77 (d, J=92 Hz, 1H), 8.39-8.43 (m, 1H), 7.48-7.87 (m ,4H), 4.49-4.58 (m, 2H), 4.00 (br-s, 1H), 3.(s, 3H), 2.32-2.40 (m, 1H), 2.07-2.08 (m, 1 H),1.26-1.70 (m, 9H),0.90-0.94(m, 1H). jI L A0 O-OH (Example 81) LC-MSm/z [M+H]+ = 458.26 [M+H]+, 1H NMR (400 MHz, DMSO-d6)6 = 12.94-12.76 (m, 1H), 10.71-10.16 (m, 1H), 9.22 (d, 6.4 Hz, 1H), 8.59 (s, 2H), 8.27-8.13 (m, 1H), 7.(s, 1H), 7.15 (s, 1H), 4.72-4.62 (m, 2H), 4.16 (s, 1H), 2.50- 2.49 (m, 1H), 2.33-2.32 (m, 1H), 1.83-1.48 (m, 10H). 247 PAT059456 FF 1 1 H HN^N^N ן—v^3’,,0H j | N-NH '—zx cf (Example 82) LC-MSm/z [M+H]+ = 441.32, 1H NMR (400 MHz, DMSO-de) = 11.64 (brs, 1H), 8.15 (brs, 1H), 7.79 (s, 1H), 7.65 (s, 1H), 4.94 (q, 1H, 2.0 Hz), 4.65-4.52 (m, 2H), 4.06-3.99 (m, 2H), 3.13 (s, 3H), 2.49 (obs, 1H), 2.28 (t, 5.6 Hz, 4H), 2.19-.(m, 1H), 1.79-1.32 (m, 10H).
J L / 0، ך n-nN-NH Cj"OH (Example 83) LC-MSm/z [M+H]+ = 409.32, 1H NMR (400 MHz, DMSO- de)6 = 13.58 (s, 1H), 9.32 (s, 1H), 8.72 (s, 1H), 8.30 (s, 1H), 7.97 (s, 1H), 4.68-4.78 (m, 1H), 4.63 (s, 1H), 4.13 (s, 1H), 2.42-2.52 (m, 1H), 2.18-2.32 (m, 1H), 1.53-1.90 (m, 7H), 1.50-1.53 (m, 2H), 1.39-1.50 (m, 1H).
M HN N N-5 Aw / /׳׳OHN-NH ^-VF F F (Example 84) LC-MSm/z [M+H]+ = 489.30 , 1H NMR (400 MHz, DMSO- de)6 = 12.81 (br-s, 1H), 8.39-8.45 (m, 1H), 7.65-7.92 (m, 3H), 4.58-4.65 (m, 1H), 4.52 (d, J = 2.8 Hz, 1H), 3.99-4.(m, 4H), 2.40-2.49 (m, 1H), 2.11-2.20 (m, 1H), 1.27-1.77 (m, 10H).
Ji X HN^N^N XQ O- (Example 85) LC-MSm/z [M+H]+ = 429.33 1H NMR (400 MHz, DMSO- de): 6 = 11.82 (brs, 1H), 8.13 (s, 1H), 7.80 (s, 1H), 7.71 (s, 1H), 4.80-4.54 (m, 4H), 4.07 (s, 1H), 2.49 (bs, 1H), 2.25- 2.17 (m, 1H), 1.76-1.50 (m, 9H), 1.46-1.34 (m, 1H), 1.05- 1.00 (m, 2H), 0.88-0.85 (m, 2H). 248 PAT059456 FF CDKi Biochemical assays Biochemical assays measured the inhibitory effects of compounds in this disclosure on the enzymatic activity of CDK enzyme in complex with Cyclin protein partner by phosphorylation of Ser-780 (S780) on retinoblastoma protein peptide (RB1) in the presence of 1 mM adenosime-5 — triphosphate (ATP) and varying concentration of test compound in 20 mM 2-[4-(2- hydroxyethyl)paperazin-1-yl] ethanesulfonic acid (HEPES), pH 7.5, 10 mM MgCI2, 1 mM dithiothreitol (DTT), 0.01% bovine serum albumin (BSA), 0.005% Tween 20. Total Reaction volume of 10 pL proceeded for 60 minutes at room temperature (25°C) and were quenched with pL of 200 mM 2',2",2"'-(Ethane-1,2-diyldinitrilo)tetraacetic acid (EDTA) pH 8.0 before addition of 5 pL detection solution containing 100 nM fluorophore conjugate streptavidin allophycocyanin (SA-APC), 2 nM Europium labelled Anti-p-RB(S780)-K (Perkin Elmer, 64CUSKAY), 50 mM HEPES, pH 7.5, 400 mM potassium fluoride (KF), 0.1% BSA, and 0.01% Tween-20. Phosphorylation of S780 on RB1 peptide (His-MBP-RB1 [773-924] - SEQ ID NO. 9) was detected by TR-FRET after 3 hour incubation with detection solution. Percent phosphorylation activity was plotted against log concentration of compound to generate an apparent IC50. The following CDK enzyme in complex with different cyclin proteins and protein peptide substrate were used in these assays: CDK1/CyclinB1 , Avi-tag, 10 pM used in the assayCDK2/CyclinE1 , Avi-tag, 100 pM used in the assayCDK4/cyclinD1, Avi-tag, 20 pM used in the assayCDK6/cyclinD3, Avi-tag, 10 pM used in the assayHis-MBP-RB1 [773-924], Avi-tag, 200 nM used in the assayThe avi-tag is a C-terminal fusion on the CDK1/2/4/6 sequence in each of these two-protein complexes. The known avi-tag sequence, GLNDIFEAQKIEWHE (SEQ ID NO. 10), is a substrate for E. coli biotin ligase BirA, which covalently attaches a biotin molecule to the e-amino group of the lysine in that sequence. The avi-tag is attached with an 8 amino-acid linker sequence GGSGGGGS (SEQ ID NO. 11), resulting in the full C-terminal fusion GGSGGGGSGLNDIFEAQKIEWHE (SEQ ID NO. 12).
The sequences of the recombinant proteins used here are provided below.
Recombinant proteins were generated as N-terminal fusions of 9x His tag - E. coli Maltose Binding Protein (MBP), with or without a C-terminal Avi-tag. 1 CDK2 and His-MBP-RB1 [773-924]- c-avi were expressed in E. coli while the remainder were expressed in Sf21 insect cells. Genes 249 PAT059456 FF were synthesized commercially (GeneArt and Twist Bioscience) using codon frequencies appropriate to the respective organisms and proprietary codon optimization strategies, and inserted into pET 24 (E. coli) or pDEST8 (insect) vectors already containing the 9x His-MBP tag using standard methods of PCR and Gibson Assembly. 2 E. coli expression was performed by auto-induction overnight at 18 or 21 C. For insect cell expression, bacmids and viruses were created, 3 then used to synchronously infect Sf21 insect cells with harvest at 40-48 hrs., per standard protocols. 4 For CDK2/Cyclin E and CDK1/Cyclin B, the CDK and Cyclin proteins were expressed separately, lysed by sonication and clarified by centrifugation. The fusion proteins were each separately purified by immobilized metal ion affinity chromatography (IMAC) (5 ml HisTrap, Cytiva) and Superdex 200 26/60 (Cytiva) size-exclusion and complexed in vitro (1-3 hrs incubation at room temperature) prior to tag cleavage by recombinant his-tagged Tobacco Etch Virus protease or his-tagged Human rhinovirus 3C protease, as appropriate. The cleaved complex is further purified by Superdex 75 26/60 (Cytiva) size-exclusion followed by reverse-IMAC, in which the complex is in the column flow-through and residual His-MBP and his-tagged proteases are retained. The final complex is concentrated as desired by centrifugal concentration (Amicon Ultra 10,000 Da MWCO ml concentrators, Millipore).
For E. coli expressed CDK2 and His-MBP-RB1[773-924]-c-avi, the proteins were biotinylated in vitro after the first IMAC step. 1 For CDK4/Cyclin D1 and CDK6/Cyclin D3, the complexes were expressed by simultaneous co- infection of insect cells by three separate viruses including one expressing untagged E. coli BirA. The expression media is supplemented with 50 uM d-biotin. The resulting protein complexes purified similarly. After lysis and clarification, the complex is purified by IMAC, Superdex 200 26/size exclusion, tag cleavage by human rhinovirus 3C protease, Superdex 75 26/60 size exclusion and reverse IMAC. BirA is typically not retained on the first IMAC, and excess CDK or Cyclin monomer is separated on the Superdex 200 size exclusion. Cleaved His-MBP and remaining monomer are removed by the Superdex 75 size exclusion and the reverse IMAC step. Final concentration by centrifugal concentrators as described above.
For the is-MBP-RB1[773-924]-c-avi, the protein was lysed by sonication and clarified by centrifugation. After IMAC capture and in vitro biotinylation, the fusion protein is purified by Q HP HiTrap (Cytiva) with a gradient elution after binding in low salt, followed by SP HP HiTrap (Cytiva) with a gradient elution. The material is finally purified on a Superdex 75 26/60 as a polishing step. 250 PAT059456 FF Although there is a TEV protease cleavage site in this construct, it is not removed for this purpose. Final concentration by centrifugal concentrators as described above. 9x His-MBP-3C-CDK2-c-avi (SEQ ID NO. 1)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSG LEVLFQGPMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKE LNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVL HRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSL GCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEWWPGVTSMPDYKPSFPKWARQDFSKVV PPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRLGGSGGGGSGLNDIFEAQ KIEWHE*9x His-MBP-TEV-Cyclin E1 (SEQ ID NO. 2)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSE NLYFQGGSGMPRERRERDAKERDTMKEDGGAEFSARSRKRKANVTVFLQDPDEEMAKIDRT ARDQCGSQPWDNNAVCADPCSLIPTPDKEDDDRVYPNSTCKPRIIAPSRGSPLPVLSWANREE VWKIMLNKEKTYLRDQHFLEQHPLLQPKMRAILLDWLMEVCEVYKLHRETFYLAQDFFDRYMA TQENVVKTLLQLIGISSLFIAAKLEEIYPPKLHQFAYVTDGACSGDEILTMELMIMKALKWRLSPLT IVSWLNVYMQVAYLNDLHEVLLPQYPQQIFIQIAELLDLCVLDVDCLEFPYGILAASALYHFSSSE LMQKVSGYQWCDIENCVKWMVPFAMVIRETGSSKLKHFRGVADEDAHNIQTHRDSLDLLDKA RAKKAMLSEQNRASPLPSGLLTPPQSGKKQSSGPEMA*9x His-MBP-TEV-CDK1-c-avi (SEQ ID NO. 3)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSE NLYFQGGMEDYTKIEAIGEGTYGVVYKGRHKTTGQVVAMKAIRLESEEEGVPSTAIREISLLKEL RHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRR VLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEWTLWYRSPEVLLGSARYSTPVDIW SIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHV KNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKMGGSGGGGSGLNDIFEAQKIE WHE* 251 PAT059456 FF 9x His-MBP-Cyclin B1 (SEQ ID NO. 4)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSE NLYFQGGMALRVTRNSKINAENKAKINMAGAKRVPTAPAATSKPGLRPRTALGDIGNKVSEQL QAKMPMKKEAKPSATGKVIDKKLPKPLEKVPMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEPI LVDTASPSPMETSGCAPAEEDLCQAFSDVILAVNDVDAEDGADPNLCSEYVKDIYAYLRQLEEE QAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKKMLQLV GVTAMFIASKYEEMYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLGRPLPLHFLRRASKI GEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAAGAFCLALKILDNGEWTPTLQHYLSYTEESL LPVMQHLAKNVVMVNQGLTKHMTVKNKYATSKHAKISTLPQLNSALVQDLAKAVAKV*9x His-MBP-CDK4-c-avi (SEQ ID NO. 5)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSE NLYFQGGSGMATSRYEPVAEIGVGAYGTVYKARDPHSGHFVALKSVRVPNGGGGGGGLPIST VREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDLRTYLDKAPPPGLPAETI KDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKLADFGLARIYSYQMALTPVVVTLWYR APEVLLQSTYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGKIFDLIGLPPEDDWPRDVSL PRGAFPPRGPRPVQSWPEMEESGAQLLLEMLTFNPHKRISAFRALQHSYLHKDEGN PEGGS GGGGSGLNDIFEAQKIEWHE*9x His-MBP-Cyclin D1 (SEQ ID NO. 6)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSE NLYFQGGSGMEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLP SMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETI PLTAEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQ TFVALCATDVKFISNPPSMVAAGSWAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRAC QEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI*9x His-MBP-CDK6-c-avi (SEQ ID NO. 7)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV 252 PAT059456 FF GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSM MGSSSSGLEVLFQGPMEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRV QTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDK VPEPGVPTETIKDMMFQLLRGLDFLHSHRWHRDLKPQNILVTSSGQIKLADFGLARIYSFQMAL TSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGE EDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQDLER CKENLDSHLPPSQNTSELNTAGGSGGGGSGLNDIFEAQKIEWHE*9x His-MBP-Cyclin D3 (SEQ ID NO. 8)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSLE VLQGPGSMELLCCEGTRHAPRAGPDPRLLGDQRVLQSLLRLEERYVPRASYFQCVQREIKPH M RKM LAYWM LEVCE EQ RCE EEVFP LAM N YLDRYLSCVPT RKAQ LQLLGAVCM LLAS KLRETT PLTIEKLCIYTDHAVSPRQLRDWEVLVLGKLKWDLAAVIAHDFLAFILHRLSLPRDRQALVKKHA QTFLALCATDYTFAMYPPSMIATGSIGAAVQGLGACSMSGDELTELLAGITGTEVDCLRACQEQ IEAALRESLREASQTSSSPAPKAPRGSSSQGPSQTSTPTDVTAIHL*9x His-MBP- RB1[773-924]-c-avi (SEQ ID NO. 9)MHHHHHHHHHMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAA TGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDV GVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGV TVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSE NLYFQGGSTRPPTLSPI PH IPRSPYKFPSSPLRIPGGNIYISPLKS PYKISEGLPTPTKMTPRSRIL VSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGES KFQQKLAEMTSTRTRMQKQKMNDSMDTSNGGSGGGGSGLNDIFEAQKIEWHE* 1. Li, Y. & Sousa, R. Expression and purification of E. coli BirA biotin ligase for in vitro biotinylation. Protein Expr. Purif 82,162-7 (2012).2. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6,343-345 (2009).3. Invitrogen. Bac-to-Bac® Baculovirus Expression System. An Efficient Site-Specific Transposition System to Generate Baculovirus for High-Level Expression of Recombinant Proteins. (2010).4. Invitrogen life technologies. Guide to Baculovirus Expression Vector Systems (BEVS) and Insect Cell Culture Techniques. (2002). 253 PAT059456 FF IC50 values determined in the biochemical assays are listed in the following table: Compound CDK2 IC50 (uM) CDK1 IC50 (pM) CDK4 IC50 (pM) CDK6 IC50 (pM) j JL ^"X/ ).N-N vX (Example 1) 0.038 1.54 0.40 0.60 3 ',,OHN™NH —/ (Example 2) 0.018 1.21 4.52 6.68 FF "،S v2)"OHN~NH 7 (Example 3)0.007 0.82 2.74 3.76 II J >0HN^N^NC X'OHN״NH k ־—/ (Example 4) 0.096 >10.00 >10.00 >10.00 JI /^oHN^N^NHN^S ( U U"OH (Example 5) 1.12 >10.00 6.69 5.73 254 PAT059456 FF /I JL / 0hn/"n' n.C / "OHN־־NH "-Z (Example 6) 0.032 2.94 0.84 2.18 n't( ~j X z״°HN^N^NAb ״ ld״oh 1 (Example 7)0.136 5.99 3.86 2.21 N'^YV-^Jl JL z 0״0״ HY N־ ^ N™NH —~Z (Example 8)0.234 >10.00 >10.00 >10.00uLL= oh ؛ /" 7 hV ، / ~־ N—N ,NH VZ (Example 9) 0.268 >10.00 >10.00 >10.00 JI J T^O/-~-0 HN' Y' JL ZOH ׳ ,, / / Z ^־־־N-NH ^-Z un (Example10) 1.22 >10.00 >10.00 >10.00 ؛° ~ JL JHN' N N״oh ^״، v2k= N <—/ p/ (Example 11) 1.354 >10.00 5.73 9.35 255 PAT059456 FF J J / 0HN^N^N ץ / ) ׳ * i rx uN---NH (Example 12) 0.020 2.24 7.37 7.90 J! X / 0HlXX'A ) ؛؟، CV' / OuN~NH ^—v (Example 13)0.012 0.92 5.28 7.10 jfY>0HN^'N^X0H ׳׳ 5 )_N״NH (Example 14) 0.030 1.55 >10.00 >10.00 JI JL / 0F HN^N^N fXJx /—F W / /,'׳OHN״NH x-~/ (Example 15)0.039 3.72 >10.00 >10.00 JL JL x 0״ hn'n''^ Cn O'0״h o/ (Example 16) 0.049 2.36 1.23 1.80 jLjjJ 0 'XS f"A-OH N־־־NH (Example 17)0.041 4.49 >10.00 >10.00 256 PAT059456 FF r? JJ J '°hn^n^n( .,l0 HN-NH (Example 18)0.114 >10.00 >10.00Not tested N^rV:nA JL /0HN^N N« N-NH (Example 19) 0.044 4.12 7.58 9.16 JI j >0HN^N^N / /,'1OHN-NH ^—V (Example 20)0.008 0.66 2.16 2.66 N^^Vx ~JL X v3־״ohN-NH ־"׳ (Example21) 0.017 2.50 2.26 4.46 n'%״<= ו עHN^N^N /"ך'^־o/ M Ju V /■"OHu N״NH —/(Example 22) 0.034 2.96 5.26 8.12 J XHN^N^N/vx (AOH /■׳، ! ■ vN-NH ،-/ (Example23) 0.015 2.43 9.45 >10.00 257 PAT059456 FF N'^VxJ. XHN^N^NF 1 /—. W • Z׳׳OH، J N-NH '—Z(Example24) 0.012 2.02 3.91 >10 N'^^X " jL X)~ ؟׳، Fx x oN-NH ----' "OHCT(Example 25) 0.024 2.44 >10 >10 j /X /^O HN^N^^Nץ־ .ס؟،Q N-NH Uon (Example 26) 0.059 >10 5.35 8.50 j /X /^O HN^N^^N FR°^ O-oh / J N-NH v—/(Example 27) 0.011 1.92 1.28 3.18 n5-° HN ، t (^/Wh O"°h (Example 28) 0.011 1.18 2.12 2.54 258 PAT059456 FF H /=0HN N N / n m X OH 1 N-NH —-/F'/ F(Example 29) 0.026 3.84 7.40 >10 1 1X°HN N No-^Ax (f / OH، i N-NHF pExample 30 0.022 4.27 6.95 9.80 1 1 M -״״/ill V /",OHp — N-NHF(Example 31) 0.021 6.57 6.30 9.70 NXrV.^F X- /F/h HNCNN / /'׳'OHN-NH v —/(Example 32) 0.006 0.34 2.76 4.80 F -X- /F/ HNCNN^'־"A 0"'OH N-NH '—/(Example 33) 0.049 3.76 >10 >10 259 PAT059456 FF / J | /=OF , HN^N^N' ־־A JI >~-xOH /״، / n-nh V(Example 34) 0.010 2.31 3.31 3.31NO hn^n^n/ ؟׳، oV / "OH ؛ m ,N H N~NH —•^/(Example 35) 0.054 3.16 >10 >10A Ko ، ، A HN N NOH /״' )/ ־" N-NH( 36 Example ) 0.039 4.99 >10 >10 fYyo v/ HN n ץ V* ' nouN-NH X Z U(Example 37) 0.031 >10 >10 >10 HN'^N'^N v / /,,'PHN-NH(Example 38) 0.008 1.04 6.10 9.20 260 PAT059456 FF I k / 0HN^N^N0xS 1 N-NH(Example 39) 0.007 1.20 1.43 2.95 Tj^° / ן ", .;u V /'"OH|__ I N"NH —/(Example 40) 0.026 2.89 >10 >10 0HN^N^NF 1F n-NH A/ "°H (Example 41) 0.005 0.73 2.68 5.09 VH /^O (HO M K1LJ V- /‘"OHnu N-NH K—z(Example 42) 0.024 3.74 3.64 3.01 X A Z°HN N N—N^v / OHN-NH x—/(Example 43) 0.019 1.76 3.09 8.84 261 PAT059456 FF /Y>0 HnAAnpF 1 /—y 7V/ / AOH , /" ׳ 0 /^- v ./ N-NH V—/(Example 44) 0.015 1.81 4.41 7.13 1 1 NHN V 7A F 1 )—,Zx,o-^Ax / v / /■',OHN-NH v—z(Example 45) 0.011 0.77 1.23 3.50 nAa _= 7 1 ע " י כ י ״../'״ (Example 46) 0.109 >10 >10 >10 nAv״ y / 7=0N__(A2j N-NH ^-V "0H(Example 47) 0.027 >10 6.38 7.55 HN^N^N oA/o^k AAV /",OH ؛ AN-NH(Example 48) 0.022 3.25 1.54 >10 262 PAT059456 FF /x. ‘ jZn X. / ® ס״°» " 5 ך ס °ל> q N™NH —' (Example 49) 0.015 2.64 9.77 >10 jXX 0HN-^bT N-O-( | N-NHN'" (Example 50) 0.125 >10 >10 >10 Xr'X< ؛| 7 5A ץ A(7 A-NH V/'0״HN (Example 51) 0.119 >10 >10 >10 = HN^N^NS (uo N™NH UH (Example 52) 0.031 5.32not tested >10 J X z^ 0o HN'^N^N O-,™N-NH ^—z(Example 53) 0.186 >10 >10 >10 263 PAT059456 FF °vW z°-A MO'OH (Example 54) 0.134 >10 >10 >10 jl ✓XHN^N'^NץגV n~nh '■0" /■•־-־H (Example 55) 0.011 1.43 8.50 >10 (Vv^ jj [HN^N^N r N_NH <__/ (Example 56) 0.010 0.80 3.13 6.28 1 X /°N HN N N/־ךN-NH '—/ ،OH (Example 57) 0.015 2.04 7.90 >10 N'^TV-jj X / °hn^n^n(/״"OHN—NH ־~־~/(Example 58) 0.016 3.54 9.50 >10 264 PAT059456 FF jI J-.. / 0CM Cy., N-NH 0H (Example 59) 0.251 >10 >10 >10 J C / 0 / /,,׳OHN™NH(Example 60) 0.162 >10 >10 >10 JI X / °N '؟' HNojx a N-NH ،---- '0H (Example 61) 0.046 >10 8.65 9.19 nM A X. / °F. HN־ 'N׳ N/־־־"N 1 /׳"',/ v^^/Ax /&1 oh ׳׳، 9 & 7 v // N"NH '—/(Example 62) 0.017 4.23 2.30 1.83 ■nA !,iXo __ /"OH (Example 63) 0.043 3.69 >10 >10 265 PAT059456 FF N'tV.aJ.N= HN N "N if O"0HN(Example 64) 0.012 2.19 4.70 6.49 HN N N0-A (.0N-NH UM(Example 65) 0.053 4.49 6.90 >10J0X JX HN N NQ,,»^ A '' ' /,'OHN-NH x—/ UM(Example 66) 0.051 4.22 >10 >10 Ji X /^°HN^N^N(־A f W / /■'!ni-i . n-NH W(Example 67) 0.023 4.13 6.91 >10 N-NH(Example 68) 0.007 0.97 4.15 7.60 266 PAT059456 FF T jl >=0 r >0 / AP-W XM nL V /",OH■ / N~NH /(Example 69) 0.006 0.80 2.61 6.03 Y || >0 RfA7־’ v .{,. /,״ohr X/ N-NH —'(Example 70) 0.006 0.82 7.69 >10 kr >؛؛ NT H /0HN^N^NfS '־ Xv Q ؛ oN-NH V_/ ''OH (Example 71) 0.044 7.59 >10 >10 k JL / 0 0O-, /0yS 10 >10 J| 3l /־ON— HN/S־N<^N(A ׳^J N-NH 0 (Example 73) 0.049 >10 >10 >10 267 PAT059456 FF fV/o HN^N^NVo-10 >10 >10 X ־^؛ N^ ךJ hn^n^n ־־־־^ cCXz'*' V. / /"OHN-NH /(Example 75) 0.072 9.16 >10 >10 0 /= 1 11F לr ־T q^A, 10 5Vv ^,_ / ׳ nj| A، /™QHN^N^N؟׳، H0■ opN-NH V-V(Example 77) 0.121 5.82 1.48 5.26 HN^N^N NH "0H ■؛־ ( A (Example 78) 0.017 2.54 2.60 3.54 268 PAT059456 FF o < ך !וn—n ™ץ N « /— 7 /",OHn-nh ^-V un(Example 79) 0.050 >10 >10 >10 hnAn^nX/AY O-°H n~nh(Example 80) 0.029 6.01 9.30 >10 jj 1M HN^IST N_ (JU Con (Example 81) 0.006 0.41 >10 >10 0 / A ר rT R 0״H (Example 82) 0.026 2.53 >10 >10 J! /!_ / 0N״N HN N^N< kA YN-NH 0 ״ / — ׳ H (Example 83) 0.031 8.62 2.18 2.67 269 PAT059456 FF N HNCNCN (AI V / /־'׳OHN~NHF ؟ FF(Example 84) 0.088 >10 >10 >10 O-on (Example 85) 0.027 1.71 4.40 >10 In vivo pharmacodynamic assessment of CDK2 inhibitors in cyclin E amplified OVCAR3 xenograft model Cyclin-dependent kinase 2 (CDK2) is a member of the protein kinase family. It plays an important role in regulating various events of the eukaryotic cell division cycle. CDK2 is involved in the inactivation of the retinoblastoma protein (RB) by phosphorylation which then allows for the G1 to S phase transition of the cell cycle. Overexpression of cyclin E, the obligate binding partner of CDK2, can cause abnormal regulation of the cell cycle, which is directly associated with hyperproliferation of cancer cells. Therefore, CDK2 is regarded as a potentially impactful therapeutic target for cancer treatment. The purpose of these studies was to evaluate the PK/PD relationship of CDK2 inhibitors in Cyclin E amplified cancer cell lines in vivo in immunodeficient mice. Plasma and tumor tissues were collected for PK analysis and PD assays (read out of RB phosphorylation inhibition) after 3 days of dosing of the CDK2 inhibitor.
Tumor cell inoculation and treatments The Cyclin E amplified ovarian cancer cell line OVCAR3 was tested to be free of mycoplasma and murine viruses using the IDEXX Impact 8 panel. Cells were cultured in RPMI 1640 media supplemented with 20% FBS for fewer than 5 passages after initial thawing and prior to cell implantation into immunodeficient mice. Cells were harvested and resuspended in sterile PBS containing 50% Matrigel. Ten million viable cells were injected at a volume of 0.2 ml per mouse into the flank of immunocompromised NSG mice (1 implant per animal). When tumors reached a mean volume of 200-300mm3, mice were randomized and treatments were initiated. Compounds were formulated in 10% HPBCD (hydroxypropyl beta cyclodextrin) and administered orally, twice a day, in a volume of 10 ml/kg. The dosing volume was adjusted based on individual mouse body weight on the day of dosing. Pharmacodynamic markers were evaluated on day 3. 270 PAT059456 FF PK analysis of plasma For determination of compound plasma concentrations, serial blood collections were performed at designated timepoints after dosing. Blood was collected in EDTA-lined tubes and placed on wet ice. Within minutes of collection, blood was centrifuged, and the plasma supernatants were aliquoted and stored at -20C until analyzed. The frozen plasma samples and tumor tissue were processed UPLC and LC-MS/MSanalysis by the addition of organic solvent and spiked with the bioanalytical internal standards. CDKinhibitor concentrations were measured by LC-MS/MS analysis on API 4500, API 5500+, or Sciex 75instruments. UPLC separation was done using a kinetexevo C18 column (50x4.6 mm, 5.0 pm) or a Waters Xbridge BEH C18 column (50x2.1 mm, 2.5 pm). The various analytes were detected using the mass transitions shown in the table below.Compound Type Parent [m/z] Daughter [m/z] Collision energyCompound 1 Analyte 371.3 273.2 25Compound 2 Analyte 386.2 259.1 42Compound 3 Analyte 454.2 336.0 44Telmisartan Internal standard515.4 276.1 60Glyburide Internal standard494.2 169.2 35 For the purposes of this Example (and for corresponding Figure 3): Compound 1 Compound 2 271 Compound 3 PAT059456 FF PD analysis of tumor samples For terminal PD biomarker analysis, mice were euthanized following 3 days of treatment (1 hour post 5th dose). Tumors were immediately excised and then sectioned into fragments. Tissue fragments were snap frozen in liquid nitrogen and stored at -80C until processing for PD biomarker analysis. Tumors were lysed with the Precellys instrument using protein lysis buffer supplemented with a phosphatase and protease inhibitor cocktail. RB phosphorylation levels of the resulting tumor protein lysates were then determined by MSD. Ten microgram protein was loaded per well and total Rb and phosphorylated RB (Ser 807/811) capture and detection antibodies were used to evaluate the phosphorylated RB signal. Values were calculated and normalized to the untreated controls. Three mice per treatment arm were used.
Results The CDK2 inhibitors Compound 1 and Compound 2, dosed at 30 mg/kg twice daily (BID), result in ~80% inhibition of RB phosphorylation at 1 hour after the last dose. In contrast, Compound 3, dosed at 60 mg/kg twice daily (BID), only results in ~50% inhibition of RB phosphorylation at that same timepoint. For each compound, plasma concentration versus time profiles was assessed on day 1 and at a single time point (1 hour) following the administration of the third dose (49 h post the initial dosing). An estimate for the tumor concentration of the various analytes was also obtained at the 49h time-point following the homogenization of the tissue.
Discussion This PK/PD study in the Cyclin E amplified OVCAR3 xenograft model demonstrates that Compound 1 and Compound 2 (dosed at 30 mg/kg, BID) result in deeper inhibition of RB phosphorylation than Compound 3 dose twice as high (60 mg/kg, BID). The lower exposure observed with Compound 3 may be the result of reduced oral bioavailability at the administered dose (60 mpk) combined with higher systemic clearance compared to Compound 1 and Compound 2. In conclusion, Compound 1 and Compound 2 can be considered more potent CDKinhibitors than Compound 3. 272

Claims (19)

1. PAT059456-WO-PCT 2 CLAIMS1. A compound according to formula (I), (I); wherein: each RA is independently *L-X, wherein * indicates the point of attachment to the remainder of the molecule, each L is independently selected from bond, O, S, SO, SO 2, C≡C, C(=O), *C(=O)-O**, C1-C6alkylene, C1-C6haloalkylene, *O-C1-C6alkylene**, *O-C1-C6haloalkylene**, *O-C1-C6hydroxyalkylene**, C1-C6alkylene-O-C1-C6alkylene, *O-C3-C6cycloalkylene**, *O-3-6 membered heterocyclylene**, C1-C6hydroxyalkylene, C3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising 1 heteroatom which is O), O-C1-C6alkylene-O, *O-C1-C6alkylene-O-C3-C6cycloalkylene** and *O-C1-C6alkylene- O-3-6 membered heterocyclylene**, wherein * indicates the point of attachment to the remainder of the molecule, and ** indicates the point of attachment to X; and each X is independently selected from H, halo, cyano, hydroxyl, C 1-C 6alkyl, C(=O)-C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl substituted by 0-3 R groups, O-C1-C6alkyl, S-C1-C6alkyl, S(O)-C1-C6alkyl, S(O)2-C1-C6alkyl, N(C1-C6alkyl)2, C(=O)N(C1-C6alkyl)2, C1- C6hydroxyalkyl, 3-6 membered heterocyclyl (e.g. comprising 1 or 2 heteroatoms independently selected from O, N and S) substituted by 0-3 R groups, 5-10 membered heteroaryl (e.g. 5, 6, 9 or 10 membered heteroaryl) comprising 1-4 heteroatoms independently selected from O, N and S substituted by 0-3 R groups, 5-10 membered partially saturated heterocyclyl comprising 1 to 4 heteroatoms independently selected from the group consisting of O, N and S substituted by 0-3 R groups, 7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R groups and C7-C 10spirocycloalkyl substituted by 0-3 R groups; and each R is independently selected from the group consisting of C1-C6alkyl, C(=O)C1-C6alkyl, halo, C1-C6haloalkyl, S-C1-C6alkyl, SO-C1-C6alkyl, SO2-C1-C6alkyl, cyano, hydroxyl, or wherein two R substituents on the same ring atom join together to form =O; or a pharmaceutically acceptable salt and/or tautomer thereof. PAT059456-WO-PCT 2
2. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1, wherein RA is selected from: a) halo, b) cyano, c) C1-C6alkyl, d) C1-C6haloalkyl, e) C1-C6hydroxyalkyl, f) O-C1-C6alkyl, g) C(=O)-O-C1-C6alkyl, h) C1-C6alkylene-O-C1-C6alkyl, i) O-C1-C6alkylene-O-C1-C6alkyl, j) C3-C6cycloalkyl substituted by 0-3 R groups, k) 5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R groups, l) 5-10 membered partially saturated heterocyclyl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R groups, m) O-C3-C6cycloalkyl substituted by 0-3 R groups, n) C≡C-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R groups, o) S-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R groups, p) C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R groups, q) O-C1-C6haloalkyl, r) O-C1-C6alkylene-N(C1-C6alkyl)2, s) O-C1-C6hydroxyalkylene-O-C1-C6alkyl, t) O-C1-C6alkylene-C3-C6cycloalkyl substituted by 0-3 R groups, u) O-C1-C6alkylene-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R groups, v) O-C1-C6alkylene-C(=O)-N(C1-C6alkyl)2, w) C1-C6alkylene-5-10 membered partially saturated heterocyclyl comprising 1-heteroatoms independently selected from N, O and S substituted by 0-3 R groups, x) O-C1-C6alkylene-7-10 membered spiroheterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R groups, PAT059456-WO-PCT 2 y) O-C1-C6alkylene-S(O)2-C 1-C6alkyl, z) O-C1-C6hydroxyalkyl, aa) O-C1-C6alkylene-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R groups, bb) O-5-10 membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O and S substituted by 0-3 R groups, cc) O-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R groups, dd) C≡C-C3-C6cycloalkyl substituted by 0-3 R groups, ee) S-C1-C6haloalkyl, ff) O-C1-C6alkylene-O-3-6 membered heterocyclyl comprising 1 or 2 heteroatoms independently selected from O, N and S substituted by 0-3 R groups, and gg) 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S substituted by 0-3 R groups.
3. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 2, wherein each R is independently selected from the group consisting of halo (e.g. fluoro), C1-C6alkyl (e.g. methyl), hydroxyl, cyano, S(O2)-C1-C6alkyl (e.g. S(O2)CH3), C(=O)-C1-C6alkyl (e.g. C(=O)CH3), O-C1-C6alkyl (e.g. OCH3) and C1-C6haloalkyl (e.g. C1haloalkyl, e.g. CHF2), or wherein two R substituents on the same ring atom join together to form =O.
4. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 2, wherein: RA is selected from halo, cyano, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, O-C1- C6alkyl, C(=O)-O-C1-C6alkyl, C1-C6alkylene-O-C1-C6alkyl, O-C1-C6alkylene-O-C1-C6alkyl, C3-C6cycloalkyl and 3 to 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S.
5. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding claims, wherein RA is CH3, OCH3 or OCH2CH3. PAT059456-WO-PCT 2
6. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1, wherein each L is independently selected from bond, O, C(=O), *C(=O)-O**, C1-C6alkylene, C1-C6haloalkylene, *O-C1-C6alkylene**, C1-C6alkylene-O-C1-C6alkylene, C1-C6hydroxyalkylene, C 3-C6cycloalkylene, 3-6 membered heterocyclylene (e.g. comprising 1 heteroatom which is O) and O-C1-C6alkylene-O, wherein *indicates the point of attachment to the remainder of the molecule, and ** indicates the point of attachment to X; and each X is independently selected from H, halo, cyano, hydroxyl, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, O-C1-C6alkyl, C1-C6hydroxyalkyl and 3-6 membered heterocyclyl (e.g. comprising 1 heteroatom that is O).
7. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1 or claim 2, wherein RA is selected from the list consisting of C1-C6alkyl, C1-C6alkylene-O-C1-C6alkyl, C1-C6haloalkyl, C(=O)-O-C1-C6alkyl, C1-C6hydroxyalkyl, 3-6 membered heteroatom comprising 1 heteroatom that is O, halo, O-C1-C6alkyl, C3-C6cycloalkyl, cyano and O-C1-C6alkylene-O-C1-C6alkyl.
8. The compound or pharmaceutically acceptable salt and/or tautomer thereof according to claim 1, selected from any one of: 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-methyl-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(difluoromethyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; methyl 4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'- pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carboxylate; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(hydroxymethyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456-WO-PCT 2 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-methoxy-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'- pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-chloro-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-cyclopropyl-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(trifluoromethyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazole-3-carbonitrile; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-methoxyethoxy)-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-ethoxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((3S,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((3R,4S)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((3S,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456-WO-PCT 2 2'-((3-(3,3-difluorocyclobutoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(3,3-difluorocyclobutoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((5'-(difluoromethyl)-1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((S)-2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((S)-2,2-difluorocyclopropyl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((1'-(difluoromethyl)-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-methyl-1H-pyrazol-4-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-ylethynyl)-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((1',5'-dimethyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(cyclopropylmethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(2-fluoroethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-cyclobutoxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(2,2-difluoroethoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(2-hydroxyethoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456-WO-PCT 2 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-methyl-1H-pyrazol-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(2,2-difluoro-3-methoxypropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((1-fluorocyclopropyl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((3-fluorooxetan-3-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(methoxy-d3)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((3R,4R)-4-fluoro-1-methylpyrrolidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl)oxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(methylthio)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((2-acetyl-2-azaspiro[3.3]heptan-6-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((2-oxaspiro[3.3]heptan-6-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-cyclopropoxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(2,2,2-trifluoroethoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456-WO-PCT 2 2'-((5'-chloro-1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(prop-1-yn-1-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-4-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane- 1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-2-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((1'-(difluoromethyl)-5'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((1r,3R)-3-hydroxy-3-methylcyclobutyl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(((R)-1,4-dioxan-2-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 1-(((4-((7'-((1R,3R)-3-hydroxycyclohexyl)-6'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-2'-yl)amino)-1H-pyrazol-3-yl)oxy)methyl)cyclopropane-1-carbonitrile; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((methylthio)methyl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((S)-2,2-difluorocyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((R)-2,2-difluorocyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456-WO-PCT 2 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(((R)-tetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7’-((1R,3R)-3-hydroxycyclohexyl)-2’-((3-(((S)-tetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5’-pyrrolo[2,3-d]pyrimidin]-6’(7’H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1H- pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((tetrahydro-2H-pyran-4-yl)oxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((-4-fluorotetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-((4,4-difluorotetrahydrofuran-3-yl)methoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-hydroxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one.; 7’-((1R,3R)-3-hydroxycyclohexyl)-2’-((3-(((S)-tetrahydrofuran-3-yl)oxy)-1H-pyrazol-4- yl)amino)spiro[cyclopropane-1,5’-pyrrolo[2,3-d]pyrimidin]-6’(7’H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-1H,1'H-[3,3'-bipyrazol]-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((3-((1r,3R)-3-methoxycyclobutoxy)-1H-pyrazol-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 2'-((3-(1,3,4-oxadiazol-2-yl)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3- hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; 7'-((1R,3R)-3-hydroxycyclohexyl)-2'-((1'-methyl-5'-(trifluoromethyl)-1H,1'H-[3,4'-bipyrazol]-4-yl)amino)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; PAT059456-WO-PCT 2 2'-((3-(1-(fluoromethyl)cyclopropoxy)-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one; or a pharmaceutically acceptable salt and/or tautomer thereof.
9. The compound according to claim 1 or claim 8, wherein the compound is , or a pharmaceutically acceptable salt and/or tautomer thereof.
10. The compound according to claim 1 or claim 8, wherein the compound is , or a pharmaceutically acceptable salt and/or tautomer thereof.
11. The compound according to claim 1 or claim 8, wherein the compound is , or a pharmaceutically acceptable salt and/or tautomer thereof.
12. The compound according to claim 1 or claim 8, wherein the compound is PAT059456-WO-PCT 2 , or a pharmaceutically acceptable salt and/or tautomer thereof.
13. The compound according to claim 1 or claim 8, wherein the compound is , or a pharmaceutically acceptable salt and/or tautomer thereof.
14. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of the preceding claims and one or more pharmaceutically acceptable carriers.
15. A combination comprising the compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of claims 1 to 13, and one or more therapeutically active agents.
16. A compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of claims 1 to 13 for use as a medicament.
17. A compound or pharmaceutically acceptable salt and/or tautomer thereof according to any one of claims 1 to 13 for use in the treatment of cancer. 20 PAT059456-WO-PCT 2
18. The compound for use according to claim 17, wherein the cancer is selected from ovarian cancer, gastric cancer, uterine cancer, breast cancer (e.g. ER+ breast cancer, e.g. ER+/Her2- breast cancer), lung cancer and endometrial cancer.
19. The compound for use according to claim 17 or claim 18, wherein the cancer is a cyclin E amplified cancer.
IL322139A 2023-02-17 2024-02-15 Cyclin-dependent kinase (cdk2) inhibitors IL322139A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363485709P 2023-02-17 2023-02-17
US202363580277P 2023-09-01 2023-09-01
PCT/IB2024/051412 WO2024171094A1 (en) 2023-02-17 2024-02-15 Cyclin-dependent kinase (cdk2) inhibitors

Publications (1)

Publication Number Publication Date
IL322139A true IL322139A (en) 2025-09-01

Family

ID=89983293

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322139A IL322139A (en) 2023-02-17 2024-02-15 Cyclin-dependent kinase (cdk2) inhibitors

Country Status (16)

Country Link
US (1) US20240360137A1 (en)
EP (1) EP4665734A1 (en)
JP (2) JP7834249B2 (en)
KR (1) KR20250150077A (en)
CN (1) CN120659790A (en)
AU (1) AU2024221477A1 (en)
CL (1) CL2025002448A1 (en)
CO (1) CO2025012422A2 (en)
DO (1) DOP2025000197A (en)
IL (1) IL322139A (en)
JO (1) JOP20250210A1 (en)
MX (1) MX2025009633A (en)
PE (1) PE20252399A1 (en)
TW (1) TW202434595A (en)
UY (1) UY40638A (en)
WO (1) WO2024171094A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026038120A1 (en) * 2024-08-12 2026-02-19 Novartis Ag Synthesis and crystalline forms of a cdk2 inhibitor
TW202606702A (en) * 2024-08-12 2026-02-16 瑞士商諾華公司 Uses of a cdk2 inhibitor in the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202192260A1 (en) * 2019-02-15 2021-12-17 Инсайт Корпорейшн CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND THEIR APPLICATIONS
US11919904B2 (en) * 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
CA3145821A1 (en) * 2019-07-02 2021-01-07 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
JP7822578B2 (en) * 2021-06-09 2026-03-03 ティーワイケー メディシンズ(ジョンジョウ),インコーポレーテッド Compounds used as CDK kinase inhibitors and their applications
CN117897384A (en) * 2021-06-28 2024-04-16 缆图药品公司 CDK2 inhibitors

Also Published As

Publication number Publication date
JP2026102718A (en) 2026-06-23
MX2025009633A (en) 2025-09-02
CL2025002448A1 (en) 2025-11-21
TW202434595A (en) 2024-09-01
JP2026507527A (en) 2026-03-04
KR20250150077A (en) 2025-10-17
AU2024221477A1 (en) 2025-07-24
UY40638A (en) 2024-08-30
PE20252399A1 (en) 2025-10-10
JP7834249B2 (en) 2026-03-23
CN120659790A (en) 2025-09-16
US20240360137A1 (en) 2024-10-31
CO2025012422A2 (en) 2025-09-29
EP4665734A1 (en) 2025-12-24
WO2024171094A1 (en) 2024-08-22
DOP2025000197A (en) 2025-10-15
JOP20250210A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
US11780839B2 (en) Compounds for treating Huntington&#39;s disease
ES3055657T3 (en) Gcn2 inhibitors and uses thereof
RU2661896C2 (en) Purine inhibitors of human phosphatidylinositol 3-kinase delta
CA2847540C (en) Pyrrolopyrimidine and purine derivatives
EP2834238B1 (en) Diacylglycerol acyltransferase 2 inhibitors
TW202246255A (en) Cdk inhibitors and methods of use thereof
US20240360137A1 (en) Cyclin-dependent kinase (cdk2) inhibitors
SG11202112504YA (en) Compounds for treating huntington&#39;s disease
KR20140015151A (en) Novel tricyclic compounds
EP3546458B1 (en) ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer
US20240174662A1 (en) Small molecule inhibitors of salt inducible kinases
IL323942A (en) SARM1 modulators, preparation methods and uses for them
CN115873000B (en) Isoquinolinone and quinazolinone compounds and their compositions and uses
US20220033396A1 (en) Further heteroaromatic compounds having activity against rsv
EA046152B1 (en) COMPOUNDS FOR THE TREATMENT OF HUNTINGTON&#39;S DISEASE
EA049687B1 (en) AZETIDENE CYCLOUREAS
WO2026038121A1 (en) Uses of a cdk2 inhibitor in the treatment of cancer
HK40008341A (en) Pyrrolo [1,2-b] pyridazine derivatives
HK1226736A1 (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders